annual report gsk annual report global biopharma company purpose unite science technology talent ahead disease aim positively impact health billion people end bold ambition patient reflect commitment growth stepchange performance company outstanding people thrive content strategic report corporate governance investor information ahead board gsk leadership team financial record performance key chair governance statement product development pipeline performance indicator corporate governance architecture product competition chair statement ahead board oversight intellectual property ceo statement key decision engagement principal risk uncertaintie business model board committee report share capital control culture people director report dividend external environment financial calendar research development annual general meeting remuneration report commercial operation tax information shareholder chair annual statement performance vaccine shareholder service contact annual report remuneration performance specialty medicine law regulation remuneration policy summary performance general medicine group company responsible business glossary term risk management financial statement principal risk summary director statement climaterelate financial disclosure responsibility naturerelate financial disclosure independent auditor report employee gender financial statement viability statement note financial statement group financial review financial statement gsk plc prepare gaap cautionary statement inside cover document cautionary statement forwardlooke statement nonifrs measure use number adjust noninternational financial reporting standard ifrs measure report performance business total report result represent group overall performance ifrs adjust result nonifrs measure consider addition substitute superior information present accordance ifrs adjust result nonifrs measure define page reconciliation near ifrs measure page gsk annual report strategic report governance remuneration financial statement investor information ahead landmark year gsk follow demerger consumer healthcare business form haleon july fully focus biopharma company prioritise innovation vaccine responsible business means get specialty medicine maximise ahead disease right way increase opportunity prevent environmental social governance esg treat disease impact embed strategy support sustainable performance longterm growth help heart focus science build trust stakeholder reduce risk immune system human genetic advanced operation deliver positive social impact technology worldleading capability vaccine medicine development focus therapeutic area infectious disease hiv culture gsk immunologyrespiratory oncology power purpose drive delivery strategy help gsk place people thrive confident future culture ambitious patient accountable impact right thing foundation bold ambition patient reflect deliver patient shareholder commitment stepchange growth performance gsk people period mean gsk vaccine medicine include innovative new product reach people beforegsk annual report performance key performance indicator financial deliver stepchange commercial execution growth portfolio prioritise investment cost discipline support strong growth operate profit earning share ep group turnover turnover product area kpi aer vaccines cer aer cer specialty medicine aer cer general medicines aer cer growth exclude covid solution aer cer total continue operating profit kpi adjust operating profit aer aer cer cer growth exclude covid solution aer cer total continue earning share adjust earning share aer aer cer cer growth exclude covid solution aer cer cash generate operation attributable continue free cash flow kpi operations kpi use number adjust nonifrs measure report performance business adjust result nonifrs measure consider addition substitute superior information present accordance ifrs adjust result nonifrs measure define page aer actual exchange rate cer constant exchange rate comparative result present table restate consistent basis previously publish reflect demerger consumer healthcare business presentation continue discontinue operation ifrs set kpi performance indicator attributable continue operation ink executive remuneration page detail gsk annual report strategic report governance remuneration financial statement investor information performance summary key performance indicator continue research development continue strengthen latestage pipeline regulatory approval positive datum readout strategic business development innovation sale kpi innovative pipeline phase iii start sale product launch vaccine specialty medicine include depemokimab year include lifecycle base science eosinophilic disease cobolimab innovation immune system secondline nonsmall cell lung cancer new approval phase iiiregistration new collaboration acquisition include affinivax sierra oncology spero therapeutic pipeline value progress kpi report externally commercial sensitivity responsible business continue recognise environmental sustainability leadership esg performance rating kpi track base performance metric met exceed metric cover new focus area access healthcare global health health security environment diversity equity inclusion ethical standard product governance page access medicine index pharmaceutical industry reduction indirect scope consecutive time global corporate sustainability carbon emission assessment score february culture culture progress kpi ambitious patient accountable impact right thing measure employee survey employee engagement score compare read base late available datum scope emission gsk annual report chair statement important year gsk history strong operational financial performance successful demerger consumer healthcare say year programme create attractive increase productivity change emma team competitive business build culture performance deliver design compelling investment proposition long embe fundamentally reconstruct worldleading consumer healthcare critical lever longerterm value strengthen gsk operational business newly focus gsk creation gsk capability clear ambitious priority strengthen balance sheet progress set sharpen commercial enable increase investment make good progress execution cost discipline improve future growth past year pipeline productivity see evidence new medicine vaccine tackle group structure benefit simple approve new capital allocation capacity shift focus business model medicine currently latestage gsk culture competitive clinical trial development performance focus operational performance gsk excellent strong good clear progress see clear evidence growth sale vaccine pipeline reflect important success strategic specialty medicine doubledigit milestone transformation growth operating profit ep respiratory syncytial virus rsv start new sustained vaccine candidate old adult deliver demerger period growth group achieve exceptional phase iii result separation gsk consumer sale operating profit forecast food drug healthcare business form haleon grow administration fda approval separate company list london cagr respectively period longacte hiv medicine july large demerger board confident administer month europe year delivery target underpin reaffirm gsk leadership culmination huge improvement seeing generation hiv treatment work year group commercial execution prevention competitiveness remain ambitious support pipeline future growth business development acquisition sierra oncology affinivax complete year delight seamless transition tony wood chief scientific officer role august replace hal barron tony outstanding highly respect scientist key architect rebuild pipeline compound annual growth rate gsk annual report strategic report governance remuneration financial statement investor information chair statement continue engage shareholder disappointing board evolution board management company remain clear position delivery demerger obviously continue maintain significant matter result change board engagement shareholder scientific consensus include departure vindi banga consistent reliable evidence vivienne cox haleon clear conversation zantac ranitidine increase risk retirement laurie glimcher vast majority shareholder cancer decision december like thank support strategy company federal court southern significant contribution gsk implement florida dismiss claim recent year despite progress case relate ranitidine board recognise commit welcome gsk continue increase investor opportunity demerger defend vigorously claim confidence ability group deepen gsk board biopharma bring state level sustain growth experience credential decade target governance delight welcome vishal sikka board adopt target elizabeth mckee anderson important gsk sale operate profit growth board year vishal perform term tsr share lightly commitment worldleade technologist price performance year important demonstration elizabeth deep commercial board understand need confidence business expertise large deliver determination hold accountable specialty biopharma short term mean delivery continue consistent yearonyear delivery line introduce new involvement hal dietz hal target sale operate remuneration policy link barron believe scientific profit include successful launch executive remuneration reward credential gsk board company key new product outperformance strong industry opportunity rsv vaccine engage extensively look forward future shareholder develop appointment highly look successful proposal recognise new reward experience julie brown new delivery strengthen system fundamental cfo starting like latestage pipeline critical architecture gsk postseparation thank outgoing cfo iain mackay vaccine specialty medicine ensure build performance outstanding work support include longacte hiv culture generate sustain year portfolio support target delivery shareholder value business development like note pleased policy achieve appointment anne beal join long term board confident positive shareholder vote board chair progress company recognise sizeable minority corporate responsibility committee making develop industryleade shareholder vote charles bancroft currently audit machine learning capability continue engage shareholder risk committee chair new application deep demonstrate believe senior independent director understand genetics incentivising outperformance provide edge able target ultimately reward finally like thank identify develop launch product shareholder value creation employee partner shareholder difference patient customer support operate responsibly deliver value shareholder commitment year operate responsibly foundation look forward promise zantac litigation stone gsk build exciting gsk group share price performance commit ensure second half year esg consideration properly impact uncertainty embed strategy associate zantac product liability litigation support longterm growth reduce risk help build trust sir jonathan symonds stakeholders board chair please continued progress esg area include gsk top independent access medicine indexgsk annual report ceo statement landmark year gsk enter strong momentum focus global biopharma company create focus global reflect huge progress strong operational performance biopharma company improve competitiveness enable increase annual landmark year gsk commercial execution investment billion successfully deliver product exceed billion demerger demerger haleon annual sale include shingrix significantly strengthen gsk significant corporate change trelegy nucala benlysta dovato balance sheet create additional company year begin shingrix deliver record year flexibility invest growth new chapter competitive billion sale hiv sale innovation acquire profitable growth enter include dovato billion bostonbased vaccine company strong momentum focus cer affinivax give access global biopharma company disruptive map technology vaccine specialty medicine ambition purpose unite high valency broad coverage represent nearly twothird science technology talent single vaccine phase sale compare ahead disease nextgeneration valent vaccine track achieve pneumococcal disease strong performance increase target revenue acquire sierra oncology include confidence deliver growth vaccine specialty medicine myelofibrosis treatment evolve portfolio momelotinib hope group sale billion prioritise investment approve sign cer drive strong innovation good cost discipline exclusive licence agreement growth vaccine specialty reflect expansion spero therapeutic tebipenem medicine adjust operating profit operate margin novel oral antibiotic latestage grow adjust eps development complicated urinary cer tract infection cutis expect targeted business development addition generate billion free cash flow support investment dividend penny share year strong momentum underpin confidence deliver ambitious sale profit outlook set time continue build strong portfolio pipeline base science immune system absorb loss revenue future patent expiration strong position deliver growth decade gsk annual report strategic report governance remuneration financial statement investor information ceo statement continue innovation support future growth bepirovirsen june introduce new pipeline undergo final stage trial code set culture vaccine specialty medicine asset pipeline aim commitment gsk potential forefront new wave people deliver bestinclass treatment ancient disease ambition purpose right way august tony wood take new hiv launch apretude esg focus access role gsk chief scientific officer longacte injectable healthcare global health health succeed hal barron hiv prevention alongside security environment diversity equity prove expertise science data cabenuva complete inclusion ethical standard new technology tony place longacte hiv treatment regimen product governance capture value opportunity mean change excellent progress maintain approach landscape hiv patient number position progress year access medicine index focus core development nextgeneration consecutive time rank therapeutic area infectious disease pipeline option include present corporate sustainability hiv immunologyrespiratory promising earlystage datum nls assessment pharmaceutical oncology overall infectious disease new broadly neutralise antibody industry hiv represent twothird look forward provide pipeline primary focus talk year investor visibility pipeline stakeholder option demand transparent report infectious disease immunologyrespiratory performance esg matter develop potential bestinclass increase investment introduce new esg performance vaccine rsv old adult support phase iii programme rating track delivery please excited present depemokimab promise potential report performance phase iii result late new longacte medicine treat track detail set demonstrate efficacy severe asthma area severe disease exceptional result gsk longstanding expertise world wait jon clear zantac prove commercial capability year rsv vaccine product liability litigation oncology report positive significant scientific achievement scientific consensus data jemperli potential submit datum consistent reliable evidence treatment patient primary regulator hope approval zantac ranitidine increase risk advanced recurrent endometrial alongside exist cancer continue defend cancer follow discussion inhouse capability vigorously state case fda take decision withdraw adjuvant map affinivax perspective important blenrep market acquisition collaboration company november base previously curevac mrna distracted main announce outcome broad suite vaccine platform priority continue deliver dreamm trial technology company strategy patient shareholder sector building trust reduce risk people deliver positive social impact important advance look ahead confidence commit run clinical development enter believe gsk responsible business builds latestage asset gepotidacin new compelling prospect trust reduce risk deliver novel antibiotic uncomplicated people fuel confidence sustainable health impact scale urinary tract infection uutis want thank shareholder return support bepirovirsen potential achieve strong people thrive provide firstinclass functional momentum deliver cure chronic hepatitis set later report optimistic future remain significant unmet make good progress excite achieve medical need people strengthen culture key globe infect deliver ambition virus purpose commit make million live chronic hepatitis gsk place talented people infection today current standard thrive culture care chronic hepatitis achieve ambitious patient accountable emma walmsley functional cure patient impact right thing chief executive officer few vaccine efficacy versus gsk annual report business model ambition positively impact health billion people end aim develop transformational vaccine medicine make available responsible price accessible patient sustainable business central success people expert science technology manufacturing regulation intellectual property commercialisation gsk people country worldwide supplier work directly gsk investment manufacturing site global centre aer cer identify research develop testing groundbreake discovery manufacture commercialise vaccine specialty medicine general medicine deliver half million portfolio specialty medicine portfolio dose vaccine day prevent treat disease hiv product encompass gsk world child respiratory disease immuno primary care medicine supply receive gsk vaccine year inflammation disease like lupus country worldwide cancer bestinclass gsk annual report strategic report governance remuneration financial statement investor information business model continue product improve health million people world core therapeutic area infectious disease hiv immunologyrespiratory oncology world leader goal minimise unlocking science emerge portfolio infectious disease like impact hiv immune system oncology potentially shingle meningitis people live understand react bring new cancer include hiv treatment prevention disease like lupus therapy patient account twothird ultimately cure eosinophilic asthma need vaccine medicine inflammatory disease pipeline steer longterm priority innovation performance trust develop new medicine commitment growth deliver strategy responsibly vaccine need significant stepchange consider esg impact well fast smart delivery lab patient help build trust combine power confident ability stakeholder reduce risk genetic genomic insight sustain growth decade operation deliver positive cause disease social impact speed scale artificial intelligence machine learning create value patient shareholder society pack medicine share dividend corporate income tax pay dose vaccine deliver addition pay duty levy transactional employment taxis people people support grow work matter reinvestment return enable reinvest discover develop new vaccine medicine continue get ahead disease company director require law promote success organisation benefit shareholder wide stakeholder include employee supplier community information issue factor stakeholder board consider relevant complying section company act find business model support esg strategy strategy support robust framework describe monitor manage risk describe page gsk annual report culture people gsk purpose unite science technology talent ahead disease put people heart success culture support people manager commit make gsk place people people manager play crucial role help thrive culture ambitious team thrive bring culture life expect people patient accountable impact right thing manager motivate focus care develop mean support people thing well team year deliver line fast focus matter mean set leader training anchor area clear objective accountability result give population addition launch new support space need succeed senior leader programme lead leader build mean responsibly care integrity leadership development senior level people patient world count organisation dedicate significant leadership preparation bring people manager energy bring life ahead purpose virtual event bring life big strategy culture gsk place real priority support manager set focused emphasis individual ownership culture ambitious objective team align small change need reality innovation performance trust culture priority change support team conversation guide simple tool globally support well fast focus diversity equity inclusion decision make great clarity accountability continue focus build diverse ambitious focus objective organisation equitable inclusive culture june introduce code set culture feel welcome value include commitment gsk people deliver leadership representation aspiration deliver ambition right way gsk people implement annual diversity equity inclusion sign code annually personally commit dei training invest development tool build inclusive leader support awardwinne code gskcom leadership development programme accelerate difference support woman ethnically diverse making gsk place people thrive leader continue evolve people core ahead ambition gsk policy process practice support recruitment place people thrive people thrive retention development diverse workforce individual believe common theme detail aspirational target dei matter firstly belief purpose people business supplier find desire live culture contribute deliver responsible business section ambition secondly feel include able opportunity grow support drive performance choice feedback space need succeed finally feel performance choice approach hybrid work good positive mental physical financial social officebased role quarter wellbee require gsk place people people continue allow find right balance feel welcome value environment include onsite remote work framework balanced policy workplace way work drive collective individual performance wholeheartedly enable support person support individual flexibility support personal deliver well wellbee drive performance make attractive employer year clear expectation spend time person help continue build sense community connectedness enable development well achieve ahead ambition httpswwwgskcomengbcompanygovernancecompliancethecode gsk annual report strategic report governance remuneration financial statement investor information culture people continue develop outstanding people understand people experience gsk commit develop outstanding people regularly measure people experience gsk give people opportunity grow gsk people include progress culture focus area place expect agree development plan work include annual survey employee regardless grade role underpin robust feature question engagement confidence inclusivity conversation understand space support need culture focus area trust priority run succeed continue invest development series pulse survey year statistically initiative training access significant population timely insight culture grow campus central platform progress hot topic moment train knowledge sharing year progress demonstrate increase engagement redesign talent framework confidence delivery ambition positive focus review people performance trend ambition patient accountability impact living culture future potential give right thing measure inclusion simple assessment process line culture support place good people critical role measure effectiveness global manager strong diverse succession plan allow population team provide feedback annual spend time development action plan survey manager receive anonymised aggregate process feedback effectiveness motivate team focus people matter lead care health wellbeing improvement inclusive leadership support performance development manager rate announce improvement health highly effective report wellbee benefit well support people different life stage sure offering fair inclusive include new global minimum recognise reward people standard week parental leave primary sharing success recognise reward secondary carer form family new global people progress minimum standard care family member end continue important life health emergency insure benefit culture addition bonus scheme reward include sex partner possible new performance company year award financial wellbeing service mental health training population extra ahead award available deliver exceptional performance line culture people identify miss november give onetime discretionary payment performance deliver people feel great impact objective live culture year addition rise costofliving challenge payment give annual bonus longterm incentive structure half global workforce give special thank people country consistent criterion determine eligible exclude gsk leadership team glt allow country recognise real time achieve preparation separation unprecedented transformation gsk receive oneoff week salary march separate bonus payout remain energised continually live evolve culture line internal external environment objective start leadership team member ambitious goal embed grow culture show act daygsk annual report external environment set major theme influence environment work government regulator industry partner provide medicine vaccine patient worldwide life science continue shape new technology rapid advance science underscore potential new infrastructure responsible access technology change life science technology approach public dataset aiml advance particularly evident improve patient outcome growth different regulatory approach expansion artificial intelligence area include nextgeneration use medicine emerge machine learning aiml vaccine collaboration need create potential transform outcome substantial increase asset common model standard patient make precise development drive regulation support innovation productive research advancement mrna dna benefit patient identify nearly company vaccine technology ead focus datum work aidriven drug discovery great use new technology platform technology page industry invest build digital tool growth aiml capability forge decentralise trial accelerate partnership strengthen drive modernisation position biopharma company clinical trial regulatory process collaborate government regulator organisation partnership continue build lesson learn company work strike compare covid expand aidriven drug discovery industry pivotal role innovation international collaboration complex manage covid pandemic trial develop policy geopolitical tension prompt country shift priority focus scientific technological advance government recognise europe march offer significant promise patient importance minimise trade enact new federal geopolitical tension put friction domestic interest remain agency advanced research pressure system need priority government project agency health deliver innovation rise encourage company localise improve government ability nationalism friction shorten value chain prioritise speed biomedical health research country conflict strategic resilience efficiency life science earmark key ukraine tension policy restrict trade secure strength government new china bring potential risk access essential item include growth plan give potential disruption face medical good persist bolster economic productivity tension government take example government protect live healthcare life interventionist action protect introduce harmful policy science likely subject domestic economic competitiveness intervention affect trade muscular industrial policy strengthen national security create pharmaceutical good intervention additional domestic job improve public support state environment define tension health scrutiny supply chain resilience trade disruption economic notable example uncertainty health life science solidarity year constructive continue view sector world trade organization discussion strategic importance government reduce tariff demonstrate advanced market include government biopharma research time focus scale mckinsey october introduce harmful deep pharma intelligence artificial intelligence drug discovery landscape overview policy intervention affect kpmg singapore key trend impact global supply chain trade pharmaceutical good global trade alert treasury growth plan september gsk annual report strategic report governance remuneration financial statement investor information external environment continue economic slowdown energy crisis inflation bite lockdown height vaccination programme concern negotiation provision pandemic weigh economy spend estimate fallen allow federal health secretary worldwide outlook continue real term fail negotiate price certain weaken global growth pace inflation medicine expensive drug year forecast slow spending expect return medicare potentially amid surge inflation heighten prepandemic growth rate limit investment innovation geopolitical uncertainty albeit pricing value cost containment tighten financial condition energy increase scrutiny see example price soar europe year economic pressure innovative contracting support increase demand restrict geopolitical disruption prudent stewardship healthcare supply contribute rise inflation government meet economic spending company payer immediate headwind cost containment continue explore innovative challenging consequence measure rise pricing model facilitate individual business healthcare budget face significant patient access support payer energy price climb pressure confidence value medicine government stage significant advanced market august vaccine time launch costly intervention protect president sign law ead pricing access household seek alternative energy inflation reduction act include source invest renewable provision drive national energy infrastructure government debt high taxis lower intervention scale risk grow energy cost lower drug fiscal deficit pressure price part act focus area public spending patient welcome include healthcare bring benefit people global growth forecast pandemic healthcare spending face challenge access slow increase government roll important vaccine green transition disrupt longterm momentum remain energy crisis investor sentiment particularly despite disruption see weaken economy see similar shift get ahead climate disrupt green transition amid esg agenda increasingly change remain longterm concern reliability supply polarise politicise investor societal expectation affordability policymaker face year florida texas implement government priority conflict priority energy measure ban pension fund reinforce billion clean transition necessary mitigate invest asset energy investment inflation climate change immediate energy manager policy reduction act setback need drive renew investment exclude fossil fuel take esg energy transition likely time traditional fossil fuel energy source factor account limited company continue european country announce plan demonstrate leadership fractured backdrop revert high coal usage issue remain committed cut corporate net zero effort remain produce electricity climate impact spotlight stakeholder take step reopen oil expectation credibility ead climate nature gas leasing public land transparency net zero continue page rise voluntary commitment coalition test example unbacked race zero drop explicit bar support new coal project allocate climate clean energy programme inflation reduction act imf world economic outlook october economist intelligence unit healthcare outlook eiucom iqvia global use medicine gsk annual report external environment continue access focus covid shine light health inequity covid demonstrate value industry seek encourage treatment pandemic life science sector holistic approach realise adverse effect potential deliver innovative equitable timely access survival year come health intervention speed future pandemic recognise system continue manage pandemic raise question multiple factor enable access longterm repercussion pace medicine sustainable fund pandemic opportunity vaccine roll shine free trade international new model care light inequality access pharmaceutical industry enable early action prevent healthcare outcome biotechs vaccine manufacturer diagnose treat disease investing country base develop country united prevention ahead disease people lowincome country vision access future clear return improve health partially fully vaccinate pandemic know berlin outcomes costeffective covid compare declaration outline industry contribute healthy life society highincome country willingness reserve allocation economy realtime production distribution scrutiny covid vaccine page price priority population future rollout reignite debate access global health pandemic success health security intersection approach rely strong intellectual property right innovation ecosystem removal access medicine vaccine regulatory trade barrier evidence trip export procurement mechanism waiver agree june low middleincome country temporarily remove develop robust health system people lowincome country obligation patent country partially fully protection covid vaccine resilient health system vaccinate covid step address need counter inequitable access instead increase threat infectious disease undermine industry ability emergency manage partner invest risk respond grow burden noncommunicable quickly future pandemic disease delay cancer diagnosis position challenge economic advocating appropriate risk uncertainty political landscape protection balance regulatory recognise health social important invest framework support discovery economic value innovative pipeline vaccine specialty delivery vaccine medicine vaccine medicine meet change medicine develop continue collaborate global unmet healthcare need emerge technology health partner increase reach time work reinforce importance global patient low income country government regulator industry diversify supply chain support delivery innovative partner sure medicine pricing environment medicine vaccine continue vaccine reach patient tougher place offer advocate investment resilient bringing value people differentiate highvalue pipeline healthcare system world need payer prevention treatment robust infrastructure need scientific innovation improve disease build new support example routine health remain critical pathway technology technique lifecourse immunisation get sustainable economic growth fast smart demand ahead future pandemic continue work datum realworld evidence manage effectively peer government support continue reimbursement happen start invest sure policy regulatory new product likely increase health system improve environment stimulate sustain continue work payer design public health innovation include example innovative solution manage financial time covid vaccine tracker global race vaccinate december gsk annual report research development science technology open possibility new vaccine medicine patient continue harness science immune system alongside genetics genomic advanced technology continue strengthen pipeline ssstttrrraaattteeegggiiiccc rrreeepppooorrrttt governance remuneration financial statement investor information gsk annual report research development highlight rd vaccine medicine new approval pipeline come pipeline infectious disease hiv potential bestinclass rsv old adult expansion depemokimab phase iii candidate vaccine file japan programme trial longacte shingrix interim year datum present inhibitor additional eosinophildriven week disease continue progress development long business development include acquisition act hiv treatment positive phase datum affinivax give access disruptive map nls broadlyneutralise antibody technology phase nextgeneration present hiv glasgow vaccine pneumococcal disease acquisition sierra oncology add pivotal phase iii trial gepotidacin momelotinib myelofibrosis patient antibiotic uutis stop early efficacy anaemia regulatory submission positive phase iib datum bepirovirsen exclusive licence spero therapeutic investigational treatment chronic give access tebipenem hbr latestage hepatitis start phase iii study antibiotic cutis early approach research team take approach follow science identify opportunity great central purpose ahead disease probability success lead differentiate vaccine combine science immune system medicine include opportunity outside area genetics genomic advanced technology outstanding scientist prioritise genetically identify target talent discover develop vaccine medicine twice likely succeed clinic transformational impact people lives prioritise infectious disease target immunemodulator expenditure million great lifecycle opportunity aer cer strengthen pipeline platform capability strategic prioritise execution technology business development mean vaccine prioritie medicine development potential firstinclass flawless execution latestage pipeline acceleration organically derive pipeline latestage align therapeutic area double technology deliver innovation infectious disease fast hiv find new way help patient lifecycle immunologyrespiratory innovation oncology target business development push new discovery gsk annual report strategic report governance remuneration financial statement investor information research development continue flawless execution acceleration find new way help patient pipeline lifecycle innovation pipeline phase potential vaccine look innovate lifecycle vaccine medicine modulate medicine explore new way treat immune system human genetic patient example include validation start phase programme approval boostrix immunisation move candidate phase start phase pregnancy prevent whooping cough newborn baby iii programme fda approval new convenient presentation achieve industryleade milestone include rotarix vaccine prevent gastroenteritis cause approval launch longacte hiv medicine rotavirus fda priority review exceptional rsv old approval priorix vaccine measle mumps adult vaccine candidate potential bestinclass rubella child months profile present new datum idweek showing shingrix provide year approval twodose regimen cervarix human protection shingle complete papillomavirus vaccine girl age china acquisition affininax approval china benlysta treat adult active lupus nephritis fda approval benlysta significant progress improve key paediatric patient active measure productivity reduce overall cycle time start new drug discovery project continue develop new monoclonal antibody end phase compare depemokimab development high affinity phase portfolio include longacte suppression function potential firstinclass medicine push new discovery strategic business development double technology deliver work commercial organisation academic innovation fast institution find new research discovery believe combination science technology opportunitie access new technology platform hold key fundamentally transform medical progress development pipeline remain agile discovery improve success rate shape ambitious look opportunity address high treat prevent challenging disease unmet medical need complement strategy technology play grow role progress vaccine medicine previously look grow pipeline acquisition think possible cover include affinivax add novel class generation pneumococcal vaccine candidate datum technology help understand innovative map technology sierra patient human biology choose target design oncology add momelotinib treatment clinical trial access large rich dataset mylefibrosis thank datafocuse collaboration include recent collaboration tempus announce new collaboration give establish partnership example andme access exciting new vaccine medicine biobank laboratory genomic research technology deepen understand university california prevent treat disease partner precision platform technology efficient design medicine company tempu oncology development new vaccine medicine area focus add pipeline new access broad set platform technology include partnership mersana therapeutic option unrivalle suite vaccine like mrna map codevelop commercialise xmt adjuvant science grow investment immunosynthen antibodydrug conjugate oncology oligonucleotide wuxi progress bispecific tcell engage antibodie oncology zheme progress phase tlr agonist hepatitis virus hbv announce new partnership wave life sciences drive discovery development oligonucleotide therapeutic include programme alphaantitrypsin deficiency novel rnaediting mechanism action announce exclusive licence agreement spero therapeutic tebipenem hbr latestage antibiotic treat cutisgsk annual report research development continue genetics genomic advanced technology ahead disease use innovative tool collaboration functional genomic provide maximise chance success accelerate insight improve target selection work pace discovery genomic predictive power range institution innovate fastmove field aiml change find right medicine crispr pioneer startup include right patient dedicate genomics research centre altius institute seattle broad institute affiliate advanced technology realworld datum bring mit harvard university boston continue patient discovery development process partner adrestia british biotech open early turn improve researcher integrate target consortium found member datum decision make disease like cancer neurological condition investigate tool like advance complement progress make genetic validation wearable genomics aiml genomics lab found crispr pioneer provide important insight well choose university california san francisco drug target specific group patient laboratory genomic research advance study portfolio active technology biology project automate advance crispr scientist work datum produce tool help academic researcher uncover new select novel target genetically validate knowledge disease mechanism immunology likely approve medicine vaccine oncology neurology scientist create new design clinical trial include patient likely technology stem crispr benefit potential medicine vaccine identify additional application technology find well starting point new medicine recruit patient fast accelerate pace clinical trial crispr tool contribute datum understand underlying cause disease improve drug discovery power information source range tissue blood sample genomics partnership human behaviour wearable technology today project pipeline proprietary aiml capability help researcher support human genetic evidence inform interpret volume datum connection large genetic dataset ongoing collaboration prediction help identify target biobank andme finngen likely succeed asset pipeline found member creation future aiml functional genomic continue play role health ambitious effort aim recruit include optimise clinical trial design example million people capture wide range medical happening bepivorisen genetic information work gene health discover south africa expand building inhouse aiml team expand work ensure diverse robust genetic collaboration representation disease aiml enable generate deep insight collaboration consumer genetic research data collaboration work apply research company andme approximately aiml primarily focus area early active joint drug discovery programme genetically discovery stage find genetically validate target validate target extend collaboration clinical stage match patient right fifth year identify validate additional new drug medicine target july year take sole build large inhouse function dedicate development responsibility phase collaboration aiml work partner lead way programme consist investigational antibody field aiml team include target novel immunooncology agent expert base key gsk site include london san investigational antibody currently francisco tel aviv philadelphia boston combine evaluated cancer alongside gsk medicine team resource expertise partner help collect datum find pattern genetic datum fast ultimately help increase success rate make lifechange medicine continue expand partnership world leader datum aggregation company tempus complement internally generate datum gsk annual report strategic report governance remuneration financial statement investor information research development continue model advanced develop technology iteration create new imaging tool external collaboration key area new medicine aiml inform target selection vaccine technology actively invest include potential business development opportunity map multiple antigen present system novel challenge complex disease area nonalcoholic highly efficient vaccine technology platform steatohepatitis nash potentially enable broad coverage generate high partnership king college london antibody response map mainly direct tumour model alongside digital pathology prevent pneumococcal disease show develop personalise immunooncology treatment promise address infectious disease pathogen solid cancer include lung gastrointestinal include cause hospitalacquire infection women cancer mrna validate launch covid vaccine potentially oxfordgsk institute molecular computational apply number disease progress medicine imcm establish partnership development mrna technology inhouse oxford university december combine human parallel curevac collaboration currently genetic functional genomic focus evaluate second generation mrna backbone neurological disease like al alzheimer parkinson develop curevac phase trial feature collaboration datum technology complement modify mrna vaccine candidate target covid exist capability resource include ongoing flu base promise preliminary analysis work cerebra pioneer high performance study evaluate safety reactogenicity computer system nvidia global leader hard immunogenicity prepare software start datum candidate latestage clinical testing collaboration rnai oligonucleotide include arohsd phase pathai global leader aipowere pathology aim programme nash inlicense arrowhead accelerate oncology nash consist rna interference rnai molecule combine predictive datadriven approach genetically validate target bepirovirsen drug discovery trial pathais model build antisense oligonucleotide design recognise algorithm uncover new insight integrate hbv dna phase iii inlicense ionis trial help predict patient announce collaboration impact wave life science allow advance preclinical programme wave prism tempus enable access library oligonucelotide platform include inlicense identify patient datum tempus dataset draw novel rnaediting oligonucleotide treat liver work oncologist academic lung disease cause alphaantitrypsin deficiency medical centre community hospital work tempus improve clinical trial design speed monoclonal antibodies mabs xevudy enrolment identify drug target initial focus covid codevelope vir biotechnology oncology research programme new way understand biology pharmacology platform technology vaccine genetically validate target good medicine intervene disease process chemical work use technology drive drug discovery biology group develop method include expand platform capability include chemogenomic library encode library technology allow broaden range option reactive fragment collaboration future medicine vaccine go exist francis crick institute novel technology help modality like small molecule antibodie adjuvant find critical starting point drug discovery project help immune response vaccine importantly natural product derive biosphere ensure remain highly competitive fast collaboration start lifemine therapeutic confident identify new medicine give access platform genetically validate target proprietary evolutionaryderive genomic drug discovery bispecific antibodie multiple autoimmune disease advance preclinical phase digitisation optimise phase vaccine development production work siemen ato world lead digital transformation technology company develop digital twin complete realtime simulation vaccine manufacturing processgsk annual report research development continue infectious disease twothird vaccine medicine pipeline vaccine generally tolerate favourable address global public health burden infectious safety profile datum present disease cause hiv rsv meningococci infectious disease society america idweek hepatitis rotavirus antibiotic resistant bacteria annual meeting washington october disease cause significant morbidity mortality share positive datum coadministration rsv strain global healthcare system old adult vaccine candidate flu vaccine key find practical immunisation generate pivotal datum rsv candidate vaccine old adult positive interim analysis readout base datum vaccine candidate grant gepotidacin antibiotic treat uutis gonorrhoea priority review fda accept potential bestinclass accelerate assessment european medicine agency ema review japanese ministry seek opportunity boost pipeline health labour welfare mhlw business development complete acquisition clinicalstage biopharmaceutical commit finding solution people high risk company affinivax pioneer novel class consequence rsv infection nextgeneration pneumococcal vaccine candidate start clinical trial explore effect rsv old include valent vaccine candidate adult adult vaccine candidate people age include complete phase paediatric version increase risk rsvlrtd compare people currently phase plus valent pneumococcal begin flu coadministration vaccine programme preclinical development trial aresvi trial continue evaluate vaccine incorporate map technology annual revaccination schedule longerterm protection multiple season new partnership spero therapeutics inc give exclusive licence agreement tebipenem hbr shingles latestage antibiotic develop spero oral carbapenem antibiotic potential approximately adult develop shingle treat cutis clear fda regulatory path potential painful potentially illness shingrix approval tebipenem hbr address unmet medical approve shingles vaccine combine nonlive antigen need novel oral antibiotic alternative adjuvant help overcome natural intravenous hospital therapy drugresistant cutis agerelate decline immunity contribute challenge protect people aged disease rsv rsv major cause acute respiratory illness old shingrix available country adult currently major infectious disease continue broaden access japan vaccine rsv worsen underlying condition shingrix approve people cause pneumonia lead approximately submit application extend indication hospitalisation death year adult include yearold risk immune industrialise country people hospitalise suppression immune deficiency cancer rsv underlying comorbiditie network recommend shingrix cancer survivor vaccine preferential recommendation company announce positive brazilian immunization society phase iii efficacy datum rsv old adult vaccine candidate interim result aresvi phase iii present new datum idweek show pivotal trial show vaccine efficacy observe shingrix provide year protection rsv low respiratory tract disease rsvlrtd shingle primary endpoint analysis adult comorbidity interest interim datum show overall efficacy severe disease overall vaccine efficacy followup period approximately year rsvlrtd meeting trial primary endpoint initial vaccination new safety concern consistent high vaccine efficacy observe identify followup period datum range prespecifie secondary endpoint include significantly add realworld evidence demonstrate severe disease adult age longterm benefit shingrix rsv strain versus versus versus case year versus case year case placebo group estimated zoe placebo group assess vaccine efficacy zoeltfu study follow confidence interval gsk annual report strategic report governance remuneration financial statement investor information research development continue meningitis provide solution new covid vaccine million people develop invasive meningococcal pandemic adjuvant technology disease imd year fatal proteinbase covid vaccine develop survivor longterm disability brain sanofi bioscience license damage deafness nervous system problem loss market vaccine important new option limb bacterial meningitis particular concern help protect covid people diagnose bacterial meningitis end die leave severe complication chronic hepatitis chronic hepatitis chb major global health issue bexsero meningitis vaccine menveo approximately million people infect meningitis acwy vaccine register approximately people die annually country protect form imd liver complication include cirrhosis liver cancer launch million dose vaccine mainstay therapy include nucleosidenucleotide distribute receive fda approval analogue take life anvisa approval brazil fully liquid suppress rarely clear virus readytouse single vial presentation menveo give healthcare provider convenient option remove bepirovirsen drug development need reconstitute vaccine monotherapy chb work reduce virus replication suppress surface antigen stimulate immune system investigational generation menabcwy candidate november phase fullstudy datum publish pentavalent vaccine combine technology new england journal medicine demonstrate bexsero menveo vaccine goal treatment bepirovirsen result sustained clearance introduce meningitis vaccine protect people hepatitis surface antigen hbsag hbv dna serotype cause disease subgroup patient follow month vaccine meningitis vaccine discontinuation bepirovirsen level hbsag potential help improve vaccination rate provide hbv dna key efficacy measure convenient way prevent imd hbsag hbv dna remain undetectable menabcwy currently phase iii development trial month medication patient consider span country participant age functional cure outcome associate expect result early new multivalent vaccine significant decrease risk develop cirrhosis like potential support global strategy hepatocellular carcinoma death currently standard defeat meningitis set world health care treatment rarely achieve functional organization global road map cure new therapy need patient diagnose chronic hbv phase iii study secondgeneration meningitis vaccine currently start early build understanding phase aim improve protection bepirovirsen work aim bepirovirsen strain allow broad age indication globally potential monotherapy backbone future therapy hepatitis patient explore potential covid sequential treatment trial expect share datum later end million case covid report world million death disease continue infectious disease challenge healthcare system innovation diptheria tetanus pertussis partner response develop treatment vaccine case pertussis whooping cough year infant treat covid xevudy likely experience complication disease xevudy sotrovimab sarscov monoclonal boostrix tetanus diphtheria pertussis vaccine antibody treatment develop vir biotechnology tdap receive approval fda october work prevent virus enter infect immunisation trimester pregnancy healthy cell body important prevention whoop cough newborn infant early treatment prevent highrisk patient make vaccine approve develop severe disease vir developed specifically use pregnancy vaccine sotrovimab discovery approval year approve country include canada deliver million dose xevudy australia new zealand country include government purchase meet current future needgsk annual report research development continue rotavirus antibiotic antimicrobial resistance november fda approve new fully accord world health organization liquid presentation rotarix vaccine prevent antimicrobial resistance amr global gastroenteritis cause rotavirus new presentation health threat undermine effectiveness make convenient healthcare provider antibiotic contribute million worldwide prepare rotarix remove need reconstitute death year dose point use expect commercially expertise develop prevention available early treatment option focus pathogen varicella high probability develop amr identify february start phase study center disease control cdc child aged month compare safety progressing new treatment urinary tract immunogenicity varicella chickenpox new infection gonorrhoea strain candidate vaccine vaccine currently develop gepotidacin novel mechanism available aim develop vaccine fit topoisomerase inhibitor uncomplicate utis advisory committee immunization practice acip gonorrhoea partnership biomedical advanced recommend immunisation schedule offer research development authority barda healthcare professional parent alternative early november receive positive result eagle current vaccine varicella new strain vaccine eagle phase iii trial evaluate gepotidacin component measlesmumpsrubella female adult adolescent uutis follow varicella vaccine recommendation independent datum monitor herpe simplex virus committee idmc stop trial early efficacy start phase study investigate potential plan submit new drug application fda gsk immunotherapeutic herpe study gepotidacin potential simplex virus hsv aim offer well solution treatment urogenital gonorrhoea eagle people virus current standard care phase iii trial potential read second half study gathering safety immunogenicity datum gsk healthy people phase development november start phase iii study focus safety immunogenicity proofof evaluate safety efficacy new vaccine concept efficacy candidate gonorrhoea prevention vaccine human papillomavirus candidate base proprietary gmma generalise human papillomavirus hpv common sexually module membrane antigen aim protect transmit infection million people year adolescent adult gonorrhoea infection infected symptom start phase study firstin cause genital wart cancer begin class fimh antagonist novel molecule block phase iii study nextgeneration adjuvante bind coli bacteria bladder epithelium vaccine develop collaboration innovax treatment recurrent urinary tract infection protect type hpv study evaluate reactogenicity safety immunogenicity investigate salmonella vaccine adjuvante vaccine candidate girl woman aged july start phase study university aim identify effective vaccine oxford investigate candidate vaccine invasive formulation phase iii trial nontyphoidal salmonellosis int vaccine use generalised module membrane antigen gmma receive approval china cervarix human technology explore potential partnering papillomavirus vaccine girl age vaccint consortium partner country twodose regiman include int endemic pneumococcal disease pneumococcal disease term illness cause bacterium streptococcus pneumoniae leading cause acute bacterial disease worldwide acquisition affinivax add novel class nextgeneration pneumococcal vaccine candidate incorporate map technology page gsk annual report strategic report governance remuneration financial statement investor information research development continue hiv recent year breakthrough treat offering range option people live prevent hiv transform patient live hiv building achievement new product offer different medicine meet vary need include longacte injectable mean people live hiv significantly reduce therapy time year portfolio antiretroviral include tivicay hiv world big health threat triumeq contain dolutegravir triumeq million new case include approximately approval dispersible oncedaily tablet formulation million people live hiv child weigh committee worldwide half subsaharan africa medicinal product human use chmp ema hiv work viiv healthcare world issue positive opinion recommend marketing specialist hiv pharmaceutical company majority authorisation triumeq child pfizer shionogi shareholder goal end million child live virus treat prevent eventually cure hiv important medicine fixeddose tablet regimen child available form easy transform experience patient fda lower minimum weight child prescribe triumeq live hiv tablet portfolio antiretroviral medicine transform experience people live hiv commitment leave person hiv instead take medicine orally day cabenuva include work develop medicine heavily treatment cabotegravir rilpivirine longacte injectable regimen experience adult treatment option allow patient treatment time safety concern intolerance resistance year treatment establish viiv healthcare announce fiveyear datum rukobia industry leader longacte hiv medicine fostemsavir firstinclass attachment inhibitor ongoing brighte study week datum show cabenuva approve dose month patient fostemsavir antiretroviral europe combination vocabria regiman virus suppress long term cabotegravir rekambys rilpivirine combination receive marketing approval japan explore way improve life dosage month fda approve label update cabenuva mean patient long people live hiv cabotegravir rilpivirine tablet month explore new type longacte therapy base start cabenuva injection cabotegravir people live hiv option medicine home involve combine viivs dolutegravir world widely prescribe cabotegravir asset earlystage pipeline integrase inhibitor hiv take million create medicine patient administer people currently hiv medication foundation dovato juluca investigate ultralongacte medicine twodrug regimen oral therapy effective dose month long base study threedrug regimen allow people few choose partner cabotegravir drug maintain viral suppression begin phase iib phase iii study combination working prevent hiv october announce positive phase iia datum prevent hiv central viiv healthcare work nls novel broadly neutralise antibody bnab late receive fda approval apretude study show strong antiviral efficacy dose level cabotegravir longacte injectable bnab recognise different strain hiv stop preexposure prophylaxis prep option reduce risk enter healthy cell block virus sexually acquire hiv approval base result replicate offer potentially new approach pivotal phase iii study hiv prevention trial treatment help combat treatment resistance network hptn demonstrate superiority effort end hiv epidemic establish standard care european study vocabria cabotegravir injection august announce datum show rekambys rilpivirine longacte injectable suspension continued superior efficacy cabotegravir longacting show treatment receive people live prep daily tablet unblinded portion hptn hiv clinic staff carisel study trial woman subsaharan africa show participant say injectable treatment substantially low rate hiv acquisition stigmatise daily tablet combination show high clinical effectiveness low rate viral failuregsk annual report research development continue immunologyrespiratory year leader medicine eosinophildriven disease associate poor advance management asthma chronic symptom control worsen asthma cause obstructive pulmonary disease copd sell breathing difficulty interfere taste smell product respiratory problem sleep draw expertise science immune system firstinclass monoclonal antibody nucala develop medicine immunemediate condition mepolizumab target interleukin reduce include lupus eosinophilicdriven disease number eosinophil treatment severe eosinophilic asthma inflammatory europe indication eosinophilic disease disease innovative medicine help million include severe eosinophilic asthma sea chronic people immune respiratory condition rhinosinusitis nasal polyps crswnp eosinophilic granulomatosis polyangiitis egpa widen access benlysta systemic hypereosinophilic syndrome lupus erythematosus sle include lupus nucala approve japan europe nephritis prefille syringe yearold sea sle chronic autoimmune disease immune prefille syringe allow healthcare professional system mistakenly attack healthy tissue part caregiver administer nucala home previously body cause symptom like swollen joint fever hair child receive medicine hospital loss facial rash potential longterm physician office prefille syrinx available complication include irreversible damage vital organ adult strength like heart kidney sle affect million people worldwide kidney inflammation caused continue develop new monoclonal antibody lupus progress kidney failure leave untreated depemokimab development high affinity approximately patient sle develop longacte suppression function current inhibitor dose week week innovative research role cell depemokimab design administer autoimmune condition lead development benlysta month mean potential belimumab biologic approve sle biologic deliver ultralongacte treatment patient benlysta monoclonal antibody target sea begin phase iii trial blymphocyte stimulator bly underlying cause sle depemokimab crswnp egpa follow reduce autoantibody level help treat initiation trial sea shortterm symptom inflammation prevent irreversible damage vital organ receive otilimab approval china benlysta treat adult active datum contrast programme examine otilimab receive fda approval benlysta potential treatment rheumatoid arthritis show paediatric patient active follow early limited efficacy support suitable benefitrisk approval adult treatment market include profile result decide progress member state japan brazil regulatory submission ambition improve outcome lupus patient treat target approach aim remission clinical advance reduce disease activity move antibody phase phase anti ccl novel anticytokine antibody pain innovate treat eosinophildriven disease osteoarthritis diabetic peripheral neuropathy eosinophildriven disease associate heighten represent novel nonopioid nonnsaid analgesic level eosinophil type white blood cell increase therapy antiil novel anticytokine antibody level eosinophil blood tissue cause atopic dermatitis identify use range symptom variety condition human genetic human translational study eosinophil infiltrate certain tissue cause inflammation organ damage time affect patient daytoday life gsk annual report strategic report governance remuneration financial statement investor information research development continue oncology cancer remain lead cause death unmet late phase perla study compare jemperli patient need emerge portfolio oncology plus chemotherapy pembrolizumab plus chemotherapy develop programme science metastatic nonsquamous nonsmallcell lung cancer immune system human genetic new technology return positive datum result support ambition jemperli backbone immunooncology oncology balanced pragmatic approach programme combine standard investment research area immunooncology care novel cancer therapy especially patient tumour celltargete therapy synthetic lethality limited treatment option investigational medicine oncology pipeline potential meaningful difference phase iii costar trial study jemperli patient cancer combination cobolimab investigational selective antitim monoclonal antibody chemotherapy grow oncology pipeline target patient advance nonsmallcell lung cancer business development acquisition collaboration progress antipdl therapy acquire sierra oncology biopharmaceutical chemotherapy combination potential company focus therapie rare form blood kind cancer myelofibrosis enter exclusive global licence option agreement mersana axis range herexpressing tumour breast gastric nonsmallcell lung cancer expand work focus immunooncology aim help global nonexclusive licence collaboration agreement immune system recognise kill cancer cell springwork therapeutic multiple myeloma effectively investigate jemperli expand exist collaboration combination novel asset target precision medicine partner tempus initial focus axis support antitumour activity oncology company access antibodie target checkpoint axis include positive readout jemperli pvrig tigit execute comprehensive colorectal cancer common form cancer development plan combine investigational million new case explore antibodie jemperli doublet triplet immunotherapy treatment curative intent therapy addition early phase trial jemperli dostarlimab subset rectal cancer asco underway phase platform study firstline non breakthrough finding present publish smallcell lung cancer begin dose patient initial new england journal medicine researcher combination jemperli tigit antibody partner memorial sloan kettere cancer center msk confirm iteo therapeutic clinical complete response patient receive treatment jemperli neoadjuvant treatment gynaecologic breast cancer mismatch repairdeficient locally advanced rectal cancer nearly million woman world february fda oncologic drug advisory diagnose gynaecologic cancer committee odac vote propose singlearm trial sufficient characterise continue explore potential exist benefit risk jemperli curativeintent set treatment advance standard care hardto patient mismatch repairdeficientmicrosatellite treat gynaecologic cancer combination instabilityhigh locally advanced rectal cancer agent secondline endometrial cancer fda grant approval jemperli february treatment adult patient mismatch repairdeficient dmmr recurrent advanced endometrial cancer determine fdaapprove test progress follow prior platinumcontaine regiman set candidate curative surgery radiationgsk annual report research development continue december announce positive headline result multiple myeloma world common blood plan interim analysis ruby cancer people develop phase iii trial investigate jemperli combination year blenrep belantamab mafodotin patient chemotherapy frontline treatment advance relapse refractory multiple myeloma receive recurrent endometrial cancer show statistically therapy significant clinically meaningful progressionfree blenrep approve europe hong kong survival pfs benefit prespecifie dmmrmsih dreamm trial investigate potential early line patient subgroup overall population treatment standard novel therapy ruby study assess jemperli combination explore dose scheduling modification zejula set initial result anticipate second half trial evaluating november announce withdraw combination potential new firstline maintenance blenrep market follow request therapy ovarian cancer result expect fda request base outcome second half dreamm confirmatory trial meet requirement fda accelerate approval regulation phase iii trial zest explore efficacy safety trial dreamm clinical trial programme zejula niraparib earlystage treatment breast continue design demonstrate benefit cancer trial use circulate tumour dna technology blenrep combination novel therapy standard time pivotal breast cancer study offer ofcare treatment early line therapy dose potential detect tumour cell early molecular optimisation maintain efficacy reduce corneal level identify woman high risk recurrence event anticipate datum dreamm mean therapy zejula start burden dreamm phase iii trial second half disease low create opportunity slow stop cancer progress effectively early science collaboration announce exclusive global licence option investigate zejula lung cancer agreement codevelop commercialise mersana evaluate zejula phase iii zeal lung cancer therapeutic xmt immunosynthen antibodydrug trial investigate zejula firstline maintenance conjugate target novel epitope therapy patient advance nonsmallcell lung design activate innate immune system cancer squamous nonsquamous histology ste signal immune cell tumour tumour receive platinumbase chemotherapy trial cell mersana initiate phase clinical study efficacy safety zejula combination trial xmt investigate potential range standard care treatment herexpressing tumour breast gastric colorectal nonsmallcell lung cancer fda blood cancer grant orphan drug designation xmt myelofibrosis rare blood cancer affect treatment gastric cancer patient additionally enhance tumourcell target anaemia diagnose develop eventually portfolio enter agreement wuxi patient need transfusion stop biologic exclusive licence treatment anaemia multispecific tcell engage tce antibodie develop momelotinib address significant medical need wuxi biologic proprietary technology platform myelofibrosis patient anaemia reduce deal allow access potential bestinclass tce dependence transfusion treat antibody optimise effective tumor symptom disease enlarge spleen kill desirable safety profile new drug application marketing authorisation application momelotinib currently review fda ema respectively momelotinib currently approve market anticipate launch request fda late restrict secondline ovarian cancer maintenance indication zejula patient population deleterious suspect deleterious germline brca mutation gbrcamut gsk annual report strategic report governance remuneration financial statement investor information research development continue opportunity drive portfolio therapy area pursue progressing new treatment opportunity emerge science indicate cholestatic pruritus primary biliary cholangitis potential important new opportunity linerixibat ileal bile acid transporter ibat inhibitor major impact address unmet need potentially treat cholestatic pruritus patient primary biliary cholangitis pbc rare autoimmune transform treatment anaemia liver disease affect approximately daprodustat people significant number pbc patient suffer million people suffer chronic kidney disease cholestatic pruritus debilitate itch ckd worldwide estimate seven new pharmacologic therapy area year anaemia treatment option limit development programme demonstrate leave untreated undertreated anaemia ckd digital technology modernise drug development associate poor clinical outcome lead novel platform run study potential substantial burden patient healthcare system increase trial diversity example new daprodustat oral treatment class medicine decentralise clinical trial dct design potential call oral hypoxiainducible factor prolyl hydroxylase improve patient recruitment retention glisten inhibitor hifphis base human genetic phase iii trial linerixibat cholestatic pruritus nobel prizewinne science show cell sense patient pbc emerge trial model adapt oxygen availability daprodustat offer assessment patient occur patient home potentially easy oral treatment current injection improve accessibility patient live near base standard care manage haemoglobin specialist expect innovation level effectively approve duvroq japan continue october report fda cardiovascular linerixibat receive orphan drug designation renal drug advisory committee crdac support europe benefit treatment daprodustat outweighs risk adult dialysis patient anaemia ckd vote adult nondialysis patient anaemia ckd crdac support benefit treatment daprodustat outweighs risk vote february fda approve daprodustat jesduvroq treatment anaemia chronic kidney disease adult dialysis march ema validate marketing authorisation application daprodustat currently regulatory review decision anticipate midgsk annual report research development continue pipeline overview asset development latestage phase iiiregistration phase bexsero infant recombinant protein menb recombinant protein difficile skycovione bioscience covid bioconjugate recombinant protein pneumoniae conjugate recombinant protein menabcwy gen recombinant subunit cmv recombinant protein rsv old adult mrna flu gepotidacin bti inhibitor uuti mrna covid bepirovirsen hbv aso hbv bivalent gmma int typhimurium enteritidis tebipenem pivoxil antibacterial carbapenem cuti recombinant protein therapeutic hsv gmma gonorrhoea xevudy sotrovimabvir monoclonal antibody covid bivalent conjugate salmonella typhoid paratyphoid blenrep antibcma adc multiple myeloma mtb inhibitor tuberculosis jemperli antipd endometrial cancer crk inhibitor visceral leishmaniasis zejula parp inhibitor ovarian lung breast cancer proteasome inhibitor visceral leishmaniasis momelotinib jak jak acvr inhibitor myelofibrosis falciparum cell inhibitor malaria cobolimab antitim nsclc fimh antagonist uuti latozinemab antisortilin frontotemporal pik inhibitor viral copd exacerbation dementia vir monoclonal antibody covid depemokimab anti asthma papd inhibitor hbv nucala antiil copd tlr agonist hbv maturation inhibitor hiv daprodustat hifphi anaemia chronic kidney disease cabotegravir mgml formulation hiv linerixibat ibat inhibitor cholestatic pruritus primary capsid protein inhibitor hiv biliary cholangitis capsid protein inhibitor hiv phase integrase inhibitor hiv recombinant protein malaria fractional dose sting agonist cancer live attenuate mmrv new strain antilag cancer gmma shigella anticd cancer viral vector recombinant protein antipvrig cancer therapeutic hbv xmt sting agonist adc cancer wholly own conjugate recombinant protein menabcwy mersana therapeutic gen antisortilin neurodegenerative disease live attenuate varicella new strain anticcl osteoarthritis pain map pneumococcal valent paediatric antiil atopic dermatitis map pneumococcal valent adult antiil multiple sclerosis proteinadiuvant hpv dnmt inhibitor sickle cell disease leucyl trna inhibitor tuberculosis advanced indication show asset sanfetrinem cilexetil serine beta lactamase inhibitor inlicence alliance relationship party tuberculosis additional indication candidate investigation bvlgsk ethionamide booster tuberculosis adjuvante gsk contribute pandemic adjuvant vir neutralise monoclonal antibody influenza gsk exclusive option codevelop post phase maturation inhibitor hiv phase iii study transition activity underway enable progression partner broadly neutralise antibody hiv imminent study start phase iii trial patient progranulin gene mutation antitigit cancer phase iii study start expect benlysta antibly systemic sclerosis associate gsk exclusive global license option codevelop commercialise candidate interstitial lung disease fda approve february hsdb sirna nonalcoholic steatohepatitis progress phase iii menb meningitis rsv respiratory syncytial virus uuti uncomplicated urinary tract infection urogenital gonorrhoea hbv hepatitis virus cuti complicated urinary tract infection adc antibody drug conjugate nsclc nonsmall cell lung cancer longacting copd chronic obstructive pulmonary disease mmrv measle mump rubella varicella hsv herpe simplex virus sirna small interfere rna hpv human papillomavirus maps multiple antigen presenting system cmv cytomegalovirus gmma generalise module membrane antigen int invasive nontyphoidal salmonella aso antisense oligonucleotide gsk annual report commercial operation performance vaccine broad vaccine portfolio target infectious disease stage life help protect people meningitis shingles flu polio herpe zoster virus shingle strategic report governance remuneration financial statement investor information gsk annual report performance vaccine turnover key product product disease total revenue key information shingrix herpe zoster aer record sale year launch shingles cer market aer cer bexsero meningitis aer approve france national group cer immunisation programme available market fluarix flulaval seasonal aer joint market sanofi influenza cer enable vaccination begin july boostrix diphtheria aer approval maternal immunisation tetanus acellular cer indication pertussis booster infanrix pediarix diphtheria aer pediarix lead market share tetanus pertussis cer volume polio hepatitis haemophilus influenza type engerix twinrix hepatitis aer travel routine immunisation hepatitis establish havrix cer recover expect shingle rotarix rotavirus aer rotarix fully liquid approve meningitis cer france national immunisation programme influenza menveo meningitis aer menveo fully liquid brazil pandemic group cer synflorix invasive disease aer affinivax acquisition nextgeneration pneumonia acute cer pcv valent great otitis medium priorix priorix measle mumps aer approval priorix support tetra varilrix rubella cer continue expansion establish chickenpox portfolio cervarix human papilloma aer china approval twodose schedule virus cer sale performance meningitis vaccine sale grow aer cer million mainly drive bexsero aer achieve strong growth vaccine drive cer million result high cdc demand record sale shingle vaccine continue increase share menveo sale geographic expansion meningitis vaccine aer cer million primarily drive vaccine turnover million aer postpandemic vaccination catchup high public cer total aer cer exclude demand international favourable pricing pandemic adjuvant sale performance reflect mix share gain favourable comparator impact covid fluarixflulaval sale grow aer decrease relate disruption market primarily cer million primarily drive low post strong commercial execution shingrix particularly pandemic demand europe partly offset europe lower expect return shingrix sale grow aer cer establish vaccine grow aer stable cer million region grow significantly reflect post million mainly result supply constraint pandemic rebound strong uptake new market mmrv vaccine low tender demand international launch half growth contribute synflorix offset hepatitis vaccine demand outside shingrix grow aer rebound europe boostrix postpandemic cer million high nonretail demand recovery increase share retail demand strong commercial execution germany china contribute strongly shingrix growth shingrix launch market available country gsk annual report strategic report governance remuneration financial statement investor information performance vaccine continue pandemic vaccine decrease aer cer primarily establish platform technology new reflect comparison pandemic adjuvant sale platform build map mrna canadian government partly offset gsk technology key vaccine growth strategy share contract european volume relate enable tackle complex disease covid booster vaccine develop birth adulthood collaboration sanofi pasteur sanofi driver growth portfolio record annual sale shingrix drive strong strategy growth demand exist market geographic expansion vaccine play critical role growth aim shingrix continue recommend adult reach billion people vaccine significant atrisk group country world drive contribution overall ambition positively impact uptake aim launch market health billion people achieve vaccine market value growth exist adult paediatric vaccine new launch focus accelerate vaccine continue strengthen leadership position pipeline particularly rsv menabcwy ensure meningitis vaccine aim double sale manufacturing capability capacity rsv shingrix continued market share growth geographic establish portfolio enter new market expansion bexsero anticipate launch prioritise target business development pentavalent vaccine year france approve complement exist vaccine portfolio give bexsero national immunisation programme access new patient launch bexsero taiwan receive marketing authorisation south korea make bexsero available vaccine complex highly technical develop total country manufacture establish generic industry generally face remain committed grow establish portfolio socalle patent cliff long lifecycle mean represent half total vaccine business vaccine remain use decade initial continue seek expand availability authorisation example boostrix infanrix priorix vaccine market world lifecycle engerix patent remain important management strategy strengthen presence part portfolio term contribution example priorix measle mump performance importantly vaccine rubella vaccine protect people worldwide strong efficacy profile portfolio sale year launch year underscore efficacy level help protect remain important establish portfolio portfolio potential disruption new receive fda approval fully liquid technology formulation rotarix rotavirus vaccine menveo meningitis acwy vaccine receive portfolio market vaccine fda approval vaccine give pregnancy boostrix industry broadest help protect people maternal administer trimester life disease include meningitis help prevent whooping cough young baby shingles flu polio measle deliver half million dose vaccine day world child receive gsk vaccine year benefit vaccination health individual vaccination programme help minimise health inequity reduce cost healthcare system potentially promote economic growth societal wellbeing acquisition affinivax approval future launch rsv vaccine old adult position adult vaccination segment key growth driver global vaccine marketgsk annual report performance vaccine continue meeting need healthcare professional strengthen manufacturing network patient hcps support vaccine growth age immune system start manufacture site country decline effective lead increase produce deliver million vaccine dose vulnerability infectious disease give despite supply challenge incoming material focus effort helping old adult healthy shipping impact cause covid global want improve physicianpatient dialogue economic environment conflict ukraine vaccination raise awareness adult vaccine site routinely inspect multiple regulatory preventable disease increase access vaccination agency inspection health physician office authority manufacturing site vaccine study report explore attitude prepare manufacturing supply belief hcp year vaccination capability support inline product growth study show hcp patient number source pipeline product pende approval include information vaccine hcp meet rsv vaccine old adult rsv production patient need lack time want avoid facility wavre belgium produce dose conflict information training market success rate ready demand ease pressure hcp start announce million investment second digital channel partnership nextdoor manufacturing facility rsv antigen production provide vaccination information directly patient belgium belgium invest capacity launch consumer campaign lyophilise product build internal mrna importance vaccination work directly capability follow acquisition affinivax hcp series vaccinology master class add map production technology platform help well equip conversation capability singapore site new patient vaccine investment gsk binney street cambridge boston research company iqvia launch overall focused increase control vaccine track datum platform help improve adult robustness supply chain good example vaccination nationwide platform give hcp manufacture key adjuvant information uptake recommend adult bring production mpl component immunisation datum hcp target effort inhouse hamilton formulate increase discussion vaccination improve batch adjuvant belgium current coverage area show relative decline future key asset shingrix mosquirix rsv immunisation candidate vaccine old adult work expert group adult vaccination year invest modernise digitise calendar hcp patient automate manufacture network example vaccine eligible quality control laboratory site go completely paperless transition launch firstever shingle awareness week production line site electronic batch record international federation ageing reach build digital capability well million people globally campaign remain operational efficiency compliance yield shorter important way increase awareness vaccine lead time preventable disease prompt patient seek hcp guidance step include preventative option globally government policymaker healthcare provider recognise potential advantage increase access vaccination additional channel vaccination centre retail pharmacy work pharmacy chain provide information patient consider vaccination option gsk annual report continue global leader hiv medicine focus pioneer treatment immunemediate condition respiratory disease emerge portfolio cancer medicine hiv virus strategic report governance remuneration financial statement investor information commercial operation performance specialty medicine gsk annual report performance specialty medicine turnover key market product product disease total revenue key information xevudy covid monoclonal antibody treatment deliver aer cer treatment aer cer million dose country approval triumeq hiv treatment aer dolutegravirbase fix dose combination cer tablet market country nucala respiratory aer treatment indicate eosinophildriven cer europe use eosinophil disease drive disease tivicay hiv treatment flat aer dolutegravir tablet use combination cer antiretroviral agent market country dovato hiv treatment aer dolutegravir base twodrug regimen cer launch market benlysta lupus lupus aer biologic approve treat sle nephritis cer europe hiv juluca hiv treatment aer dolutegravir base twodrug regimen mmunoinflammation cer market country respiratory zejula ovarian cancer aer parp inhibitor commercially available cer maintenance markets pandemic maintenance market oncology cabenuva hiv treatment aer complete longacting vocabria cer injectable regimen cabotegravir rilpivirine rekamby launch country europe japan blenrep blood cancer aer antibodydrug conjugate commercially multiple myeloma cer available country patient relapse refractory multiple myeloma rukobia hiv treatment aer extendedrelease tablet people live cer multidrug resistant hiv use combination antiretroviral approve canada europe apretude hiv prevention longacte injectable cabotegravir hiv prevention launch jemperli endometrial aer pdblocking antibody available cancer cer country continue investigate future monotherapy combination regimen multiple tumour type sale performance new hiv product deliver sale billion million aer cer represent specialty medicine sale million total hiv portfolio compare year aer cer drive consistent doubledigit growth growth primarily drive sale dovato therapy area specialty medicine exclude sale cabenuva dovato record sale million xevudy million aer cer aer cer cabenuva record sale hiv sale million growth aer million apretude deliver sale million cer performance benefit strong immunoinflammation respiratory sale patient demand new hiv medicine dovato million aer cer strong cabenuva juluca rukobia apretude performance benlysta nucala benlysta sale contribute approximately quarter growth million aer cer represent price favourability yearend inventory build strong underlying demand worldwide nucala contribute growth sale million aer cer partially offset international tender decline reflect continue strong patient demand launch additional indication gsk annual report strategic report governance remuneration financial statement investor information performance specialty medicine continue oncology sale million aer immunologyrespiratory continue strong cer zejula sale million aer demand benlysta nucala cer drive firstline indication diagnosis benlysta systemic lupus erythematosus lupus treatment rate continue impact nephritis adult child continue perform pandemic especially sale blenrep strongly patient initiate therapy million grow aer cer include chinas biologic medicine impact withdrawal market kind help patient sale xevudy million compare focus support early identification great million sale sale deliver region urgency treat patient lupus progress comprise million million europe organ damage occur million international nucala target biologic therapy approve use eosinophilic disease continue strategy growth driver growth expand access nucala portfolio specialty medicine focus approval europe japan therapeutic area infectious disease hiv immunology syringe use home child follow early respiratory oncology leader infectious approval athome use adult evidence disease hiv innovation build nucala continues grow share position immunology oncology twoyear datum realitia realworld study year expect specialty medicine hiv nucala patient severe eosinophilic asthma specialty continue important growth demonstrate inhibition everyday practice increase convergence disease prevention help achieve treatment goal pioneer treatment expertise vaccine medicine work inhibition continue research mean uniquely place focus connection depemokimab monoclonal antibody specifically treatment prevention engineer increase affinity long duration action allow long period time accelerate pipeline injection prioritise strategic business development oncology zejula monotherapy parp inhibitor complement exist portfolio acquisition approve firstline therapy newly diagnose patient sierra oncology global licence agreement advance ovarian cancer regardless biomarker mersana therapeutic group patient represent significant area driver growth portfolio growth healthcare provider parps hiv strategy growth future firstline set covid see number build innovative portfolio medicine patient present doctor ovarian cancer transform hiv treatment prevention landscape symptom decline volume newly diagnose ovarian cancer patient precovid launch dolutegravirbase twodrug monthly average expect number increase regimen dovato continue build positive momentum patient return normal health practice benefit people live hiv globally work develop combination therapy deliver million revenue zejula longacte therapy central growth deliver result launch daprodustat treatment anaemia chronic kidney market disease marketleade prefer hifphi japan available duvroq february launch longacte treatment daprodustat approve jesduvroq regimen cabenuva know vocabria rekamby adult dialysis seek approval europe markets noninferior daily antiviral expect decision mid therapy dose month cabenuva address challenge associate daily oral covid treatment xevudy develop vir therapy stigma adherence daily pill fatigue biotechnology continue play important role january launch apretude pandemic response vulnerable patient date longacte medicine hiv prevention offering deliver million dose superior efficacy daily oral prevention ftctdf country generate billion sale tablet twomonthly dose launch support directtoconsumer campaign innovative communitydriven intervention focus reach key population benefit preventative option estimate longacting regimen cabenuva apretude generate billion sale represent hiv net salesgsk annual report performance specialty medicine continue build commercial capability use digital data analytic extend drive medical affair effectiveness advanced analytic deliver growth portfolio continue text mining produce medical insight allow focus discipline commercial medical execution highquality scientific engagement expert capability enhancement competitive resourcing improve patient outcome continue prioritise use customerface activity rigorous investment omnichannel communication platform medical affair allocation engage hcp late scientific advance attain keep lead position market mean attract retain good people manage global supply chain industry focus develop leader internally supply chain global network enable recruit specific marketing commercial expert produce deliver billion pack outside business streamline network small agile year senior commercial leadership resilient capacity capability bring appointment specialty medicine internal generation medicine patient globe recruit senior people externally drive growth amid geopolitical uncertainty focus oncology supplement specialty global marketing availability energy commodity manage capability market constraint freight resource need focus strengthen sale execution supply medicine patient despite challenge capability market appoint general programme productivity efficiency improvement manager bring fresh leadership remain track year deliver million position saving programme take cumulative total million target programme maintain strong link healthcare deliver million saving saving professional patient support improvement gross margin connect hcp patient help meet site manufacture medicine gsk need help inform clinical network overall site productivity increase data product pipeline upcoming launch year year year effectively interact well understand science product benefit well strengthen manufacture base use modern manufacturing facility help launch specialty scale use datale omnichannel medicine quickly build strengthen communication platform reach patient faceto market position performance face digitally date digitally enable june open new manufacturing facility brand campaign market double barnard castle sustainably design effort compare year result paperless fully automate robotic aseptic incremental growth market share fill technology increase efficiency facility manufacture exist new biopharmaceutical asset pipeline gsk annual report strategic report governance remuneration financial statement investor information performance specialty medicine continue open expand facility upper merion support innovation ambition pennsylvania advanced specialty medicine supply chain continue support singleuse facility manufacture bulk drug innovation strategy deliver launch product substance able manufacture wide range therapy area region worldwide make biopharmaceutical pipeline asset include monoclonal internal external network flexible enable antibodie expand facility rockville maryland ontime launch upcoming medicine target start manufacture facility work invest rapid knowledge transfer combine singleuse system largescale stainless steel chemistry manufacturing control project team manufacture automation produce lupus manufacturing site treatment benlysta investment million increase capacity rockville follow successfully manage rapid launch covid therapeutic xevudy sotrovimab end invest million new oral solid million dose xevudy supply dose facility ware help deliver new globally prepare successful launch product pace partnership product supply latestage asset like daprodustat performance qualification set batch momelotinib approve specialty medicine confirm commercial manufacturing process perform supply chain support multiple latestage clinical expect start second half programme upcoming launch second streamline supply chain help control cost half allocate capital develop launch details general medicine supply chain marketing medicine include invest aiml help optimise yield inventory ontime infull otif delivery maintain consistent reliable supply reliable highquality supply product essential meet patient need maintain performance routinely update quality management system qms pace evolve regulatory environment new scientific understanding product process policy procedure simple understand implement improve deviation rate reliability supply remain strong otif measure supply chain specialty medicine information product governance data recall regulatory inspection audits page gsk annual report commercial operation performance general medicine antibiotic inhale medicine asthma copd general medicine product leader class make life well million people worldwide escherichia coli coli bacteria gsk annual report strategic report governance remuneration financial statement investor information performance general medicine turnover key market product product disease total revenue key information trelegy ellipta copd asthma aer prescribe single inhal triple therapy aer cer cer worldwide reach estimate million patient launch seretideadvair asthma copd aer marketleading icslaba cer treatment worldwide relvarbreo asthma copd aer lead icslaba treatment ellipta cer worldwide power hour sustain efficacy convenience ellipta inhaler device ventolin asthma copd aer global marketleading saba reliever cer augmentin common bacterial aer global leader oral antibiotic available infection cer country lamictal epilepsy bipolar aer brand sale value global disorder cer lamotrigine market respiratory anoro ellipta copd aer global market leader lamalaba general medicine cer class approve country avodart benign prostatic aer market leader sale value global duodart hyperplasia bph cer dutasteride dutasteridetamsulosin fdc market respectively approve country avamys allergic rhinitis aer global leader inhale corticosteroid veramyst cer prescription class dermovate inflammatory aer global leader topical corticosteroid betnovate skin condition cer market globally cutivate eumovate labalama longacte beta agonistslongacte muscarinic antagonist icslaba inhale corticosteroidlongacte beta agonist saba shortacte beta agonist fdc fix dose combination key information source iqvia sale performance partially offset ongoing adverse impact generic competition approximately percentage general medicine sale year million point impact aer cer divestment aer cer impact generic cephalosporin product competition europe japan offset trelegy growth respiratory postpandemic rebound antibiotic market general strategy impact medicine general medicine portfolio encompass primary care medicine prelaunch asset growth respiratory sale million aer establish product general medicine cer performance drive trelegy sale contribute gsk sale help fuel million aer cer include strong growth investment growth region advairseretide sale million decrease aer cer predominantly combination product reflect adverse impact generic competition market leader expect impact live growth certain international market target million patient year product promotion offset decrease supply country worldwide deliver total medicine supply volume general medicine sale million day medicine improve health life decrease aer cer augmentin sale well million people world million aer cer reflect postpandemic rebound antibiotic market international europe regionsgsk annual report performance general medicine continue expect growth trelegy anoro establish maximise commercial capability product portfolio emerge market successful target investment strategy deliver return gepotidacin tebipenem commit back large opportunity brand positively impact life day geographic maximise launch new medicine continue focus maximise investment indication parallel target investment growth brand new opportunity manage appropriately optimise return mature brand expect decline product mature market broad range opportunity risk lose exclusivity decline establish continue invest omnichannel digital customer product manage target investment engagement digital play important role growth opportunity reflect continue strong connect customer especially important demand core product general medicine give expansive global footprint datadriven customer experience ddcx programme driver growth portfolio trelegy recognise externally international main source growth general medicine customer experience awards icxa sector trelegy anoro augmentin company initiative enter trelegy single inhaler tripletherapy asthma silver award trelegy compete copd continue accelerate strongly growth industry follow category region include big growth good businesstobusiness customer experience strategy driver exclude xevudy gsk portfolio year trelegy prescribe country business change transformation dual indication key market new approval customer experience team year receive expand trelegys availability asthma patient argentina taiwan new zealand maintain efficient supply chain oman bahrain south korea kuwait copd demand product general medicine patient kuwait indonesia portfolio increase significantly covid lockdown lift global market recover effect trelegy lead market share large market pandemic increase pack supply billion japan market share significantly exceed billion growth demonstrate large competitor competitive market resilience general medicine brand anticipate position trelegy strengthen network increase billion metaanalysis triple therapy class demonstrate differentiation copd singleinhaler triple supply chain lean continue simplify therapy continue expect trelegy key driver portfolio standardise packaging format growth general medicine come year discontinue product end general medicine reduce number brand anoro approve approximately country portfolio plan treatment symptomatic copd anoro remain global discontinue nonpriority brand market leader lamalaba class continue growth global sale exus anoro robust clinical take key decision focus datum profile include headtohead datum productivity efficiency example outsource lamalaba class versus common initial manufacture amoxicillin maintenance therapy option lama rigorously benchmark performance general augmentin global leader oral antibiotic medicine supply chain competition available country reach billion thoughtful choice optimise cost patient launch year ago continue cash footprint portfolio grow strongly emerge market augmentin grow aer cer million recovery key emerge global supply chain cover specialty medicine page market europe recover strong competitor postpandemic today augmentin recognise impact recently bronze good pharmaceutical product category prix galien golden jubilee awards october important product latestage pipeline anticipate future growth driver general medicine include gepotidacin uutis urogenital gonorrhoea tebipenem hbr latestage antibiotic license exclusively spero therapeutic treat cutis page gsk annual report responsible business approach esg integral strategy investment case help build trust create value shareholder society ahead disease ssstttrrraaattteeegggiiiccc rrreeepppooorrrttt governance remuneration financial statement investor informationgsk annual report responsible business responsible business mean get ahead metric develop stakeholder input disease right way need understand key issue industry consider esg impact company commit ensure esg lab patient esg embed performance rating respond stakeholder expectation strategy support sustainable performance continue review metric business longterm growth help build trust deliver external expectation change return stakeholder reduce risk operation create esg performance rating management deliver positive social impact seek metric esg focus area define ensure standardised approach deliver purpose embed esg identify esg focus consistently future year area address material business ambitious achievable issue matter stakeholder focus externally assure area core strategy area meaningful stakeholder great positive impact society urgent challenge focus area assess performance access healthcare glt accountable deliver progress global health health security metric regularly review performance environment board corporate responsibility committee crc individual metric assess track metric meet diversity equity inclusion exceed track work ethical standard metric achieve track metric miss product governance approach guide extensive stakeholder addition order calculate overall esg engagement key issue relevant industry performance rating performance metric company result recent materiality aggregate single score illustrate assessment reaffirm material issue track track work track rating business align esg focus area define aware responsible business static requirement operating environment track metric track continue change pace continue adapt track work metric respond proactively change approach ensure track track work gsk continue deliver strong esg performance track metric track esg performance rating esg performance rating support integration esg strategy delivery esg performance rating track base esg performance measurable verifiable performance metric meet exceed introduce new esg performance rating rate corporate kpis measure progress assessment performance annual target key metric align focus area review overall esg performance include metric cover rating score externally assure performance section report external benchmarking detailed perform key esg rating ftsegood member ftsegood index frequently ask investor cdp climate change water security access medicine rank access forest palm oil forest timber medicine index industry leader sustainalytic low risk rating antimicrobial resistance benchmark msci rating corporate sustainability assessment rank moody esg solution rank pharmaceutical industry score pharmaceutical sector february include djsi world europe index iss corporate rating rating detail progress focus area late materiality assessment esg performance rating metric esg performance report gsk annual report strategic report governance remuneration financial statement investor information responsible business continue access ambition positively impact health billion vaccine people end achieve partner gavi foundation develop vaccine medicine make reserve low vaccine price gavi available responsible pricing strategic access similar organisation pass milestone programme partnership supply gavi billion vaccine commitment partnership include supply cervarix critical product available valuebase price vaccine low income country address cervical sustainable business implement access cancer supply million dose strategy increase use medicine pneumococcal vaccine synflorix gavieligible vaccine treat protect underserved people country low price rotarix vaccine rotavirus reach child gavieligible country assess performance gavi country march develop externally publish pricing access synflorix offer rotarix principle humanitarian mechanism civil society organisation progress goal reach billion serve refugee work emergency situation people low income country product longstanding supplier oral polio vaccine opv unicef supply progress million dose help eradicate polio put right value innovation neglect tropical disease follow set pricing access principle publish donate million dose albendazole time help balance medicine help eliminate lymphatic filariasis right responsible pricing sustainable treat soiltransmitted helminth extend profitable business allow reinvest financial soiltransmitte helminth commitment include pre return future innovation ensure people school child additional commitment access medicine vaccine donate albendazole treatment echinococcosis gsk viiv healthcare patient hiv assistance program foundation provide prescribe viiv healthcare medicine patent pool medicine vaccine lowincome mpp sign new voluntary licensing agreement allow uninsured underinsured medicare patient generic manufacturer develop manufacture supply year combine average net cabotegravir longacte hiv preexposure prophylaxis price discount rebate allowance viiv healthcare voluntary licensing agreement pharmaceutical vaccine portfolio increase generic manufacturer produce sell lowcost average list price increase compare single fixeddose combination product contain list industry demonstrate hiv medicine dolutegravir adult low middle responsible pricing decision past income country direct licence year average net price product decrease mpp similar agreement generic annually average list price rise manufacturers child cover country compare list industry result voluntary licence agreement reach patient low income country million people live hiv country goal reach billion people low income access generic product contain dolutegravir country product end end people live hiv access initiative voluntary licensing donation antiretroviral low middleincome country work gavi vaccine alliance viiv healthcare donate pack reach million people product supply antiretroviral medicine ngo partner national hiv additional million dose albendazole aid programme support people live hiv rank access medicine index eighth impact conflict ukraine viiv consecutive time provide positive action programme support communitybase organisation industry average source drug channel annual brandname humanitarian response activity ukraine drug list change report surround country host refugee million figure include people reach synflorix rotarix cervarix opv mosquirix vaccine people access generic dolutegravir product voluntary licensing agreement include people reach albendazole assessment gskgsk annual report responsible business continue positive action viiv healthcare community grantgiving prerequisite agencies procure programme celebrate anniversary vaccine important step roll country yearlong campaign showcase people heart moderate high falciparum malaria transmission programme partner implementation gsk path bharat biotech agree product progress collaboration invest transfer help ensure longterm supply rtss million reach approximately malaria vaccine commit supply people provide grant country million dose year addition malaria donation million dose whocoordinate work partner million child malaria vaccine implementation programme ghana africa receive dose malaria kenya malawi vaccine mosquirix rtssa september detail progress focus area award prequalification vaccine esg performance report global health health security use expertise address big health march australian regulator therapeutic challenge underserve people world good administration approve use singledose medicine tafenoquine child aged commitment combination chloroquine radical cure vivax malaria develop novel product technology treat prevent priority disease include pandemic threat fda approve triumeq dispersible single tablet formulation contain dolutegravir child assess performance weigh increase age progress global health pipeline asset address appropriate treatment option child live hiv priority disease end chmp ema issue positive opinion recommend marketing authorisation progress triumeq child global health invasive nontyphoidal salmonella disease life june gsk include viiv healthcare announce threaten children africa key driver billion investment help ahead amr innovative vaccine technology infectious disease low income country year partnership university oxford vaccint investment support new medicine vaccine develop potential candidate vaccine prevent treat tuberculosis malaria hiv enteric generalise module membrane antigen technology disease neglect tropical disease reduce help support global december amr progress global health pipeline announce fourth proposal asset address priority disease include malaria africa open lab proposal aim african exceed target earlycareer scientist base subsaharan want discover shorter simple safe treatment africa focus infectious disease alongside partner public disproportionately affect subsaharan population private research consortium continue progress malaria neglect tropical disease pipeline novel medicine announce get ahead antimicrobial resistance positive phase iia study result gsk new project medicine firstinclass candidate medicine patient vaccine relevant amr range early result study demonstrate potential latestage development include gepotidacin candidate component simple treatment novel oral antibiotic treatment regimen future uncomplicated urinary tract infection year partnership bioversys university lille announce exclusive licence agreement innovative medicine initiative imi project trictb spero therapeutic tebipenem hbr latestage successfully complete phase trial bvlgsk antibiotic treat complicated urinary tract potential help tackle drug resistance infection project target pathogen deem boost activity exist antibiotic critical urgent cdc pipeline partner bring product prevention treatment malaria market world vaccine malaria singledose radical cure vivax malaria gsk annual report strategic report governance remuneration financial statement investor information responsible business continue surveillance central tackle amr share declaration state sector willingness reserve datum longrunne survey antibiotic resistance allocation realtime production medicine soar study track communityacquire respiratory vaccine distribution priority population infection new amr register develop vivli determine health authority future pandemic work amr industry alliance gsk conclude series contract publish new antibiotic manufacturing standard provide million dose pandemic provide clear guidance manufacturers global influenza vaccine government world antibiotic supply chain help ensure antibiotic responsibly compliance scientifically february extend pandemic influenza robust discharge limit vaccine stockpile contract united states government follow renew agreement detail progress focus area esg performance report june supply pandemic influenza vaccine july contract government future pandemic preparedness canada seasonal pandemic influenza vaccine july gsk major biopharmaceutical sign agreement europe reservation company sign berlin declaration set future production supply pandemic influenza industry vision equitable access future vaccine continue partner barda pandemic manufacture assess safety immunogenicity pandemic influenza vaccine candidate environment continue work hard protect waste material environment partnership set operational waste material reduction site clear measurable target help achieve goal biodiversity number highrisk material implement commitment sustainable source roadmap commit net zero nature positive healthy planet ambitious goal set progress climate assess performance set clear pathway net zero impact follow metric include esg performance climate ambitious goal rate support delivery carbon nature update climate target line new ambition science base target initiative sbti netzero standard climate aim reduce carbon emission operational emission reduction scope scope baseline marketbase emission remain offset investment highquality naturebase solution set long industrialisation green ventolin initiate clinical term target reduce carbon emission nonclinical datum available support regulatory remainder tackle highquality offset submission additional context change page percentage carbon offset volume project pipeline esg performance report water target average percentage gsk site supplier reduction carbon emission investment compliant wastewater active pharmaceutical naturebase solution remain ingredient limit percentage supplier footprint scope compliant amr industry alliance common antibiotic manufacture framework discharge renewable electricity scope limit net zero emission value chain scope target measure baseline previously state net zero new longerterm target align sbti netzero standard definition net zerogsk annual report responsible business continue performance environmental impact reduction product reduce scope carbon emission packaging compare primarily waste reduction supply chain increase use renewable electricity continue positive impact biodiversity site delivery energy efficiency site agricultural forestry marinederive material installation new solar panel upgrade lighting sustainably source deforestation free replace chiller reduce use ozone deplete refrigerant member commit performance source renewable electricity reduce overall water use operation reach increase site high water stress region decrease overall water use site high water stress region baseline follow demerger consumer healthcare achieve overall water use reduction target business restating value chain carbon footprint review site good baseline year latest available water steward line alliance water datum scope emission reduce compare stewardship definition reduction reflect evolution product portfolio initially identify water basin water stress area algeria india pakistan approximately total emission footprint come manufacture site aim water neutral good service buy september manufacturing facility nashik india build launch sustainable procurement programme plant rainwater harvesting require supplier thing disclose emission set carbon reduction target align site supplier switch renewable power heat manufacture antibiotic comply amr alliance industry standard safe discharge work peer energize programme encourage use renewable energy continue reduce waste site pharmaceutical sector supply chain increase material recover supplier form energize buyer cohort circular route like reuse recycling target purchase terawatthour material exist product portfolio renewable electricity progressing plan net positive biodiversity page disclosure climate risk site invest individual site action plan resilience line task force climaterelate improve habitat protect specie improve soil financial disclosure tcfd framework water quality complete baseline biodiversity assessment site commence nature biodiversity uplift project large facility commit work goal complete assessment net positive impact nature reduce biodiversity impact entire value chain environmental impact water waste material take target action address highly biodiversity investing protect stress area restore nature leadup convention biological diversity target critical cop conference canada end achieve good water stewardship site work partner mandatory disclosure business financial institution impact dependencie nature reduce overall water use operation leaf coalition lower emission water neutral operation key accelerate forest finance privatepublic effort supplier waterstresse region protect tropical forest test framework voluntary carbon credit voluntary carbon market zero impact active pharmaceutical ingredient api level integrity initiative work establish globally site key supplier standardise benchmark guide use carbon credit zero operational waste include eliminate singleuse company plastic page plan disclose impact dependencie nature line emerge taskforce naturerelate financial target measure baseline disclosure tnfd framework environment basis report definition zero impact predict effect concentration detail progress focus area esg performance report regulatory obligation allow exclude plastic critical product discovery development health safety gsk annual report strategic report governance remuneration financial statement investor information responsible business continue diversity equity inclusion diversity equity inclusion dei central gsk science summer initiative offer free purpose get ahead disease handson stem learn student traditionally inclusive diverse business business underrepresented group stem career inclusively make successful making resource community reach people potential increase positive impact student nationwide nurture people commitment woman hold vpandabove role globally create diverse equitable inclusive workplace compare woman enhance recruitment diverse patient population employee management role clinical trial support diverse community publish sixth gender pay gap report gender pay gap permanent ukbased gsk assess performance employee mean compare national phase iii trial initiate proactive average publish ethnicity pay plan place design enrol appropriately diverse gap report approach trial participant consistent disease epidemiology gender pay gap ethnicity pay gap permanent performance aspiration fair ukbased gsk employee mean time equitable opportunity national average comparator woman hold vpandabove role country meet criterion datum globally end confidentiality anonymity disclose race ethnically diverse leader role ethnicity people level set aspirational increase target currently meet criterion percentage black african american hispanic ethnically diverse leader latinx vpandabove leader year year level reach aspirational ethnically diverse leader target increase percentage role increase black african american hispanic latinx people percentage black vpandabove leader year role year year year ethnically diverse leader continue improve yearonyear spend certify usbased progress aspirational target diverseowne supplier reach black representation remain flat focus effort progress achieve aspiration yearonyear growth build inclusive business member government disability commit improve diversity clinical trial confident scheme active member enrolment disease insight set valuable pledge group global company diversity enrolment goal end gsk committed place disability inclusion leadership phase iii trial diversity plan place enrol agenda deliver scheme objective group affect disease study base longterm measurable disability confidence epidemiology datum example hepatitis trial plan include educate people issue disease disproportionately affect people african introduce new global minimum standard asian descent participant asian origin week parental leave primary secondary carer actively work improve representation form family new global minimum standard participant african descent care family member end life health supplier diversity programme establish emergency insure benefit include sex partner expansion plan develop possible new financial wellbeing service target increase spend annually certify mental health training available usbase diverseowned supplier significantly year recognise gold employer exceed combination spend stonewall global employer index allyship increase select supplier marketing sale programme receive award recognise tangible technology identification new global diverse impact campaign live lgbt supplier strong multiyear strategy engagement employee achieve human right campaign key advocacy group foundation good place work lgbt equality standard detail progress focus area esg performance reportgsk annual report responsible business continue ethical standard culture guide people right thing uphold commitment human right speak concern important signatory global compact people live expect human right position statement lay commitment supplier guiding principle business human right year establish human right commitment steering group formal reporting mechanism promote ethical behaviour business board corporate responsibility committee support employee right thing work develop guidance enhance supplier visit supplier share standard operate help employee well understand labour human responsible way right noncompliance support guidance develop deliver labour right training assess performance environment health safety ehs procurement employee complementary worker employee well equip spot human right complete gsk mandatory training issue visit supplier percentage employee believe committed application fair equitable speak thing feel right general pay practice include ensure employee industry benchmark globally receive pay competitive local number employee leave gsk employment market sufficient support sustainable standard misconduct month versus threeyear live complete global living wage roll average review partnership fair wage foundation direct highrisk supplier achieve gsk minimum assess pay employee people ecovadis score improvement plan place country difference detect few case country necessary adjustment progress end quarter factor living wage datum standard support gsk people right thing compensation process ensure continue launch new code conduct offer fair wage build annual living wage reflect purpose unite science technology talent review standard cycle ahead disease new code set commitment company work party deliver purpose ambition expect party meet abac labour employee complementary worker right standard comply standard complete accompany global mandatory learning quality health safety environment page curriculum year end information certain highrisk role geographic region update thirdparty risk management tprm complete additional antibribery corruption programme evaluate mitigate risk introduce abac training employee party engage gsk provide good complementary worker complete training service year end approach manage abac risk highrisk party determine risk relate ethical standard form location highrisk market size spend embed risk management framework perform assessment risk area describe detail page assessment present risk reporting investigate concern area party good service year update report breakdown provider distributor wholesaler contract type policy violation provide granularity manufacturer supplier direct material case class see overall decrease supplier use tool assess supplier disciplinary case attribute revision manage risk include ecovadis desktop assessment procedure discipline late completion mandatory training report employee conduct category general industry benchmark accord research kornferry gsk annual report strategic report governance remuneration financial statement investor information responsible business continue visit site person virtually help supplier well privacy ethical use datum global understand control risk relaxation travel mandatory learn curriculum live code restriction allow increase inperson visit people complete ensure key privacy identify reduce risk enable conduct physical personnel certification sufficient training visit priority supplier year complete experience carry role effectively warehouse safety survey priority supplier invest aiml capability example contract manufacturing supplier large warehouse help analyse patient genetic datum mindful hold stock year survey generate machine learning raise ethical issue corrective preventative action plan subject evolve decision policymaker expect complete well promote trust system avoid conduct supplier audits compare unintended outcome harmful impact follow industry standard pharmaceutical oversight board new advisory supply chain initiative guideline corrective panel oversee control manage use preventative action track completion reuse datum respond bioethical question train supplier employee ehs esg research activity fundamental revise ehs contractual obligation track management action completion political engagement help supplier improve ecovadis score major multinational company seek contribute information public policy debate especially relation life science healthcare political engagement datum engagement commit ensure adhere high create new digital privacy information ethical standard legislative requirement security team legal compliance streamline corporate political contribution sponsor support provide expertise gsk digital party political meeting world datum strategy detail progress focus area esg performance report product governance ensure quality safety reliable supply total number class iii external product recall product critical protect patient deliver market health impact register disclose human subject research gsk product specifically register protocol summary commitment study initiate disclose result summary commit maintain robust quality safety study result process datum new technology responsibly progress focus quality management assess performance gsk quality management system detail average number critical major finding specific framework describe comply fdamhraema regulator regulatory requirement standard percentage inspection regulator markets address global local regulation critical finding official action indicate manufacture distribution process base principle define international council number fda warning letter harmonisation technical requirement pharmaceutical human use ehs priority supplier api supplier medically revenuecritical gsk high spend supplier supplier employee train include datum previous consumer healthcare business consider observation fda majorgsk annual report responsible business continue inspection recall audit maintain pharmacovigilance regulatory inspection pharmacovigilance aim protect use manufacturing site local operating company medicine vaccine support public health compare remain prepared programme reliable comprehensive information inspection regulator receive warning letter overall benefitrisk balance product fda critical finding medicine establish rigorous worldwide system monitor healthcare product regulatory agency mhra ema review safety product clinical regulator receive critical finding development regulatory approval chinese regulator continue learn vigilance falsify medicine vaccine respond inspection finding take necessary robust approach handle falsify product action address incident ensure case confirm counterfeit class product recall product report relevant few class iii recall regulatory authority actively participate legal hesitate voluntarily recall product protect patient proceeding illegal actor provide regular training custom local authority monitor online working supplier quality marketplace social medium request takedown expect contract manufacturer supplier site illicitly sell prescriptiononly medicine comply gsk standard regularly conduct audits verify conduct quality commit transparency audits supplier increase focus api supplier commitment protocol summary summary result available comprehensive quality oversight model setup gsk trial register align quality management system use list study datum share wwwvivliorg riskbase approach assess qualify manage wwwclinicalstudydatarequestcom monitor thirdparty supplier drive continuous performance detail progress focus area esg performance report critical find inspection chinese regulator thirdparty manufacturing facility gsk class recall trigger reasonable probability use exposure violative product cause adverse health consequence death class recall address use exposure violative product cause temporary medically reversible adverse health consequence probability adverse health consequence remote class iii recall relate use exposure violative product likely cause adverse health consequence gsk annual report strategic report governance remuneration financial statement investor information risk management board continuously review oversee risk management internal control framework reflect responsible biopharma company bold ambition patient manage risk line longterm assess emerge current risk prioritie risk assessment process consider likelihood embed risk management internal control impact risk timescale risk framework give board ability evaluate occur consider current risk evaluate oversee company manage principal emerge risk affect ability achieve emerge risk line strategy longterm longterm priority risk threeyear horizon priority fullyfocuse biopharma company follow line viability statement define risk year demerger haleon companywide policy emerge need know likely set requirement role responsibility materialise impact management governance risk control evaluate investigate support guidance essential element classify principal risk internal control framework routinely evaluate risk management compliance board level framework improvement organisation identify emerge risk ongoing basis rocc discuss emerge risk meet board oversight risk appetite time scan risk horizon management system year identify external trend opportunitie board oversee risk management system andor emerge risk monitor business activity establish risk appetite support audit risk internal environment committee arc corporate responsibility committee rocc conduct annual risk review assess principal crc science committee assess emerge risk company review effectiveness risk management strategy fall support extensive analysis external trend define remit risk oversight compliance insight seniorlevel interview recommendation council rocc help arc crc science risk management compliance board risk owner committee oversee risk strategy rocc share annual review arc board address alongside risk management assessment form basis follow year compliance board group promote tone risk management focus establish risk culture oversee effectiveness risk management activity enable effective risk management line communicate information internal control culture management hold accountable delivering objective line establish risk appetite define enterprise risk plan include description pertain principal risk enterprise risk owner risk context assessment risk appetite responsible principal risk oversee glt treat risk action business need member risk owner report risk mitigation rocc line internal control framework mitigate risk appropriate board committee quarter legal plan enable board committee assess compliance support effort advise effectiveness risk management strategy business strategy activity risk control audit report risk rocc board committee assurance provide assessment adequacy quarter drive dynamic datadriven discussion effectiveness framework agile risk management strategy oversight report exist control measure implementation emerge risk external insight key risk indicator risk reporting threshold align risk appetite include risk mitigation associate relevant event covid geopolitical tensionsgsk annual report risk management continue code set overarch expectation covid pandemic employee complementary worker risk potential impact covid pandemic gsk management framework complement culture trading performance principal risk continually speak process make sure identify assess appropriate mitigation plan place mitigate risk effectively monitor important asneede basis gsk encourage risk action address issue annual uptake vaccine medicine company confirmation exercise check key risk remain confident underlying demand vaccine manage action place address gap medicine especially give significant number principal risk include control respond problem covid vaccination booster administer risk plan business continuity worldwide pandemic remain dynamic planning embed framework critical ongoing risk continue monitor process continue business operation emergence new variant current rate infection event crisis predominantly drive circulation subvariant descendent lineage current risk dominant subvariant omicron globally covid table start show current principal vaccine update omicron variant risk respective trend assessment mitigation provide broad immunity circulate emerge activity year order significance variant subvariant potential future variant risk definition potential impact context concern potentially impact gsk trading result mitigate activity principal risk uncertaintie clinical trial supply continuity employee materially page separation principal risk remove july follow successful demerger change risk analysis residual risk december annual risk review arc agree risk level principal risk roccs recommendation principal risk opportunity relate esg include environmental remain largely unchanged identify new sustainability climate change manage principal risk legal matter bring great focus area describe esg performance focus range legal risk result antibribery report additional information climaterelate risk corruption long standalone principal risk management climaterelate financial disclosure additionally expand information security page principal risk explicitly include cyber risk identify datum management new emerge risk evaluate year emerge risk geopolitical tension healthcare reform embed risk management activity year report separately iability statement report nternal control framework egal proceeding nvironment limaterelate financial disclosure report gsk annual report strategic report governance remuneration financial statement investor information principal risk summary trend versus risk prior year assessment mitigation activity patient external risk environment remain stable regulatory environment remain safety external challenge recent example evolve regulatory requirement relate safety report clinical trial risk external party include regulatory agency technology company reach conclusion communicate information safety product base realworld evidence available inhibit ability timely decision appropriate action relation safety product confirm refute conclusion assert external party risk exposure remain stable continue balance resource change programme maintain routine activity allocate resource gsk optimise pharmacovigilance operation advance innovative solution safety case management simplify key safety process change initiative shortterm potential distract focus key business priority change reduce overall risk exposure increase workload capacity organisational capability product external risk environment stabilise remain high follow covid quality external regulator resume multiple onsite inspection check product quality expectation meet continue focus datum governance datum integrity requirement evaluation product presence nitrosamine regulatory environment evolve respect continue use titanium dioxide medicine ema decision potential discontinuation risk exposure stabilise return prepandemic level health authority inspection continue inspection readiness programme ensure preparedness gsk continue invest technology digital platform strengthen control good datum management practice complete nitrosamine product assessment line regulatory expectation financial external risk environment remain challenge political uncertainty propose control external increase obligation director auditor increase threat cyber attack report fraud increase esg disclosure requirement risk exposure remain stable ongoing focus resilience personnel gsk test internal control framework implement optimal risk mitigation transformational programme technology centralise process risk control assessment maintain effective tax treasury strategy continually strengthen control framework collaborate external body set standard antibribery external risk environment remain stable enforcement anticorruption law corruption external regulation remain priority country particular abac continue focus investigate use party bribe foreign public official result rigorous antibribery corruption control expect disruption global supply chain commercial pressure cause higherthanusual inflation rate increase risk bribery corruption certain context come year risk exposure remain stable continuously improve abac programme sure control match evolve emerge risk enhance gsk mandatory abac training employee provide role risktailore abac training ongoing basis impose stringent abac training requirement certain party provide service behalf commercial external risk environment stabilise macroeconomic factor energy price practice external increase inflationary pressure ongoing effect covid pandemic contribute challenging environment stakeholder competitive pressure remain intense therapy area market segment government remain focused initiative drive medicine vaccine cost consumer risk exposure remain stable mature robust control environment gsk evolve match competitive enhancement commercial practice include high volume engagement healthcare professional strengthen sale force incentive schemesgsk annual report principal risk summary continue trend versus risk prior year assessment mitigation activity scientific external risk environment remain stable continue characterise complex patient external dynamic disease area treatment increase patientcentric focus engagement phase product lifecycle increase diversity engagement platform virtual engagement risk exposure remain stable continue mitigate risk modernise adjust engagement practice internal control rapidly evolve environment gsk internal network foster collaboration good practice share identification emerge risk associate scientific patient engagement activity datum ethic external risk environment continue increase global landscape datum privacy external protection privacy cyber law develop give current pace technology focus innovation expect continue company need mindful relevant potential legislation regulation increase trend datum sovereignty initially affect tech company affect healthcare company ability drive medical innovation effectively operate internationally risk exposure increase context unstable privacy regulatory environment gsk multinational footprint realign digital transformation focus datadriven science law key market china india continue evolve include relate international datum transfer mechanism research external risk environment remain stable research remain critical development practice external safe effective product advance technology use datum societal expectation ethical consideration new entrant sector continue influence environment global regulation quality standard continue evolve particularly impactful expectation change countryspecific requirement risk exposure remain stable law regulation continually evolve gsk continue perform robust risk scan assessment inform evolution control framework response regulatory change ensure clear accountability action environment external risk environment remain stable manufacturing site operate health external staffing level work location arrangement maintain safety safety wellbee employee affect ukraine conflict ehs risk exposure remain stable continue focus safety leadership training embed life save rule adhere ehs standard introduce gsk safety leadership experience global supply chain operation programme train leader ehs accountability sure people understand importance adhere ehs standard information external risk environment continue rise digital footprint increase threat security external hacker sophisticated grow geopolitical conflict significantly increase cyber risk large corporation government tighten regulatory framework regard data information see rise enforcement risk exposure continue increase operate increasingly digital healthcare gsk ecosystem continue expand digital footprint response cyber security maturity programme continue improve control governance identify protect detect respond recover cyber incident supply external risk environment increase unpredictable external force continuity external pressure resilience supply chain include geopolitical tension grow nationalistic approach include uschina decouple risk exposure remain stable medicine vaccine supply chain continue focus strategic material plan parameter adapt change gsk external environment include inventory strategy safety stock hedge make concerted effort stabilise accelerate newly acquire asset focus make sure recruit right people support future portfolio gsk annual report strategic report governance remuneration financial statement investor information risk management continue climaterelate financial disclosure gsk climaterelate financial disclosure consistent metric include climaterelate metric recommendation recommend disclosure reduction scope emission reach key task force climaterelate financial disclosure milestone programme reduce greenhouse tcfd include tcfd allsector guidance gas emission ghg meter dose inhaler asthma compliance requirement chronic obstructive pulmonary disease list rule gsk leadership team glt gsk report climaterelate financial glt meet regularly opportunity member disclosures accordance tcfd recommendation discuss strategic financial reputational matter purpose building trust regis simard president global supply chain glt connect strategic financial disclosure member management responsibility environmental climate change year update climate sustainability include climate change scenario model transition physical risk responsible governance oversight risk enable extend timeframe model risk opportunity ensure effective framework datum available broaden scope place manage risk opportunity include gsk supply chain continue monitor business unit deliver emerge risk new datum include future commitment net zero nature positive healthy assessment planet ambitious goal set entire value chain governance board regis support gsk vice president sustainability regularly review progress board consider climaterelate matter cochair quarterly gsk sustainability council year assess risk management process place challenge endorse business plan glt review discuss midyear budget include oversee major capital expenditure performance key environmental metric include acquisition divestment committee climaterelate one review gsk esg exercise oversight provide guidance review performance rating esg performance include climaterelated risk opportunitie environmental performance gsk sustainability council target crc sustainability council hold quarterly attend senior leader business play key role committee support glt rocc deliver commitment net zero nature positive receive quarterly update environmental sustainability healthy planet ambitious goal set include climate regular attendee include ceo entire value chain member include president global supply chain crc report leader procurement finance compliance detail board architecture manufacturing council cochaire crc meet time key area focus president global supply chain sustainability support global sustainability team discuss climaterelated issue separate provide specialist expertise advice business occasion management include progress deliver climate ambition implication council geopolitical landscape key milestone decision receive monthly performance dashboard cover key require achieve net zero target performance metric escalation potential review midyear performance key environmental concern issue metric include climaterelated metric hold quarterly performance review area review gsk esg performance rating programme delivery focus review aspect approve gsk tcfd statement public programme implementation sustainable environmental reporting disclosure source strategy recommendation refresh remuneration committee support gsk science base target commitment council crc introduce measure gsk longterm review include decision intervention support incentive plan opportunity senior leader base key required maintain progress target metric relate gsk esg performance review insight esg trend regulation approve propose sustainability datum strategygsk annual report risk management continue order address key priority climate impact supply chain emission share challenge gsk meter dose inhaler specific council sector working peer collaborative establish attend senior leader initiative commercial supply chain regulatory activate programme help active pharmaceutical business align gsk respiratory business ingredient api supplier accelerate decarbonisation council chair president global supply chain initiative decisionmake body energize programme encourage use programme reduce climate impact meter renewable energy pharmaceutical dose inhaler contribute approximately sector supply chain gsk total ghg emission clinical manufacture initiative encourage supplier trial successful measure manage reduce emission advocacy engagement regulator september launch sustainable policymaker procurement programme require supplier industrialisation strategy progress disclose emission set carbon reduction target align business support sustainability programme steering team use meter dose inhaler patient coordinate sustainability programme asthma chronic obstructive pulmonary disease associate workstream oversight monitoring make total climate impact performance progress enabler require invest programme reduce greenhouse gas deliver sustainability programme emission vital medicine potentially business unit sustainability council meet quarterly reduce climate impact clinical review business unit performance delivery study confirm new propellant company sustainability ambition appropriate replacement gsk work secure capital allocation board cab include approval regulator market new product cfo group financial controller review climate available patient process related capital expenditure annual planning time gsk focus meeting commitment capital allocation process considerable investment achieve goal finance sustainability network include leader finance sustainability procurement science base target initiative sbti accredit focus key financial enabler deliver climate target set prior demerger align sustainability programme pathway reduction pathway significantly ambitious currently seek strategy reaccreditation sbti target fully gsk commitment net zero nature positive healthier focus biopharma company planet embed gsk strategic longterm priority recognise global energy crisis describe consider social environmental disrupt delay green governance impact laboratory transition world impact pace patient decarbonisation short term setback team gsk involve process energy transition expect timelimite ensure sound strategic decision develop threeyear plan embed process identify assess climaterelate risk climate risk analysis material area business opportunity set risk management focus risk impact direct operation tcfd section achieve climate ambition update climate scenario model active holistic management climaterelate risk transition physical risk enable extend component important addition risk timeframe model climate risk datum continue identify opportunity gsk risk available broaden scope include gsk opportunity describe table page site supplier geography strategic revenue dependency align supply chain risk order achieve reduction emission management process operation transition plan focus maximise energy efficiency site transition renewable electricity increase use electric vehicle sale fleet gsk annual report strategic report governance remuneration financial statement investor information risk management continue continue monitor emerge risk new current trajectory scenario ssp rcp datum include future assessment external party scenario set extent announce provide horizon scan insight esg trend ambition target path deliver regulation emission reduction require achieve net zero emission temperature rise exceed gsk prioritise scenario modelling follow risk noticeable shift happen half century net zero pledge emission change regulation govern supply high scenario necessarily mean emission global warming potential gwp substance energy sector need reach net zero government restrict gsk ability allocation carbon offset pledge manufacture meter dose inhaler breach planetary boundary scenario future regulatory policy response address climate ssp rcp change lead imposition carbon taxis scenario align pledge lay country gsk manufacture source good paris agreement country party unable meet united nations sustainable increase level water stress lead development goal scenario severe interruption supply water gsk thirdparty physical consequence planet temperature rise supply site exceed lead high loss biodiversity increase frequency impact extreme weather specie extinction event cause disruption gsk thirdparty risk opportunity analyse include supplier site manage gsk metric target climate scenario place potential impact profit low review update climate scenario million medium million million high develop climate scenario million threshold scenario modelling transition risk net zero low inherent uncertainty nature carbon current trajectory scenario risk gsk strategy business model climate model physical risk low carbon current trajectory relate issue monitor time horizon breach planetary boundary short term year medium term year net zero scenario ssp rcp long term year scenario set narrow achievable pathway comparison disclosure extend global energy sector achieve net zero emission timeframe climate risk assessment rely emission reduction datum available able differentiate outside energy sector achieve goal scenario potential longterm outcome different climate scenario consistent limit global temperature rise temperature overshoot net zero mean base different climate scenario analysis huge decline use coal oil gas shift perform take consideration climate risk renewable energy source opportunity identify geography describe table test resilience low carbon scenario ssp rcp gsk business strategy identify material scenario current net zero pledge achieve impact business resilience extensive effort realise nearterm emission reduction advanced economy reach net zero emission china country late scenario consistent limit global temperature rise level net negative emission temperature rise reduce iea net zero emission scenario httpswwwieaorgreportsglobal energyandclimatemodelnetzeroemissionsbyscenarionze access november iea world energy outlook chapter download report httpswwwieaorgreportsworldenergyoutlookoverview access november iea announce pledge httpswwwieaorgreportsglobalenergy andclimatemodelannouncedpledgesscenarioap access november gsk annual report risk management continue potential physical risk financial impact description gsk response scenario timeframe metric target risk identify water basin current medium site achieve increase level waterstresse area algeria india trajectory good water water stress lead pakistan manufacturing site achieve stewardship interruption aim water neutral long term water supply water year stewardship site manufacturing facility nashik india gsk site build plant rainwater harvesting total thirdparty supply supply reduce site climate scenario analysis identify breach low water overall water number site supplier site locate planetary gsk use water basin water boundary long term party supplier use operation stress add year freshwater watch list monitor change risk main source water level update site water risk manufacture assessment appropriately medicine vaccine water availability restrict factory production operation interrupted increase frequency climate scenario modelling indicate low business extreme weather seven physical peril flood rainfall carbon continuity climate event cause present high likelihood acute scenario plan related risk disruption gsk interruption risk flooding review business thirdparty supplier rainfall extreme weather annually continuity site event expect remain low identify extreme weather perform risk assessment current low event manufacturing operation trajectory take action precipitation business continuity plan place scenario long term kgate rainfall flood review annually respond year precipitation tidal impact extreme weather event include flood extreme wind adopt appropriate mitigation plan wildfire extreme heat gsk establish loss prevention breach extreme cold risk engineering programme identify planetary result shortterm range risk impact site boundary interruption flood risk exist take action scenario manufacturing mitigate risk gsk supplier site regulation invest programme current high onoff track governing use reduce greenhouse gas emission trajectory high global warming meter dose inhaler treat asthma scenario medium delivery reduction potential gwp copd good progress year key carbon substance reformulate alternative gas milestone emission update potentially reduce climate impact scope clinical trial programme update recently successful plan respectively portfolio dry powder lead inhaler product use propellant increase cost impact risk restrict ability manufacture meter dose inhaler mdi product use high gwp propellant hfaa gsk annual report strategic report governance remuneration financial statement investor information risk management continue potential transitional risk financial impact description gsk response scenario timeframe metric target future regulatory gsk manage risk reduce scope net zero medium scope policy response emission follow scenario carbon address climate gsk energy efficiency programme emission reduction change lead transition renewable electricity medium scope carbon imposition year carbon emission carbon taxis long term scope investigate option renewable heat emission country gsk year technology manufacture transition sale fleet electric vehicle source good respectively shadow carbon pricing capital low medium party investment tonne ghg carbon emission scenario medium gsk manage risk reduce scope year emission follow term fall programme reduce greenhouse gas low emission meter dose inhaler long term new supply chain programme require year supplier action carbon set target align switch renewable power heat current low collaborate sector peer energize trajectory medium activate programme manufacture scenario year initiative long term join sustainable market initiative health year system task force reduce healthcare supply chain emission potential profit impact opportunity gsk response scenario timeframe metric target cop reduce scope carbon net zero scope november emission turn reduce scope scenario footprint customer supplier carbon reduction country example site irvine scotland closed emission carbon world commit loop heat system helped drive reduction emission total provide low carbon operating cost onsite renewable low waste scope healthcare system biogas provide energy carbon low material lead ecodesign programme reduce scenario respectively increase demand impact product package long low carbon invest programme reduce year zero medicine operational greenhouse gas emission meter dose vaccine inhaler treat asthma copd current waste good progress reformulate trajectory alternative gas potentially reduce scenario climate impact clinical trial successful portfolio dry powder inhaler product low carbon footprint september gsk microsoft announce current long report innovative collaboration centre trajectory year applicable applicable exploring impact health disease study chds nepal scenario climate change pilot project leverage microsofts health showing premonition system gsk expertise health climate change disease investigate robotic affect water support local community response vector vectorborne disease borne disease climate change lead july gsk annual palio conference increase demand explore role vaccine find solution new medicine global healthcare protect people planet vaccinesgsk annual report risk management continue risk management physical risk typically identify asset project level manage depend level risk describe risk management section assess increase level water stress physical risk gsk risk management policy design address reduce availability water type risk include group principal risk operation affect location important risk uncertainty climate risk assessment follow gsk use freshwater main source water policy framework manufacture medicine vaccine water availability nature risk opportunity climate restrict factory production operation change depend physical aspect interrupted perform water stewardship risk climate change regulatory commercial assessment manufacture site update change market gsk operate include year pressure reduce climate impact gsk meter transition risk typically identify enterprise level dose inhaler medicine market level currently transition risk term gsk climate risk management policy priority gsk regulatory commercial risk specific dedicated environmental sustainability risk manage investment decision management plan place risk sustainability transformation programme legal management plan cover expectation gsk point view consider risk arise address impact environment product claim base environmental performance environment increase impact operational manage risk use external accreditation process resilience access energy water natural organisation review evidence support resource product anticipate cost environmental claim product criterion increase regulatory change environmental taxis technological point view gsk develop tool policy development global national level incorporate ecodesign principle design monitor potential impact example development new product identify opportunity result montreal protocol kigali amendment reduce environmental impact exist product mandate global phase use high communication governance affair team global warming potential hydrofluoroalkane gas manage corporate reputation identification government introduce propose introduce monitor climaterelate issue undertake quota restriction hfaa gsk proactive reactive engagement relevant manufacture meter dose inhaler treat asthma stakeholder group communicate gsk position copd gsk industry consultation annual basis crossfunctional team gsk department environment food rural business unit sustainability team finance perform affair government develop specific review risk climate change identify new regulation control fgase emerge risk determine update risk gsk policy procedure place identify risk assessment require exist risk climaterelate climate change thing change example risk consider strategic operational assess climate impact merger acquisition perspective ensure maintain comprehensive view activity construction new building major different type climate risk face different capital expenditure furthermore internal control time horizon affect gsk review framework establish environmental approve sustainability finance vps sustainability include appointment dedicate gsk business unit senior leader environmental sustainability ensure identify risk assess climate risk working governance process place effective group consider likelihood financial impact purpose tcfd disclosure risk gsk different climate scenario use tcfd distinction physical impact assessment approve president global transition climaterelate risk supply chain company level responsibility environmental sustainability sustainability risk identify include potential effect finance vps gsk business unit result operation asset level performance business level share business unit risk management control development regional level extreme weather board rmcb finance rmcb ensure risk transition low carbon economy contextualise business risk manage appropriately allow management holistic view optimise risk mitigation response ensure response climaterelate risk properly integrate relevant business function activity gsk annual report strategic report governance remuneration financial statement investor information risk management continue metric target gsk commit net zero nature positive healthy planet water waste annually esg performance report ambitious goal set entire detailed performance datum environmental kpi value chain gsk report progress reduce scope public response cdp climate water carbon emission scope carbon emission energy use forest questionnaire disclose gsk consider key metric follow guidance table metric metric consistent crossindustry climaterelate metric describe tcfd base strategic organisation metric assess climate risk scope emission marketbase locationbased approach describe table opportunity scope emission describe table line renewably source electricity describe table strategy risk total supply water describe table management total waste material describe table process esg composite metric senior leader remuneration policy site achieve water stewardship describe table esg performance report include additional metric support strategic metric list isclose scope energy carbon emission table applicable scope emission energy scope ghg scope source emission scope emission marketbase related risk scope emission locationbase scope emission metric scope emission intensity metric prioritise physical transition risk include strategy section describe target target measure baseline applicable reduction carbon emission investment naturebase solution remain organisation footprint scope manage climate renewable electricity scope relate risk net zero emission value chain scope opportunity achieve good water stewardship site performance reduce overall water use operation target zero operational waste water neutral operation key supplier waterstresse region performance target find page basis report esg resource section gskcom httpswwwgskcomengbresponsibilityesgresource detailed methodology measure reporting gsk environmental kpisgsk annual report risk management continue metric datum carbon emission carbon emission tonne coe scope emission energy scope emission scope emission marketbase scope emission locationbase scope emission scope emission metric scope emission energysale revenue tonne coem scope emission energyfte tonne coefte total energy gwh energy gwh renewably source electricity total supply water million total waste material metric tonne site achieve water stewardship datum report exclude previous consumer healthcare business specify carbon emission calculate accord greenhouse gas protocol corporate accounting reporting standard revise edition gsk use marketbase scope emission reporting purpose report scope emission category esg performance report ask external assurance provider deloitte provide limited assurance isae energy scope select scope carbon emission datum water wastewater data methodology report measurement provide basis report esg resource section gskcom httpswwwgskcomengbresponsibilityesgresource refer emission sale force vehicle propellant emission release manufacture inhaler majority propellant emission release patient use include scope carbon emission onsite waste wastewater treatment refrigerant gas loss collect publish scope datum category recent scope datum available process compile datum complete scope emission patient use inhaler disclose esg performance report publish datum available include esg performance report naturerelate financial disclosure gsk commit play minimise strategy impact dependencie nature helping commit net positive impact protect restore nature perform nature reduce environmental impact assessment impact nature value chain water waste material biodiversity set target reduce pressure line invest nature protection restoration evolve guidance science base target conduct assessment gsk naturerelate risk nature sbtn line commitment nature opportunity line late tnfd guidance building achievement climaterelate november follow late tnfd leap financial disclosure gsk currently pilot locate evaluate assess prepare methodology recommendation taskforce naturerelate able well understand magnitude financial disclosure tnfd ahead launch gsk physical transitional risk nature tnfd final framework expect september pressure continue refine assessment pilot work understand follow methodology tnfd look utilise tnfd guideline report risk report final version available impact dependencie nature present additionally gsk company conduct business make initial disclosure materiality assessment value chain line particular focus strategy metric target sbtn methodology well understand impact early finding result inprogress analysis dependency include gsk annual report strategic report governance remuneration financial statement investor information risk management continue process clearly indicate achieve net target continue evolve incorporate nature positive require build portfolio finding materiality assessment progress pressurespecific initiative drive action target achieve net nature positive support landscape region impact progress actively engage external partner commitment acknowledge collaboration include sbtn world business council different stakeholder continue imperative sustainable development ensure target metric multiyear journey ultimately direction provide meaningful robust sbtn technical guidance help shape addressing impact natural world strategy ensure minimise impact understand impact change state nature dependencie nature globally globally gsk small undertake proud pioneering use naturerelate financial metric target disclosure industry ultimately deliver positive address gsk pressure nature exist outcome environment fundamental deliver target water waste material biodiversity positive outcome human health gsk excited continue path unite science technology talent ahead disease nonfinancial information statement follow align nonfinancial reporting requirement contain section company act description business model human right policy diligence outcome business model human right risk management work party principal risk uncertaintie social matter datum engagement viability statement access audit risk committee report global health health security antibribery corruption ethical standard nonfinancial key performance employee report investigate indicator culture people concern performance key employee engagement performance indicator diversity equity inclusion environmental matter wellbee development environment policy gender pay gap climaterelate financial public policy code ethical standard disclosure standard available gskcom board diversity naturerelate financial disclosure employee gender male female total board management employee senior manager define company act strategic report director report regulation gsk annual report risk management continue viability statement accordance provision revision downside scenario consider gsk cash flow code gsk assess prospect group sustainability dividend fund strategy insurance long period month require go provision recovery key financial ratio concern provision director confirm period metric subject reasonable expectation gsk continue operate sensitivity analysis involve flex number meet liability fall main assumption underlie forecast individually year director assessment combination mitigate action reference gsk current position prospect realistically take avoid reduce impact strategy board risk appetite gsk principal risk occurrence underlie risk manage detailed page follow hypothetical downside scenario strategic report evaluate board review internal control risk scenario business performance risk include key management policy approve governance performance risk include low sale new product structure code conduct appraise great adverse impact generic competition approve major financing investment license competitive launch gsk product decision evaluate monitor performance possible supply manufacturing challenge prospect gsk focus largely improve longterm financial performance scenario external macroeconomic risk scenario delivery company business strategy align reflect incremental risk business drive outside priority factor intense competition increase pricing pressure europe potential board review gsk strategy make significant impact material negative change macro capital investment decision longterm time horizon economic healthcare environment base multiyear assessment return capital performance company market opportunity scenario principal risk scenario include severe medicine vaccine approach align assessment potential loss impact principal gsk model achieve balanced growth invest risk relate patient safety product quality supply chain high quality innovative product patient continuity environmental harm antibribery healthcare provider internal corruption consequent regulatory action external parameter increasingly unpredictable fine significant litigation long time horizon gsk focus detailed fundamentally threaten operation risk plan threeyear cycle plan review manage mitigating activity describe page annually director approve business forecast show expect financial impact director believe scenario option exercise scenario evaluate threeyear assessment period viability additional funding requirement assume early statement appropriate align group potential exercise outstanding option hold establish business planning process balance partner hiv business longterm nature investment medicine vaccine assessment period threeyear review make certain assumption analysis nearterm business performance realistically normal level capital recycling likely occur visible consider additional financing facility require respective level funding flexibility plan stress test series robust headroom operational principal risk downside scenario board review risk plan assume result stress testing certain year challenge healthcare industry combination hypothetical scenario continue pressure pricing pharmaceutical gsk increase funding demand gsk require mitigating assume premature loss exclusivity key product change group funding strategy light period anticipate launch proceed liquidity available group base plan despite ongoing recovery healthcare analysis director reasonable expectation system impact covid pandemic severe stress test group uncertain economic condition prevail market able continue operation meet liability gsk operate fall threeyear period assessment gsk annual report group financial review section summary year result financial performance report framework adjust item cash generation conversion financial position resource approach tax treasury policy critical accounting policy gsk annual report group financial review summary year result year growth growth year year aer cer turnover total continue operate profit total eps total continue eps total discontinue eps adjust operate profit adjust eps cash generate operation attributable continue operation free cash flow amount present continue operation adjust result exclude consumer healthcare business discontinue operation amount present discontinued eps demerger consumer healthcare business presentation continue discontinue operation ifrs set comparative result restate consistent basis previously publish reflect demerger consumer healthcare business impact share consolidation implement july total turnover total continue operate profit total turnover million aer total operating profit continue operation cer reflect strong performance product million compare million group commercial operation turnover exclude covid include billion upfront income receive solution sale grow aer cer specialty settlement gilead sciences inc gilead increase profit medicine include million sale xevudy turnover growth cer fair value gain doubledigit growth therapy area vaccine growth investment partly offset high remeasurement charge reflect strong shingrix meningitis performance partially contingent consideration liability offset pandemic adjuvant sale general medicine reflect recovery antibiotic market strong total continue adjust operate profit performance trelegy respiratory region adjust operate profit million high aer cer adjust operate margin specialty medicine percentage point high aer specialty medicine sale million aer percentage point high cer compared cer drive consistent doubledigit growth primarily reflect impact low margin covid therapy area specialty medicine exclude sale xevudy solution sale xevudy offset operate leverage million aer cer strong sale growth mix benefit low inventory adjustment writeoff high royalty income vaccine vaccine turnover million aer total earning share cer total aer cer exclude total eps compare pandemic adjuvant sale performance reflect increase primarily reflect profit taxation favourable comparator impact covid discontinued operation recognise consumer relate disruption market primarily healthcare business demerger upfront income receive strong commercial execution shingrix particularly settlement gilead increase profit fair value europe gain investment partly offset high remeasurement general medicine charge contingent consideration liability general medicine sale year million unfavourable comparison credit million aer cer impact generic competition taxation europe japan offset trelegy growth respiratory postpandemic rebound antibiotic market general medicine strategic report governance remuneration financial statement investor information gsk annual report group financial review continue total continue earning share cash generate operation attributable total ep continue operation compare continue operation primarily reflect upfront income cash generate operation attributable continue receive settlement gilead increase profit operation year million million turnover growth fair value gain investment increase primarily reflect significant increase partly offset high remeasurement charge contingent operating profit favourable exchange impact favourable consideration liability unfavourable comparison time collection partly offset unfavourable timing credit million taxation profit share payment xevudy sale increase cash contribution define benefit pension scheme total discontinue earning share increase contingent consideration payment higher ep discontinue operation compare increase inventory increase primarily reflect gain arise demerger consumer healthcare recognise profit free cash flow taxation discontinue operation free cash inflow continue operation million million increase primarily reflect adjusted earning share significant increase operating profit favourable exchange adjust eps compare reduce purchase intangible asset favourable timing operate leverage strong sale growth beneficial mix collection partly offset unfavourable timing low inventory adjustment writeoff high royalty profit share payment xevudy sale increase cash income low effective tax rate partly offset contribution pension increase contingent consideration increase investment launch high supply chain payment high tax payment low proceed freight distribution cost higher noncontrolle disposal high capital expenditure high increase interest inventorygsk annual report group financial review continue financial performance total result group set growth turnover turnover cer turnover cost sale gross profit sell general administration research development royalty income operating expensesincome operating profit net finance cost loss disposal interest associate share aftertax lossesprofit associate joint ventures profit taxation taxation profit taxation continue operation year profit taxation discontinue operation gain demerger remeasurement discontinue operation distribute shareholder demerger profit taxation discontinue operation total profit taxation year profit attributable noncontrolle interest continue operation profit attributable shareholder continue operation profit attributable noncontrolle interest discontinue operation profit attributable shareholder discontinue operation total profit attributable noncontrolle interest total profit attributable shareholder earning share continue operation earning share discontinue operation total earning share earning ad continue operation earning ad discontinue operation total earning ad adjust result group set reconciliation total result adjust result set page growth turnover turnover cer turnover cost sale sell general administration research development royalty income adjust operate profit adjust profit attributable shareholder adjust profit attributable noncontrolle interest adjust profit tax adjust earning share comparative result restate consistent basis previously publish reflect demerger consumer healthcare business impact share consolidation implement july strategic report governance remuneration financial statement investor information gsk annual report group financial review continue report framework total adjust result cost ordinary course small scale restructure legal charge expense retain total group financial review discuss operate adjust result financial performance group cash flow financial position resource result year adjust result include benefit major restructuring compare primarily result precede year programme exclude significant cost amortisation intangible asset computer software total result capitalise development cost significant legal major total report result represent group overall restructure transaction item performance regard complete picture group financial gsk use number adjust nonifrs measure performance present total result report performance business adjust result exclusion adjust item result adjusted nonifrs measure consider addition earning materially high low total earning substitute superior information present particular significant impairment restructure accordance ifrs adjust result define charge legal cost exclude adjusted earning nonifrs measure define high total earning gsk believe adjust result consider gsk undertake number major restructure total result provide investor analyst programme response significant change group stakeholder helpful complementary information trading environment overall strategy follow material understand well financial performance position acquisition cost cash noncash group period period allow group programme provide individual element performance easily compare majority approve meet accounting recognition criterion peer company measure result charge incur number year management planning reporting purpose follow initiation major restructure programme directly comparable similarly describe measure significant legal charge expense arise company settlement litigation government investigation gsk encourage investor analyst rely normal course materially large single financial measure review gsk annual report regularly occur individual matter include include financial statement notes entirety certain major legacy matter reconciliation total adjust result provide adjusted result information key adjust item adjust result exclude profit discontinue set page operation consumer healthcare business gsk provide earning guidance investor community detail follow item relation basis adjust result line peer company continue operation total result tax expectation investor community support easy effect item comparison group performance peer gsk amortisation intangible asset exclude computer software able guidance total result reliably capitalise development cost forecast certain material element total result impairment intangible asset exclude computer particularly future fair value movement contingent software goodwill consideration option give rise significant adjustment drive external factor major restructuring cost include impairment currency movement capital market tangible asset computer software specific board approve programme structural significant scale cost individual relate project exceed million include integration cost follow material acquisition transactionrelated accounting adjustment relate significant acquisition proceed cost disposal associate product business significant settlement income significant legal charge net insurance recovery expense settlement litigation government investigation operate income royalty income itemsgsk annual report group financial review continue report framework continue historical record adjust item reconciliation total adjust operating profit continue operation year summarise follow total operating profit continue operation intangible amortisation intangible impairment major restructuring transactionrelate item divestment significant legal item adjust result analysis impact transactionrelated item operating profit year follow contingent consideration shionogiviiv healthcare include shionogi preferential dividend viiv healthcare option pfizer preferential dividend contingent consideration novartis vaccine business contingent consideration acquisition affinivax adjustment transactionrelate item hree year financial datum present reflect restate result follow demerger consumer healthcare business financial result restate present comparative result restate consistent basis previously publish reflect demerger consumer healthcare business reconciliation total adjust result include continue discontinue operation set page explanation adjust item report page nonifrs measure return capital employ return capital employ calculated total profit free cash flow taxation percentage average net asset year free cash flow define net cash inflowoutflow continue operating activity capital expenditure total net debt property plant equipment intangible asset net debt define total borrowing cash cash contingent consideration payment net finance cost equivalent liquid investment shortterm loan dividend pay noncontrolle interest plus proceed party subject insignificant risk change value sale property plant equipment intangible note net debt calculation net debt asset dividend receive joint venture associate management planning total operating margin report purpose discussion presentation total operating margin operate profit dividend turnover investment analyst rate agency free cash flow growth calculate report basis reconciliation compound annual growth rate cagr net cash inflow continue operating activity free cash flow set cagr define compound annual growth rate show annualise average rate revenue growth work capital number give year assume growth take place exponentially compound rate work capital represent inventory trade receivables trade payable cer aer growth order illustrate underlying performance group practice discuss result term constant exchange rate cer growth represent growth calculate exchange rate determine result overseas company sterling remain unchanged comparative period cer represent growth constant exchange rate aer represent growth actual exchange rate strategic report governance remuneration financial statement investor information gsk annual report group financial review continue report framework continue noncontrolle interest viiv healthcare cash payment reflect cash flow statement partly operate cash flow partly invest trading profit allocation activitie tax relief payment reflect viiv healthcare subsidiary group group adjust item tax charge operate result turnover operate profit profit payment relate original estimate fair value tax include group income statement contingent consideration acquisition portion earning allocate noncontrolle shionogiviiv healthcare joint venture million interest own shareholder line report investing activity cash flow statement respective equity shareholding pfizer inc pfizer payment relate increase shionogi ltd shionogi shareholder liability acquisition report operate cash include gsk entitle preferential dividend flow determined performance certain product movement contingent consideration payable shionogi shareholder contribute relative performance follow product change time proportion overall earning allocate shareholder change particular increase proportion sale dolutegravir contingent consideration begin year cabotegravircontaine product favourable remeasurement income statement impact proportion preferential dividend movement allocate gsk adjust item allocate cash payment operate cash flow shareholder base equity interest gsk entitle cash payment invest activity approximately total earning contingent consideration end year adjust earning viiv healthcare remeasurement liabilitie preferential dividend contingent consideration payable posttax basis allocate pfizer shionogi include shionogi december million december operating incomeexpense million expect pay year acquisitionrelate arrangement exit right consideration acquisition shionogis interest pfizer request ipo viiv healthcare time shionogiviiv healthcare joint venture shionogi gsk consent ipo offering receive equity stake viiv healthcare viiv complete month pfizer require gsk healthcare agree pay additional future cash acquire shareholde original agreement gsk consideration shionogi contingent future sale unconditional right long subsequent performance product develop joint distribution shareholder withhold consent venture dolutegravir cabotegravir ifrs business exercise pfizer option result accordance combination gsk require provide estimate ifrs gsk recognise liability option fair value contingent consideration time balance sheet gsk notify pfizer acquisition require update liability latest irrevocably give right accordingly estimate fair value subsequent period end recognise liability option group liability contingent consideration recognise balance sheet initial value balance sheet date acquisition million million consistent revise treatment end subsequent remeasurement reflect gsk recognise liability future preferential operating incomeexpense adjust item dividend anticipate payable pfizer income statement period shionogi group balance sheet cash payment settle contingent consideration pfizer right require gsk acquire shareholding shionogi viiv healthcare quarter base viiv healthcare certain circumstance time actual sale performance income relevant option liability record group balance product previous quarter payment reduce sheet current liability measure gross balance sheet liability record income redemption basis derive internal valuation viiv statement cash payment shionogi viiv healthcare business healthcare million closing balance liability related pfizer liability require record fair value shareholding follow estimate future payment significant timing difference charge record total income statement reflect movement fair value pfizer option liability actual cash payment settle liabilitygsk annual report group financial review continue report framework continue original agreement shionogi report definition request gsk acquire shareholding viiv healthcare sixmonth window commence gsk covid solution unconditional right long subsequent covid solution include sale pandemic adjuvant distribution shareholder withhold consent covid solution include vaccine exercise shionogi option result gsk manufacturing xevudy associate cost recognise liability option balance sheet include reinvestment categorisation gsk notify shionogi management believe helpful investor irrevocably give right accordingly recognise provide clarity result group show liability option group balance sheet contribution growth covid solution initial value million shionogi irrevocably agree waive option result gsk general medicine derecognise liability option group general medicine usually prescribe primary balance sheet directly equity value liability care community setting general healthcare million derecognise practitioner gsk include medicine inhale respiratory dermatology antibiotic disease gsk option shionogis shareholding viiv healthcare original agreement specialty medicine exercisable sixmonth window commencing gsk irrevocably agree waive specialty medicine typically prescription medicine exercise window sixmonth window treat complex rare chronic condition gsk remain option fair value value comprise medicine infectious disease hiv oncology accounting purpose immunology respiratory settlement gilead share consolidation february viiv healthcare reach agreement shareholder receive new ordinary share nominal gilead settle global patent infringement litigation value pence exist ordinary share relate commercialisation gilead biktarvy nominal value pence earning term global settlement licensing agreement share diluted earning share adjust earning share gilead upfront payment billion viiv dividend share retrospectively adjust healthcare february addition gilead pay reflect share consolidation period present royalty future sale biktarvy respect bictegravir component future bictegravir earning share contain product sell royalty earning share retrospectively adjust payable gilead viiv healthcare february share consolidation july apply ratio new expiry viiv healthcare patent ordinary share exist ordinary share october gilead obligation pay royalty extend period regulatory paediatric exclusivity total earning share award state total earning share refer impact settlement gilead contingent total basic earning share principle apply consideration liability ccl increase million continue discontinue earning share posttax basis obligation viiv healthcare pay future cash consideration shionogi share upfront future sale performance biktarvy product contain bictegravir liability discount million december posttax basis impact settlement pfizer option liability increase million include remeasurement december strategic report governance remuneration financial statement investor information gsk annual report financial performance group turnover specialty medicine group turnover business turnover specialty medicine aer growth cer growth aer growth cer growth group turnover vaccine aer growth cer growth general medicine aer growth cer growth specialty medicine turnover group turnover geographic region pecialty turnover exclude covid solution aer growth cer growth aer growth cer growth europe pandemic turnover aer growth cer growth aer growth cer growth international revise growth growth aer growth cer growth cer hiv group turnover oncology gsk revise operating segment year immunoinflammation respiratory previously gsk report result segment pharmaceutical pharmaceutical vaccine consumer healthcare gsk report result pandemic segment commercial operation total specialty medicine note consolidated financial statement revise reflect change product group previously report detail establish pharmaceutical commercial operation segment product group hiv specialty medicine vaccine general medicine hiv sale million growth aer specialty medicine product include gsk market cer performance benefit strong patient product hiv oncology immunoinflammation demand new hiv medicine dovato cabenuva juluca respiratory specialty medicine include nucala rukobia apretude contribute approximately pandemic solution xevudy quarter growth pricing favourability yearend accine product include sale gsk adjuvant inventory build contribute growth pandemic solution partially offset international tender decline general medicine product include product new hiv product deliver sale billion previously report establish pharmaceutical million aer cer represent sale trelegy ellipta anoro ellipta previously report total hiv portfolio compare year growth respiratory category specialty product primarily drive sale dovato cabenuva dovato product typically access patient record sale million aer cer primary care setting cabenuva long act injectable treatment hiv infection record sale million apretude group turnover million year aer long act injectable prevention hiv deliver cer sale grow aer cer exclude sale million covid solutionsgsk annual report group financial review continue financial performance continue oncology vaccine oncology sale million aer cer zejula sales million aer cer turnover drive line indication diagnosis treatment rate continue impact pandemic aer growth cer growth especially sales blenrep million grow aer cer include impact withdrawal group turnover market immunoinflammation respiratory immunoinflammation respiratory sale million aer cer strong performance benlysta nucala benlysta sale million aer cer represent strong vaccine turnover underlie demand worldwide nucala sales million aer cer reflect continue accine turnover exclude strong patient demand launch additional covid solution indication pandemic aer growth cer growth sale xevudy million compare million pandemic turnover sale sale deliver region comprise million million europe million million international aer decline cer decline growth growth cer meningitis influenza shingle establish vaccine pandemic vaccine vaccine meningitis meningitis vaccine sale grow aer cer million mainly drive bexsero aer cer million result high cdc center disease control demand increase share menveo sale aer cer million primarily drive postpandemic vaccination catchup high public demand international favourable pricing mix share gain influenza fluarixflulaval sale grow aer decrease cer million primarily drive low postpandemic demand europe partly offset lower expect return strategic report governance remuneration financial statement investor information gsk annual report group financial review continue financial performance continue shingles general medicine shingrix sale grow aer cer million region grow significantly reflect postpandemic turnover rebound strong uptake new market launch half growth contribute outside aer growth cer growth shingrix grow aer cer million high nonretail retail demand strong commercial execution germany china contribute group turnover strongly shingrix growth shingrix launch market available country establish vaccine establish vaccine grow aer stable cer million mainly result supply constraint mmrv vaccine low tender demand international general medicine turnover synflorix offset hepatitis vaccine demand rebound europe boostrix postpandemic demand recovery increase share revise growth growth cer respiratory pandemic vaccine general medicine pandemic vaccine decrease aer cer primarily general medicine reflect comparison pandemic adjuvant sale canadian government partly offset gsk share revise reflect change product group previously report contract european volume relate covid establish pharmaceutical booster vaccine develop collaboration sanofi pasteur sanofi respiratory respiratory sale million aer cer performance drive trelegy sale million aer cer include strong growth region advairseretide sale million decrease aer cer predominantly reflect adverse impact generic competition growth certain international market targeted promotion offset decrease general medicine general medicine sale million decrease aer cer augmentin sales million aer cer reflect post pandemic rebound antibiotic market international europe region partially offset ongoing adverse impact generic competition approximately percentage point impact aer cer divestment cephalosporin product gsk annual report group financial review continue financial performance continue turnover region general medicine sale million decrease aer cer reflect ongoing impact generic competitive pressure seretide divestment sales million aer cephalosporin product cause percentage cer sale adjust covid solution aer point drag growth aer cer partly cer sale xevudy million offset strong demand trelegy growth specialty hiv sale million aer augmentin follow postpandemic rebound cer growth benefit strong patient demand antibiotic market new hiv product pricing favourability yearend international inventory build new hiv medicine dovato cabenuva international sale million aer juluca rukobia apretude sales million cer include xevudy sale million sale grow aer cer nucala respiratory benlysta aer cer exclude sale covid solution immunology continue grow doubledigit reflect ongoing strong patient demand oncology sale specialty hiv sale million stable aer increase aer cer diagnosis decrease cer primarily drive tender decline treatment rate continue impact pandemic exclude tender international grew drive strong dovato zejula withdrawal blenrep market growth combine tivicay triumeq sale million aer cer nucala sales million grow aer cer reflect vaccine sale million aer cer strong market growth patient uptake benlysta sale exclude impact pandemic adjuvant sale sale million grow aer cer reflect growth increase aer cer performance biological market japan inclusion china primarily drive shingrix sale million national reimbursement drug list aer cer high nonretail retail demand strong commercial execution demand recovery vaccine sale million aer cer establish vaccine share gain meningitis vaccine reflect percentage point drag aer cer contribute growth covid vaccine adjuvant sale growth exclude covid solution drive strong shingrix takeup general medicine sale million aer china canada japan offsetting impact cer trelegy aer cer supply constraint mmrv vaccine low synflorix reflect increase patient demand growth single tender demand market inhaler triple therapy market flovent grow launch authorise generic year overall general medicine sale million aer percentage point reduction growth general medicine cer respiratory sale million increase aer prior period return rebate rar adjustment cer trelegy sale aer cer year reflect strong demand inclusion chinas national reimbursement drug list sale advairseretide europe aer cer adverse impact generic europe sale million aer competition offset growth certain market cer include covid solution sale million target promotion general medicine sale contribute percentage point growth aer cer million increase aer cer reflect growth specialty medicine hiv sale million augmentin follow postpandemic rebound aer cer primarily drive strong patient demand antibiotic market partially offset generic dovato cabenuva juluca dovato deliver sale competition price reduction certain market million juluca million cabenuva million benlysta immunology nucala respiratory oncology medicine zejula blenrep jemperli continue strong doubledigit growth vaccine sale million aer cer performance drive shingrix sale million aer cer particularly germany pandemic adjuvant sale million contribute percentage point growth aer cer strategic report governance remuneration financial statement investor information gsk annual report group financial review continue financial performance continue cost sale research development growth growth growth growth cer cer total cost sale total research development adjust cost sale adjust research development comparative result restate consistent basis previously publish reflect demerger consumer comparative result restate consistent basis healthcare business previously publish reflect demerger consumer healthcare business total cost sale percentage turnover total expenditure million aer percentage point low aer percentage point cer include amortisation impairment high cer term adjust expenditure fullyear increase adjust cost sale percentage turnover aer cer million reflect continued percentage point high aer percentage point increase investment vaccine clinical development high cer compare primarily reflect include investment mrna technology platform high sale low margin xevudy compare continued investment latestage portfolio include high margin pandemic adjuvant sale increase early discovery programme expenditure relate cost sale margin percentage point aer cer recent acquisition affinivax inc affinivax impact increase commodity price freight cost partially offset favourable mix addition specialty medicine level investment primarily increase sale shingrix increase support phase iii respiratory programme europe increase sale hiv medicine depemokimab potential new medicine treat severe low inventory adjustment write off vaccine asthma bepirovirsen study chronic hepatitis continue contribution restructure saving preparation start phase iii trial oncology investment increase earlystage immunooncology sell general administration asset momelotinib mmb potential new treatment myelofibrosis patient anaemia acquire growth growth cer recent sierra oncology acquisition increase total sell general investment offset decrease related completion administration latestage clinical development programme adjust selling general reduce investment covid pandemic solution administration versus comparative result restate consistent basis previously publish reflect demerger consumer royalty income healthcare business royalty income million million total sga cost percentage turnover aer cer increase primarily reflect royalty percentage point low aer stable cer compare income gilead settlement licensing include reduction restructuring charge agreement gilead announce february gardasil royalty income increase million adjust sga cost percentage turnover high sale percentage point high aer percentage point high cer adjust sga cost increase aer cer primarily reflect increase level launch investment specialty medicine particularly hiv vaccine include shingrix drive postpandemic recovery demand support market expansion growth adjust sga reflect unfavourable comparison beneficial legal settlement impairment provision relate russia ukraine growth partly offset continue benefit restructure tight control ongoing costsgsk annual report group financial review continue financial performance continue operating incomeexpense adjust operate profit business net operate expense million commercial operation operate profit million million reflect accounting charge million aer cer turnover increase million arise remeasurement contingent cer operating margin percentage consideration liability liability pfizer point low aer percentage point low cer option pfizer shionogi preferential dividend viiv primarily reflect strong sale low margin healthcare include remeasurement charge xevudy increase investment launch specialty million million contingent consideration medicine include hiv vaccine plus high commodity liability shionogi include unwind freight distribution cost adverse comparison discount million charge million favourable legal settlement partly offset primarily change exchange rate leverage strong sale growth mix low inventory adjustment sale forecast partly offset adjustment writeoff continue tight control ongoing million upfront income receive settlement cost benefit continue restructure increase gilead fair value gain investment include million royalty income biktarvy gardasil sale retain stake haleon plc haleon reflect segment operating expense million increase share price list milestone income aer cer primarily reflect increase investment disposal vaccine include priority investment mrna late stage portfolio expenditure acquisition affinivax operate profit specialty medicine early stage hiv depemokimab total operating profit continue operation partly offset decrease related completion million compare million latestage clinical development programme include million upfront income receive reduce investment covid pandemic solution settlement gilead increase profit turnover versus growth aer cer fair value gain investment include million retain stake haleon partly offset high remeasurement charge contingent consideration liability adjust operate profit million high aer cer turnover increase cer adjust operate margin percentage point high aer percentage point high cer compare primarily reflect impact low margin covid solution sale xevudy reduce adjusted operate profit growth aer cer reduce adjust operate margin approximately percentage point aer approximately percentage point cer offset operate leverage strong sale growth mix benefit low inventory adjustment write off high royalty income contingent consideration cash payment shionogi company reduce balance sheet liability record income statement total contingent consideration cash payment amount million million include cash payment shionogi million million strategic report governance remuneration financial statement investor information gsk annual report group financial review continue financial performance continue net finance cost charge million represent effective tax rate total result reflect different finance income tax effect adjust item include interest income credit million result remeasurement defer tax asset follow enactment propose fair value movement change corporate income tax rate tax adjust profit amount million represent effective adjust tax rate finance expense interest expense unwind discount provision issue relate taxation describe note financial statement taxation group continue believe remeasurement fair value movement adequate provision liability likely arise finance expense lease liability period open agree tax finance expense authority ultimate liability matter vary amount provide dependent outcome agreement relevant tax authority comparative result restate consistent basis previously publish reflect demerger consumer healthcare business noncontrolle interest total net finance cost million compare allocation total profit continue operation million adjust net finance cost million noncontrolling interest amount million compare million increase mainly million increase primarily increase allocation drive cost associate sterling note repurchase viiv healthcare profit million million high interest tax offset increase include gilead upfront settlement income partly offset interest income high interest rate large cash increase credit remeasurement contingent consideration balance result consumer healthcare demerger liability high net profit group entity noncontrolle interest share tax profit associate joint allocation adjust earning continue operation venture noncontrolle interest amount million share tax loss associate joint venture million increase allocation primarily reflect increase million million share profit allocation viiv healthcare profit million million high net profit group loss disposal interest associate entity noncontrolle interest group report net loss disposal earning share continue operation interest associate million primarily drive loss disposal interest associate innoviva inc total ep continue operation compare primarily reflect million profit tax upfront income receive settlement gilead increase profit turnover growth cer fair take account net finance cost share profit value gain investment include retain stake associate loss disposal interest associate profit haleon partly offset high remeasurement charge taxation million compare contingent consideration liability unfavourable million comparison credit million taxation result remeasurement defer tax asset taxation adjust eps compare aer cer cer turnover increase operate current year charge leverage growth sale specialty medicine include hiv vaccine beneficial mix low inventory rest world current year charge adjustment writeoff high royalty income low chargecredit respect prior period effective tax rate partly offset increase investment total current taxation launch specialty medicine include hiv total defer taxation vaccine plus high supply chain cost freight taxation total profit distribution cost high noncontrolle interest growth low margin covid solution sale reduce adjust comparative result restate consistent basis eps growth aer cer previously publish reflect demerger consumer healthcare business gsk annual report group financial review continue financial performance continue profit earning share discontinue guidance outlook operation gsk expect turnover increase cent discontinue operation include consumer healthcare adjust operate profit increase cent business certain corporate cost directly attributable adjust earning share increase consumer healthcare business profit taxation cent guidance provide cer exclude discontinue operation amount million contribution covid solution million include million gain arise outline guidance group certain demerger consumer healthcare split assumption healthcare sector different market distribute shareholder demerger million profit group operate delivery revenue taxation discontinue operation retain stake financial benefit current portfolio pipeline million addition profit taxation restructuring programme phase quarterly result discontinue operation consumer healthcare business result comparator gsk expect turnover million million adjust operating profit growth slightly low half ep discontinue operation compare include challenge comparator increase primarily reflect gain arise somewhat high second half relative fullyear demerger consumer healthcare business expectation despite ongoing recovery healthcare system detail impact covid pandemic uncertain economic condition prevail market gsk operate total earning share continue expect variability performance quarter total eps compare increase primarily reflect profit taxation discontinue expect sale specialty medicine increase mid high operation recognise consumer healthcare business singledigit cent sale vaccine increase midteen demerger upfront income receive settlement cent sale general medicine decrease slightly gilead increase profit fair value gain investment partly offset high remeasurement charge contingent covid solution consideration liability unfavourable comparison base know bind agreement government gsk credit million taxation anticipate significant covid pandemicrelate sale operate profit sale covid solution dividend billion expect reduction turnover board declare interim dividend result total growth approximately reduction adjust dividend year share retrospectively adjust operate profit growth company share consolidation dividend share continue discuss future opportunity support government retrospectively adjust share consolidation note healthcare system patient covid solution financial statement dividend address emergence new covid variant concern dividend policy june new gsk investor update gsk set progressive dividend policy implement guide percent payout ratio investment cycle dividend policy total expect cash distribution respective dividend payout ratio gsk remain unchanged gsk previously state expect declare share dividend half share dividend second half share dividend share consolidation target dividend share increase step share consolidation maintain aggregate dividend payout absolute sterling term accordingly consolidation ratio gsk expect dividend fourth quarter convert new ordinary share result expect total dividend second half new ordinary share expect dividend convert new ordinary share line original expectation convert share consolidation round strategic report governance remuneration financial statement investor information gsk annual report group financial review continue adjust item profit divestment adjust result reconciliation discon intangible intangible significant december total tinued asset asset major transaction legal adjust result operation amortisation impairment restructure relate item result turnover cost sale gross profit sell general administration research development royalty income operate expenseincome operating profit net finance cost share aftertax loss associate joint ventures profit taxation taxation tax rate profit taxation continue operation profit taxation discontinue operation gainslosse demerger remeasurement discontinue operation distribute shareholder demerger profit taxation discontinue operation total profit taxation year profit attributable noncontrolle interest continue operation profit attributable shareholder continue operation profit attributable noncontrolle interest discontinue operation profit attributable shareholder discontinue operation total profit attributable noncontrolle interest total profit attributable shareholder earning share continue operation earning share discontinue operation total earning share weight average number share million gsk annual report group financial review continue financial performance continue profit divestment adjust result reconciliation discon intangible intangible significant december total tinued asset asset major transaction legal adjust result operation amortisation impairment restructure relate item result turnover cost sale gross profit sell general administration research development royalty income operate expenseincome operating profit net finance cost loss disposal interest associate share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation continue operation profit taxation discontinue operation gainslosse demerger profit taxation discontinue operation total profit taxation year profit attributable noncontrolle interest continue operation profit attributable shareholder continue operation profit attributable noncontrolle interest discontinue operation profit attributable shareholder discontinue operation total profit attributable noncontrolle interest total profit attributable shareholder earning share continue operation earning share discontinue operation total earning share weight average number share million comparative result restate consistent basis previously publish reflect demerger consumer healthcare business impact share consolidation implement july strategic report governance remuneration financial statement investor information gsk annual report group financial review continue financial performance continue profit divestment adjust result reconciliation discon intangible intangible significant december total tinued asset asset major transaction legal adjust result operation amortisation impairment restructure relate item result turnover cost sale gross profit sell general administration research development royalty income operate expenseincome operating profit net finance cost share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation continue operation profit taxation discontinue operation gainslosse demerger profit taxation discontinue operation total profit taxation year profit attributable noncontrolle interest continue operation profit attributable shareholder continue operation profit attributable noncontrolle interest discontinue operation profit attributable shareholder discontinue operation total profit attributable noncontrolle interest total profit attributable shareholder earning share continue operation earning share discontinue operation total earning share weight average number share million comparative result restate consistent basis previously publish reflect demerger consumer healthcare business impact share consolidation implement july gsk annual report group financial review continue adjust item continue profit discontinue operation cash charge million separation preparation programme primarily arise restructure discontinue operation include consumer healthcare administrative function global supply chain business certain corporate cost directly attributable function commercial noncash charge consumer healthcare business profit taxation million primarily reflect writedown asset discontinue operation amount million administrative manufacturing location impairment million include million gain arise asset demerger consumer healthcare split distribute shareholder demerger total cash payment million million profit taxation discontinue operation million million million relate retain stake million addition profit separation preparation restructure programme million taxation discontinue operation consumer relate significant acquisition nil million healthcare business million million million relate legacy programme include settlement certain charge accrue previous intangible asset amortisation quarter description information intangible analysis major restructuring charge income asset amortisation statement line follow intangible asset impairment description information intangible cost sale asset impairment individual intangible asset account sell general administration material impairment research development total major restructuring cost continue major restructure integration operation pharmaceutical sector highly regulate comparative result restate consistent basis manufacturing operation supply chain long life previously publish reflect demerger consumer cycle business mean restructure programme healthcare business particularly involve rationalisation closure benefit restructuring programme manufacture site likely year billion primarily relate separation preparation complete restructuring programme major restructuring cost relate specific group initiate separation preparation boardapprove major restructuring programme programme prepare separation gsk exclude adjusted result major restructuring company programme aim programme include integration cost follow material acquisition structural drive common approach improve capital significant scale cost individual relate allocation project exceed million ordinary course small align improve capability efficiency global scale restructuring cost retain total adjust support function support gsk result optimise supply chain product portfolio total major restructuring charge incur include divestment noncore asset million million analyse follow prepare consumer healthcare operate standalone company non non cash cash total cash cash total programme deliver billion annual saving target deliver billion total cost separation estimate billion billion expect preparation cash cost proceed divestment largely cover restructure cash cost programme programme significant acquisition legacy program comparative result restate consistent basis previously publish reflect demerger consumer healthcare business strategic report governance remuneration financial statement investor information gsk annual report group financial review continue adjust item continue transactionrelated adjustment viiv healthcare contingent consideration liability fair value ifrs explanation accounting transactionrelated adjustment continue operation noncontrolle interest viiv healthcare set result net charge million million include net million accounting charge remeasurement contingent consideration liability divestment significant legal charge liabilitie pfizer option pfizer shionogi preferential dividend viiv healthcare item divestment significant legal charge item chargecredit primarily include million upfront settlement income contingent consideration shionogiviiv receive gilead fair value gain investment healthcare joint venture include shionogi include million retain stake haleon preferential dividend milestone income gain number asset viiv healthcare option pfizer disposal partly offset certain adjusting item preferential dividend contingent consideration novartis discontinue operation vaccine business group start report additional cost contingent consideration acquisition prepare establishment consumer healthcare affinivax business independent entity separation cost adjustment present discontinue operation total total transactionrelated charge separation cost incur million comparative result restate consistent basis million include million relate transaction cost previously publish reflect demerger consumer incur connection demerger preparatory healthcare business admission cost relate list haleon million charge relate contingent total separation cost date million include consideration shionogiviiv healthcare joint million relate transaction cost venture represent increase valuation contingent consideration shionogi result unwind discount million charge million primarily adjustment sale forecast settlement gilead update exchange rate assumption million charge relate viiv healthcare option pfizer preferential dividend represent increase valuation option result settlement gilead offset low cash update exchange rate assumptionsgsk annual report group financial review continue cash generation conversion summary consolidate cash flow statement set capital expenditure financial investment cash payment tangible intangible fix asset amount million million disposal realise million million cash payment total net cash inflow operating activity acquire equity investment amount million total net cash outflow invest million sale equity investment realise activity million million total net cash inflowoutflow financing activity decrease cash bank overdraft free cash flow free cash flow cash generate group cash bank overdraft begin year meeting obligation contingent consideration exchange adjustment interest tax dividend pay noncontrolle interest decrease cash bank overdraft capital expenditure property plant cash bank overdraft end year equipment intangible asset cash bank overdraft end year comprise cash cash equivalent free cash inflow overdraft comparative result restate consistent basis previously publish reflect demerger consumer healthcare business reconciliation net cash inflow continue total cash payment shionogi relation viiv operating activity free cash inflow healthcare contingent consideration liability year million million million reconciliation net cash inflow operating activity recognise cash flow operating activity close equivalent ifrs measure free cash flow million recognise contingent consideration pay show invest cash flow payment deductible tax purpose net cash inflow continue operating activity future cash flow purchase property plant equipment long term expect future cash generate purchase intangible asset operation sufficient fund operate debt proceed sale property plant servicing cost normal level capital expenditure obligation equipment exist licensing agreement expenditure arise proceed sale intangible asset restructure programme routine outflow include net finance cost tax pension contribution dividend subject dividend joint venture associate principal risk uncertainty discuss page contingent consideration pay report time time additional demand invest activity finance acquisition access multiple contribution noncontrolle interest source liquidity short longterm capital market distribution noncontrolle interest financial institution need addition cash free cash inflow flow operation comparative result restate consistent basis previously publish reflect demerger consumer healthcare business investment appraisal capital allocation strong framework capital allocation include board govern allocation capital business utilise consistent cash return invest capital croic methodology prioritise investment group effectively compare return business allocate capital consider impact ep credit profile relevant strategic report governance remuneration financial statement investor information gsk annual report group financial review continue financial position resource property plant equipment business sciencebase technologyintensive highly asset regulate governmental authority allocate significant noncurrent asset financial resource renewal maintenance property plant equipment property plant equipment vehicle minimise risk right use asset interruption production ensure compliance goodwill regulatory standard number process use intangible asset hazardous material investment associate joint venture total cost property plant equipment investment december million net book value defer tax asset million land building represent derivative financial instrument million plant equipment vehicle million asset noncurrent asset construction million invest total noncurrent asset million new property plant equipment mainly current asset relate large number project renewal inventory improvement expansion facility worldwide current tax recoverable site support new product development launch trade receivable improve efficiency exist supply chain derivative financial instrument property mainly hold freehold new investment finance current equity investment liquid resource december liquid investment contractual commitment future capital expenditure million believe property plant facility cash cash equivalent adequate current requirement asset hold sale total current asset right use asset total asset right use asset amount million december liability compare million december current liability decrease year reflect impact depreciation shortterm borrowing transfer asset hold saledistribution million contingent consideration liability million respectively disposal impairment trade payable amount million partly offset addition derivative financial instrument business combination million addition current tax payable million shortterm provision total current liability goodwill noncurrent liability goodwill decrease million december million primarily result transfer asset longterm borrowing hold saledistribution million consumer corporation tax payable healthcare demerger partially offset increase defer tax liability million acquisition sierra oncology affinivax pension postemployment benefit provision intangible asset derivative financial instrument contingent consideration liability intangible asset include cost intangible noncurrent liability acquire party computer software net book value intangible asset december total noncurrent liability million million decrease total liability primarily reflect transfer asset hold saledistribution net asset million impairment loss net reversal total equity amortisation million offset addition net disposal writeoff million exchange rate gain milliongsk annual report group financial review continue financial position resource continue investment associate joint venture trade payable hold investment associate joint venture december trade payable carry value december million million compare million december million note financial statement investment note financial statement trade associate joint venture detail payable decrease mainly drive consumer healthcare demerger profit share collaboration offset current equity investment increase promotional activity region current equity investment amount million december nil current equity investment comprise provision equity investment group hold intention sell carry defer tax provision shortterm sell short term acquire noncurrent provision million december intention measure fair value profit million provision yearend include loss fvtpl initially record fair value plus million million relate legal transaction cost remeasure subsequent reporting dispute million million relate major date fair value unrealised gain loss recognise restructuring programme provision legal income statement investment million nil dispute indemnify disposal liability employee represent share hold haleon demerger relate liability cost restructure programme extent balance sheet date legal investment constructive obligation exist reliably estimate held investment carry value december million million pension postemployment benefit significant investment hold december account pension postemployment vir biotechnology nimbus discovery investment arrangement accordance ias net deficit fair value december million million million pension arrangement million million million respectively million million unfunded post investment include equity stake company employment liability note financial statement research collaboration provide pension postemployment benefit access biotechnology development potential interest interest company arise business divestment noncurrent liability noncurrent liability amount million derivative financial instrument asset december million hold current derivative financial asset fair value million million noncurrent derivative financial contingent consideration liability asset hold fair value nil million majority contingent consideration amount million financial instrument relate foreign exchange contract december million million designate designate accounting hedge million represent estimate present value amount payable shionogi relate viiv healthcare inventory million nil represent estimate present value inventory amount million contingent consideration payable shareholder december decrease mainly drive affinivax million million represent consumer healthcare demerger partially offset vaccine estimate present value contingent consideration payable stock build novartis relate vaccine acquisition liability shionogi million respect trade receivables preferential dividend explanation accounting trade receivables amount million noncontrolle interest viiv healthcare set million december decrease mainly drive consumer healthcare demerger low total contingent consideration payable posttax pandemic adjuvant sale compare year basis december million million expect pay year consideration defer tax asset payable expect pay number year defer tax asset amount million result total estimate liability discount million december present value posttax basis posttax discount rate derivative financial instrument liabilitie shionogiviiv healthcare contingent consideration liability hold current noncurrent derivative financial liability discount novartis vaccine contingent fair value million million primarily consideration liability discount partly partly relate foreign exchange contract designate designate accounting hedge strategic report governance remuneration financial statement investor information gsk annual report group financial review continue financial position resource continue maturity profile bond debt equivalent gbp bonds eur bond usd bond net debt december gsk cash liquid investment hold follow liquid investment bank balance deposit cash cash equivalent treasury treasury repo money short term borrowing market fund long term borrowing liquidity fund net debt end year cash cash equivalent liquid investment government security december net debt billion compare billion december comprise gross debt billion cash liquid investment billion net cash liquid investment billion billion debt reduce billion primarily billion free cash hold centrally december flow continue operation billion disposal equity analysis cash gross debt effect investment billion decrease discontinue hedging follow operation result demerger primarily reflect billion preseparation dividend attributable gsk fund consumer healthcare debt partly offset purchase liquid investment business billion net cash acquire reflect cash cash equivalent acquisition sierra oncology affinivax dividend pay gross debt fix shareholder billion net adverse exchange impact float billion translation nonsterle denominate debt net debt exchange financing item billion purchase equity investment movement net debt december gsk shortterm borrowing include overdraft lease liability repayable month billion billion repayable total net debt begin year subsequent year decrease cash bank overdraft decrease liquid investment net decrease longterm loan net decrease shortterm loan repayment lease liability debt subsidiary undertaking acquire exchange adjustment noncash movement decreaseincrease net debt continue operation decreaseincrease net debt discontinue operation total net debt end year gsk annual report group financial review continue financial position resource continue total equity contractual obligation commitment december total equity decrease financial commitment summarise note million december million financial statement commitment summary movement equity set follow table set contractual obligation commitment december fall payment total equity beginning year total comprehensive income year total yrs yrs yrs noncash distribution noncontrolle interest deconsolidation subsidiary loan dividend shareholder interest loan ordinary share issue finance lease obligation change noncontrolle interest future finance charge lease noncash dividend shareholder lease contract hedge gainloss transfer nonfinancial commence asset intangible asset transaction noncontrolle interest property plant sharebase incentive plan equipment tax sharebase incentive plan investment contribution noncontrolle interest purchase commitment distribution noncontrolle interest pension post total equity end year retirement benefit total share purchase commitment respect loan future interest payable december gsk hold million share treasury loan disclose take account effect share million share cost million derivative million deduct retain earning enter number research collaboration develop new compound pharmaceutical ordinary share repurchase period january company term arrangement include march company expect upfront fee equity investment loan commitment ordinary share repurchase remainder fund specify level research addition million treasury share transfer agree payment future milestone employee share ownership plan esop trust achieve million share transfer prior share consolidation agreement relate compound early share hold trust satisfy future exercise stage development potential obligation option award group share option award milestone payment continue number year scheme compound successfully development proportion share hold trust respect process generally close product marketing award rule scheme require gsk satisfy approval great probability success amount exercise market purchase issue show intangible asset represent maximum new share share hold trust match pay milestone achieve option award grant decrease commitment result reduction outstanding loan commitment december esop trust hold million million gsk share future exercise share option share award carry value million million deduct reserve market value share million million strategic report governance remuneration financial statement investor information gsk annual report group financial review continue financial position resource continue connection demerger consumer healthcare normal course business provide december pension scheme valuation identify cash indemnification guarantee respect business disposal fund technical provision deficit gsk pension legal dispute subsequently arise scheme scottish limited partnership slp provision outflow resource consider established provide funding mechanism gsk probable reliable estimate likely define benefit pension scheme slp hold outcome dispute include note share represent total issue share capital financial statement provision haleon provide outcome tax legal dispute pension scheme slp interest entitle outflow resource consider probable receive distribution slp equal reliable estimate outflow december net proceed sale haleon share receive dispute provision dividend income haleon share receive possible reliable estimate aggregate equal agree threshold proceed potential outflow fund require settle threshold proceed threshold total million dispute possibility outflow increase notional interest remain balance remote time time payment fully fund ultimate liability matter vary significantly cash funding technical provision deficit amount provide dependent scheme show december valuation negotiation relevant tax authority outcome proceed threshold reach gskcontrolled litigation proceeding relevant discuss general partner slp entitle sell remain principal risk uncertaintie page haleon share hold slp distribute proceed note financial statement legal gsk december million remain proceeding outstanding pension trustee contingent liability contingent liability set note financial statement contingent liability follow table set contingent liability comprise performance guarantee letter credit item arise normal course business expect expire total yrs yrs yrs guarantee contingent liability total gsk annual report group financial review continue approach tax business make major contribution public purse seek maintain open constructive relationship tax contribution include direct taxis tax authority worldwide meeting regularly discuss tax corporate income tax indirect taxis vat affair real time business update possible custom duty taxis employment monitor government debate tax policy key taxis property taxis important jurisdiction understand share inform company explain approach tax help inform point view potential future change tax law dialogue tax tax policy relevant provide pragmatic constructive supportive effort ensure company business input tax policy maker directly appropriately transparent tax affair industry trade body advocate reform support economic manage tax strategy set detail growth job creation need patient public policy section website key stakeholder support exchange countrybycountry reporting group corporate tax charge million cbcr datum tax authority validate million profit tax million exist information hold taxpayer support million represent effective tax rate ability ensure multinational group pay right cash tax payment tax right place million year million addition taxis pay profit pay duty levy transactional global biopharmaceutical company employment tax substantial business employment presence country world pay significant adjust tax rate tax include corporate income tax business rate benefit closure open issue tax tax associate employee collect tax authority jurisdiction subject material significant tax behalf government change product mix material change tax supply chain include employee regulation law country operate group average effective adjust tax rate subject taxation supply chain expect worldwide nature operation mean crossborder supply route necessary ensure supply group total tax rate medicine numerous country result conflict lower adjust tax rate reflect different tax claim tax authority profit tax effect adjust item individual country lead double taxation government confirm spring finance bill profit tax country include legislation introduce global minimum profit recognise territory reference activity corporate income tax rate effect detail perform value generate ensure measure account profit recognise jurisdiction align activity finalise possible accurately quantify undertaken line current oecd guideline impact gsk stage base transfer pricing policy arm length principle detail corporate tax charge year support transfer price economic analysis set note report comparative result restate consistent basis engage artificial tax arrangement previously publish reflect demerger consumer business commercial substance seek healthcare business avoid tax use tax haven transaction fully disclose tax authority zerotolerance approach tax evasion facilitation tax evasion tax risk country operate manage robust internal policy process train compliance programme board director audit risk committee responsible approve tax policy risk management arrangement wide internal control framework strategic report governance remuneration financial statement investor information gsk annual report group financial review continue treasury policy report sterling pay dividend sterling cash interest rate risk management flow role treasury monitor manage gsk objective minimise effective net interest cost group external internal funding requirement balance mix debt fix float interest financial risk support strategic objective gsk rate time policy interest rate risk management operate global basis primarily subsidiary limit net float rate debt specific cap company manage capital ensure review agree annually board subsidiary able operate go concern optimise return shareholder appropriate foreign exchange risk management balance debt equity treasury activity govern objective minimise exposure overseas operating policy approve annually board director subsidiarie transaction risk match local currency recently october treasury management income local currency cost possible foreign group tmg meeting chair chief financial officer currency transaction exposure arise external internal take place regular basis review treasury activity trade flow selectively hedge gsk internal trading member receive management information relate transaction match centrally manage activity intercompany payment term reduce foreign currency risk possible manage cash surplus borrow treasury operation requirement subsidiary company centrally forward objective gsk treasury activity minimise contract hedge future repayment originate posttax net cost financial operation reduce currency volatility order benefit earning cash flow gsk use variety financial instrument finance operation order reduce foreign currency translation exposure derivative financial instrument manage market risk seek denominate borrowing currency operation derivative principally comprise foreign principal asset cash flow primarily exchange forward contract swap denominate dollar euros sterling swap borrowing liquid asset currency require borrowing swap currency require group purpose interest rate swap borrowing denominate swap foreign manage exposure financial risk change interest currency match investment overseas group asset rate treat hedge relevant asset derivative exclusively hedge purpose forward contract major currency reduce relation underlie business activity trading exposure group investment overseas group asset speculative instrument tmg review ratio borrowing asset major currency regularly capital management commodity risk management gsk financial strategy implement group financial architecture support gsk strategic priority objective minimise income statement volatility arise regularly review board manage capital fluctuation commodity price practical structure group appropriate mix debt cost effective tmg authorise approve equity continue manage financial policy execution certain financial derivative hedge commodity credit profile particularly target shortterm credit rating price exposure maintain single longterm rating counterparty risk management consistent target set global counterparty limit banking gsk longterm credit rating standard poor investment counterpartie base longterm credit rating stable outlook moodys investor service moodys moodys standard poor usage limit stable outlook shortterm credit rating actively monitor breach limit standard poor moodys respectively report chief financial officer immediately liquidity risk management addition relationship bank credit rating gsk policy borrow centrally order meet anticipate review regularly change rating occur funding requirement cash flow forecast funding change investment level authority limit requirement monitor tmg regular basis appropriate banking counterparty limit review strategy diversify liquidity source range annually facility maintain broad access financial market day sweep cash number global subsidiary central treasury account liquidity management purposesgsk annual report group financial review continue critical accounting policy group consolidated financial statement medicaid programme stateadministere prepared accordance international accounting programme provide assistance certain poor standard conformity requirement vulnerable patient medicaid drug rebate company act international financial program establish reduce state federal reporting standard ifrs issue international expenditure prescription drug patient accounting standard board iasb protection affordable care act law participate provide rebate state accrual require estimate assumption medicaid rebate calculate base specific affect amount asset liability revenue expense term relevant regulation patient protection report financial statement actual amount affordable care act result differ estimate cash discount offer customer encourage critical accounting policy relate follow area prompt payment accrue time turnover invoicing adjust subsequently reflect actual taxation note experience legal dispute note record accrual estimate sale return apply historical experience customer return contingent liability note amount invoice marketrelate information pension postemployment benefit note stock level wholesaler anticipate price information judgement estimate increase competitor activity area give note financial statement critical reconciliation gross turnover net turnover accounting judgement key source estimation commercial operation follow uncertainty turnover margin margin margin respect turnover accounting policy large gross turnover business commercial operation market complex arrangement rebate discount marketdriven segment allowance follow briefly describe nature government arrangement existence commercial operation mandate arrangement certain indirect customer state programme customer able buy product cash discount wholesaler reduce price chargeback represent customer return difference invoice price wholesaler prior year indirect customer contractual discount price adjustment accrual estimate chargeback calculate base item term agreement historical experience total deduction product growth rate net turnover customer rebate offer key manage care group purchasing organisation direct indirect reconciliation revise include vaccine customer arrangement require customer commercial operation year achieve certain performance target relate value marketdriven segment consist primarily manage care product purchase formulary status predetermine market medicare plan negotiate contract pricing share relative competitor accrual customer rebate honour rebate chargeback mandate estimate base specific term agreement segment consist primarily medicaid federal historical experience product growth rate government programme receive government mandate pricing rebate chargeback strategic report governance remuneration financial statement investor information gsk annual report group financial review continue critical accounting policy continue overall sale deduction percentage sale consistent involved significant legal proceeding year year sale growth come primarily trelegy respect possible meaningfully assess specialty product include viiv deduction outcome result probable outflow year split approximately follow general medicine quantify reliably estimate liability result specialty medicine vaccine ultimate resolution proceeding case appropriate disclosure case include december total accrual rebate discount annual report provision allowance return commercial operation amount million million position change time assurance loss result outcome monthly process operate monitor inventory level legal proceeding exceed material wholesaler abnormal movement process use provision report group financial gross sale volume prescription volume base party statement datum source information receive key wholesaler aim maintain inventory consistent level like pharmaceutical company face year year base pattern consumption complex product liability antitrust patent litigation investigation operation conduct basis commercial operation inventory level governmental regulatory agency wholesaler distribution channel december year general counsel group head group estimate approximately week legal function senior vice president head turnover calculation use party information global litigation group responsible accuracy totally verify believe litigation government investigation routinely brief sufficiently reliable purpose chief executive officer chief financial officer board director significant litigation pende legal dispute group governmental investigation group respect accounting policy legal dispute follow briefly describe process meeting appropriate detail status significant determine level provision necessary litigation government investigation review matter number claim notify information accordance requirement ias provision potential claim notify assessment validity contingent liability contingent asset provide claim progress settle claim recent settlement anticipate settlement cost outflow resource level potential reimbursement insurer consider probable reliable estimate likely outcome dispute legal expense meeting include assessment arise claim group sufficient information available able reliable estimate potential outcome dispute external counsel assist litigation matter investigation assist briefing board senior management follow discussion matter possible reliable estimate provision require level provision legal dispute review adjust appropriate matter discuss note financial statement legal proceeding strategic report strategic report approve board director march iain mackay chief financial officer march gsk annual report corporate governance section board gsk leadership team chair governance statement corporate governance architecture ahead board oversight key decision engagements board committee report director report strategic report governance remuneration financial statement investor information gsk annual report board sir jonathan symonds cbe skill experience nonexecutive chair jon extensive international financial life science governance experience jon serve independent nonexecutive director hsbc holdings plc april age deputy group chairman august retirement board nationality british february previously chairman hsbc bank plc chief financial officer appoint september novartis partner managing director goldman sachs chief financial officer astrazeneca plc partner kpmg governance experience include role nonexecutive director chair audit committees diageo plc qinetiq group plc nonexecutive chair proteus digital health inc nonexecutive director rubius therapeutics inc jon fellow institute charter accountant england wale external appointment nonexecutive director genomics england limited previously serve chairman nonexecutive chair energy aspect member european round table industry senior advisor chatham house dame emma walmsley skill experience chief executive officer prior appointment gsk ceo emma ceo gsk consumer healthcare joint venture gsk novartis creation march emma join gsk age loreal work year variety role paris london new york nationality british shanghai emma previously nonexecutive director diageo plc appoint january emma hold classic modern language oxford university chief executive officer external appointment april independent director microsoft inc iain mackay skill experience chief financial officer prior join gsk iain group finance director hsbc holdings plc position hold year charter accountant iain live work asia europe age hsbc general electric schlumberger dowell price waterhouse iain nationality british previously trustee british heart foundation chair audit risk committee appoint january iain hold business study account hold honorary doctorate chief financial officer aberdeen university scotland april iain member institute chartered accountant scotland iain step cfo executive director continue employee leave company december external appointment nonexecutive director chair audit risk committee member remuneration committee national grid plc member court university aberdeen chair remuneration committee member group chair stakeholder communication reporting committee elizabeth liz mckee anderson skills experience independent nonexecutive director liz bring significant experience commercial biopharmaceutical season biotech board member significant experience commercial biopharmaceutical age operationally board level deep understanding biotechnology sector nationality american invaluable gsk pure biopharma company appoint september prior current role liz serve worldwide vice president commercial leader infectious disease vaccine immunology oncology janssen pharmaceutical vice president general manager wyeth vaccine liz previously board member bavarian nordic huntsworth plc external appointment board member biomarin pharmaceutical inc board member revolution medicines inc board member insmed inc trustee wistar institute director aro biotherapeutic company key committee chair corporate responsibility science nomination corporate governance audit risk remunerationgsk annual report board continue charles bancroft skill experience senior independent nonexecutive charlie wealth financial management experience global biopharma director charlie retire successful career bristol myers squibb bms march hold number leadership role commercial strategy finance begin career age bms hold position increase responsibility finance organisation nationality american commercial operational responsibility latin america middle east africa canada appoint japan pacific rim country appoint chief financial officer senior independent nonexecutive director chief financial officer executive vice president global business operation july executive vice president head integration strategy business development charlie successfully steer bms period strategic transformation include billion acquisition celgene charlie serve member board colgate palmolive company march external appointment board member kodiak sciences inc board member biovector inc advisory board member drexel universitys lebow college business board determine charlie recent relevant financial experience agree appropriate qualification background audit committee financial expert hal barron skill experience nonexecutive director hal join gsk chief scientific officer president august transition role nonexecutive director additional responsibility support age prior join gsk hal president calico llc california life company nationality american alphabetfunde company use advanced technology increase understanding appoint january lifespan biology prior hal executive vice president head global product chief scientific officer development chief medical officer roche responsible product president april combine portfolio roche genentech genentech senior vice president transition role nonexecutive development chief medical officer hal nonexecutive director chair director august science technology committee juno therapeutics inc march acquire celgene corporation hal previously serve nonexecutive board director grail inc advisory board member verily life sciences llc external appointment ceo board cochair altos labs inc associate adjunct professor epidemiology biostatistics university california san francisco anne beal skills experience independent nonexecutive director anne bring extensive healthcare experience board physician entrepreneur combine passion patient advocacy recognise health policy expert age development global national programme improve healthcare access nationality american patient group ensure voice patient reflect research programme appoint prior current role anne spend year harvard medical school massachusetts general hospital instructor paediatric hold leadership role commonwealth fund aetna foundation anne previously deputy executive director chief engagement officer patientcentere outcomes research institute chief patient officer global head patient solution sanofi external appointment founder ceo absolutejoi skincare board member academyhealth board member prolacta bioscience key committee chair corporate responsibility science nomination corporate governance audit risk remuneration strategic report governance remuneration financial statement investor information gsk annual report board continue harry hal dietz skill experience independent nonexecutive director hal bring extensive experience field human genetic central gsk approach president american society human genetic scientific medical expert recognise world lead authority genetic disorder know marfan syndrome age bring experience development novel therapie particular relation nationality american diseasemodifye treatment fibrotic neurodegenerative disease total hal author original publication peerreviewe journal career appoint january physician scientist dedicate entire career care study individual heritable connective tissue disorder primary perturbation extracellular matrix homeostasis function lab identify gene condition use model system elucidate disease mechanism hal receive multiple prestigious award include curt stern award american society human genetics colonel harland sanders lifetime achievement award medical genetics taubman prize excellence translational medical science harrington prize american society clinical investigation harrington discovery institute pasarow award cardiovascular research inbevbaillet latour health prize country belgium research achievement award american heart association inductee american society clinical investigation american association advancement science association american physicians national academy medicine national academy sciences external appointment victor mckusick professor paediatric medicine molecular biology genetics department genetic medicine johns hopkins university school medicine investigator howard hughes medical institute consultant chair scientific advisory board aytu biopharma independent chair gsk human genetic scientific advisory board found previously scientific adviser blade therapeutic jesse goodman skill experience independent nonexecutive director jesse bring scientific public health expertise board deliberation wealth experience span science medicine vaccine regulation public health scientific medical expert prove record addressing press public health need academic federal age sector nationality american jesse previously serve senior leadership position food drug administration appoint january fda include recently fdas chief scientist previously deputy commissioner science public health director center biologics evaluation research cber jesse play leadership role develop fda regulatory science medical countermeasure initiative work collaboratively industry academia government global public health regulatory partner prepare respond major public health threat include emerge infectious disease disaster terrorism lead fdas response west nile virus influenza pandemic serve senior leadership team white house medical countermeasure review jesse previously member scientific advisory committee regulatory legal working group coalition epidemic preparedness innovation cepi external appointment professor medicine attend physician infectious disease georgetown university direct georgetown university center medical product access safety stewardship compass board member president united states pharmacopeia usp board member scientific counselor infectious disease center disease control prevention cdc board member intellia therapeutics inc member national academy medicine board member adaptive phage therapeutics inc key committee chair corporate responsibility science nomination corporate governance audit risk remunerationgsk annual report board continue urs rohner skill experience independent nonexecutive director urs broad business bank legal background extensive senior level experience multinational company age urs serve chairman number board recently credit suisse group nationality swiss april prior join credit suisse urs serve chairman appoint january executive board ceo prosieben prosiebensat media follow number year private practice major law firm switzerland admit bar canton zurich switzerland state new york external appointment member international advisory board investcorp chair vega cyber associates vishal sikka skill experience independent nonexecutive director vishal distinguished background technology particularly field artificial intelligence machine learn central gsk approach age founder ceo vianai systems inc silicon valleybase company provide nationality american advanced technological software service machine learn large appoint july enterprise world prior found vianai system vishal serve ceo infosys limited member executive board sap vishal phd artificial intelligence stanford university coauthore research abstract relate technology database management external appointment founder ceo vianai systems inc board member oracle corporation member supervisory board bmw key committee chair corporate responsibility science nomination corporate governance audit risk remuneration director depart manvinder singh vindi banga sept july retired board appointment haleon plc board effective demerger dame vivienne cox july july lynn elsenhans july july retired board year service laurie glimcher sept oct retired board year service strategic report governance remuneration financial statement investor information gsk annual report gsk leadership team glt skill experience emma walmsley emma join gsk glt board biography page chief executive officer iain mackay iain join gsk glt board biography page chief financial officer diana conrad diana appoint chief people officer member glt april chief people officer previously senior vice president pharmaceuticals play key strategic role leader people culture agenda support transformation diana join gsk canadas team hold role increase responsibility senior vice president consumer healthcare prior join gsk hold role company include capital gennum corporation zenon environmental laboratories diana honour bachelor art mcmaster university canada james ford james join glt appoint senior vice president group svp group general counsel general counsel later take responsibility compliance corporate security investigation join gsk serve general counsel consumer legal compliance healthcare general counsel global pharmaceutical vice president corporate legal act head global ethic compliance prior gsk james solicitor clifford chance dla hold law degree university east anglia diploma competition law king college qualified solicitor england wales attorney new york state bar james base london practise law live singapore hong kong james cochair usbase civil justice reform group director european general counsel association association corporate counsel sally jackson sally join glt march senior vice president global communications ceo svp global communication office lead communication government affair function globally ceo chief staff ceo office prior sally senior vice president office ceo cfo previously serve head investor relation join gsk sally hold degree natural science university cambridge luke miel luke join gsk glt chief commercial officer responsible chief commercial officer commercial portfolio medicine vaccine luke cochair portfolio investment board tony wood member viiv healthcare board outside gsk luke member singapore economic development board previously work astrazeneca executive vice president european business prior executive vice president global product portfolio strategy global medical affair corporate affair head asia roche base shanghai singapore prior hold role increase seniority roche sanofiaventis europe asia luke hold bachelor science degree biology flinder university adelaide mba macquarie university sydney shobie ramakrishnan shobie join glt appoint chief digital technology officer chief digital technology officer join gsk deep broad experience biotech hitech company recently lead digital technology gsk global commercial organisation transform company capability digital data analytic play pivotal role establish agile commercial operating model join gsk shobie hold senior technology leadership role organisation include astrazeneca salesforce genentech roche member board director remediant member board director sustainableitorg shobie hold bachelor degree electronic engineering vellore institute technology university madra india iain mackay step board glt succeed cfo julie browngsk annual report gsk leadership team continue skill experience david redfern david join glt chief strategy officer responsible corporate president corporate development development strategic planning previously senior vice president northern europe responsibility gsk pharmaceutical business region senior vice president central eastern europe join gsk david appoint chairman board viiv healthcare limited nonexecutive director aspen pharmacare holdings limited board bachelor science degree bristol university chartered accountant regis simard regis join glt president pharmaceutical supply chain president global supply chain responsible manufacturing supply gsk medicine vaccine addition lead quality environment health safety sustainability corporate level regis join gsk site director france rise senior vice president global pharmaceutical manufacture current role previously hold senior position sony konica minolta tyco healthcare member board viiv healthcare mechanical engineer hold mba phil thomson phil join glt appoint president global affairs president global affair responsibility group strategic approach stakeholder engagement reputation policy development previously phil senior vice president communication government affair join glaxo wellcome commercial trainee phil chair whitehall industry group hold degree english history russian study durham university deborah waterhouse deborah appoint glt january chief executive officer ceo viiv healthcare president viiv healthcare april addition viiv deborah lead gsk global health organisation gsk global health deborah join gsk prior viiv senior vice president primary care gsk business strong track record performance specialty primary care deborah lead hiv business head hiv centre excellence pharma europe hold role general manager australia new zealand senior vice president central eastern europe deborah nonexecutive director schroders plc hold degree economic history english literature liverpool university tony wood tony appoint chief scientific officer cso designate january chief scientific officer cso head member glt august join gsk pfizer senior vice president medicinal science technology responsible science technology platform drive delivery new innovation tony lead largescale global organisation drug discovery development multiple therapeutic area include immunology oncology infectious disease time pfizer tony responsible invention new antiretroviral medication treat hiv infection fellow academy medical sciences honorary fellow royal society chemistry rsc high honour give rsc fellow royal society biology tony bsc chemistry phd organic synthesis university newcastle postdoctoral fellow imperial college london currently visit professor imcm oxford glt member depart hal barron member glt chief scientific officer august transition nonexecutive director roger connor member glt president global vaccine december leave company strategic report governance remuneration financial statement investor information gsk annual report chair governance statement important year gsk recent history see delivery strong operational financial performance successful demerger consumer healthcare establishment new gsk fully focus global biopharma company intensity board work support oversee require number additional meeting schedule illustrate board activity predemerger january july postdemerger july december routine additional routine additional board board nomination corporate governance nomination corporate governance science science corporate responsibility corporate responsibility audit risk audit risk remuneration remuneration chair chair additional activity additional activity development approval demerger cfo succession documentation forecast zantac litigation haleon plc haleon chair appointment board business development development gsk remuneration policy development investor approval gsk board development cso succession business development execute demerger create new gsk include heart robust focus shareholder value creation embody ambition company board work half year primarily communicate investor update february occupy oversee smooth execution demerger haleon previously june gsk consumer healthcare gsk result creation strong business culminate approval gsk circular haleon prospectus overwhelmingly approve shareholder general meeting july vote cast favour work separation process discipline board approach gsk investor haleon investor haleon deliver demerger update update demerger creation worldleading consumer healthcare business competitive longterm growth prospect compelling financial proposition newly focus gsk strengthen balance sheet haleon chair haleon prospectus investment pipelinerd board circular appointment publish company clear target upperquartile growth set investor updatesgsk annual report chair governance statement continue investor update set believe consider deal respect contribution competitive financial aspiration new gsk ambition period cumulative topline growth operate profit growth board review proposal know exclude covid solution important aspect establish focus aspiration billion billion sale value associate transaction ambition board enter lightly contribute further strategy plan important demonstration confidence board process include appraisal approval business determination hold accountable acquisition stepchange improve performance strong operational financial performance good platform sierra oncology biopharmaceutical company focus progress target therapy rare form cancer acquisition include momelotinib new medicine unique dual similarly haleon focus topline growth mechanism action intend address critical unmet aspiration signal business upper quartile medical need myelofibrosis patient anaemia growth potential view robustly test unsolicited conditional nonbinding proposal acquire affinivax clinical stage biopharmaceutical company consumer healthcare business receive exercise provide gsk access generation fiduciary duty proposal evaluate reject pneumococcal vaccine candidate highly innovative board good interest shareholder multiple antigen presenting system know map proposal fundamentally undervalue transaction review board include haleon business future prospect board licensing agreement spero therapeutic confident haleon deliver sustain organic sale tebipenem hbr latestage antibiotic target treat growth range cer medium term complicated urinary tract infection significant unmet pleasing separation haleon medical need subsequently announce strong performance collaboration wave life science bring key aspiration gsk restructuring wave oligonucleotide platform gsk expertise gsk balance sheet appropriate level debt genetic genomic haleon seek ensure competitiveness company separation gsk ability continue collaboration tempus provide gsk access invest external internal science improve tempus aienable platform include library refinance approximately billion indebtedness deidentifie patient datum world large successfully complete quarter time source clinical molecular datum opportune give current environment gsk receive billion preseparation dividend attributable gsk shareholder perspective engagement fund consumer healthcare debt continue hold board believe importance maintain high haleon share divest course continuous level engagement shareholder date publication report hold business development individual meeting range investor previously describe succession process approximately company share register charle follow cso transition hal barron tony bancroft appoint new sid demerger wood please smooth process hold introductory meeting shareholder make make good progress register please able board receive regular report wood hold annual governance meeting london december science committee follow review person meet extend progress achieve organic inorganic business invitation shareholder represent holding total development approximately share register event please representative participate virtually efficient board cadence support person prime importance maintain clear scientific screening target undertake understand investor view company science committee advance board performance meeting help achieve provide consideration ensure confident key input board plan scientific rationale underpin deal progress board proposal late late stage target asset undertake commercial review forecast commercial assumption underpin strategic report governance remuneration financial statement investor information gsk annual report chair governance statement continue board priority externally facilitated board review agree priority way work focus value creation governance oversight ahead strategy delivery performance target execution pipeline business development longterm strategy approach peopletalentculture esg leadership zantac litigation defence mitigation focus shareholder value creation new gsk board priority frame board discussion consider strategic decision action take join board september gsk enter period significant transition run separation connect business people group board engage structured externally facilitate appraisal governance architecture follow covid restriction board able board committee output board meet person time set aside enable agenda focus link directly business nonexecutive director informal time need innovation pipeline performance culture glt member present meet separation refine committee architecture colleague meeting location reinforce priority board board committee follow separation time set new board priority hall business advisory company engage board agenda seeks focus duplicate facilitate work follow success previous review work committee remit define agenda support work comprise key aspect priority committee chair continue responsible sharing board work committee undertake review current way work main issue oversee highlight recommendation improvement establish specific committee paper believe benefit priority board agenda year board wider understand nonexecutive director evaluation board committee attend committee meeting access agenda paper time time chair committee board align management deliver new specific board committee convene ahead purpose strategy culture strong specific topic create flexibility enable board emphasis value creation time period nearterm agile require give increase biopharma base deliver public commitment expertise new board management medium longterm board sharing proposal opportunity early stage programme set accordingly facilitate efficient decisionmake report formal independent external board follow snapshot aspects board committee performance review set committee work board culture decisionmake audit risk committee assist establishment board fully support new purpose strategy robust internal control risk management control performance culture new gsk wellpositione framework haleon independent list company deliver public commitment growth create confirm gsk framework remain fit new sustainable longterm value board discussion focus future committee take lead role complete powerful combination science technology talent scrutiny subsequently recommend board realise gsk desire culture support aim demerger list document shareholder approval general meeting july ambitious patient accountable impact right thinggsk annual report chair governance statement continue demerger group share price performance science committee good progress second half year impact uncertainty committee continue support ambitious agile associate zantac product liability litigation development pipeline organically committee continue primary board smart business development oversee review accountability zantac litigation include accounting application science committee support seamless disclosure communication assessment behalf transition leadership tony wood hal board committee clear remit recommend barron tony role key architect rebuild pipeline decision navigation litigation board key appropriate reiterate point company corporate responsibility committee new culture gsk remain confident position matter power purpose drive defend vigorously claim bring delivery strategy help gsk place nomination corporate governance committee people thrive committee continue focus support demerger consumer healthcare business oversight evolve company esg performance assist haleon chair designate completing please able report track composition haleon board include transfer new esg rating reassure demerger serve director vindi banga enhancement esg report datum oversight dame vivienne cox committee feel strongly remuneration committee focus new remuneration particular skill experience valuable haleon policy fundamental architecture new importantly provide continuity gsk postseparation critical build strong new haleon board performance culture generate sustain delivery committee focus continue complete shareholder value new policy seek achieve composition new gsk board change key linkage executive remuneration reward glt key focus deepening board scientific outperformance biopharma skills committee select new director engage extensively shareholder shareholder strong emphasis life science technology help representative body develop new policy deepen biopharma expertise experience recognise importance new reward system support vishal sikka worldleade technologist field new gsk success final policy modify reflect advanced enterprise technology extraordinary feedback receive whilst recognise sizeable minority credential machine learn shareholder vote continue engage shareholder demonstrate importance liz mckee anderson deep commercial expertise place rewarding overperformance policy large specialty biopharma specific crucial stage new gsk development strong experience global commercialisation market access operational financial performance company specialism respiratory immunology vaccine encourage start gsk hiv underperformed term tsr share price performance julie brown join gsk april incoming cfo year new policy firmly focus address considerable list pharmaceutical commercial reversing trend outturn award experience recognise significant improvement performance board scientific credential ideally suit overall good progress board new purpose strong clear increase investor confidence industry move away broad experience ability group sustain growth board originally join pleased decade debate discussion board committee meeting thank continued support look forward evolve new purpose deep connect year annual enrich result committee continue recruit general meeting share continue diverse director scientific biopharma expertise progress meet evolve need board oversee company strategy global biopharma business sir jonathan symonds chair march strategic report governance remuneration financial statement investor information gsk annual report corporate governance architecture board ceo chair corporate science nomination audit risk remuneration committee responsibility committee corporate committee committee committee governance glt committee corporate governance architecture framework design improve effectiveness board support oversight gsk leadership team glt delivery strategy continue evolve support infrastructure priority pure biopharma business gsk internal control risk management arrangement integral overall corporate governance framework describe page page ensure framework optimal effectiveness require clear division responsibility individual collective board role describe appropriate distribution workload board committee requisite focus skill highly commit board director motivate discharge role responsibility success company ommittee role committee report committee role focus membership chair act behalf board schedule meeting decision urgent sir jonathan symonds matter accordance matter authority delegate board time company chair time senior independent director chair board committee corporate consider gsk trust priority oversight responsible business approach esg anne beal chair responsibility strategy performance reporting reflect important issue responsible jesse goodman sustainable business growth oversight view interest internal vishal sikka external stakeholder review issue potential impact gsk business reputation science support board understand key strategic theme company hal dietz chair strategy base external transaction perform indepth review january underlie scientific assumption board technical assurance undertake jesse goodman indepth risk oversight rdrelate risk chair december hal barron nomination review structure size composition board appointment member sir jonathan symonds corporate board committee appointment corporate officer make recommendation chair governance board appropriate plan assess orderly succession executive charles bancroft nonexecutive director review management succession plan ensure adequacy anne beal urs rohner responsible reporting board oversee monitor corporate governance arrangement make recommendation board ensure company standard arrangement consistent exist corporate governance standard emerge good practice review board glt conflict interest audit risk review financial reporting process integrity company financial statement charles bancroft external internal audit process system internal control identification chair management risk company process monitor compliance law elizabeth mckee regulation ethical code practice oversee esg datum report assurance anderson urs rohner initiate audit tender selection appointment external auditor set remuneration exercise oversight work remuneration set company remuneration policy regard gsk workforce remuneration urs rohner chair gsk able recruit retain motivate executive charles bancroft anne beal remuneration policy regularly review ensure consistent company elizabeth mckee scale scope operation support business strategy growth plan align anderson wide workforce help drive creation shareholder value chair ceo responsible evaluating make recommendation board remuneration arrangement policy nonexecutive director board committee write term reference approve board review annually ensure comply late legal regulatory requirement reflect good practice development current term reference board committee available gskcom board committee meeting attendance oversight company policy external appointment set gsk annual report corporate governance architecture continue leadership independent oversight rigorous challenge chair nonexecutive director jonathan symond provide strong independent element board lead manage business board constructively support challenge management provide direction focus scrutinise performance achieving agree ensure clear structure effective operation deliverable board committee shape proposal strategy offer specialist advice maintain dialogue shareholder management governance company letter appointment set term set board agenda ensure sufficient time condition directorship allocate promote effective debate support sound devote time necessary proper decisionmake performance duty ensure board receive accurate timely clear expect attend meeting require information meet continuously nonexecutive director independence statement discuss individual contribution performance board consider nonexecutive director train development need identify page exception share peer feedback provide hal barron independent assess board evaluation process provision financial reporting council frc meet regularly nonexecutive director corporate governance code code independently executive director independence commitment jesse goodman chair role description available gskcom urs rohner serve board year subject rigorous review chief executive officer gsk nonexecutive director role description available gskcom emma walmsley responsible management group senior independent director business charles bancroft develop group strategic direction consideration act sound board chair trust approval board intermediary director implement agree strategy nonexecutive director lead support member glt annual review chair performance take maintain continual active dialogue account view executive director shareholders respect company performance discuss result chair effectiveness review chair chief executive officer role description available gskcom lead search appointment process make recommendation board new chair act additional point contact shareholder maintain understand issue concern major shareholder meeting investor briefing company secretary investor relation senior independent nonexecutive director role description available gskcom company secretary secretary board board committees victoria whyte supports board committee chair annual agenda planning ensure information available board member timely fashion support chair designing deliver board induction coordinate continue business awareness training requirement nonexecutive director undertake internal board committee evaluation request chair advise director board practice procedure corporate governance matter chair group disclosure committee operate boardapprove appointment policy reflect board external appointment requirement code point contact shareholder corporate governance matter strategic report governance remuneration financial statement investor information gsk annual report corporate governance architecture continued board committee attendance nomination corporate corporate board chair responsibility science governance audit risk remuneration total number routine meeting current member attend attend attend attend attend attend sir jonathan symonds emma walmsley iain mackay elizabeth mckee anderson hal barron charles bancroft anne beal harry dietz jesse goodman urs rohner vishal sikka retire member vindi banga dame vivienne cox lynn elsenhans laurie glimcher number additional meeting number bracket denote number meeting individual eligible attend board committee change details committee member skill experience include biography board page frc corporate governance code provision require alignment pension rate executive director available local workforce financial experience january current executive director pension rate accordance frc code board align wide workforce local determine charle bancroft recent relevant replicate requirement pension arrangement financial experience agree new executive director appoint gsk appropriate qualification background audit committee financial expert define sarbane addition provision require base salary oxley act determine pensionable pension arrangement employee independent mean security exchange allow basic salary bonus pensionable follow act amend hal barron transition nonexecutive director effect august frc code requirement compliance meet board please report compliance provision frc code board please report consistently exception code provision apply principle frc code set page remuneration report copy code available frc website wwwfrcorguk nonexecutive director expect devote time necessary performance duty director require attend minimum schedule board committee meeting recognise rare occasion possible special allowance give year board membership calendar align high attendance record schedule board committee meeting director serve set board director external appointment govern board approve policy external appointment help board glt member widen expertise knowledge perform role effectively propose new nonexecutive director appointment board approval board take account demand individual time prior appointment board individual require disclose significant commitment indication time involve additional prospective external appointment serve board director consider approve board note nature role type organisation time commitment potential conflict envisage company secretary maintain register commitment potential conflict board satisfied give director interest sufficient time carry role executive nonexecutive director undertake maximum list company directorship respectivelygsk annual report ahead board oversight board discharge responsibility annual programme meeting paper presentation provide board committee focus strengthen fundamental element business ahead pursuit company strategy deliver gsk growthbased performance ambition oversee demerger list haleon establish gsk pure biopharma business drive esg leadership priority paper presentation highlight relevant stakeholder impact perspective material enable board effective decisionmake input oversight business performance governance key item business consider critical gsk longterm success achievement gsk key priority highlight area focus demerger board preparation demerger valuebased process include list haleon discuss strategy plan consumer healthcare period separation haleon receive regular performance report scrutinise oversee consumer healthcare capital market day approach material support appointment haleon board include transition vindi banga dame vivienne cox haleon scrutinise respond unsolicited proposal consumer healthcare business advance demerger approve gsk shareholder circular recommend demerger oversee haleon prospectus approval demerger subsequent gsk share consolidation build gsk board oversight creation gsk pure biopharma business delivery stepchange performance include pure biopharma regularly discuss scrutinise transformation plan gsk business scutinising update strategy progress progression company pipeline request remuneration committee renew remuneration policy focus incentivise overdelivery reward new performance culture board management succession planning include approval appointment new chief scientific officer transition hal barron nonexecutive director appointment new independent nonexecutive director new chief financial officer approval charles bancroft successor vindi banga role senior independent director approval change approach workforce engagement ahead board oversight fundamental commercial execution cost base management capital allocation pipeline culture include strengthen set approve board priority fundamental receive regular progress update provide input company vaccine mrna strategy plan value creation receive discuss commercial strategy performance report pharmaceutical vaccine viiv healthcare receive update strategy pipeline progress approve business development transaction acquisition strategic partnership party include sierra oncology affinivax mersana therapeutic spero therapeutic wave life science tempus receive quarterly report ceo cfo cso scrutinise group financial performance set company new purpose simplify culture new code conduct enhance board oversight new culture embed esg core esg leadership approve support new gsk culture approve responsible business section annual report approve task force climaterelate financial disclosure section annual report final approval pricing access policy principle oversee gsk overall response situation ukraine regular board programme governance include corporate review quarterly financial result dividend proposal earning guidance investor material result announcement governance receive report external auditor oversight approve final annual report form set annual budget forwardlooke threeyear plan conduct annual review board enterprise risk responsibility framework enterprisewide risk undertake annual board evaluation implement agree outcome review continue evolve board governance architecture evaluate ceo performance set objective review talent succession plan annually receive report board committee work engage gsk stakeholder wide workforce gather understand view company activity operation review employee pulse survey result receive report wide corporate governance regulatory development company secretary report approve company modern slavery statement gender pay gap positioning review stakeholder perception research strategic report governance remuneration financial statement investor information gsk annual report ahead board oversight continue action point board performance consideration discussion follow action board evaluate performance point improve performance agree committee year evaluation normally carry key area focus board continue externally year facilitate organic inorganic meeting pipeline goal jan hall business advisory company deliver shareholder value see connection gsk board feel priority helpful conduct evaluation follow completion demerger haleon importance science committee working formation gsk new biopharma company cso help optimise pipeline support onboarde new cfo julie brown preparation board succession planning progress ensure meet chair ceo advance evaluation broad range diverse candidate consideration update board operate understand successor remuneration committee chair gsk future priority agree review objective scope timetable company secretary provide board committee access board committee material review board committee focus progress information involve virtual interview committee member conduct behalf respective committee interview chair committee consider operate effectively november december conduct follow enhancement agree confidential detailed interview board select glt member company secretary gsk external auditor importance optimise concise feedback committee chair board follow income outgoing independent remuneration committee meeting adviser seek view board effectiveness meeting reflect agree discussion guideline follow agreement overall board priority send participant include key topic board agenda committee chair agree review financial reporting council guidance main area responsibility committee line board effectiveness relevant requirement board priority incorporate corporate governance code limit committee programme feedback participant particular importance science committee support organic inorganic evolve review way committee work cso review seek determine board priority team year build board agenda evaluation result suggest chair step include summary report compile discuss initially chair ceo senior sid seek feedback chair performance independent director sid review present director individually collectively conclude board january cover follow main area chair operate effectively lead board effectiveness review result review note discuss chair sid overall review board board organisation agenda information board dynamic challenge input future strategy development performance deliverygsk annual report key decision engagement particular board continuous engagement section statement investor people set section page companys corporate governance architecture board member require law promote success process summarise page organisation benefit shareholder wide stakeholder include employee supplier summary set board consider relevant community statement meet requirement set matter make principal decision contribute section section cza company act formation attractive viable business act state year director compelling investment proposition address matter set section deliver separation haleon gsk strong act perform duty focus shareholder value demerger board consider statement focus risk build gsk pure biopharma company opportunitie strategically important gsk ambitious patient accountable impact consistent group size complexity allow right thing new gsk properly understand potential impact decision make stakeholder demerger represent key step multiyear transformation gsk improve focus performance engagement main stakeholder group include competitiveness maximise value shareholder patient shareholder consumer customer employee demerger provide right opportunity implement level organisation summarise legal change company glaxosmithkline page strategic report plc gsk plc design mark new gsk brand culture protect build future change longterm result likely consequence decision long term newly independent global leader consumer health focus strategy drive penetration growth end board assess company portfolio capitalise new emerge growth readiness proceed demerger approve opportunity underpin strong execution gsk circular agree haleon prospectus send financial discipline haleon independent company shareholder final stage demerger able deliver sustainable abovemarket board exercise section duty review growth moderate sustainable adjust operate margin work management audit risk corporate expansion medium term attractive return responsibility remuneration transformation shareholder separation committee progress separation new gsk pure biopharmaceutical company mid include portfolio focus vaccine specialty medicine extensive consultation hold key stakeholder general medicine clearly define financial sharing longterm growth ambition investor ambition clear ambition deliver largescale event gsk june haleon february longterm positive human health impact strong consider reject unsolicited conditional balance sheet enable growthoriente capital nonbinding proposal receive acquire consumer allocation policy attractive shareholder return healthcare business board believe demerger unlock recommend proposal create potential business strengthen balance sheet independent company effectively serve new gsk ability invest growth maximise patient customer respectively board firmly longterm return shareholder believe decision establish shareholder duly approve resolution propose general meeting hold july demerger effect july strategic report governance remuneration financial statement investor information gsk annual report key decision engagement continue workforce interest group employee attend glt member nonexecutive board member include chair board continual regard interest people remain new gsk addition annual bonus longterm depart form haleon achieve incentive structure board give special thank employee voice mechanism describe page people exclude glt allow recognise help explain future shape company achieve preparation understand assess impact change demerger transformation company organisation experience pure biopharma company result receive people oneoff payment equivalent week salary march separate bonus payout significant focus dedicate bring life new gsk ahead purpose strategy culture people ensure treatment award option group strong emphasis give hold gsk employee depart haleon individual ownership new culture formally employee deliver fair outcome accordance launch june event hold rule share scheme demerger company location globally gsk share consolidation business relationship importance develop group business ethical behaviour promote business relationship supplier customer support people right thing work supplier share standard operate key imperative board gsk responsible responsible way new code conduct seek set business ensure company develop monitor expectation regard partnership ultimately serve patient benefit relationship support party expect meet abac achievement ambition describe page labour right standard comply standard strategic report example quality health safety environment approximately total emission footprint come achieve ahead ambition positively good service buy september impact health billion people end support net zero carbon impact climate require development vaccine medicine ambition launch sustainable procurement make available responsible pricing programme require supplier strategic access programme partnership thing disclose emission set carbon reduction target switch renewable power heat community environment establish area esg focus new gsk global biopharma company fundamental impact group operation community dna success area detail page environment directly contribute longterm shareholder value approach make positive impact guide contribute health impact support thrive extensive stakeholder engagement key issue people reduce risk environment relevant new gsk prior demerger haleon principal esg focus area environmental respective industry nature company scorecard measure introduce longterm board seek achieve incentive plan incentivise reward progress preparation demerger working haleon deliver net zero impact climate net management team develop distinctive positive impact nature public ambition responsible business approach esg framework board focus new gsk ahead bespoke need customer ambition impact live billion patient community serve involve scrutinise year human capital key gsk framework propose target include seek strengthen early stem education environmental sustainability target present investment support longterm diverse talent haleon investor update february pool increase positive impact volunteering activity community servegsk annual report key decision engagement continue reputation desire maintain reputation high standard reach agreement trustee gsk business conduct pension scheme package measure include funding protection relation demerger duty guide board approach demerger gsk pension scheme triennial actuarial valuation creation new gsk achieve ensure gsk remain company transformation company initially launch operate point demerger override early include fundamentally review emphasis drive topline growth improve margin structure cost base way work effectiveness biopharma consumer healthcare implement plan area esg focus new business implement target enhancement gsk outline investor june help retain advance demerger develop gsk reputation esg leadership responsible business conduct choose optimal form separation demerger list location structure develop distinctive holistic responsible business haleon gsk result haleon operate case esg framework haleon outline premium list legal corporate governance investor february support haleon standard environment common business purpose strategy culture premium list ethical value gsk company focus key responsible business issue extensive legal financial diligence ensure board people new gsk engagement key regulator investor key commit annually new code conduct introduce stakeholder undertake prepare gsk june code sets board endorse circular haleon prospectus haleon ahead purpose culture performance commitment people deliver company ambition right way fairness shareholder aim act fairly member group shareholder receive prorate shareholding haleon demerger receipt haleon fundamental importance board able share gsk share hold additionally haleon ensure shareholder treat fairly share inception demerger equal demerger demonstrate right participate capital dividend profit decide appropriate capital structure distribution haleon require company competitive gsk share consolidation achieve consistency stock exchange haleon list gsk share price pre postdemerger enable extent distribute share haleon gsk comparability new gsk earning share shareholder retain stake haleon share price previous period preserve shareholder right vote vote far reasonably possible value share option share basis general meeting demerger award grant people demerger new gsk share consolidation relate party transaction resolution ensure shareholder possible participate meet shareholder able ask question vote electronically person vote majority excess record resolution approach continuous engagement board place main stakeholder heart renew culture people stakeholder rightly high expectation ambitious patient accountable impact dynamic operating environment present challenge right thing culture describe page opportunity board aim sure strategic report commercially successful balanced align meeting stakeholder expectation uphold reputation influence importance different stakeholder group maintain licence operate building trust vary depend matter consider certain board engage brief view stakeholder interest conflict meaning board stakeholder ensure identifie respond need balanced judgement expectation effectively appropriately continuous stakeholder engagement feedback help engage main stakeholder group including identify emerge issue enable board patient shareholder consumer customer employee decision context relevant important company cover page strategic report strategic report governance remuneration financial statement investor information gsk annual report key decision engagement continue principal board committees glt undertake workforce engagement dame vivienne conclude engagement board behalf accordance workforce engagement activity half year remit mean build detailed understanding prior transfer haleon board july action plan areor impact stakeholder separation consumer healthcare business insight share board programme visit conduct basis describe previous annual report particular board receive briefing stakeholder perspective work corporate responsibility dame vivienne provide focus employee engagement committee discuss page designate workforce engagement director december tenure coincide entirety board member regularly receive programme transform gsk focus biopharma ceos board report company demerger consumer healthcare form specific external stakeholder report provide haleon continue question gather feedback strategic insight base analysis key development board employee future strategy shape achievement risk impact reputation culture new independent company perception external stakeholder build separation hold listening event crosssection regular investor relation report summarise investor perception consumer healthcare employee april prior transfer haleon regular corporate governance litigation regulatory update digital tech employee june help ensure strong secure technology platform board learn stakeholder view company engagement feedback event quarterly prior separation board review formal workforce investor result call annual general meeting employee engagement arrangement decide survey report board workforce engagement specific workforce engagement director model apply activity expert present board committee alternative arrangement method set meeting addition chair investor checkin meetings frcs code give new gsk board recently hold ongoing basis new sid charle refresh term tenure half independent bancroft join meeting charles meet nonexecutive director ned serve individually investor introduce gain year gsk renew purpose focus personal understanding issue view global biopharma company consider important adopt collective board engagement model agree opportunity board member gain wide effective approach ensure new board stakeholder view annual strategy meeting member meet people hear view glt annual review strategy budget implement planning process include review specific aspect return direct inperson reception local employee company policy strategy addition board member follow covid restriction board site visit encourage meet individually employee second half include stevenage shareholder key stakeholder induction global hub boston ongoing basis encourage report global brentford board experience relevant material chair undertaking range site visit include raleigh people durham meet viiv employee king cross london meet artificial intelligence wellestablishe strong engagement machine learn team respiratory supply mechanism colleague describe chain employee base ware aranda spain page monitor regularly board key governance channel help communicate chair corporate responsibility committee chair people think board meeting leader employee resource group erg discuss experience gsk regular board update chief people officer hear view progress diversity equity ceo culture talent inclusion dei agenda ambition feedback range pulse survey vary size utilise variety bespoke engagement employee group help check sentiment culture enable broad open dialogue facilitate quickly frequently provide valuable insight hand engagement discussion ned impact major initiative event communication people individually small group direct engagement board prior demerger encompass perspective strategy purpose designate workforce engagement director dame ahead culture dei vivienne cox specific mandate connect peoplegsk annual report key decision engagement continue shareholder annual governance meeting board seeks directly engage directly year event hybrid meeting central london accountable institutional investor private retail institutional shareholder key investment industry body shareholder seeks discharge direct continuous proxy advisory firm invite institutional accountability way include regular shareholder attend event represent approximately communication annual general meeting general company issue share capital chair meet annual governance meeting join new sid committee chair gsk external work investor relation team chair sir jonathan audit partner successor symond company secretary victoria whyte share investor priority focus board year ceo emma walmsley cfo iain committee progress mackay give quarterly result presentation institutional include investor analyst medium webcast execution clear plan separation haleon regularly join cso chief commercial officer gsk strong focus shareholder value creation ceo viiv healthcare gsk global health able creation attractive viable business provide investor detailed insight specific compelling investment proposition area responsibility build highlyqualifie board complement regular meeting emma iain ongoing world class management team active dialogue institutional shareholder performance plan objective ceo hold rearchitecting gsk board total engagement major shareholder represent support haleon board build approximately company share register cfo hold total engagement investor make approval new bind remuneration policy align nearly company share register delivery gsk public growth esg commitment announce investor update june chair maintain constant dialogue shareholder include fund portfolio manager continuous engagement shareholder engage governance esg professional stakeholder date publication report meeting wellreceive shareholder feedback chair hold meeting range investor share subsequently board approximately company share register annual general meeting enable gain current understanding investor view please able hold hybrid meeting insight perspective company discuss sofitel heathrow meet aspect board governance oversight succession able hold person attendance onset charles bancroft appoint new sid july covid pandemic pleased increase demerger consumer healthcare business attendance shareholder compare introduce shareholder seek view agm hold virtually register office gsk discuss key matter importance brentford shareholder join meet person appointment sid date publication report shareholder join virtually watch listen update meeting investor make chair ceo ask question vote share register exception propose remuneration policy resolution chair ceo rest board particular focus receive shareholder approval propose communicate final process demerge resolution approve shareholder majority haleon ambition gsk global biopharma business range demerger progression pipeline agm year hold hybrid format key focus period sofitel heathrow shareholder seek investor feedback new remuneration flexibility able watch listen vote ask question policy meeting virtually lumi platform ask question video connection detail general meeting addition board convene general meeting sofitel heathrow july seek shareholder approval authorise demerger haleon relate share consolidation gsk chair ceo cfo present person company secretary rest board join meet virtually shareholder join meet person shareholder join virtually resolution approve shareholder majority excess strategic report governance remuneration financial statement investor information gsk annual report board committee report esg performance deep dive corporate responsibility committee report year committee discuss management follow area esg focus anne beal access pricing principle committee review corporate responsibility committee recommend board adoption publication please present report chair gsk pricing access principle principle corporate responsibility committee committee principle highlevel articulation management join committee succeed lynn current approach pricing access elsenhans chair july comprehensive prepare extensive internal external consultation transition handover time chair lynn validated key audience include patient outstanding contribution oversee shape advocacy group draw embed trust priority approach committee detail input principle responsible business recently establish sure capture area esg focus gsk pure biopharma company area detail page directly impact value gsk innovation term economic contribute longterm shareholder value contribute benefit health impact support thrive people reduce health equity country risk importance supply network access draw extensive healthcare experience principle sufficiently flexible evolve time physician public health expert include time subject regular review chief patient officer sanofi combine passion patient advocacy continue build committee diversity equity inclusion dei committee continue work frame work scrutiny committee regularly assess progress gsk dei approach follow question key metric identify drive performance metric support area form new esg performance company committee know rating explore perform esg focus area work include effort increase leadership challenge improve diversity build diverse talent pipeline foster inclusive performance culture committee please note strong overall good report key stakeholder progress gender level impact ethnicity aspiration particular please ethnic diversity aspiration drive board oversight enhance exceed year work esg performance undertake increase black representation central element committee work firmly believe gsk outstanding work month devoted accelerate improvement area please committee esg performance understand manage feedback utilise management improve performance maximum impact committee agree introduction disclosure new esg performance rate company kpis committee review progress effort broaden key management tool drive delivery esg diversity clinical trial participant grow supplier esg focus area rate derive assess diversity improve health equity country expand performance number stretch independently equitable access stem education assure metric focus area arrive single environment committee recently review progress composite measure committee regularly monitor company ambition net zero impact climate company progress metric net positive impact nature committee satisfy course year recommend board good progress date dual focus publication final track esg rating alongside maximise success inflight initiative esg disclosure annual report esg develop target action maintain momentum performance report detail find stretching ambition strategic report esg performance report human right committee review management available gskcom approach progress human right include supply chain party interaction consider complex rapidly evolve legal regulatory landscape human rightsgsk annual report board committee report continue esg disclosure report gsk capability respect science committee report esg report continually evolve challenge good report clearly concisely jesse goodman performance take place great scrutiny esg stakeholder esg report increasingly science committee move voluntary mandatory pleased present report chair science committee consider gsk strong mature committee committee activity esg report approach opportunity bring demerger consumer healthcare haleon level control esg data level control july financial data mind committee approve establish esg datum assurance hub key activity strengthen esg datum oversight result demerger gsk pure biopharma business goal unite science technology talent collaborating board committee well prevent treat disease combine careful division responsibility power genetic genomic insight cause allocation workload committee disease speed scale artificial intelligence remuneration committee respect introduction machine learning well prediction specific esg target short longterm incentive treatment work plan begin monitor renew focus evident committee help remuneration committee determine vest discussion time excite future outcome opportunity bring gsk patient audit risk committee arc support committee committee key activity split follow discussion introduction measurement key area cover detail disclosure esg performance rating committee pipeline review monitor gsk pipeline work closely arc year onwards scientific deepdive discussion analysis key implementation operation enhance esg datum scientific theme drive company strategy assurance oversight determination arc chair set report business development undertake technical review assurance underlie science potential business anne beal development transaction corporate responsibility committee chair march pipeline progress fundamental gsk achievement growth ambition delivery successful pipeline committee continue monitor year committee participate chief scientific officer cso succession planning process lead appointment tony wood august wood continue build outstanding progress hal barron prior appointment cso wood integrally involve deliver productivity improvement helped develop gsk current approach focus science immune system human genetic advanced technology consequently wellplaced implement pipeline deliver gsk bold ambition patient exceptional milestone year positive result latestage respiratory syncytial virus vaccine candidate vaccine demonstrate unprecedented efficacy old adult potential help reduce disease death major respiratory infection vaccine preventable regulatory submission vaccine accept review japan accept european medicine agency accelerate assessment submitted grant priority review status food drug administration fda strategic report governance remuneration financial statement investor information gsk annual report board committee report continue committee delight positive phase iii spero therapeutic licensing agreement spero result gepotidacin novel oral antibiotic treatment therapeutic tebipenem hbr latestage antibiotic uncomplicated urinary tract infection important treat complicated urinary tract infection step gsk continue scientific commitment investment significant unmet medical need novel oral antibiotic address antimicrobial resistance amr potentially provide alternative intravenous therapy particularly patient multidrug resistant organism license agreement spero therapeutic provide evidence continue leadership wave life science collaboration bring focus tackle infectious disease amr wave prismtm oligonucleotide platform gsk expertise genetics genomics drive discovery number key approval obtain year development oligonucleotide therapeutic focus fda approval boostrix immunisation pregnancy novel genetic target prevention whoop cough newborn infant tempus collaboration tempus provide gsk fda approval menveo new singlevial presentation access tempus aienabled platform include library help prevent disease cause meningococcal bacteria deidentifie patient datum world large source serogroup clinical molecular datum lead aiml fda approval priorix prevention measle mump capability gsk work tempus identify new drug rubella individual month age old target improve clinical trial design speed enrolment completion accelerate development exciting latestage pipeline personalise treatment patient robust earlystage portfolio number innovative programme capable transforming live patient gsk dedicated aiml team large inhouse strategic function biopharma industry collaboration business development transaction technology gsk increasingly important drug discovery enable gsk rapidly gsk view research development holistically effectively design new vaccine medicine place great importance external internal innovation source promise new medicine vaccine scientific deepdive year committee continue assess business development transaction scientific perspective committee dedicate significant proportion acceleration business development key support time discuss exciting innovative gsk organic pipeline growth transaction review area science driving company committee year include strategy deepdive undertaken year include sierra oncology acquisition sierra oncology phase pipeline review biopharmaceutical company focus target therapy rna base therapeutic vaccines rare form cancer acquisition include momelotinib oncology new medicine unique dual mechanism action intend address critical unmet medical need particular committee discussion rna include myelofibrosis patient anaemia new drug application oligonucleotide therapeutic provide important insight momelotinib treatment myelofibrosis emerge science potential transform life accept august fda december patient november company publish positive ema result phase iib trial evaluate safety efficacy bepirovirsen potentially transformative treatment affinivax acquisition affinivax clinicalstage people live chronic hepatitis biopharmaceutical company provide gsk access generation pneumococcal vaccine candidate highly result offer early indication bepirovirsen innovative multiple antigen presenting system map potential treatment monotherapy combination technology drug result functional cure gsk expertise human genetic functional genomics aiml mersana therapeutic collaboration mersana identify novel genetically validate target therapeutic codevelopment commercialisation recent collaboration wave life sciences refer xmt firstinclass sting antibody drug demonstrate wellpositione conjugate initially treatment advanced breast leader oligobase therapeutic cancergsk annual report board committee report continue committee change nomination corporate governance previously mention august tony wood committee report succeed hal barron cso tony outstanding jonathan symond highly respect scientist committee engage nomination corporate governance committee regularly advance appointment barron transition nonexecutive director member please present fourth report chair committee committee gsk continue nomination corporate governance committee benefit expert advice support scientific matter committee laurie glimcher retired board october key activity like thank laurie valuable expertise scientific insight contribute committee year committee continue important role tenure process finally chair committee inception deliver demerger haleon group key year ago rotation chair conclude effective board governance workstream january hal dietz join committee create attractive viable business january succeed committee chair compelling investment proposition direct overseen experience human genetic central gsk highly capable board approach prove invaluable achieve orderly target manner committee discussion excellent successor build highlyqualifie board complement world role chair class leadership team privilege work gsk outstanding support shaping creation haleon board scientist leader fellow committee member chair committee restructuring gsk board new focus expertise transformational period company pure biopharma business scientific field operate remain member committee look forward continue progress haleon board appointment outline today report year describe work committee appoint ceo cfo chair designate haleon jesse goodman disclose nonexecutive member gsk science committee chair board expect transfer haleon board march completion demerger committee subsequently support haleon chair sir dave lewis finalise search appointment high calibre nonexecutive director complete haleon board committees board subsequently endorse committee recommendation transition vindi banga dame vivienne cox haleon board completion demerger committee consider haleon board benefit knowledge experience provide important continuity haleon postdemerger separately company consumer healthcare joint venture partner pfizer exercise right appoint nonexecutive director haleon board shape new biopharma board previously describe process transition gsk board pure focus global biopharma company work undertaken committee designing plan optimal structure composition new biopharma board new nonexecutive director committee want ensure new nonexecutive director appointment deepen biopharma skill expertise experience board global search process activate appoint director deep life sciences commercial expertise artificial intelligence machine learn aiml expertise diverse list candidate identify shortlist interview committee member ceo cso chief people officer strategic report governance remuneration financial statement investor information gsk annual report board committee report continue follow careful review committee pleased committee propose board approve recommend appointment high calibre individual appointment julie brown successor iain mackay vishal sikka elizabeth mckee anderson independent cfo julie currently chief operate financial officer nonexecutive director effect july burberry group plc join gsk april work september respectively iain transition responsibility responsibility cfo executive director cfo vishal distinguished background worldleading succession process describe detail technologist particularly field aiml central gsk approach committee view ideal successor iain embrace group liz bring significant prove cfo global public company deep commercial understanding experience commercial biopharmaceutical experience need biopharmaceutical season biotech board member effective business partner ceo successful delivery contribution prove invaluable board gsk growth ambition important fully focus biopharma company committee successor good fit new culture high energy positive mindset detail vishal lizs experience biography find page rationale thorough global search initiate agree appointment include company announcement profile shortlist viable candidate identify august respectively available role ceo member committee chief gskcom people officer meet julie unanimous support recommend iain successor hal dietz appoint board end join board designate scientific medical expert board look forward welcome julie gsk january extensive experience field highly respect cfo extensive experience human genetic central gsk approach biopharma medtech sector detail julie recruitment process appointment experience rationale appointment include committee describe report year company announcement september year board dietz begin rotation science available gskcom committee chair january succession jesse glt change goodman addition new cso cfo committee senior independent director sid succession review follow internal senior executive change vindi banga perform role sid year vindi glt help bring simplification alignment transition haleon board completion demerger glt area create opportunity appoint successor luke miel chief commercial officer assume committee determine charles bancroft serve accountability strategic commercial product year board experience work development vaccine alongside current investor role cfo bristol myers squibb deep accountability strategic product development understand pharma industry experience specialty general medicine commercial nonexecutive director list company performance gsk portfolio market sufficient time dedicate role ideal successor succeed vindi effect july regis simard president global supply chain assume board fully endorse appointment accountability vaccine medicine supply deborah waterhouse chief executive officer viiv continue shape gsk board healthcare assume overall accountability gsk global future health management succession planning roger connor president vaccines global health leave gsk progress new role healthcare outside biopharma previously describe work committee appointment tony wood successor hal barron committee continue review talent succession cso member glt transition dr wood pipeline development plan key management role barron role cso nonindependent non successor executive director take effect plan august nonexecutive director succession planning cfo succession committee regularly review board composition cfo iain mackay advise board intention skill work science committee step board leave company potential add scientific medical expert committee activate cfo succession plan target board seek contribute biopharma skill search highquality executive cfo succession expertise support growth ambition committee undertake role profile look identify successor urs rohner cfo gsk pure biotech remuneration committee chair retire board look forward provide update role yeargsk annual report board committee report continue composition tenure nonexecutive tenure industry experience number board member year year year life sciences tech finance consumer predemerger postdemerger board seek balance composition tenure pure biopharma company include life science committee refresh time pharmaceutical industry tech vaccine enable board benefit experience long healthcare medical research academia financial serve director fresh perspective insight service collectively wealth experience new appointee nonexecutive director complex business global reach draw industry background relevant diversity equity inclusion ethnicity gender female composition ethnically diverse white postcfo historic expect succession demerger refocus arget female representation board datum gsk annual report publish quarter year current female representation date publication expect rise postcfo succession commit diversity board gsk attribute include character intellect judgement honesty commit equal opportunity employee level courage organisation board management seek committee responsible develop measurable encourage diverse inclusive culture objective monitor progress achievement company assist implementation board diversity policy effective board need range balance skill policy include gender ethnic diversity minimum experience knowledge ethnicity gender socialeconomic seek align policy objective financial background independence individual conduct authority ftse woman leader review parker prepare challenge collaboratively mix review diversity target ensure consistent need complement diversity personal board public diversity equity inclusion dei aspiration oard glt gender diversity diversity objective status performance board position hold woman objective woman chair sid role board andor meet objective director ceo woman chief executive officer finance director role end glt position hold woman meet objective board director ethnically diverse exceed objective director strategic report governance remuneration financial statement investor information gsk annual report board committee report continue julie brown new cfo female continue oversee develop pipeline direct board representation stand gsk report glt gender ethnically diverse allfemale executive board run ftse background company expect fully restore board gender detail gsk representation woman ethnically diversity meet exceed diverse leader cover diversity board please year gender global workforce progress dei representation objective excess target commitment include gender ethnicity illustrate board position hold woman illustrate esg performance report gskcom good previous committee report composition progress incentivise introduction diversity board currently transitional period esg dei measure annual bonus arrangement follow demerger reshape board executive director glt member new biopharma company transfer board member haleon retirement female board director board committee glt membership role change directorglt member membershiprole appointment date retirement date elizabeth mckee anderson audit risk remuneration committee september hal barron science committee follow transition role august nonexecutive director charles bancroft science committee february step hal dietz join committee senior independent director july remuneration committee july vindi banga audit risk nomination corporate governance july remuneration committee senior independent director anne beal corporate responsibility committee chair nomination corporate governance july remuneration committee audit risk committee october dame vivienne cox corporate responsibility remuneration committee july hal dietz science committee january science committee chair january lynn elsenhans corporate responsibility committee chair audit risk corporate responsibility nomination july corporate governance committees jesse goodman science committee chair december laurie glimcher audit risk science committee october urs rohner audit risk committee july vishal sikka corporate responsibility committee july roger connor president global vaccine december tony wood chief scientific officer glt member augustgsk annual report board committee report continue audit risk committee report way working committee seeks follow good practice charle bancroft appointment recommend agree criterion audit risk committee role appropriate interview panel please present report second consider comprehensive diverse long list chair audit risk committee committee candidate shortlist candidate interview assess choose criterion diligence report year speak initial favourable undertaken committee make final impression people process system culture recommendation executive search firm appoint gsk underpin successful management financial accordance company procurement policy report audit litigation compliance risk please base expertise relative role report gsk continue exhibit strong compliance culture consistent tone engagement committee agree search firm run organisation financial signatory voluntary code conduct executive reporting control framework remain robust search firm gender diversity good practice require fundamental change year engage committee work number executive search key activity firm provide additional consultancy key decision usual busy year service company outline committee work regular programme korn ferry general recruitment executive search activity make important decision support assessment service coach hrrelate board progression key priority summary service recommend board approval plan egon zehnder executive search assessment separation consumer healthcare business july coaching service specific senior executive base committee awareness review transaction haleon operational readiness heidrick struggle executive search service approval final issuance public document entry committee review potential conflict associate legal agreement interest judge appropriate exercise oversight zantac product liability litigation safeguard conflict provide regular report board progress conduct robust review process cfo look forward report progress year report select appoint replacement current lead audit partner fiveyear audit partner rotation sir jonathan symonds rule rotate publication annual report nomination corporate governance committee chair detail set march completion demerger highlight report year detail technical work committee key demerger governance workstream include oversee evolution financial reporting matter risk control public document associate deliver demerger list form haleon work continued intensify half point committee able complete review process recommend approval gsk circular haleon prospectus form associate document matter board separately committee review process establish financial reporting system development robust internal control risk management framework haleon significant critical demerger workstream successfully deliver month prior demerger businessasusual basis strategic report governance remuneration financial statement investor information gsk annual report board committee report continue information cyber security audit quality indicator principal risk regularly audit quality indicator aqi quantitative qualitative committees agenda committee oversaw measure external audit quality audit firmlevel merge programme deliverable update cyber engagement level management company maturity plan cmp additional capability continue perspective lead audit partner ahead dynamic threat environment committee please participate project carry frc review benchmarke target cyber identify useful engagement level aqi relevant maturity industry bestpractice framework know audit help improve transparency drive audit quality national institute standard technology cyber improvement engagement frc focus security framework nistcsf learning recent annual report consider interaction incorporate cmp committee continue auditor committee audit perform regular assessment delivery plan process constructive dialogue hope enhance capability maturity cyber helpful frc progressing work promote key security framework please committee driver audit quality oversight area strengthen year expertise fellow board director colleague committee aim vishal sikka advise committee enterprise committee remit expand onwards risk vishal distinguished career tech industry board request exercise oversight review serve ceo infosys limited provide committee gsk esg data assurance work committee management valuable insight currently oversee build implementation new dedicated esg datum assurance hub finance key risk indicator organisation support year compliance function work hub ensure minimum standard control risk owner management develop report governance datum quality assure accuracy esg committee key risk indicator kris enterprise level datum support company performance esg market core process metric compliance new esg reporting requirement enhancement technology datum corporate responsibility committee behalf analytic capability employ datadriven approach board continue exercise oversight esg strategy risk management constantly evolve risk performance assessment report landscape strengthen compliance oversight culture internal control framework early year committee examine review board recognise obligation present fair balanced principal risk result simplified process few kri understandable assessment gsk current position new kris revise definition prioritisation prospect reflect responsibility accountable meaningful indicator company committee evaluate approve effectiveness gsk internal pleased note simple approach result control include financial operational compliance focus few kri report risk oversight control risk management process compliance council rocc report ensure reliability financial reporting committee great focus bring bear compliance law regulation internal escalation issue concern material gsk control framework comprehensive enterprisewide risk operational datum monitor finding management model support board continuous establish risk continue analyse risk owner identification evaluation management group ensure appropriate risk mitigation continue escalation principal emerge risk require frc code necessary framework design manage risk gsk achieve business objective zantac litigation oversight year primary oversight zantac litigation fitforpurpose framework complement corporate relate accounting disclosure communication culture speak process ensure risk assessment continue undertaken associate business activity actively effectively committee report committee conclusion control line agree risk appetite believe gsk matter board committee continue receive framework provide reasonable absolute assurance regular legally privileged update december material misstatement loss welcome rule united states district court southern district florida dismiss federal case allege remain cancer multidistrict litigation continue defend claim bring state level vigorously base sciencegsk annual report board committee report continue board mandate group rocc senior leader authority delegate committee assist committee oversee risk management board conduct robust assessment group principal internal control activity provide business risk assessment line frc code framework risk management upward escalation include consideration nature extent risk significant risk risk management compliance board board willing achieve gsk strategic objective rmcbs group promote tone board committee oversee effectiveness establish risk culture ensure effective oversight internal control environment risk management internal control risk management process process group year principal risk assign risk owner draw approval date annual report senior management accountable managing review group risk management approach principal risk oversight glt member includes discuss risk management section strategic setting implement risk mitigation plan risk owner report page report quarterly respective risk management approach progress rocc appropriate board management principal risk explain committee compliance function assist rocc principal risk uncertaintie page rmcbs compliance responsible advance enterprise group viability discuss group risk management wide risk management develop riskbase section strategic report ethically sound work practice actively promote ethical behaviour enable employee operate line significant issue relate financial culture comply applicable law statement regulation consider gsk quarterly financial result announcement audit assurance function provide independent financial result annual report assurance senior management board committee review significant issue management effectiveness risk management groupwide line judgement determine result review management agree assurance plan help senior management paper set key area risk action take quantify board meet oversight advisory responsibility effect relevant issue judgement fulfil gsk strategic objective build trust management appropriate accounting require address patient stakeholder dual reporting line issue financial statement cfo committee significant issue consider relation financial committee receive regular report principal risk statement year end december set owner compliance area significant risk follow table summary financial outcome group relate internal control report assess appropriate committee external auditor internal control environment principal risk area discuss significant issue address committee include enhancement strengthen control follow year area particular audit focus consideration report committee report annually describe independent auditor report page board effectiveness gsk internal control strategic report governance remuneration financial statement investor information gsk annual report board committee report continue significant issue consider committee relation financial statement issue address committee go concern basis preparation committee consider outcome management halfyearly yearend financial statement review current forecast net debt position financing facility option available group committee consider management review impact current economic environment climate change impact follow consideration assessment include stress testing viability scenario sources liquidity funding forecast estimate committee confirm application go concern basis preparation financial statement continue appropriate revenue recognition include return committee review management approach time recognition rebate rar accrual revenue accrual customer return rebate rar accrual commercial operation billion december committee review basis accrual concurred management judgement amount involved full description process operate commercial operation determine level accrual necessary set critical accounting policy page provision legal matter include committee receive detailed report actual potential litigation investigation group internal external legal counsel include zantac litigation commercial practice number detailed update investigation group commercial practice management outlined level provision correspond disclosure consider necessary respect potential adverse litigation outcome area possible determine provision necessary december provision legal matter billion note financial statement provision detail provision uncertain tax position committee consider current tax dispute area potential risk concur management judgement level tax contingency require december tax payable liability billion include provision uncertain tax position recognise group balance sheet impairment intangible asset committee review management process review testing goodwill intangible asset potential impairment committee accept management judgement intangible asset require writing result impairment charge million note financial statement intangible asset detail valuation contingent consideration committee consider management judgement necessary relation viiv healthcare increase liability pay contingent consideration primarily result update exchange rate assumption increase sale forecast unwind discount cash payment nearly billion year december group balance sheet include contingent consideration liability billion relation viiv healthcare note financial statement contingent consideration liability detail viiv healthcare option committee review agree accounting pfizer option concur management judgement valuation option billion december consumer healthcare demerger committee review management process present consumer healthcare discontinue operation subsequent demerger accounting gain demerger billion include significant value relate fair value asset distribute ownership haleon retain net asset noncontrolle interest distributedderecognise cumulative foreign exchange recycle note acquisition disposal financial statement detailsgsk annual report board committee report continue effectiveness quality external auditor independence qualification objectivity expertise resource audit process committee commit ensure gsk receive committee agree recommend highquality effective external audit evaluate reappointment deloitte board forthcoming deloitte performance prior make agm make recommendation committee free recommendation reappointment early influence party committee review effectiveness performance criterion agree management auditor reappointment begin detailed criterion judge external auditor effectiveness deloitte external auditor available external auditor appointment gskcom base audit approach strategy tender december ensure highquality independent audit effective partnership value money transition year committee monitor engagement external shareholder approval current auditor stakeholder relevant committee area oversight include frc security exchange commission audit annual report year end december year frc audit quality review aqr team new lead audit engagement partner review deloitte audit group financial audit tender require regulation effect statement annual inspection audit firm committee receive review final report contractual similar obligation restrict aqr team identify key finding assess group choice external auditor audit require limited improvement note area good practice audit partner rotation committee seek ensure deloitte deliver external auditor require rotate audit smooth thorough efficientlyexecuted audit engagement partner gsk year undertake review committee consider current audit partner step overall quality audit position audit gsk financial statement independence deloitte conclude deloitte exhibit appropriate level challenge robust review process committee scepticism work involvement cfo select replacement deloitte length tenure take account committee approve appointment audit assess independence objectivity give engagement partner effect financial year commence role auditor commence january committee consider effectively assume role committee satisfied deloitte manage auditor committee consider feedback orderly handover new audit engagement partner external audit survey committee member ensure seamless transition maintenance high financial management team corporate level audit quality effectiveness business unit level survey cover effectiveness auditor challenge audit tender integrity deloitte committee consider company transparency reporting management comply mandatory audit process audit committee committee responsibility provision competition market authority statutory audit service order clarity auditor communication way work alignment audit group investment deloitte continue maintain independence system application product sap objectivity committee remain satisfied performance gsk intend tender external quality audit team leadership auditor contract end current require period skill experience audit team year identify consider good interest shareholder committee mindful committee chair regularly meet independently financial year new cfo gsk audit audit partner committee meet auditor partner deloitte help mitigate risk privately end meeting discuss progress overfamiliarity company auditor appropriate review feedback note area improvement implement audit team committee satisfied effectiveness auditor external audit process strategic report governance remuneration financial statement investor information gsk annual report board committee report continue nonaudit service fee pay company auditor associate set overleaf detail give note management operate presumption financial statement operate profit accountancy firm provide nonaudit services gsk external auditor skill experience year fee auditrelate assurance suitable supplier nonaudit support service million include million relate auditrelated matter tax service continue work year associate deloitte reporting good interest company line gsk accountant role prepare demerger consumer nonaudit services policy committee ensure auditor healthcare business include audit fee respect gsk objectivity independence safeguard review pension scheme million fee auditrelate preapprove external auditor provision assurance service represent annual audit service company policy complie frc service fee exclude demerger work revise ethical standard sarbanesoxley act quarterly review work fee auditrelate observe follow core policy feature engage assurance service represent external auditor nonaudit services annual audit fee gsk nonaudit services policy key feature committee rationale originally hire deloitte undertake reporting accountant role set process nonaudit service competitive gsk annual report tender financial service provider line group procurement process skill committee consider level nonaudit service experience external auditor suitable incur annual review deloitte independence supplier set previous satisfied auditor safeguard adequate safeguard establish continued independent exercise objectivity objectivity independence group audit threaten compromise fee cap total fee payable nonaudit services fair balanced understandable assessment exceed annual audit fee special circumstance clear advantage need annual report fair balanced auditor undertake additional work understandable key compliance requirement company financial statement ensure gsk annual prohibition gsk policy include whitelist permit nonaudit service line relevant regulation service report meet requirement wellestablished list prohibit document process govern coordination review preapproval nonaudit service require preapproval set groupwide contribution publication run table ensure service approve consistent parallel process follow external auditor gsk nonaudit policy permissible service committee receive summary management approach process ensure service fall scope service gsk annual report ensure meet requirement permit preapproved committee frc code enable committee represent delegation authority preapproval board confirm gsk annual report value preapprover fair balanced understandable provide necessary committee chair cfo information shareholder assess company position group financial controller performance business model strategy designate group code conduct report line financial controller number wellestablishe policy include new code conduct available gskcom audit service comparison detail confidential speak line report investigate unlawful conduct charles bancroft audit risk committee chair march audit assurance service service include tax regulatory compliance treasuryrelate service service relate consumer healthcare demerger preparation note financial statement provide detail fee payable company auditorgsk annual report director report director power nomination corporate governance committee review register potential conflict authorisation director power determine legislation register conflict january committee article association contain rule report board conflict appointment replacement director provide appropriately authorise process director appoint ordinary resolution authorisation continue operate effectively committee member resolution board provide recommend approval register conflict appoint board director retire annual board subsequently approve general meeting follow appointment describe note financial statement relate article provide director require seek party transaction end financial year reelection annually annual general meeting director person closely associate material interest accordance frc code contract significance group company director cease director article prohibit director voting resolution bankrupt concern appointment term termination appointment cease director virtue company act article independent advice suffer mental physical ill health board resolve company agree procedure director shall cease director independent legal andor financial advice company miss director meeting continuous period expense deem necessary month permission board resolve shall cease director indemnification director prohibit director law qualify party indemnity provision define company act force benefit director resign offer resign board accept offer director hold office require resign board approval signature annual report director conflict interest change control essential contract director duty company act contract arrangement avoid situation direct individually fundamental ability business indirect conflict interest possible conflict operate effectively company party company article provide general power board material agreement effect alter authorise conflict terminate change control follow takeover bid agreement director board review new potential actual conflict provide compensation loss office employment record company secretary director result takeover provision count quorum authorisation actual company share plan cause option award potential conflict nomination corporate grant plan vest takeover governance committee review register conflict annual basis board subsequently approve detail termination provision executive director service contract give version company continue basis director responsible remuneration policy available gskcom inform company secretary new actual investor section potential conflict arise change circumstance affect authorisation previously give provide authorisation director absolve statutory duty promote success company actual conflict arise postauthorisation board choose exclude director receipt relevant information participation debate suspend director board resort require director resign strategic report governance remuneration financial statement investor information gsk annual report director report continue follow information incorporate content director report director report purpose company act location annual report director report gsk plc year end december interest capitalise financial statement comprise note publication unaudited financial group financial review director report information section page detail longterm incentive scheme remuneration report corporate governance report waiver emolument director applicable employee engagement waiver future emolument director applicable director statement responsibility non preemptive issue equity cash applicable investor information non preemptive issue equity cash applicable strategic report set matter require unlisted major subsidiary undertaking disclose director report consider parent company participation place applicable strategic importance list subsidiary provision service control applicable strategic report shareholder shareholder waiver dividend financial statement section page note risk management objective policy shareholder waiver future dividend financial statement note likely future development company agreement control shareholder applicable research development activity business relationship director report diversity draw present accordance provision information consultation reliance english company law liability employees director connection report shall subject carbon emission limitation restriction provide law section statement approve board director march sign behalf sir jonathan symonds chair march gsk annual report remuneration section committee chair annual statement annual report remuneration remuneration policy summary strategic report governance remuneration financial statement investor information gsk annual report remuneration report committee chair annual statement dear shareholder engage extensively shareholder gain view feedback change table behalf remuneration committee please set detail process present remuneration report include annual statement explain committee work year result adjustment quantum clarity annual report remuneration summary disclosure outcome transparency relation remuneration policy approve shareholder target set feature final policy agm detail propose operate agm new policy approve policy year shareholder vote favour committee recognise significant minority shareholder vote gsk remuneration policy follow agm committee ensured continue detail year introduce new remuneration consultation shareholder understand range policy well link executive remuneration delivery view include vote proposal outperformance committee thank shareholder feedback new arrangement design reward delivery remain committed engage remuneration continue bold new performance ambition set investor believe incentivising outperformance stretching update deliver sale growth target create longterm value shareholder note cagr adjust operate profit growth new issue raise committee comfortable cagr ambition represent step change require annual bonus plan change performance group achievement committee review shareholder evolving deliver quartile performance sector need business advance renewal remuneration policy committee conclude design exist remuneration policy framework remain fit purpose administrative amendment remuneration give drive longterm performance policy propose shareholder approval consistent yearonyear improvement main aim agm detail set target change shortterm annual bonus plan determine key imperative remuneration outcome strong operating performance gsk year main change plan significantly reduce new remuneration arrangement highlight annual bonus opportunity belowtarget performance importance incentivising exceptional performance increase annual bonus opportunity exceptional performance salary increase overall annual set early annual report group bonus opportunity increase cash reward deliver strong sale growth vaccine specialty opportunity incremental reward deliver form medicine doubledigit growth operate profit share defer year earning share committee aware sensitivity stakeholder level executive pay remuneration policy engagement detail extensive consultation committee company chair remuneration policy prior agm vote continue engagement shareholder set investor share capital engagement event date participation represent initial individual consultation meeting october large november shareholder invitation november investor annual governance meeting attendance december investor followup letter annual governance meeting nonattendee set january february investors propose remuneration policy ask input meet remuneration committee company chair letter circulate advise feedback incorporate final remuneration march investor policy submit annual general meeting bind approval meeting hold shareholder prior agm january april investor invitation november investor annual governance meeting attendance december investor meeting hold agm publication annual report meeting february principal proxy advisory firm consult remuneration policy process include invitation annual governance meeting receipt engagement letter meeting company remuneration committee chairsgsk annual report committee chair annual statement continue remuneration award year reflect excellent operating performance alongside successful delivery pay performance outcome demerger consumer healthcare form haleon large demerger europe year lti vest outcome performance period end december annual bonus bonus outcome ceo cfo relative adjust determine reference performance stretch total sale adjust operate profit diversity equity tsr free cash flow inclusion dei target committee assessment individual performance specific strategic overall vest operational measure total sale growth rate target growth pipeline innovation rate adjust operate profit growth rate progress sale target growth rate lead overall payout financial element salary vested target set consideration give analyst lapse consensus committee comfortable payout represent exceptional performance target range set combine assessment nature strategic operational objective nonfinancial element overall payout salary executive director line agree ceo salary deliver deferred share annual bonus focus particularly individual area salary cfo salary deliver accountability deliver company strategy example defer share ceo clear pipeline delivery objective executive objective require demonstration contribution committee believe bonus outcome appropriately lead live culture performance integrity reflect overall performance achieve detail board believe critical lever longterm value provide creation gsk longterm incentive lti awards committee reflect length investor input performance share plan psp award vest appropriate esg measure focus target set pipeline progress innovation sale theme arise consultation possibility adjust free cash flow relative tsr introduce metric access medicine disappointingly nilveste relative tsr gsk industry leader area strong performance metric evidence deeply engraine company culture value vest cash flow element partial vest committee feel necessary include pipeline progress innovation sale reflect progress specific metric incentive instead committee include positive datum company potential new rsv select measure aim specific gsk challenge vaccine strong sale product launch opportunity environmental sustainability dei year include shingle vaccine shingrix generate performance target calibrate consider sale billion year number internal external reference point particular follow review contextual factor include previous analyst consensus consider financial metric payout committee believe formulaic outcomes available committee satisfied appropriately reflect performance round target set sufficiently stretch consider experience stakeholder include shareholder employee committee salary deem necessary exercise discretion incentive awards committee agree ceo receive relation accordance salary increase low average remuneration policy increase wide workforce addition average salary increase company remuneration policy implementation implement number monetary nonmonetary annual bonus lti performance measure initiative colleague reaction cost living follow change bonus crisis explain statement maintain performance measure incentive plan continue align strategic goal workforce fairness annual bonus measure annual total sale growth set executive pay important committee annual adjust operating profit growth personal good understanding group wide workforce performance strategic operational measure pay approach emphasis fairness equity esg diversity equity inclusion dei end annual basis meet senior human lti measure relative tsr total sale growth resource leader company understand year adjust operate profit growth perspective pay gsk remuneration arrangement year pipeline progress esg environment wide workforce year fourth annual composite scorecard meeting hold strategic report governance remuneration financial statement investor information gsk annual report committee chair annual statement continue performance measure align strategy performance measure alignment strategy weighting lti total sale growth ambition sale growth adjust operate profit growth ambition profit growth pipeline emphasis innovation reward acceleration strengthen pipeline relative total shareholder return alignment shareholder esg ambition nature climate ambition dei priority strategic operational individual accountability delivery strategy public ambition key annual bonus lti longterm incentive meeting discuss gsk continue support new cfo julie browns salary preliminarily diversity aspiration fair pay process proactive set line predecessor september review enhancement employee benefit salary join increase include line increase agree ceo award wide workforce new global minimum standard parental leave care family member agm review medical insure benefit focus equity finally like thank shareholder value sex couple legally possible input engagement welcome feedback new financial education support look forward receive support report annual general meeting give challenge economic environment cost living pressure country management take action support current employee attract talent urs rohner competitive salary increase oneoff support remuneration committee chair payment staff low grade enhancement march workforce wellbee programme start change annual bonus plan glt level reflect great focus consideration potential windfall gain performance new plan generally receive committee aware guidance investor payment body consider potential executive benefit arise share award grant time director change stock market fall onset covid pandemic august hal barron transition plan march role cso nonindependent nonexecutive director remuneration policy contain sufficient flexibility barron contractually entitle receive prorate reduce vest award require target bonus respect receive lti grant committee determine reduction require respect award grant march announce appointment julie brown cfo make determination committee consider iain mackay step share price follow point board previously communicate mackay continue share price time february award receive base salary leave gsk end year eligible receive annual bonus respect eligible receive lti award share price final quarter receive salary increase detail share price time march award retirement arrangement include treatment inflight lti grant previous award award find whilst upward downward movement gsk share price period take point consideration committee satisfied risk windfall gainsgsk annual report annual report remuneration total remuneration audit fix pay pay performance annual bonus vested lti awards ceo cfo overall bonus overall vest salary salary deliver share subject twoyear hold bonus period vest benefit total cash remuneration defer share pension measure vest measure total sale growth relative tsr adjust operate adjust free cash flow profit growth innovation sale individual strategic pipeline progress operational objective pivotal trial start major esg dei regulatory approval ead page page page total remuneration audit hal barron cso emma walmsley ceo iain mackay cfo july fix pay salary benefit pension total fix pay pay performance annual bonus vest psp lti awards total pay performance total remuneration note mandatory defer annual bonus plan dabp bonus deferral set payment show barron represent prorate ontarget payment respect january july lieu annual bonus opportunity barron transition role cso nonexecutive director august salary include basic salary earn time cso january july plus payment lieu accrue holiday take accordance gsk standard employee holiday pay policy nonexecutive director fee earn august december detail psp vest figure ceo inclusive topup award salary following vote favour remuneration policy company agm award vest final actual value receive psp restate annual report psp value base vest price february ad price share ad price february main date grant respect topup award ceo share price vest amount executive director attributable share price appreciation performance period committee exercise discretion relation vest award share price change value hal barron illustrative award vest august accordance term executive senior management recoupment policy actual value receive restate annual report committee specific circumstance line state principle apply malusclawback determine appropriate follow consideration committee recovery sum pay clawback reduction outstanding award vest level malus apply respect ceo cfo cso strategic report governance remuneration financial statement investor information gsk annual report annual report remuneration continue total remuneration audit continue follow section provide detail element total remuneration committee implement company shareholderapprove remuneration policy year term fix performance pay fix pay audit salary table provide analysis total benefit gross tax receive executive director table set base salary executive director year compare increase benefit benefit workforce salary emma walmsley effective date change benefit available employee businessrelate service employee april total benefit emma walmsley iain mackay january iain mackay hal barron benefit available employee businessrelate service ith effect august barron transition nonexecutive director role receive salary date receive total benefit nonexecutive director fee describe barron base salary increase effect hal barron august annual report detail benefit available employee businessrelate service detail salary level provide accommodation whilst business travel benefit total benefit remuneration reporting regulation require note company add executive director total benefit represent oneoff refund accommodation cost relate item deem tax authority taxable benefit comprise employee benefit line policy employee vary location role businessrelate service provide employee assist enable carry role tax authority deem taxable benefit individual business expense company meet tax arise item show gross tax include business travel relate business costsgsk annual report annual report remuneration continue fix pay audit continued pension january pension arrangement executive director align wide workforce detail give executive director member pension arrangement emma walmsley pension contribution base salary matching contribution iain mackay salary cash payment base salary lieu pension salary excess line plan rate hal barron july member plan open employee executive supplemental saving plan essp saving scheme open executive accrue benefit plan limit receive base salary contribution essp equivalent total base salary bonus net bonus defer dabp addition line wide workforce january combine contribution rate essp plan core contribution plus match total base salary bonus net bonus defer dabp follow table show breakdown pension value include total remuneration calculate accordance methodology set large mediumsize company group account report regulation amend remuneration regulation emma walmsley iain mackay hal barron janjul pension remuneration value define contribution define benefit employer cash contribution total pension remuneration value hal barron defer member style define benefit plan detail pension value barron set table accrue benefit annual pension accrue date calculate increase accrue benefit adjust inflation multiply reflect fact benefit receive number year normal retirement age cash balance pension plan age barron receive additional benefit retire early accrue pension pension remuneration july december value hal barron pension value fund unfunded total strategic report governance remuneration financial statement investor information gsk annual report annual report remuneration continue pay performance audit annual bonus strategic total sale adjust operating esg diversity operational growth profit growth equity inclusion annual bonus measure annual bonus performance measure follow table show annual bonus earn compare bonus opportunity bonus opportunity bonus outcome adjust strategic total sale operate operational total target maximum growth profit growth measure esg bonus total bonus salary salary salary salary salary salary salary salary bonus emma walmsley iain mackay detail mandatory deferral executive director dabp bonus set barron receive prorate ontarget payment lieu bonus opportunity transition nonexecutive director role august contractual payment accordance company remuneration policy include remuneration annual bonus table financial performance measure performance target target outcome position weight growth rate growth rate achieve total sale growth adjust operate profit growth target set follow consideration analyst consensus internal budget annual target exceed longterm sale profit target state investor update respectively committee comfortable achievement represent exceptional performance threshold maximum performance target set target growth respectively total sale adjust operating profit target outcome purpose annual bonus calculation base cer exclude commercial benefit covid solution overview performance financial performance measure see stepchange commercial execution earning guidance update year momentum grew drive strong sale growth specialty medicine vaccine exceed guidance sale operating profit deliver fullyear report group sale billion aer cer specialty growth aer cer doubledigit growth specialty therapy area vaccine growth aer record year shingrix outcome adjust exclude benefit covid solution adjust group operate profit million target drive high sale support prioritise investment effective cost control outcome adjusted exclude commercial benefit covid solution adjust eps aer cer ahead guidance exclude covid solutionsgsk annual report annual report remuneration continue pay performance audit continue strategic operational measure performance committee receive consider performance assessment report executive director show extent achievement individual personal strategic operational measure agree committee support delivery strategic commitment committee review hal barron performance july release contractual ontarget bonus payment financial element annual bonus committee satisfied scale executive director achievement year exceptional nature particular achievement relate pipeline commercial execution haleon demerger strategic operational measure performance achieve emma walmsley committee determine ceo clearly exceed meet individual objective strengthen pipeline potential new medicine vaccine candidate development phase registration build gsk reputation twothird pipeline focus infectious disease innovation significant progress strengthen pipeline advance key asset include rsv vaccine bepirovirsen gepotidican daprodustat depemokimab offset termination decision otilimab rsv maternal continued progress development longacte hiv treatment include launch apretude hiv prevention positive datum new broadly neutralise antibody nls successful business development support future growth focus vaccine specialty medicine include affinivax sierra oncology spero therapeutic demonstrate continued stepchange commercial execution doubledigit sale growth specialty medicine vaccine commercial execution product exceed billion annual sale include trelegy nucala benlysta dovato excellence strong momentum shingrix sale billion reflect post pandemic rebound new geographic launch excellent commercial execution complete separation haleon successfully demerge schedule gsk july largest demerger europe year unlocked value meaningful progress value recognition prior impact market uncertainty follow zantac litigation demonstrate strong sustained lead esg performance delivery global health environment inclusion diversity environmental social commitment governance esg credential maintain sectorleading ranking key esg index rank number access medicine index build trust future delivery consecutive time corporate sustainability assessment pharmaceutical industry demonstrate strong culture drive rapid ownership new culture launch roll new internal gsk code talent management leadership performance choice programme employee engagement versus continue development succession planning leadership team tony wood appoint cso new chief financial officer designate appoint iain mackay committee determined cfo successfully meet individual objective demonstrate financial group financial target exceed total sale billion aer cer excl covid adjust leadership operate margin adjust operate profit growth aer cer excl covid adjust eps cer cost discipline cash prioritise investment cost discipline support strong growth operating profit eps flow management transformation programme deliver billion annual saving end track deliver billion end cash generate operation billion free cash flow billion complete separation haleon successfully demerge schedule gsk july largest demerger europe year unlocked value meaningful progress value recognition prior impact market uncertainty follow zantac litigation demonstrate strong finance tech engagement confidence culture inclusivity employee survey score increase culture leadership versus esg diversity equity inclusion dei performance annual bonus esg measure reinforce achievement dei ambition set dei important business imperative aspirational target set warrant additional reward stay track aspirational target diversity senior leadership committee agree interim annual aspirational target include global gender representation race ethnicity representation interim annual aspiration agree committee ceo internal governance team comprise member reward legal audit performance interim aspiration consideration committee interim aspiration achieve year end gender representation ethnicity ethnicity employee population track meet aspiration addition directorate perform strongly respective contribution aspiration directorate achieve expect contribution aspirational target include finance strategic report governance remuneration financial statement investor information gsk annual report annual report remuneration continue pay performance audit continue vest psp lti award follow set performance achieve company psp include update performance outstanding award line committee agree principle actual performance measure carefully review adjustment appropriate ensure vest outcome reflect genuine underlie business performance deliver line culture responsible business priority overall psp award vest target set pipeline progress innovation sale adjust free cash flow relative tsr disappointingly nilveste relative tsr strong performance metric evidence vest cash flow element partial vest pipeline progress innovation sale period significant progress achieve accelerate delivery pipeline notably company rsv vaccine depemokimab niraparib robust oversight result number asset discontinue resource reprioritise focus great potential major approval period include niraparib ovarian cancer sotrovimab emergency use authorization covid cabenuva hiv treatment apretude hiv preexposure prevention innovation sale period reflect particularly strong performance hiv medicine shingle vaccine shingrix outcome vest level performance measure relative weighting performance target outcome maximum award pipeline progress pipeline progress measure target rewarding strengthen pipeline progression high quality asset pivotal trial achievement regulatory approval major market point base achievement allocate equally weight element lti award threshold maximum point measure point pivotal trial start point point point point major regulatory point point point point approval milestone innovation sale innovation sale measure recognise importance launch new product billion successfully drive performance key commercial success measure aggregate threeyear sale new innovative product launch threeyear performance period precede year innovation sale billion vest maximum threshold adjust free line company agree principle afcf figure include billion cash flow afcf adjustment number material distort item include legal settlement performance exchange rate movement special pension contribution original revise target billion target billion vest maximum threshold revise target adjust annual report note overleaf relative tsr tsr ranking comparator group vest rank performance maximum threshold median tsr comparator group astrazeneca bristolmyers squibb eli lilly gsk johnson johnson merck novartis pfizer roche holding sanofi vest schedule base deliver vest median performance comparator group company median fall company total vest respect award gsk annual report annual report remuneration continue pay performance audit continue adjusted free cash flow afcf target revise line disclosure annual report restate account demerger remove share target cash flow related consumer healthcare follow demerger revise phase future ready programme restructure cash payment base detailed programme planning undertake revise timing divestment result target decrease billion billion committee exercise discretion relation vest award share price change psp vest value grant vested vested share emma walmsley iain mackay hal barron prorate vested number share value represent vest include dividend reinvestment performance period base vest price closing ad price february share grant emma walmsley include additional topup award vest final actual value receive attributable share price appreciation performance period restate annual report psp award hal barron vest august term executive senior manager financial recoupment policy performance ongoing lti awards committee review performance psp award grant executive director follow chart provide estimate vest level award take account performance december actual vest level determine base performance threeyear performance period indication regard prediction final vest level afcf measure target threshold associate vest scale award adjust net overall impact decrease target billion billion award adjustment take account follow item removal share target cash flow relate consumer healthcare follow demerger revise phase future ready programme restructure cash payment revise timing divestment change measure psp award psp award rank rank threshold target target maximum maximum median median threshold threshold relative tsr innovation adjust free relative tsr total sale adjust esg sale cash flow pipeline growth operating pipeline progress profit growth progress commercially sensitive target publish vest estimate vest level pivotal trial start major regulatory approval milestone threshold performance award vest respect performance measure individual lti award level appear annual report set lti awards strategic report governance remuneration financial statement investor information gsk annual report annual report remuneration continue pay performance audit continued lti awards dabp award respect deferral bonus psp award show table dabp award psp awards total bonus number face value award level number face value defer share award base salary share award emma walmsley share share iain mackay share share hal barron ad face value dabp award calculate base share price ad price closing price february day grant nilcost option executive director restrict share executive director performance condition attach dabp award reflect mandatory threeyear deferral respect annual bonus face value psp award calculate base share price closing price february day grant conditional share base performance measure outline barron receive psp award give transition nonexecutive director role august performance period psp award january december awards vest maximum threshold performance barron dabp award vest normal year date grant historical vest lti plan follow table summarise lti vest performance measure gsk year relative tsr adjust free cash flow innovation sale previously new product pipeline progress business diversification total vested malus clawback policy detail exist policy malus clawback refer company remuneration policy report annual report available gskcom committee review disclose recoupment committee exercise malus clawbackdisclosure matter subject public report misconduct fully resolve legally permissible disclose unduly prejudice company shareholder line disclosure guideline committee recoupment committee exercise malus clawback administrative amendment propose malus clawback section remuneration policy shareholder approval agm describe policy detail exist policy recruitment remuneration loss office termination payment refer remuneration policy report page annual report available gskcomgsk annual report annual report remuneration continue director pay wider set internal context remuneration structure employee compare executive director glt element wide workforce pay comparison executive director glt pay salary market competitiveness base salary executive director glt follow company assess local market level performance review increase base salary competitiveness role measure consider line market practice average external market internal peer keep increase wide employee population regular review comparotor tool increase reflect change increase reflect change scope scope individual role responsibility individual role responsibility experience experience agree increase executive director glt committee mindful multipli effect individual total remuneration pension company seek provide appropriate executive director glt eligible receive pension benefit package align benefit broadly line policy benefit competitive market practice country employee vary location company operate pension arrangement structure accordance employee base executive director glt member expect retire current future executive director pension arrangement align wide workforce location january annual exception sale force participate executive director glt participate plan bonus separate arrangement wide workforce base assessment combination stretching participate plan base performance financialbusiness esg dei personal objective business financial measure executive director bonus salary structure reflect priority specific pay cash share defer business area year bonus earn excess plan design reward employee maximum salary deliver fully collective contribution business achievement share defer year separate mechanism place recognise glt member bonus salary pay outstanding individual performance address cash share defer year underperformance bonus earn excess maximum salary deliver fully share defer year clawback andor malus provision apply lti plan employee senior vice president svp executive directors glt grant annual vice president level participate psp psp award performance target executive director glt period employee performance target period executive director require hold vested award clawback andor malus provision apply additional twoyear period svp employee director clawback andor malus provision apply manager glt receive annual share executive director glt receive share value plan award restrict share value plan award follow appointment allemployee share plan dilution limit executive director participate majestys award plan incorporate dilution revenue custom approve allemployee share plan limit consistent guideline publish wide workforce company share save investment association limit rolling share reward plan tenyear period plan roll tenyear period executive share plan grant senior executive participant company share save plan save estimate dilution exist award month year end period year december follow option buy gsk share discount share price start saving contract gsk employee share plan participant share reward plan contribute month purchase gsk share company match basis detail executive share plan actual limit strategic report governance remuneration financial statement investor information gsk annual report annual report remuneration continue director pay wide set continue ceo pay ratio option methodology low quartile median upper quartile pay ratio calculate actual earning financial year ceo employee ceo total single figure remuneration detail total remuneration fulltime equivalent employee december calculate line single gsk continue use option methodology figure methodology reflect actual earning receive robust statistically accurate way calculate exclude business expense ratio option available remuneration produce percentile calculation option regulation pay ratio broadly similar remuneration regulation business expense reduction influence change workforce exclude reimbursed employee composition follow consumer healthcare demerger sufficiently substantial value significantly impact ratio table show salary total pay benefit percentile salary total pay benefit committee believe median pay ratio consistent company pay reward progression policy base salarie employee include executive director set reference range factor include market practice experience performance role supplemental additional ratio relative importance spend pay ceo pay ratio likely vary potentially significantly table show total employee pay group dividend time drive largely ceo variable pay outcome pay shareholder line reward principle ceo large portion change pay base performance individual total employee pay mean depend gsk performance dividend pay year ratio increase decrease significantly figure table reflect payment committee believe senior executive year impact movement exchange significant proportion pay link directly performance rate set page cash light provide supplemental ratio dividend declare respect million lti compensation exclude million decrease note believe provide additional view ltis form financial statement detail substantial percentage ceo total remuneration total employee pay base employee average highly variable dependent business performance number people employ ceo total remuneration exclude lti compensation note financial statement detail share repurchase company ceo pay ratio lti award option methodology financial year gsk annual report aannnnuuaall rreeppoorrtt oonn rreemmuunneerraattiioonn ccoonnttiinnuueedd director pay wide set continue external context comparator group tsr performance graph committee pay comparator group follow graph set performance company consider executive pay european cross relative ftse index global pharmaceutical industry comparator group primary comparator group performance comparator group tenyear period ceo cfo global pharmaceutical december index select comparison comparator group secondary group ceo purpose reflect primary index gsk measure relative tsr performance constituent industry operate european crossindustry comparator group roche holding linde deutsche telekom novartis sanofi kere lvmh astrazeneca heineken anheuserbusch inbev diageo basf unilever siemens vinci sap christian dior adida loreal inditex bayer novo nordisk bat safran airbus volkswagen reckitt benckiser global pharmaceutical comparator group france sanofi abbvie amgen switzerland novartis bristolmyer squibb roche holdings eli lilly johnson johnson merck astrazeneca pfizer abbvie amgen include remuneration benchmarking include relative tsr comparator group target ceo total remuneration positioning review ceo remuneration committee gsk total return gsk pharma peer ftse total return index total return index primary comparator group european crossindustry index comprise astrazeneca bristolmyers squibb eli lilly johnson comparator group reference pay global johnson merck novartis pfizer roche holding sanofi pharmaceutical comparator group historic ceo remuneration european emma walmsley crossindustry group total remuneration global maximum pharmaceutical group annual bonus award vest lti award low quartile median upper emma walmsley sir andrew witty median quartile current position remuneration include salary expect value incentive base total remuneration committee agree benchmarke methodology maximum annual bonus award vest lti awards emma walmsley total remuneration include pay period january march ceo sir andrew witty receive prorata payment lieu variable bonus opportunity accordance remuneration policy psp dabp awards sir andrew witty grant vest april accordance term executive financial recoupment policy strategic report governance remuneration financial statement investor information gsk annual report annual report remuneration continue implementation remuneration policy fix pay pay performance salary annual bonus committee aware sensitivity change operation annual bonus plan stakeholder level executive pay review detail policy refer page executive director salary consider average increase annual report award employee level executive director mindful multipli effect increase bonus opportunity salary base pay consideration wide economic target maximum context individual performance market position emma walmsley agree appropriate award increase iain mackay wide workforce ceo equivalent salary defer portion year addition average salary increase excess defer company implement number monetary weighting performance measure initiative colleague wide workforce reaction adjust strategic esg diversity cost living crisis find page total sale operate operational equity growth profit growth measure inclusion emma walmsley base salary change iain mackay wide workforce inevitably target link directly financial strategic emma walmsley plan commercially sensitive committee iain mackay consider appropriate disclose annual bonus target base average increase budget employee level glt year result competitive harm detail performance target usual disclose know leaver december mackay eligible receive salary increase retrospective basis annual report benefit defer annual bonus plan dabp significant change provision benefit award propose table provide detail mandatory deferral detail policy relation benefit refer dabp annual bonus payment remuneration policy report associate award grant share award annual report performance condition hold year regardless continue employment pension total bonus defer dabp award table provide overview pension share share arrangement executive director emma walmsley executive director pension reduce align iain mackay wide workforce effective january performance share plan psp award new executive director pension align table provide detail award grant appropriate wide workforce appointment psp pension contribution salary share emma walmsley base salary contribution define emma walmsley iain mackay contribution plan match contribution salary accordance term plan lti performance measure base salary cash payment lieu measure weighting award remain pension contribution salary excess unchanged award weighting lti measure base salary cash payment lieu lti measure measure weight pension contribution innovation pipeline progress performance relative tsr total sale growth adjust operate profit growth trust esg environment gsk annual report annual report remuneration continue implementation remuneration policy continue innovation performance pipeline progress measure seek reward acceleration relative tsr continue measure gsk strengthen pipeline base global pharmaceutical comparator group equally weight element key asset indication total sale growth adjust operate profit growth measure threeyear performance period measure recognise importance commercial ambition committee set target align point allocate successful asset sub ambition target total sale growth measure base forecast commercial value peak adjust operate profit growth commercially sensitive year sale end performance period time grant submeasures award vest follow esg environment pivotal trial start esg environment measure base goal focuses mainly phase iii registrational trial start nature net positive climate net zero impact include phase start page target esg performance level point payout environment measure grant base series nature goal relate water waste material threshold nil reduction biodiversity impact climate goal threshold incorporate scope emission reduction target carbon offset industrialisation green ventolin maximum esg environment measure include key performance measure major regulatory approval climate ambition performance level point payout nature ambition threshold nil achieve threshold vest measure meet target maximum vest measure pipeline progress measure commercially sensitive climate nature exceed time grant end performance period target provide disclosure achieve shareholding versus share ownership share subject performance condition exclude executive director sor calculation end requirement sor audit performance period vest share include align interest executive director director sor extent performance shareholder require build maintain condition meet value holding significant holding share gsk time executive calculate posttax basis director require continue satisfy share ownership requirement sor hold sor emma walmsley iain mackay date publication month leave gsk report exceed sor hal barron exceed sor month leave gsk sor prior transition nonexecutive director role august value holding salary sor company process place ensure salary march december executive director maintain sor leave gsk emma walmsley executive director agree term sor iain mackay service contract strategic report governance remuneration financial statement investor information gsk annual report annual report remuneration continue implementation remuneration policy continue termination arrangement executive director announce iain mackay step cfo executive director continue employee leave company december remuneration element summary treatment annual bonus eligible receive bonus determine committee base combination business individual performance service psp eligible receive psp award outstanding psp dabp award exist lti award retain psp award prorate time dabp defer bonus award award respect bonus defer prior year vest normal vesting date addition iain mackay require maintain sor accordance company remuneration policy remuneration arrangement julie brown committee consider remuneration arrangement committee seek ensure brown compensate appropriate enable company recruit likeforlike basis far possible concluding retain experience cfo criterion role buyout payment set company remuneration policy sum bonus buyout equivalent brown give julie browns wealth experience cfo target burberry bonus period april industry agree remuneration set march forego leave burberry line iain mackay remuneration follow sum lti buyout equivalent aggregate value outstanding burberry ltis sip share remuneration element note lose leave burberry price equivalent salary brown salary preliminarily set line average price share onemonth period predecessor september end september value salary dividend equivalent accrue share join high date award departure burberry give figure line increase agree ceo burberry ltis subject performance measure comparator group pay performance underpin discount cfo remain european apply value share calculate crossindustry comparator group set committee agree payment stage year period follow cash amount annual bonus ontarget bonus equivalent maximum incremental exceptional bonus buyout onethird lti buyout performance mackay pay payroll follow award long term assume expect value commencement employment gsk incentive ltis award performance share psp onethird lti buyout pay multiple base salary payroll follow anniversary mackay commencement employment share ownership line requirement sor salary remuneration policy onethird lti buyout pay payroll follow second anniversary pension pension arrangement line wide commencement employment workforce accordance addition pay equivalent gsk commitment january lti buyout payroll follow commencement employment brown agree invest benefit benefit line gsk net tax proceed tranche gsk share policy arrangement executive support reasonably available opportunity subject deal undertaking role clearance hold share period year brown sor cfo time base salary require build timegsk annual report annual report remuneration continue remuneration governance committee role membership statement consideration shareholder view detail available incorporate committee engage regular dialogue shareholder reference report chair ceo chief people hold annual meeting gsk large investor officer head reward group financial controller discuss feedback remuneration policy company secretary assisted committee year practice governance matter adviser committee agm voting company undertake commercial tender process detail voting level respect remuneration appoint willis tower watson llp wtw arrangement set independent adviser committee effect december wtw replace pricewaterhousecooper llp vote total vote total vote total vote withhold pwc serve independent adviser december cast billion million year total agm wtw pwc member remuneration remuneration report consultant group voluntarily operate remuneration policy code conduct relation executive remuneration consulting code conduct find service contract letter appointment wwwremunerationconsultantsgroupcom table set date executive director service contract available review wtw provide additional market datum committee company register office gskcom exception consulting service company prior julie brown contract available gskcom appointment independent committee adviser follow appointment executive director service year addition provide consultancy service contract contain month notice period committee pwc provide consult assurance service company prior wtws appointment date contract effective date expiry date emma walmsley line protocols agree set committee iain mackay chair wtw pwc provide advice julie brown committee satisfied advice objective independent respective tenure nonexecutive director letter appointment pwc wtw provide independent commentary available view company register office matter consideration committee update nonexecutive director expect serve board market practice legislative requirement end agm follow anniversary appointment subject election subsequent committee review potential conflict annual reelection subject mutual agreement interest judge appropriate safeguard expect serve year conflict wtws pwcs fee advice year appointment line provision frc period charge time corporate governance code subject annual reelection material basis respectively committee satisfy fee compromise firm independence strategic report governance remuneration financial statement investor information gsk annual report annual report remuneration continue remuneration governance continue committee focus item discuss remuneration policy prepare agree propose remuneration policy committee set remuneration policy remuneration impact consumer healthcare demerger shareholder approval determine shareholder advisory body engagement new remuneration remuneration executive director chair policy detail corporate officer line policy review consideration shareholder proxy adviser feedback amendment propose remuneration policy follow careful consideration shareholder feedback continue engagement shareholder salary review executive director glt benchmarking competitiveness committee periodically review consider gsk comparator group remuneration environment executive director glt glt company secretary salary review recommendation approve appropriate annual adjustment necessary regard performance market executive director salary review recommendation position remuneration wide workforce set remuneration julie brown new cfo review company chair fee annual bonus ceo executive director glt bonus recommendation committee responsible set specific ceo executive director bonus objective performance measure annual bonus propose new annual bonus performance measure align assessment performance measure june investor update commitment lti plan lti performance outcomes award vest ceo committee responsible approve lti plan rule executive director glt change grant assessment performance confirmation lti grant ceo executive director glt vest lti awards executive director glt include interim award propose new performance condition align june investor update commitment governance area focus remuneration consideration committee programme committee adhere robust remuneration review term reference governance framework ensure alignment committee evaluation annual review internal action external reportingcompliance remuneration report requirement confirmation group budget remuneration purpose agm remuneration report feedback external remuneration environment performance target disclosure incentive plan remuneration report disclosure include ceo pay ratio annual governance meeting key committee message committee chair consultation employee representative set pay wide workforce pay practice remuneration adviser tender processgsk annual report annual report remuneration continue nonexecutive director fee chair nonexecutive director company aim provide chair non executive director fee competitive pay company equivalent size complexity subject limit contain article association chair fee chair fee set annum nearly year ago september appoint board remain unchanged time review independently source datum committee january agree appropriate increase fee january increase rate originally set chair invest approximately pretax fee notional share gsk ned share allocation plan ned plan september invest approximately net fee purchase gsk share nonexecutive director fee nonexecutive director fee apply set table annum standard annual fee supplemental fee chair audit risk committee senior independent director scientific medical expert chair remuneration corporate responsibility science committee workforce engagement director science committee member undertake significant additional responsibility behalf gsk support nonexecutive director undertake intercontinental travel meeting meet standard annual fee nonexecutive director standard nonexecutive director annual fee increase follow review independently source datum recognise everincrease workload nonexecutive director agree appropriate increase standard annual fee annum january view simplicity create great transparency overall standard nonexecutive director fee base review independent datum go forward intercontinental travel allowance meeting add standard fee ordinarily nonexecutive director expect travel overseas attend meeting year expect receive travel allowance payment total chair receive allowance add nonexecutive director standard fee january bring total standard fee nonexecutive director share ownership requirement follow approval new remuneration policy agm july agree implement minimum non executive director share ownership requirement sor time annual standard fee chair fee maintain retirement board chair nonus base nonexecutive director newly appoint nonexecutive director commence purchasing share ad market new nonexecutive director sor september nonexecutive director begin purchase ad sor january shareholder approval seek agm administrative amendment nonexecutive director section remuneration policy allow notional share ad previously allocate nonexecutive director plan deliver chair nonexecutive director time committee board consider appropriate applicable tax withholding subject chair nonexecutive director undertake hold share ad retire board change company great operational flexibility reduce administrative burden operate nonexecutive director plan ensure chair nonexecutive director directly maintain meaningful prudent level investment close align interest shareholder company expect significant change fee structure nonexecutive director remainder remuneration policy period strategic report governance remuneration financial statement investor information gsk annual report annual report remuneration continue total fee audit audit table set value fee benefit receive nonexecutive director form cash share ad detail ned plan set nonexecutive director fee pay currency sterling convert average exchange rate review time time average exchange rate update nonexecutive director fee convert dollar exchange rate benefit comprise gross cash value travel subsistence cost incur normal course business relation attendance board committee meeting fulfil role nonexecutive director nonexecutive director fix fee fix fee emolument audit cash sharesad benefit total pay cash sharesad benefit total pay sir jonathan symonds elizabeth mckee anderson charles bancroft hal barron anne beal hal dietz jesse goodman urs rohner vishal sikka retire director vindi banga dame vivienne cox lynn elsenhans laurie glimcher etired board july etired board october gsk annual report annual report remuneration continue director interest share audit executive director interest share interest executive director company office person closely associate pca show table december unvested share plan interest beneficial subject total director interest interest subject performance performance march december sharesad sharesad option sharesad share emma walmsley iain mackay ad hal barron total director interest include beneficial interest unvested share plan interest subject performance emma walmsley iain mackay balance march include sharesad award psp dabp vest february sell satisfy tax liability vest amount relevant ad award psp dabp hal barron vest august accordance term executive senior management recoupment policy executive director shareholding sor outline eneficial interest include sharesad hold executive director pcas emma walmsley include share purchase gsk share reward plan iain mackay currently participate share reward plan employee hal barron eligible participate share reward plan open employee barron beneficial interest include ad notional ad hold way investment gsk plan executive supplemental saving plan essp detail barron membership plan find nveste sharesad subject performance represent psp sharesad vest subject additional twoyear hold period unvested ad subject performance barron represent bonus deferral describe note unvested option subject performance represent bonus deferral dabp award nilcost option describe note figure exclude option hold emma walmsley gsk share save plan unvested sharesad subject performance represent unvested psp award vest unexercised option director hold vested unexercised option abp table show bonus deferral subsequent reinvestment dividend dabp amount represent gross sharesad balance prior sale sharesad satisfy tax liability vest employee bonus deferral dabp grant nilcost option emma walmsley iain mackay dabp bonus deferral march december january shares emma walmsley iain mackay ad hal barron option exercise follow table set detail option include nilcost option dabp exercise executive director iain mackay exercise option year number share date market price type award date grant option exercise grant price exercise gain exercise emma walmsley deferral award dabp share save respect nilcost option award dabp bonus defer executive director record remuneration annual bonus total remuneration table respect number share option include initial award reinveste dividend accrue date exercise respect option gsk share save plan remuneration receivable executive director calculate date option vest remuneration difference executive director require pay buy share total value share vest date executive director choose exercise option vest date subsequent increase decrease realise movement share price vest date date exercise increase decrease value result investment decision executive director record remuneration strategic report governance remuneration financial statement investor information gsk annual report annual report remuneration continue director interest share audit continued nonexecutive director interest share interest nonexecutive director company office person closely associate pca show table share allocation plan nonexecutive director total director interest number sharesad beneficial interest december december dividend december elect reinveste adjustment allocate march date date date share january retirement retirement year end retirementconsolidation year share sir jonathan symond vindi banga dame vivienne cox urs rohner ads elizabeth mckee anderson charles bancroft anne beal hal barron hal dietz lynn elsenhans laurie glimcher jesse goodman vishal sikka otal director interest include beneficial interest notional sharesad receive fee ne plan dividend receive notional sharesad ne plan year january convert notional sharesad january beneficial interest include sharesad hold nonexecutive director pcas otional sharesad allocate year ned plan include dividend reinveste year reinvestment demerger equivalent value haleon plc sharesad attributable nonexecutive director notional allocation gsk plc sharesad note align closely possible treatment nonexecutive director respect ned plan allocation shareholder demerger share consolidation ned plan allocation adjust follow equivalent value haleon plc share ad attributable nonexecutive director notional holding gsk plc sharesadss reinveste increase notional allocation gsk plc sharesad july notional gsk sharead allocation ne plan include allocation arise consolidated ratio new notional gsk sharesad notional gsk sharesad hold july vindi banga dame vivienne cox lynn elsenhans retired board july laurie glimcher retired board october gsk annual report annual report remuneration continue percentage change remuneration director percentage change percentage change percentage change salaryfee benefit bonus salaryfee benefit bonus salaryfee benefit bonus employee executive director emma walmsley iain mackay hal barron nonexecutive director sir jonathan symonds elizabeth mckee anderson charles bancroft hal barron anne beal hal dietz jesse goodman urs rohner vishal sikka retire nonexecutive director vindi banga dame vivienne cox lynn elsenhans laurie glimcher table provide accordance schedule company director remuneration policy director remuneration report regulation employee population consider relevant comparison closely reflect economic environment encounter majority executive director percentage change calculate base total remuneration table executive director total fee table nonexecutive director increase benefit nonexecutive director increase travel cost follow return inperson meetings postcovid information executive director salary benefit find hal barron transition nonexecutive director role august fee nonexecutive director include fee receive cash form share ad term ned plan detail nonexecutive director change year director senior management information provide compensation interest director senior management group group purpose group define executive nonexecutive director member glt company secretary financial year follow table set aggregate remuneration group period serve capacity remuneration total compensation pay aggregate decrease accrue pension benefit net inflation aggregate payment define contribution scheme member group award share ad company lti plan set table align interest senior management shareholder executive director glt member require build maintain significant holding share gsk time glt member require hold share equivalent multiple time base salary continue satisfy share ownership requirement minimum month leave gsk award dividend reinvestment award award share ad share ad performance share plan defer investment award share value plan otional share ad executive director eligible receive defer investment award participate share value plan strategic report governance remuneration financial statement investor information gsk annual report annual report remuneration continue director senior management continue march group pcas follow interest share ad company interest award lti plan describe note financial statement employee share scheme page interest march share ad own unexercised option defer annual bonus plan performance share plan defer investment award share value plan otional share xecutive director eligible receive defer investment award participate share value plan fee respect executive director external appointment ceo emma walmsley independent nonexecutive director microsoft corporation receive deliver cash stock option microsoft corporation defer compensation plan nonemployee directors cfo july iain mackay independent nonexecutive director national grid plc receive fee deliver cash payment past director audit payment past director exception value defer bonus accrue dividend simon dingeman describe annual report payment loss office audit loss office payment remuneration policy continue reflect provision corporate governance code code clarity simplicity remuneration arrangement executive director set clear simple way remuneration policy whilst compile finalise remuneration policy committee consult extensively shareholder represent issue share capital ensure understanding view policy transparency clarity proposal implement fix remuneration element salary benefit pension closely align wide workforce arrangement pay performance plan annual bonus longterm incentive reward delivery financial strategic esg objective short long term risk line code operate deferral postvesting hold arrangement addition operate malus clawback provision committee retain discretion adjust award outcome zero appropriate consider payout determine appropriately reflect overall position performance company predictability proportionality remuneration policy define maximum limit total annual bonus longterm incentive opportunity payout element link fulfilment performance condition support company publicly state ambition implementation maximum reward short longterm plan achievable material outperformance state ambition alignment culture gsk purpose strategy culture continue directly reflect performance condition set annual bonus longterm incentive particular introduce esg measure short longterm plan currently reinforce diversity equity inclusion aspiration nature net positive climate net zero ambition share ownership requirement strengthen focus strategic aim ensure alignment interest experience shareholder employment committee believe remuneration policy operate intended term company performance quantum gsk annual report remuneration policy summary company remuneration policy approve gsk annual general meeting operate intend approval policy available gskcom investor section administrative amendment company remuneration policy propose bind shareholder approval gsk annual general meeting describe executive director remuneration policy salary provide core reward role set level appropriate secure retain high calibre individual need deliver group strategic priority operation opportunity individual role experience performance independently formal maximum limit ordinarily salary source datum relevant comparator group consider increase broadly line average increase determine salary level wide gsk workforce salary increase typically effect quarter increase higher reflect change year scope individual role responsibility experience salary adjustment reflect wide market condition salary normally pay currency executive geography individual operate director home country detail current salary level set annual report remuneration performance measure overall performance individual key consideration determine salary increase benefit level set recruit retain high calibre individual execute business strategy operation executive director base outside require travel fulfil responsibility executive director eligible receive benefit line role attend board meeting subject tax policy employee vary location business travel expense include limited car allowance provision accommodation healthcare life assurancedeath service provide reality represent business expense tax treatment individual pension arrangement personal require travel accommodation expense financial advice contractual postretirement benefit include benefit business context line policy employee executive director tax liability cover company grossedup eligible receive overseas relocation allowance basis international transferrelate benefit require executive director eligible participate benefit provision tailor reflect market practice allemployee share scheme share save share geography executive director base reward plan subject term different policy apply current future executive employee director base different country order recognise high business travel requirement opportunity role executive director entitle car travel formal maximum limit benefit cost exceptionally accompany spousepartn fluctuate depend change provider cost individual business trip benefit include expense incur circumstance ordinary course business deem taxable benefit individual detail current benefit cost set annual report remuneration performance measure strategic report governance remuneration financial statement investor information gsk annual report remuneration policy summary continue executive director remuneration policy continue pension pension arrangement provide competitive level retirement income pension arrangement provide competitive level retirement new executive director receive date income appointment base salary contribution define contribution plan operation match contribution subject pension arrangement structure accordance relevant cap line implementation principle plan operate country individual likely member plan retire individual choose member base salary cash payment lieu pension pension plan cash lieu relevant pension contribution portion relevant cap contribution pay instead executive director entitle join define contribution pension plan base salary cash payment lieu pension receive cash payment lieu pension contribution contribution individual member gsk legacy define benefit plan define contribution plan alternative supplemental cash balance pension plan provide annual pension plan arrangement subsequently appoint contribution base salary total base salary board remain member plan bonus net bonus defer dabp gsk plan essp core contribution opportunity salary bonus match contribution policy current executive director salary bonus january current executive director base salary contribution define contribution plan role pension arrangement align match contribution subject new executive director arrangement follow relevant cap line implementation principle new executive director receive date member plan appointment base salary cash payment lieu pension gsk plan essp core contribution contribution portion relevant cap salary bonus match contribution salary bonus base salary cash payment lieu pension global contribution eligible appropriate equivalent arrangement excess january current director usuk arrangement role pension arrangement align new executive director arrangement follow performance measure event change plan operate similar treatment provide successor arrangement introduce market bonus defer dabp offset equal contribution essp move pension plan line wide workforce january annual bonus incentivise recognise execution business strategy annual basis reward achievement stretch annual financial strategic operational measure operation committee adjust formulaic vest outcome ensure overall outcome reflect financial operational business target set start underlie business performance vest period year committee bonus level determine clawback andor malus provision apply describe committee base performance annual report target strategic operational measure set start opportunity year committee performance maximum bonus opportunity executive director measure assess committee salary target performance bonus payout financial measure nil target executive director require defer bonus earn performance bonus payout salary share ad appropriate year equivalent salary defer portion excess defer deferred bonus share eligible dividend equivalent date vestinggsk annual report remuneration policy summary continue executive director remuneration policy continue performance measure base combination financial target individual reason majority annual bonus opportunity strategic esg performance objective majority base formal review performance stretch bonus assess financial measure financial target remainder bonus subject weight different measure determine assessment individual performance key strategic year accord business priority detail include operational measure align company measure financial year provide key objective financial year andor assessment annual report remuneration performance esg target annual bonus financial target set reference selection annual bonus measure internal budget external consensus target annual bonus design drive achievement gsk annual financial strategic operational measure performance incentivise recognise delivery long term business priority financial growth share plan psp increase shareholder value compare pharmaceutical company addition provide alignment shareholder interest retention element encourage longterm shareholding discourage excessive risk take operation opportunity conditional award annually vest dependent normal maximum award limit grant achievement performance condition year psp individual year set table subject additional twoyear hold period psp target set reference internal budget external salary consensus target ceo award eligible dividend equivalent date cfo vest release executive director committee adjust formulaic vest outcome performance measure ensure overall outcome reflect base combination financial share price relate underlie business performance vest period strategic esg performance condition align company strategic plan measure clawback andor malus provision apply describe award vest threshold performance detail annual report include performance target attach psp respect year weighting target psp award provide annual report remuneration selection longterm incentive measure major adjustment calculation performance measure disclose shareholder vest committee select performance measure focus executive director longterm remuneration delivery audit risk committee chair member gsk key strategic priority long term addition member remuneration committee provide input set robust target committee implement number audit risk committee review group safeguard ensure target meet sustainable way performance oversight risk factor relevant performance reflect genuine achievement target remuneration decision represent delivery value shareholder detail rationale performance measure performance measure impact acquisition select calculate set divestment quantify adjust annual report remuneration event strategic report governance remuneration financial statement investor information gsk annual report remuneration policy summary continue executive director remuneration policy continue share ownership requirement change align interest executive director minimum executive director require maintain shareholder require build maintain share ownership requirement end significant holding share gsk time year follow retirement company requirement executive director follow end second year salary ceo executive director detail policy clawback malus approach recruitment remuneration loss office termination payment refer remuneration policy report page annual report available gskcom investor section difference remuneration policy executive director employee set remuneration executive director employee directly consult respect committee consider company strategic priority remuneration policy urs rohner committee chair prevail market condition global talent competitive meet senior representative business environment comparison remuneration review employee feedback dame vivienne cox executive company similar size complexity independent nonexecutive director engage employee international reach position relativity pay topic include remuneration role employment condition broad gsk workforce workforce engagement director board member engage employee board meeting particular committee consider range base encourage share view company management salary rise workforce part gsk remuneration executive director employ consider relevant comparison population reflect approval policy board closely economic environment encounter evolve approach workforce engagement detail individual provide principle apply remuneration policy wide organisation align performance executive director employee reward system innovation performance remuneration offer executive director responsible business priority culture anchor policy strong emphasis performancerelate pay purpose performance performance system evaluate offer employee group employee need senior people disincentivise unethical salary benefit include pension tailor working practice clawback mechanism allow local market recover performancerelate pay annual bonus plan apply wide employee population base business performance combination performancerelate restricted share plan apply wide employee population allemployee share plan available employee include revenue customs approve share save share reward plansgsk annual report remuneration policy summary continue nonexecutive director remuneration policy nonexecutive director fee element purpose link strategy operation chair fee provide inclusive flat formal maximum fee review annually set reference rate fee competitive review chair performance independently source market datum pay committee responsible evaluating make recommendation board company equivalent size fee payable chair chair participate discussion respect complexity subject fee limit contain gsk article association basic fee formal maximum chair fee review annually set reference independently source datum chair ceo responsible evaluating make recommendation board fee payable company nonexecutive director fee payment alignment shareholder fee pay cash nonexecutive director include chair require invest total net fee share ad company company replace minimum investment requirement minimum share ad ownership requirement time nonexecutive director chair gross annual standard fee retain retirement board administrative amendment section remuneration policy propose bind shareholder approval agm describe supplemental compensate non additional fee senior independent director committee chair scientific medical fee executive director expert workforce engagement director role intercontinental travel chair take company authority pay additional fee equivalent committee additional board chair supplement nonexecutive director company require significant additional responsibility time commitment exceptional unforeseen circumstance undertake intercontinental company authority pay additional fee nonexecutive travel director exclude chair member science committee undertake additional responsibility behalf gsk support benefit facilitate execution travel subsistence cost nonexecutive director incur normal course responsibility dutie business relation meeting board committee matter gskhoste event require role overseasbase nonexecutive director include travel meeting event necessary business purpose whilst normal practice nonexecutive director accompany spouse partner meeting event cost associate meet company instance deem taxable treat benefit nonexecutive director approach recruitment remuneration follow policy principle apply role chair nonexecutive director nonexecutive director seek ensure alignment fee level new nonexecutive director set shareholder requirement invest company basis exist nonexecutive director share ad company subject local law regulation chair event nonexecutive director different role fee set level competitive pay responsibility appoint fee level company equivalent size complexity fee benchmarke set reference comparable role pay partly share company equivalent size complexity loss office chair nonexecutive director entitle receive payment respect fee loss office retire step board strategic report governance remuneration financial statement investor information gsk annual report administrative amendment remuneration policy propose amendment clawback malus administrative amendment companys shareholder approval seek amend clawback remuneration policy policy approve year malus section policy expressly refer agm propose ordinary resolution bind company ability update clawback policy shareholder approval agm policy disclosure relation clawback case require subject renewal respect remuneration give applicable regulatory requirement include recently change purely administrative consultation adopt securities exchange commission sec rule employee undertake amendment new york stock exchange nyse list standard implement rule clawback event nonexecutive director minimum share accounting restatement ownership requirement sec adopt new rule late require nonexecutive director section policy nyse adopt new listing standard include requirement nonexecutive director include require list company clawback erroneously award chair invest minimum net basic fee incentivebase compensation require share ad company policy state prepare accounting restatement correct error company replace requirement share previously issue financial statement result ad previously acquire accordance minimum material misstatement error correct current investment requirement continue hold period leave uncorrected current period new previous arrangement count expect listing standard expect effective late minimum ownership requirement iii deliver gsk share list trade nyse release follow nonexecutive director chair form ad gsk result subject new retirement board listing standard expect require clawback circumstance wide currently provide company replace minimum investment company policy relate sec rule requirement set annual report require gsk certain disclosure connection minimum share ad ownership requirement clawback policy annual report form include time nonexecutive director chair gross annual filing copy clawback policy sec standard fee retain retirement board propose change clawback malus element policy intend ensure clarity expressly refer shareholder approval sought amend non company ability update clawback policy executive director section policy allow share disclosure relation clawback case ad acquire previous minimum investment require applicable regulatory requirement include requirement delivered release nonexecutive sec nyse requirement committee update director chair time board exclude current recoupment policy require meet new nyse nonexecutive director chair consider appropriate listing standard relate sec disclosure requirement subject applicable tax withholding effective continue hold previous arrangement subject nonexecutive director chair undertake company hold share ad company retire board company great operational flexibility reduce administrative burden implementation new minimum share ownership requirement whilst ensure nonexecutive director chair continue maintain meaningful prudent level investment align interest shareholdersgsk annual report operation scope remuneration policy remuneration policy policy set page policy come effect provide term annual report intend policy payment consistent shareholderapprove gsk executive nonexecutive director operate remuneration policy force time agree period year date approval iii time relevant individual director company annual general meeting company opinion committee committee write policy principally relation payment consideration individual remuneration arrangement executive director whilst director company purpose payment take account possible recruitment replacement include committee satisfy award variable additional executive director operation remuneration relation award share ad policy committee intend policy operate term payment agree time award period set entirety grant consideration seek change policy period performance share plan psp award subject believe appropriate longterm term psp plan rule award success company consultation shareholder grant committee adjust amend award seek shareholder approval general meeting accordance provision plan rule include committee reserve right remuneration make adjustment reflect oneoff corporate event payment andor payment loss office include change company capital structure exercise discretion available connection committee minor amendment payment notwithstanding line policy regulatory exchange control tax administrative policy term payment agree purpose account change legislation agm date company obtain shareholder approval amendment shareholderapprove director remuneration policy come effect basis preparation annual report remuneration prepare annual report remuneration approve accordance company act large board director sign behalf mediumsize company group account report amendment regulation regulation accordance regulation follow part urs rohner annual report remuneration subject audit total remuneration committee chair remuneration figure executive director include march detail element remuneration salary benefit pension annual bonus longterm incentive awards nonexecutive director fee emolument receive year director interest share include interest gsk share plan payment past director payment loss office share ownership requirement holding opinion thereon express remain section annual report remuneration subject audit page refer audit section gsk annual report financial statement section director statement responsibilitie independent auditor report financial statement note financial statement financial statement gsk plc prepare gaap gsk annual report director statement responsibility director responsible prepare annual report director responsible keep adequate remuneration report group parent company accounting record sufficient explain financial statement accordance applicable law company transaction disclose reasonable accuracy regulation time financial position group enable ensure group financial statement company law require director prepare financial remuneration report comply company act statement financial year director require responsible safeguarding asset prepare group consolidated financial statement group take reasonable step accordance international accounting standard prevention detection fraud irregularity conformity requirement company act international financial reporting standard ifrs group financial statement year end issue international accounting standard board december comprise principal statement iasb director elect prepare parent support note set financial statement company financial statement accordance united page report parent company kingdom accounting standard applicable law unite financial statement year end december kingdom generally accept accounting practice financial comprise balance sheet statement change report standard reduce disclosure framework equity year end december support company law director approve note set page financial statement satisfied responsibility auditor relation financial true fair view state affair group statement set independent auditor report profit loss period prepare financial page statement director require financial statement year end december include annual report publish print select suitable accounting policy apply form available website director consistently responsible maintenance integrity corporate judgement accounting estimate financial information include company website reasonable prudent legislation united kingdom govern preparation dissemination financial statement differ state group financial statement comply legislation jurisdiction ifrs issue iasb conformity requirement company act current director name function list corporate governance section annual state regard parent company financial report confirm good knowledge statement applicable accounting standard follow subject material departure disclose group financial statement prepare explain parent company financial statement accordance ifrs issue iasb conformity requirement company act true fair view asset liability financial prepare financial statement go concern basis position profit group inappropriate presume group parent company continue business strategic report risk section annual report represent management report include fair prepare group financial statement international review development performance business accounting standard require director properly select position company group take apply accounting policy present information include description principal risk accounting policy manner provide relevant uncertainty face reliable comparable understandable information provide additional disclosure compliance specific annual report financial statement take requirement ifrs standard insufficient enable user fair balanced understandable provide understand impact particular transaction information necessary shareholder assess event condition entity financial position company position performance business model financial performance assessment strategy company ability continue go concern gsk annual report strategic report governance remuneration financial statement investor information director statement responsibility continue disclosure information auditor corporate governance code director office date annual report board consider gsk plc apply principle confirm complie provision corporate governance code maintain financial reporting council far aware relevant audit describe corporate governance section page information company auditor unaware board consider annual report take take step ought fair balanced understandable provide take director aware information necessary shareholder assess relevant audit information establish group position performance business model company auditor aware information strategy confirmation give interpret require financial conduct authority list rule accordance provision section auditor consider director statement company act compliance relation point corporate governance code specify review go concern basis page page contain information annual report performance group financial position cash flow annual report year end december net debt position borrowing facility climate relate comprising report director remuneration risk information include treasury risk management report financial statement additional information policy exposure market credit risk hedge investor approve board director activity give note financial statement sign behalf financial instrument relate disclosure assess principal risk matter consider sir jonathan symond connection viability statement director chair consider appropriate adopt go concern basis march accounting prepare financial statement internal control board audit risk committee review assessment risk internal control framework operate gsk consider effectiveness system internal control operation group year cover annual report date approval board director detail review internal control set governance report gsk annual report independent auditor report members gsk plc report audit financial statement opinion basis opinion opinion conduct audit accordance international standard audit isas applicable law financial statement gsk plc parent company responsibility standard subsidiary group true fair view describe auditor responsibility audit state group parent company affair financial statement section report december group profit year end independent group parent company accordance ethical requirement relevant group financial statement properly audit financial statement include prepared accordance united kingdom adopt financial reporting council frc ethical standard international accounting standard international apply list public interest entity fulfil financial reporting standard ifrss issue ethical responsibility accordance international accounting standard board iasb requirement confirm provide parent company financial statement nonaudit service prohibit frc ethical standard properly prepare accordance united kingdom group parent company note audit risk generally accept accounting practice include frs committee report corporate governance section reduce disclosure framework annual report disclosure provide financial statement prepare accordance note fee payable group auditor requirement company act believe audit evidence obtain audit financial statement comprise sufficient appropriate provide basis opinion group audit scope execution consolidate balance sheet december structure approach audit reflect consolidated income statement year end group organise ensure audit consolidate statement comprehensive income effective risk focus audit approach year end summarise follow area enable obtain evidence require form opinion group consolidate statement change equity year end parent company financial statement consolidate cash flow statement year risk assessment audit planning group level end central control common system group enable structure audit centrally use note financial statement include accounting principle policy datum analytic tool allow detailed understanding flow transaction enable parent company focus risk assessment design target audit testing procedure risk assessment procedure consider balance sheet december factor impact global pandemic statement change equity year end climate change account balance disclosure company practice appoint partner note financial statement include group audit team lead global audit revise accounting principle policy operate segment commercial operation research development consumer healthcare addition financial reporting framework apply partner responsible component legal entity preparation group financial statement applicable audits country segment partner meet law united kingdom adopt international accounting regularly senior segment management understand standard ifrss issue iasb financial strategy performance matter arise report framework apply preparation year impact financial parent company financial statement applicable law report risk assessment audit planning include united kingdom accounting standard include frs consideration separation consumer healthcare reduce disclosure framework united kingdom generally business group july addition hold accept accounting practice regular meeting member internal audit internal legal counsel global ethic compliance team understand work review report enhance risk assessment gsk annual report strategic report governance remuneration financial statement investor information independent auditor report continue report audit financial statement continue audit work perform global share service centre control deficiency disclose key audit matter section significant group operational process report mitigate control exist allow cover financial reporting undertake share service continue reliance control plan centre group audit team include senior individual audit scope address group responsible global process coordinate revenue group profit tax audit work share service centre inscope group total asset group audit enable develop good understanding endtoend process support material account impact climate change audit balance class transaction disclosure climate change potential impact group group financial statement evaluate number way set strategic report page effectiveness internal control financial report annual report note process consider implication financial statement group set remainder audit work environmental goal paris climate accord audit work execute component level individual legal net zero impact climate net positive impact entity follow component subject audit nature procedure assessment effectiveness planning audit consider potential internal control financial reporting include impact climate change group business inscope entity consumer healthcare segment prior financial statement demerger australia belgium canada china france germany italy japan spain united kingdom united seek understand group identification state group audit team active dialogue assessment potential impact climate change audit component audit team risk influence group strategy implication responsible audit work direction financial statement supervision group audit team include determine group assessment focus impact work plan perform accordance frequent extreme weather condition water scarcity change overall group audit strategy requirement political landscape medium focus group audit instruction component propensity cause change consumer market plan perform site visit component behaviour volatility cost availability material overseas travel restriction allow satisfy resource impact future financial performance oversight supervision appropriate perform asset valuation reviews audit work paper increase frequency length review depend significance risk consultation climate change specialist component continued attend planning conduct detailed risk assessment procedure clearance meeting component inscope balance transaction determine risk audit procedure undertake group level material misstatement financial statement parent company addition perform apply expect impact climate change audit work group parent company financial understand business statement include limited consolidation challenge appropriateness group assessment group result preparation financial statement potential impact climate change impact certain disclosure director remuneration report financial statement include area litigation provision exposures addition entity level intangible asset describe section report oversight control relevant financial reporting assessment impact climate change component legal entity annual revenue great challenge group assessment go concern total group revenue include include consider potential impact future audit scope component legal entity cover performance availability financing audit scope subject analytical procedure confirm conclusion significant risk audit procedure require read material misstatement aggregate financial consider disclosure consider information materially inconsistent financial statement knowledge obtain audit identify internal control testing approach test material inconsistency result procedure effectiveness internal control financial reporting inscope entity include consumer healthcare segment predemerger entity level control application materiality group level common system allow relevant define materiality magnitude misstatement control test centrally component financial statement make probable economic consumer healthcare demerger impact relevant system decision reasonably knowledgeable person prior demerger reflect scope change influence use materiality planning test able place reliance control scope audit work evaluate result work plan efficient notwithstanding itgsk annual report independent auditor report continue report audit financial statement continue base professional judgement determine set performance materiality level low materiality financial statement follow materiality reduce probability aggregate uncorrected undetected misstatement exceed parent company group financial statement financial statement materiality financial statement group parent company performance materiality set materiality million million million million group parent materiality respectively audit basis determine benchmark materiality determine performance materiality determine materiality consider determined consider factor include materiality metric investor total asset risk assessment include assessment group reader financial benchmark cap statement particular group overall control environment consider consider statutory profit materiality appropriate rely control number business tax adjust profit materiality represent process tax revenue net cash flow total asset operation past experience audit indicate low professional judgement number correct uncorrected misstatement determine materiality identify prior period million materiality reduce compare prior agree audit risk committee year predominantly report committee audit difference excess low benchmark result million million difference consumer healthcare threshold view warrant reporting qualitative demerger remove impact gilead settlement ground report audit risk committee million receive disclosure matter identify assess determine profit overall presentation financial statement tax benchmark nonrecurre item reflective underlie trade conclusion relate go concern size distort audit financial statement conclude materiality director use go concern basis accounting benchmark preparation financial statement appropriate continue operation consider evaluation director assessment group relevant user parent company ability continue adopt go financial statement concern basis accounting include metric enquiry group director management statutory profit tax assumption go concern model include adjusted profit potential impact climate change tax revenue evaluate group exist access source net cash inflow financing include undrawn commit bank facility operating activity include impact change interest rate reconciliation statutory profitability profit tax adjust profit tax detail adjusting read analyst report industry datum external item section strategic report information determine provide corroborative rationale give importance parent company contradictory evidence relation assumption metric investor hold group benchmark reader financial investment compare forecast sale recent historical financial apply statement conclude profit information statutory profit tax orient strength primary benchmark balance sheet testing underlie datum generate prepare adjusted profit tax key measure forecast scenario determine revenue net cash inflow financial health adequate support assumption underlie operating activity important forecast support benchmark shareholder component materiality primary concern evaluate group disclosure go concern allocate inscope parent company requirement ias component range payment million million dividend base work perform identify range materiality allocate benchmark total material uncertainty relate event condition asset component include individually collectively cast significant doubt appropriate metric parent company audit group parent company ability continue go prior year group financial concern period month statement financial statement authorise issue million million gsk annual report strategic report governance remuneration financial statement investor information independent auditor report continue report audit financial statement continue relation reporting group apply responsibilitie responsibility director corporate governance code material add respect go concern describe relevant section draw attention relation director statement report account financial statement director consider appropriate adopt go concern basis accounting key audit matter key audit matter matter professional judgement significance audit financial statement current period include significant assess risk material misstatement fraud identify matter include great effect overall audit strategy allocation resource audit direct effort engagement team include additional key audit matter consumer healthcare demerger valuation contingent liability significant legal proceeding reflect additional audit effort require year relation matter address context audit financial statement form opinion financial statement provide separate opinion matter key audit matter description scope audit respond key audit matter valuation viiv healthcare shionogi contingent audit procedure perform consideration liability perform follow audit procedure group complete number significant relate sale forecast transaction result recognition material obtain group assessment key input contingent consideration liability key source assumption forecast challenge estimation uncertainty significant reasonableness include enquiry key liability viiv healthcare shionogi contingent individual senior leadership team commercial consideration liability viiv ccl strategy team key personnel involve budgeting group complete acquisition remain forecasting process inspection support evidence interest shionogiviiv healthcare joint venture challenge volume assumption group completion group recognise contingent estimate sale forecast involve benchmarking forecast consideration liability fair value expect market share datum external datum total future payment shionogi december prescription volume new patient prescription volume liability value million order assess source contradictory evidence identify viiv ccl key audit matter challenge reasonableness pricing assumption significant estimate assumption relate group compare forecast return sale forecast valuing viiv ccl rebates rate product current rate sensitivity valuation input assess forecast return rebate significant relate sale forecast united comparable product consider expect change state certain product treatment portfolio payer policy healthcare reform implication forecast base assessment expect launch date ability shift market practice consider result clinical study undertake year prescriber behaviour longacte injectable group key competitor order assess treatment drug regimen impact healthcare corroborative contradictory assumption reform subsequent sale volume price product portfolio sale forecast incremental challenge forecasting sale associate benchmarke group sale forecast recently launch product lack historical include report analyst consider sale actual data forecast require significant audit forecast total viiv basis individual product effort perform appropriate audit procedure challenge basis assess identify contradictory datum evaluate reasonableness forecast test control key input assumption contingent consideration liability include viiv ccl valuation contingent consideration liability disclose key source estimation uncertainty include review control sale forecast note group financial statement treatment product portfolio value viiv ccl disclosure provide note matter discuss audit risk committee report key observation communicate audit risk committee corporate governance section annual report sale forecast valuation reasonable line relevant support information satisfy sale forecast appropriately reflect trend overall hiv treatment prevention market include impact competition healthcare reform predict shift longacte injectable product approach value viiv ccl consistent prior period overall satisfied valuation liability reasonable consistent ifrsgsk annual report independent auditor report continue report audit financial statement continue key audit matter description scope audit respond key audit matter valuation return rebate rar accrual audit procedure perform group sell customer perform follow audit procedure commercial government mandate contract relate estimate rar accrual reimbursement arrangement include rebate challenge assumption selection utilisation rate chargebacks right return certain pharmaceutical focus certain product conclude product revenue recognition reflect grosstonet accrual sensitive assumption challenge sale adjustment adjustment know include comparison historical utilisation rate return rebate rar accrual source consideration historical accuracy driver market significant estimation uncertainty change impact competition material impact report revenue macroeconomic trend commercial operation million rar supplement substantive analytical procedure deduction gross revenue million develop independent expectation accrual result net revenue million balance sheet balance key segment base historical accrual december commercial operation claim receive adjusted reflect market change amount million period include assessment time lag significant payer channel refer initial point sale claim receipt compare buy group rar accrual relate independent expectation record evaluate manage healthcare organisation medicaid ryan white appropriateness year end accrual position medicare consider historical accuracy estimate main cause significant estimation uncertainty evaluate forecast assumption appropriately update selection case utilisation rate portion total sale actual rebate claim differed accrue payer channel estimate group recording accrual utilisation assumption evaluate appropriateness completeness challenge key assumption periodend adjustment liability derive accrual give influence market ongoing review estimate accrual demand factor outside control group test key control estimation rar accrual include control associate forecasting time lag point sale point utilisation rate process monthend accrual review exact rebate amount know group control receipt claim payer channel long key observation communicate audit risk committee time lag result great accrue period great level estimation uncertainty estimate satisfied estimate liability rar accrual period end accrual yearend appropriate observe level prudence estimate assess level estimation uncertainty impact independent expectation accordance significant shift channel mix drive change requirement ifrs revenue contract customer competitive landscape include competitor generic limit risk significant reversal revenue product launch macroeconomic factor focus utilisation assumption product deem level estimation uncertainty significant furthermore auditing standard presume significant fraud risk exist revenue recognition line presumption focus periodend adjustment rar accrual adjustment reflect update initial assumption include forecasted rar rate view present great opportunity fraud revenue recognition notwithstanding existence internal control commercial operation return rebate disclose key source estimation uncertainty note group financial statement disclosure provide note matter discuss audit risk committee report corporate governance section annual report gsk annual report strategic report governance remuneration financial statement investor information independent auditor report continue report audit financial statement continue key audit matter description scope audit respond key audit matter valuation intangible asset audit procedure perform december group hold million perform follow audit procedure intangible asset include license patent relate future sale pricing volume growth rate trademark trade name exclude goodwill probability technical regulatory success profit margin computer software include million level discount rate assessment intangible asset acquire business combination valuation intangible asset sierra oncology inc affinivax inc year inquire key individual corporate impairment charge million development team commercial forecasting lead key record personnel involve asset research development individual intangible asset intangible asset process discuss evaluate group evidence form cashgenerate unit impair support future pricing volume sale growth rate carry exceed recoverable probability regulatory technical success recoverable intangible asset relie evaluate key input assumption apply estimate certain assumption estimate future trading sale profit margin forecast include benchmarke performance create estimation uncertainty forecast external market datum include future trading performance intangible asset include independent market research therapeutic area price point key assumption sale pricing volume growth rate price growth rate anticipate competitor market probability technical regulatory success landscape currently time forecast regulatory ongoing clinical trial include assumption time approval plus assessment source contradictory cash flow determine anticipate launch year peak evidence year sale subsequent sale erosion generic product inspect independent research literature consider competition profit margin level addition corroborative contradictory evidence assess impact uncertainty drive ongoing global assumption probability technical regulatory success macroeconomic volatility valuation intangible asset affect discount rate assumption compare forecast sale profit margin level group plan datum asset asset internal forecast approve gsk leadership team board director identify valuation intangible asset indevelopment intangible asset forecast launch key audit matter inherent judgement involve year period estimate future cash flow auditing assumption estimate require extensive audit effort challenge assess historical accuracy sale forecast evaluate reasonableness forecast judgement perform retrospective review market asset business disclosure relate intangible asset include acquire business combination consider event transaction occur include note group financial balance sheet date reporting date affect statement matter discuss audit risk conclusion reach carry value asset committee report corporate governance section associate disclosure annual report engage internal fair valuation specialist ifvs assess reasonableness discount rate valuation methodology apply test review control key input assumption valuation intangible asset control encompass review valuation model contain number assumption probability technical regulatory success launch date plus revenue cost assumption number assumption revenue growth rate profit margin key observation communicate audit risk committee intangible asset acquire period sierra oncology inc affinivax inc business acquisition identify control deficiency conclude complex assumption underpin fair value intangible asset reflect purchase price allocation reasonable accordance ifrs intangible asset indevelopment subject impairment review conclude judgement director reasonable accordance ifrs satisfied control intangible asset design operate effectively control deficiency identify mitigated compensate controlsgsk annual report independent auditor report continue report audit financial statement continue key audit matter description scope audit respond key audit matter valuation uncertain tax position include transfer pricing audit procedure perform group operate numerous jurisdiction support tax specialist assess open tax transfer pricing matter exposure appropriateness uncertain tax provision perform overseas tax authority rise follow audit procedure uncertain tax position wide range possible assess challenge provision uncertain tax outcome provision contingency certain position evaluation possible outcome judgement respect estimate tax exposure procedure focus jurisdiction contingency require order assess adequacy group great potential exposure tax provision complex result high level judgement require consideration require multiple tax law regulation assess assumption judgement require determine range possible outcome recognition december group record provision measurement uncertain tax position compliance million respect uncertain tax position requirement ifric valuation uncertain tax position disclose key involve transfer pricing specialist evaluate source estimation uncertainty note group transfer pricing methodology group associate financial statement disclosure include approach provision recognition measurement note matter discuss audit risk committee report corporate governance section consider evidence actual result annual report recent tax authority audits enquiry thirdparty tax advice obtain group tax specialist knowledge market practice relevant jurisdiction test key control preparation review report judgmental tax balance transaction include provision uncertain tax provision key observation communicate audit risk committee satisfied estimate relation uncertain tax position relate disclosure accordance ifrs work conclude consistent approach apply estimate uncertain tax provision whilst continue prudent require ifric appropriate supportable gsk annual report strategic report governance remuneration financial statement investor information independent auditor report continue report audit financial statement continue key audit matter description scope audit respond key audit matter consumer healthcare demerger audit procedure perform set note july gsk plc separate perform follow audit procedure consumer healthcare business gsk group form relate consumer healthcare demerger haleon independent list company separation consult technical accounting specialist evaluate effect way demerger gsk entitys accounting conclusion respect relevant hold consumer healthcare business gsk accounting standard demerger step include shareholder gsk retain haleon hold scottish limited partnership structure slp presentation consumer healthcare result recognise equity investment set note discontinued operation group derecognise net asset liability calculation gain demerger billion recognise gain demerger billion retain stake demerger consumer healthcare trading result demerger date present discontinue recalculate gain demerger fair value operation comparative result restate consumer healthcare business demerger date consistent basis demerger date asset test accuracy completeness perimeter liabilitie consumer business demerge business inspect legal agreement derecognise balance sheet difference recalculate cumulative exchange difference arise value net asset fair value translation foreign currency net asset demerge business recognise consolidated engage tax specialist assess impact income statement gain demerger cumulative demerger group tax balance exchange difference arise translation consumer healthcare foreign currency net asset engage specialist assess impact relevant previously include comprehensive income system prior demerger consumer healthcare recognise consolidated income statement test key control report identify demerger consumer healthcare consumer healthcare demerger include review key audit matter significant estimate approval accounting consideration accuracy relate calculate gain demerger completeness transaction demerger date remeasuring retain stake demerger assess cumulative exchange reserve adjustment require perimeter demerge business validate relation classification continue cumulative exchange difference arise translation discontinue operation foreign currency net asset divest business key observation communicate audit risk committee evaluate group tax treatment demerger assess impact relevant system prior satisfied group accounting conclusion demerger require high degree auditor judgment calculation gain demerger presentation increase extent effort include need discontinued operation respect demerger involve technical accounting tax specialist consumer healthcare business appropriate perform audit procedure accordance ifrs matter discuss audit risk committee report corporate governance section annual reportgsk annual report independent auditor report continue report audit financial statement continue key audit matter description scope audit respond key audit matter system impact financial reporting audit procedure perform system group form critical component audit scope drive level reliance place group financial reporting activity impact technology obtain sufficient audit evidence business account balance process technology deem relevant audit base financial datum system configure automate control identify system impact financial reporting andor key financial report reside key audit matter specialist support evaluation risk associate pervasive reliance complex technology integral technology testing design operation key business process financial operation control report testing technology deem relevant audit reliance technology continue increase include follow area line business strategy increase general control include user access change use automation group management control importance control maintain effective key financial report system configure automate control environment key interdependency exist control ability rely control ability rely financial data system configure automate control provide assurance completeness control system report accuracy relevant data migration include gsk consumer healthcare separation activity continue remediation control support application system relevant group financial testing remediation previously identify deficiency report activity risk assessment procedure include assessment separation activity undertake technology impact unremediated control deficiency determine environment gsk consumer healthcare impact audit plan relevant audit plan separation programme adjust include test additional manual business process control mitigate unaddresse risk system impact financial reporting discuss audit risk committee report corporate key observation communicate audit risk committee governance section annual report satisfied control impact group financial reporting activity design operate effectively control deficiency identify remediate year end mitigate compensating control significant progress remediate control deficiency relate user access change management group layer business process control mitigate risk associate remain control deficiency gsk annual report strategic report governance remuneration financial statement investor information independent auditor report continue report audit financial statement continue key audit matter description scope audit respond key audit matter valuation contingent liability significant legal audit procedure perform proceeding perform follow audit procedure group operate environment subject test group control completeness significant legal administrative proceeding include provision robustness provision product liability intellectual property tax antitrust requirement ias appropriateness judgement consumer fraud governmental regulation determine good estimate completeness group currently expose number regulatory accuracy datum process litigation matter current year group evaluate assessment provision associate classified zantac litigation significant legal matter probability potential outcome accordance ias increase case group provision matter million december matter disclose contingent liability criterion evaluate methodology datum significant recognise provision ia provision contingent judgement assumption valuation liability contingent asset meet provision appropriate context applicable financial reporting framework identify contingent liability significant legal proceeding key audit matter inquire inspect correspondence significant judgement require group determine group internal external counsel assess litigation ia particular relation zantac matter evaluate group significant judgement matter assumption outcome result probable outflow provision critically evaluate particularly outcome litigation uncertain group conclusion supportive contradictory evidence subject additional court proceeding requirement ias particularly respect zantac matter determination reliable estimate amount obligation respect zantac matter inspect evidence present relevant scientific study outcomes nature extent contingent liability product liability litigation jurisdiction underlie significant estimation uncertainty disclose alongside entitys assessment possible outcome contingent liability significant legal proceeding ongoing future trial disclose note respectively key audit evaluate disclosure financial matter discuss corporate governance statement appropriately reflect fact critical section annual report accounting judgement key observation communicate audit risk committee satisfied estimation provision contingent liability disclosure consistent requirement ias gsk annual report independent auditor report continue report audit financial statement continue information information comprise information include annual report financial statement auditor report thereon director responsible information contain annual report opinion financial statement cover information extent explicitly state report express form assurance conclusion thereon responsibility read information consider information materially inconsistent financial statement knowledge obtain course audit appear materially misstate identify material inconsistency apparent material misstatement require determine give rise material misstatement financial statement base work perform conclude material misstatement information require report fact summarise work relation area information include area specifically require report matter specifically require report responsibility report principal risk viability statement review confirmation description light knowledge set corporate governance statement gather audit consider director section material report add process support statement challenging key judgement draw attention respect matter estimate consideration historical forecasting accuracy evaluate macroeconomic assumption consider statement align relevant provision code director remuneration report report director remuneration report audit set opinion matter prescribe properly prepare disclosure specify company act company act section opinion director remuneration report audit prepared accordance company act strategic report director report report consistent audit financial statement set opinion matter prepare accordance applicable legal requirement prescribe company act section opinion base work undertake course report identify material misstatement report audit information report light knowledge understanding group consistent audit financial statement parent company environment obtain course prepare accordance applicable audit legal requirement reference provide limited assurance accordance international standard assurance engagement isae assurance engagement greenhouse gas emission isae issue international auditing assurance standard board iaasb select metric gsk annual report strategic report governance remuneration financial statement investor information independent auditor report continue report audit financial statement continue report information responsibility report alternative performance measure apm apm measure define generally accept opinion accounting practice gaap typically include use calculation disclosure apm financial statement annual report group use apm consistent group publish definition adjust profit free cash flow constant currency growth policy rate report financial performance use apm group report result review assess calculation report consistent guideline produce esma metric assess consistency group publish definition frc policy item appropriate balance use consider assess use apm statutory metric apm clear group report result consistent guideline produce definition reconciliation apm regulator european security market authority financial reporting esma guideline use apm frc alternative performance measure thematic review publish october consider appropriate balance use statutory metric apm addition clear definition reconciliation apm financial reporting provide dividend distribution policy consider dividend policy transparent dividend opinion dividend policy appropriately pay consistent policy outline strategic report disclose dividend pay consistent policy responsibility director auditor responsibility audit explain fully director responsibilitie financial statement statement director responsible preparation objective obtain reasonable assurance financial statement satisfy financial statement free true fair view internal control director material misstatement fraud error determine necessary enable preparation financial issue auditor report include opinion reasonable statement free material misstatement assurance high level assurance guarantee fraud error audit conduct accordance isa prepare financial statement director detect material misstatement exist responsible assess group parent company misstatement arise fraud error consider ability continue go concern disclose applicable material individually aggregate matter related going concern go concern reasonably expect influence economic decision basis accounting director intend user take basis financial statement liquidate group parent company cease description responsibility audit operation realistic alternative financial statement locate frc website www frcorgukauditorsresponsibilitie description form auditor reportgsk annual report independent auditor report continue report audit financial statement continue extent audit consider audit response risk identify result perform identify valuation capable detecting irregularity include fraud return rebate accrual key audit matter irregularity include fraud instance noncompliance related potential risk fraud key audit matter law regulation design procedure line section report explain matter detail responsibility outline detect material describe specific procedure response key misstatement respect irregularity include fraud audit matter common audits isas extent procedure capable detecting require perform specific procedure respond irregularity include fraud detail risk management override identify assess potential risk relate addition procedure respond risk irregularity identify include follow identify assess risk material misstatement review financial statement disclosure test respect irregularity include fraud noncompliance support documentation assess compliance law regulation consider follow provision relevant law regulation describe nature industry sector control environment direct effect financial statement business performance include design enquire senior leadership team audit risk group remuneration policy key driver director committee inhouse external legal counsel remuneration bonus level performance target concern actual potential litigation claim result enquirie senior leadership team internal perform analytical procedure identify unusual audit audit risk committee include obtain unexpected relationship indicate risk material review support documentation concern misstatement fraud group policy procedure relate read minute meeting charge identify evaluate comply law governance review internal audit report regulation aware instance correspondence regulator noncompliance address risk fraud management override detect respond risk fraud control test appropriateness journal entry knowledge actual suspect alleged adjustment assess judgement fraud make accounting estimate indicative potential internal control establish mitigate risk relate bias evaluate business rationale significant fraud noncompliance law regulation transaction unusual outside normal course business matter discuss engagement team include significant component audit team involve communicate relevant identify law relevant internal specialist include tax valuation regulation potential fraud risk engagement team pension industry specialist member significant component audit team fraud occur financial statement remain alert indication fraud noncompliance potential indicator fraud law regulation audit obtain understand legal regulatory report legal regulatory requirement frameworks group operate focus provision law regulation direct effect determination material amount disclosure opinion matter prescribe financial statement key law regulation company act consider context include provision opinion director remuneration report company act pension legislation tax legislation audit properly prepare accordance consider key law regulation company act fundamental effect operation group include good clinical practice fda regulations general datum opinion base work undertake course protection requirement antibribery corruption policy audit foreign corrupt practice act information give strategic report director report financial year financial statement prepare consistent financial statement strategic report director report prepared accordance applicable legal requirement gsk annual report strategic report governance remuneration financial statement investor information independent auditor report continue report audit financial statement continue light knowledge understanding group director remuneration parent company environment obtain company act require report course audit identify material opinion certain disclosure director remuneration misstatement strategic report director report director remuneration report audit agreement account corporate governance statement record return list rule require review director statement report respect matter relation go concern longerterm viability corporate governance statement relate group matter require address compliance provision corporate governance code specify review auditor tenure base work undertake audit follow recommendation audit risk committee conclude follow element effect january appoint corporate governance statement materially consistent board director audit financial statement financial statement knowledge obtain year end december subsequent financial audit period period total uninterrupted engagement firm year director statement regard appropriateness adopt go concern basis accounting consistency audit report additional report material uncertainty identify set audit risk committee director explanation assessment group audit opinion consistent additional report prospect period assessment cover audit risk committee require provide period appropriate set accordance isa directors statement fair balanced use report understandable annual report set report solely parent company member board confirmation carry robust body accordance chapter assessment emerge principal risk set company act audit work undertake page state parent company member section annual report describe review matter require state auditor report effectiveness risk management internal control purpose full extent permit law system set page accept assume responsibility parent company parent company member section describe work audit risk body audit work report opinion committee set form matter require report course require financial conduct authority fca disclosure guidance transparency rule dtr exception financial statement form adequacy explanation receive accounting record european single electronic format esefprepare annual company act require report financial report file national storage mechanism opinion fca accordance esef regulatory technical standard esef rts auditor report provide receive information explanation assurance annual financial report require audit prepare single electronic format specify adequate accounting record keep esef rts parent company return adequate audit parent company pass resolution accordance receive branch visit section company act senior parent company financial statement statutory auditor state agreement accounting record return report respect matter deloitte llp statutory auditor london united kingdom march gsk annual report consolidated income statement year end december note turnover cost sale gross profit sell general administration research development royalty income operate expenseincome operating profit finance income finance expense loss disposal interest associate share tax lossprofit associate joint ventures profit taxation taxation profit taxation continue operation profit taxation discontinue operation gainslosse demerger remeasurement discontinue operation distribute shareholder demerger profit taxation discontinue operation total profit taxation year profit attributable noncontrolle interest continue operation profit attributable shareholder continue operation profit attributable noncontrolle interest discontinue operation profit attributable shareholder discontinue operation total profit attributable noncontrolle interest total profit attributable shareholder basic earning share penny continue operation basic earning share penny discontinue operation total basic earning share penny dilute earning share penny continue operation dilute earning share penny discontinue operation total diluted earning share penny consolidate statement comprehensive income year end december note total profit year comprehensive incomeexpense year item subsequently reclassify continue operation income statement exchange movement overseas net asset net investment hedge reclassification exchange movement liquidation disposal overseas subsidiary associate fair value movement cash flow hedge reclassification cash flow hedge income statement defer tax fair value movement cash flow hedge item reclassify continue operation income statement exchange movement overseas net asset noncontrolle interest fair value movement equity investment tax fair value movement equity investment remeasurement lossesgain define benefit plan tax remeasurement lossesgain define benefit plan fair value movement cash flow hedge comprehensive expense year continue operation comprehensive income year discontinue operation total comprehensive income year total comprehensive income year attributable shareholder noncontrolle interest total comprehensive income year comparative restate consistent basis previously publish reflect demerger consumer healthcare business note andor impact share consolidation note gsk annual report strategic report governance remuneration financial statement investor information consolidate balance sheet december note noncurrent asset property plant equipment right use asset goodwill intangible asset investment associate joint venture investment defer tax asset derivative financial instrument noncurrent asset total noncurrent asset current asset inventory current tax recoverable trade receivables derivative financial instrument current equity investment liquid investment cash cash equivalent asset hold sale total current asset total asset current liability shortterm borrowing contingent consideration liability trade payable derivative financial instrument current tax payable shortterm provision total current liability noncurrent liability longterm borrowing corporation tax payable deferred tax liability pension postemployment benefit provision derivative financial instrument contingent consideration liability noncurrent liability total noncurrent liability total liability net asset equity share capital share premium account retain earning reserve shareholder equity noncontrolle interest total equity financial statement page approve board march sign behalf sir jonathan symonds chairgsk annual report consolidate statement change equity year end december shareholder equity share share retain noncontrolle total capital premium earning reserve total interest equity december profit year comprehensive expenseincome year total comprehensive income year distribution noncontrolle interest contribution noncontrolle interest change noncontrolle interest dividend shareholder realise profit taxation disposal equity investment share associates joint venture realise profit disposal equity investment share issue share acquire esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december profit year comprehensive expenseincome year total comprehensive income year distribution noncontrolle interest contribution noncontrolle interest dividend shareholder share issue realise tax profit disposal equity investment share associates joint venture realise profit disposal equity investment writedown share hold esop trust sharebase incentive plan transaction noncontrolle interest tax sharebase incentive plan december profit year comprehensive expenseincome year total comprehensive income year distribution noncontrolle interest noncash distribution noncontrolle interest contribution noncontrolle interest change noncontrolle interest deconsolidation subsidiary dividend shareholder noncash dividend shareholder realise tax loss disposal liquidation equity investment share associates joint venture realise profit disposal equity investment share issue writedown share hold esop trust share acquire esop trust sharebase incentive plan tax sharebase incentive plan hedge gain taxation transfer nonfinancial asset december analysis reserve present note movement equity gsk annual report strategic report governance remuneration financial statement investor information consolidated cash flow statement year end december note cash flow operating activity profit taxation continue operation year adjustment reconcile profit tax operating cash flow cash generate operation attributable continue operation taxation pay net cash inflow continue operating activity cash generate operation attributable discontinued operation taxation pay discontinued operation net operating cash flow attributable discontinued operation total net cash inflow operating activity cash flow investing activity purchase property plant equipment proceed sale property plant equipment purchase intangible asset proceed sale intangible asset purchase equity investment purchase business net cash acquire proceed sale equity investment contingent consideration pay disposal business investment associate joint venture proceed disposal associate joint venture interest receive decreaseincrease liquid investment dividend associate joint venture net cash outflow continue investing activity net cash invest cash flow attributable discontinued operation total net cash outflowinflow investing activity cash flow financing activity issue share capital repayment longterm loan issue longterm note repayment shortterm loan increase inrepayment shortterm loan repayment lease liability interest pay dividend pay shareholder distribution noncontrolle interest contribution noncontrolle interest finance item net cash outflow continue financing activity net financing cash flow attributable discontinued operation total net cash inflowoutflow financing activity increasedecrease cash bank overdraft cash bank overdraft begin year exchange adjustment increasedecrease cash bank overdraft year cash bank overdraft end year cash bank overdraft end year comprise cash cash equivalent overdraft comparative result restate consistent basis previously publish reflect demerger consumer healthcare business note gsk annual report note financial statement presentation financial statement description business financial period gsk global biopharma group make innovative financial statement cover financial year vaccine specialty medicine prevent treat disease january december comparative figure gsk focus science immune system financial year january december human genetic advanced technology primarily appropriate january december follow therapeutic area infectious disease hiv income statement cash flow comparative oncology immunologyrespiratory restate consistent basis previously publish reflect classification consumer healthcare compliance applicable law ifrs business discontinue operation note financial statement prepare accordance international accounting standard conformity accounting principle policy requirement company act international financial statement prepare financial reporting standard issue iasb historical cost convention modify revaluation certain item state accounting policy composition financial statement go concern basis consolidated financial statement draw sterling financial statement prepare accordance functional currency gsk plc accordance group accounting policy approve board ifrs accounting presentation financial statement describe note accounting principle policy comprise information application accounting policy consolidate income statement include area estimation judgement give note critical accounting judgement key source estimation consolidate statement comprehensive income uncertainty consolidated balance sheet preparation financial statement conformity consolidate statement change equity generally accept accounting principle require management consolidated cash flow statement estimate assumption affect report amount asset liability disclosure contingent note financial statement asset liability date financial statement composition group report amount revenue expense report period actual result differ estimate list subsidiary associate opinion director principally affect profit net parent company financial statement asset group give note principal group financial statement parent company gsk plc company prepare accordance gaap accounting presentation company balance sheet present accounting policy give page accounting principle policy consolidation group ability exercise joint control right net asset entity entity consolidated financial statement include account joint venture group asset liability result cash flow ability exercise joint control arrangement company subsidiary include esop trust right specify asset obligation specify liability group share result net asset associate arrangement arrangement account joint venture joint operation group ability exercise significant influence entity account group share asset liability revenue expense associate result asset liability associate joint operation joint venture incorporate consolidated financial statement entity consolidate financial statement equity method accounting december year asset liabilitie revenue expense joint operation entity group power direct include consolidated financial statement relevant activity affect return group accordance group right obligation generally control financial operating interest acquire entity consolidated date policy account subsidiary group acquire control interest sell consolidated date control cease gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information accounting principle policy continue transaction balance subsidiary eliminate exchange adjustment arise open net asset profit tax take sale subsidiary profit year retain overseas subsidiary product sell customer outside group associate joint venture translate sterling relevant proportion profit transaction joint venture exchange difference arise related foreign currency joint operation associate defer borrowing hedge group net investment product sell party transaction non operation take separate component equity control interest record directly equity defer tax retain earning relief unrealise intragroup profit account translate sterling asset liability result extent consider recoverable cash flow overseas subsidiary associate joint venture report currency hyperinflationary business combination economy adjustment material reflect business combination account acquisition current price level loss net monetary asset charge accounting method identifiable asset liability contingent consolidated income statement liability acquire measure fair value acquisition date consideration transfer measure fair value revenue include fair value contingent consideration turnover fair value contingent consideration liability group receive revenue supply good external reassess balance sheet date change customer order receive majority contract recognise income statement payment contingent gsk enter relate sale order contain single consideration reduce balance sheet liability result performance obligation delivery pharmaceutical record income statement vaccine prior demerger consumer healthcare payment relate original estimate business consumer healthcare product average duration fair value contingent consideration acquisition report sale order month investing activity cash flow statement product revenue recognise control good payment relate increase liability pass customer point control pass acquisition date report operate cash flow determine customer arrangement generally occur consideration transfer non delivery customer control interest exceed fair value net asset product revenue represent net invoice value include fix liability contingent liability acquire excess variable consideration variable consideration arise sale record goodwill cost effecting acquisition good result discount allowance give accrual charge income statement period estimate future return rebate revenue recognise incur highly probable significant reversal goodwill capitalise separate item case cumulative revenue recognise occur subsidiary cost investment case methodology assumption estimate rebate joint ventures associate goodwill denominate return monitor adjust regularly light currency operation acquire contractual legal obligation historical trend past experience project market condition estimate associate return cost acquisition group interest rebate revisit reporting date net asset acquire difference recognise directly resolve revenue adjust accordingly refer income statement note detail rebate discount allowance equity subsidiary acquire non group enter collaborative agreement typically control interest recognise fair value pharmaceutical biotechnology company develop noncontrolle interest share net asset subsidiary produce market drug candidate vaccine casebycase basis change group ownership qualify joint arrangement gsk control percentage subsidiary account equity commercialisation activity group recognise turnover cost foreign currency translation sale gross basis profit sharing amount royalty counterparty record cost sale cost sale foreign currency transaction book functional include profit sharing cost royalty counterparty currency group company exchange rate ruling million million million date transaction foreign currency monetary asset counterparty control commercialisation activity record liability retranslate functional currency sale group deem principal customer contract rate exchange rule balance sheet date exchange instead record share gross profit copromotion difference include income statement income net basis turnover nature copromotion consolidation asset liability include related activity group record cost sale goodwill overseas subsidiary associate joint venture commercial operation turnover include copromotion revenue translate sterling rate exchange million million million reimbursement rule balance sheet date result cash flow counterparty collaboration agreement overseas subsidiary associate joint venture sell general administration research development translate sterling average rate exchange cost record net respective line consolidate income statementgsk annual report note financial statement continue accounting principle policy continue operate income royalty income liability include group portion total cost gsk enter development marketing collaboration portion potentially responsible party cost outlicence group compound product probable able satisfy party contract rise fix variable respective share cleanup obligation recovery consideration upfront payment development milestone reimbursement record asset virtually certain salesbased milestone royalty legal dispute income dependent achievement development provision anticipate settlement cost legal milestone recognise highly probable significant dispute group outflow reversal cumulative revenue recognise resource consider probable reliable estimate occur usually relate event occur salesbase likely outcome respect product liability milestone income recognise highly probable claim relate certain product provision sale threshold reach sufficient history claim settlement salesbase royalty licence intellectual property enable management reliable estimate recognise relevant product sale occur provision require cover assert unasserted claim revenue time recognition revenue certain case incur report ibnr actuarial payment customer expect technique determine estimate addition year impact material provision legal expense arise consideration discount appropriate discount rate claim receive dispute value add tax sale taxis exclude revenue group involved legal proceeding respect possible meaningfully assess expenditure outcome result probable outflow expenditure recognise respect good service quantify reliably estimate liability case receive supply accordance contractual term appropriate disclosure case include provision obligation exist future liability provision respect past event cost associate claim group obligation reliably estimate manufacturing startup party charge income statement incur cost validation achievement normal production expense incur pension postemployment benefit advertising promotion expenditure charge cost provide pension define benefit scheme income statement incur calculate project unit credit method spread shipment cost intercompany transfer charge cost period benefit expect derive sale distribution cost sale customer include employee service consistent advice qualified sell general administration expenditure actuary restructuring cost recognise provide pension obligation measure present value estimate appropriate respect direct expenditure business future cash flow discount rate reflect yield reorganisation plan sufficiently detailed highquality corporate bond pension scheme asset advanced appropriate communication measure fair value balance sheet date affect undertaken cost postemployment liability calculate software service saas configuration cost expense similar way define benefit pension scheme spread incur software configure period benefit expect derive control saas provider employee service accordance advice qualified actuary research development service cost provide retirement benefit employee research development expenditure charge year cost curtailment income statement period incur charge operating profit year development expenditure capitalise criterion actuarial gain loss effect change recognise asset meet usually regulatory filing actuarial assumption recognise statement major market approval consider comprehensive income year arise highly probable property plant equipment research development capitalise depreciate group contribution define contribution plan accordance group policy charge income statement incur environmental expenditure environmental expenditure relate exist condition result past current operation current future benefit discernible charge income statement group recognise liability sitebysite basis reliably estimate gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information accounting principle policy continue employee share plan finance cost charge income statement produce constant periodic rate charge remain incentive form share provide employee balance obligation accounting period share option share award scheme variable rent lease liability right use fair value option award calculate asset payment charge income statement grant date blackschole option pricing model incurred lease rental cost shortterm lowvalue lease charge income statement relevant vesting period capitalise charge income statement group provide finance esop trust purchase company incur share meet obligation provide share employee nonlease component account separately exercise option award cost run esop trust lease component plant equipment lease charge income statement separately account land building vehicle share hold esop trust deduct reserve lease transfer reserve retain earning modification reassessment lease obligation occur vest period relate share option award lease liability right use asset remeasure reflect ultimate proceed receivable employee exercise right use asset title expect pass gsk point future depreciate basis consistent property plant equipment similar own asset case right use asset property plant equipment ppe state cost depreciate short useful life asset purchase construction provision depreciation lease term impairment financing cost capitalise cost qualifying asset construction goodwill goodwill state cost impairment goodwill depreciation calculate write cost residual deem indefinite useful life test value ppe exclude freehold land straightline impairment annually basis expect useful life residual value life review appropriate adjust annually fair value interest acquire entity normal expect useful life major category ppe asset liabilitie contingent liability exceed consideration pay excess recognise immediately gain income statement freehold building year leasehold land building lease term year intangible asset plant machinery year intangible asset state cost provision equipment vehicle year amortisation impairment disposal ppe cost relate accumulate licence patent knowhow marketing right separately depreciation impairment remove financial acquire acquire business combination statement net proceed take amortise estimate useful life generally income statement exceed year straightline basis time available use estimate useful life lease determine amortisation charge account patent group recognise right use asset lease live exclusivity period applicable value arrangement lessee shortterm obtain period nonexclusivity pharmaceutical lease define lease lease term month intangible asset depend characteristic lease low value asset right use asset own competitive environment estimate longterm profit party lease agreement capitalise asset book value amortise inception lease recognise consolidated exclusivity period straightline basis balance sheet remain book value amortise nonexclusivity period year straightline basis vaccine correspond liability lessor recognise intangible asset cost usually amortise exclusivity lease obligation short longterm borrowing period plus year year exclusivity period carry subsequently increase reflect interest grant straightline basis asset life review lease liability reduce lease payment appropriate adjust annually calculate discount lease liability lease annual contingent milestone payment recognise point payment million implicit rate lease contingent event probable available incremental borrowing rate development cost incur group associated lease specific adjustment available acquire licence patent knowhow marketing right lease annual payment million write income statement incur incremental borrowing rate incremental borrowing criterion recognition internally generate intangible rate calculate rate interest gsk asset meet usually regulatory filing able borrow similar term similar security major market approval consider highly probable fund necessary obtain similar asset similar marketgsk annual report note financial statement continue accounting principle policy continue acquire process market product value financial instrument independently fair value business acquire party value substantial long financial asset term brand contractual legal financial asset measure amortise cost fair value nature sell separately rest business comprehensive income fvtoci fair value acquire profit loss fvtpl measurement basis determine reference business model cost acquire develop computer software manage financial asset contractual cash flow internal use internet site external use capitalise characteristic financial asset financial asset intangible fix asset software site support trade receivable month expect credit loss significant business system expenditure lead ecl allowance record initial recognition creation durable asset control group erp subsequent evidence significant increase credit risk system software amortise seven year asset allowance increase reflect lifetime computer software year ecl realistic prospect recovery asset straightline basis write impairment noncurrent asset expect credit loss recognise income statement carry value noncurrent asset review financial asset measure amortise cost fair impairment standalone basis large value comprehensive income apart equity cash generating unit indication investment asset impair additionally goodwill intangible current equity investment asset available use test current equity investment comprise equity investment impairment annually provision impairment charge group hold intention sell sell income statement year concern short term acquire intention impairment goodwill reverse impairment loss measure fvtpl initially record fair value noncurrent asset reverse remeasure subsequent reporting date fair change estimate determine recoverable amount value unrealised gain loss recognise extent revise recoverable amount income statement dividend income recognise exceed carry value exist net income statement group right receive payment depreciation amortisation impairment establish purchase sale current equity investment recognise account trade date investment associate joint venture joint investment operation investment comprise equity investment investment associate joint venture carry investment limited life fund group elect consolidated balance sheet group share net designate majority equity investment measure asset date acquisition postacquisition fvtoci initially record fair value plus retain profit loss comprehensive income transaction cost remeasure subsequent goodwill arise acquisition reporting date fair value unrealised gain loss group recognise asset liability revenue expense recognise comprehensive income disposal joint operation accordance right equity investment gain loss defer obligation comprehensive income transfer directly retain earning inventory investment limited life fund measure fvtpl inventory include financial statement initially record fair value remeasure low cost include raw material direct labour subsequent reporting date fair value unrealise gain direct cost relate production overhead net loss recognise income statement realisable value cost generally determine dividend equity investment distribution fund basis prelaunch inventory hold asset recognise income statement group right high probability regulatory approval product receive payment establish point provision carrying value reduce recoverable provision purchase sale investment account reverse point high probability trade date regulatory approval determined gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information accounting principle policy continue trade receivables hedge accounting trade receivables measure accordance business derivative designate hedge instrument classify model portfolio trade receivables hold inception hedge relationship cash flow hedge net group portfolio business model investment hedge fair value hedge ifrs collect contractual cash flow change fair value derivative designate cash factoring agreement place measure amortise cost flow hedge recognise comprehensive income sell contractual cash flow trade receivable extent hedge effective accumulate sell factoring agreement measure fvtpl cash flow hedge reserve ineffective portion collect sell contractual cash flow trade recognise profit loss immediately amount defer receivables sell factoring arrangement cash flow hedge reserve reclassify income measure fvtoci trade receivables measure amortise statement hedge item affect profit loss cost carry original invoice allowance hedge forecast transaction purchase nonfinancial expect credit loss asset defer cash flow hedge reserve expect credit loss calculate accordance transfer directly equity include carry simplify approach permit ifrs provision matrix value recognise nonfinancial asset apply lifetime historical credit loss experience trade net investment hedge account similar way receivables expect credit loss rate vary depend cash flow hedge reclassify income extent settlement trade statement hedge item affect profit loss receivables overdue adjust appropriate reflect current economic condition estimate future change fair value derivative designate fair condition purpose determine credit loss rate value hedge record income statement customer classify grouping similar loss change fair value hedge asset pattern key driver loss rate nature liability business unit location type customer taxation trade receivable determine reasonable current tax provide amount expect pay expectation recovery write firstly apply tax rate enact substantively expect credit loss allowance available enact balance sheet date tax charge income statement period recognise income statement statement subsequent recovery amounts previously provide comprehensive income directly equity accord write credit income statement longterm accounting treatment relate transaction receivables discount effect material defer tax provide temporary difference arise tax basis asset liabilitie cash cash equivalent carry amount financial statement defer tax cash hold deposit account measure amortise cost asset recognise extent probable investment money market fund hold fair value future taxable profit available profit loss fund fail solely temporary difference utilise defer tax provide payment principal interest sppi test temporary difference arise investment subsidiary borrowing associate joint venture time borrowing initially record proceed reversal temporary difference control receive net transaction cost borrowing subsequently probable temporary difference reverse carry amortise cost difference foreseeable future defer tax provide rate tax proceed net transaction cost enact substantively enact redemption recognise charge income balance sheet date defer tax asset liability statement period relevant borrowing offset legally enforceable right offset current tax asset current tax liability relate derivative financial instrument income taxis levy tax authority derivative financial instrument manage exposure company subsidiary intend settle current tax market risk principal derivative instrument asset liability net basis gsk foreign currency swap interest rate swap foreign defer tax asset liability recognise exchange forward contract option group temporary difference arise initial recognition hold issue derivative financial instrument trading goodwill initial recognition asset speculative purpose liabilitie transaction business combination derivative financial asset liability include derivative affect account taxable profit embed host contract separate loss unrecognised defer tax asset reassess host contract classify heldfortrading reporting date recognise extent measure fair value change fair value probable future taxable profit allow derivative instrument qualify hedge defer tax asset recover accounting recognise immediately income statementgsk annual report note financial statement continue accounting principle policy continue uncertain tax position identify management asset liability hold sale distribution judgement probable outcome discontinue operation assume relevant tax authority knowledge disposal group classify held sale distribution situation assess economic outflow carrying recover principally sale probable arise provision good estimate distribution shareholder continue liability estimate liability gsk apply use available sale distribution present riskbase approach take account appropriate condition sale distribution consider highly probability group able obtain probable asset hold asset hold sale distribution compensatory adjustment international tax treaty measure low carrying fair value estimate account specific circumstance cost sell distribute noncurrent asset include dispute relevant external advice asset hold sale distribution depreciate discount amortise asset liability classify held sale distribution present current asset current time value money material balance liability separately asset liability discount current value appropriate discount rate balance sheet unwind discount record finance income finance expense discontinue operation component group dispose distribute classify hold sale distribution represent separate major line business result discontinue operation present separately consolidated income statement consolidate statement comprehensive income consolidate statement cash flow comparative restate consistent basis critical accounting judgement key source estimation uncertainty prepare financial statement management require sale pharmaceutical vaccine product judgement item complex arrangement rebate discount allowance recognise financial statement estimate turnover commercial operation product assumption affect amount asset liability million million revenue expense report financial statement record deduction million million actual amount result differ estimate rebate allowance return discount follow consider critical accounting december total accrual amount million judgement key source estimation uncertainty million nature accrual practicable meaningful sensitivity estimate turnover large volume variable contribute overall report group turnover million rebate chargeback return revenue accrual million significant variability final outcome group apply constraint measure variable estimate element revenue revenue recognise gross turnover reduce rebate discount allowance suitably cautious objective constraint product return give expect give ensure highly probable significant reversal vary product arrangement buy group revenue occur uncertainty resolve arrangement purchase organisation dependent constraint apply make suitably cautious submission claim time initial estimate input assumption estimate recognition sale accrual time sale variable consideration amount estimate rebate discount allowance payable estimate fully reflect final outcome return base available market information amount subject change dependent historical experience thing type buy group product sale mix constraint apply recognise revenue mean risk material downward adjustment revenue comparative result restate consistent basis financial year low previously publish reflect demerger consumer healthcare business gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information critical accounting judgement key source estimation uncertainty continue level accrual rebate return review legal dispute adjust regularly light contractual legal legal cost year million million obligation historical trend past experience project december provision legal dispute market condition market condition evaluate amount million million wholesaler thirdparty analysis market research datum internally generate information reasonably estimate possible significant adjustment management make judgement sufficient month recognise additional revenue actual information able reliable estimate likely outcome well cautious constrain estimate outcome dispute legal expense revenue recognise highly probable arise claim group insufficient information significant reversal cumulative revenue available provision disclosure claim recognise occur turnover recognise give year performance obligation satisfy previous estimate provision account specific period set note turnover segment information circumstance dispute relevant external advice indication level sensitivity estimate inherently judgemental change substantially future event cause assumption time dispute progress new fact emerge accrual base change materially affect detail status uncertainty involve future result group significant unresolved dispute set note legal proceeding taxation company director take legal advice tax charge year million establish provision take account relevant million december current tax payable fact circumstance matter accordance million million noncurrent corporation tax accounting requirement respect product liability claim payable million million current tax relate certain product sufficient history claim recoverable million million settlement enable management reliable estimate provision require cover unasserted claim estimate group open tax issue number revenue group involved legal proceeding respect authority management make judgement possible meaningfully assess sufficient information able reliable estimate outcome result probable outflow quantify reliably outcome dispute insufficient information estimate liability case appropriate disclosure available provision case provide provision contingent liability quantify sufficient information available estimate potential tax liability gsk apply riskbased approach take ultimate liability legal claim vary amount account appropriate probability group provide dependent outcome litigation able obtain compensatory adjustment proceeding investigation possible settlement negotiation international tax treaty estimate account position change time specific circumstance dispute relevant assurance loss result outcome external advice inherently judgemental change legal proceeding exceed provision substantially time dispute progress new report group financial statement material fact emerge contingent consideration december group recognise provision income statement charge contingent million respect uncertain tax position consideration million million million number uncertain tax position hold number jurisdiction relate december liability contingent consideration practicable meaningful sensitivity estimate amount million million uncertain tax position individually significant group million million related acquisition shionogiviiv healthcare joint venture factor affect tax charge future year set note taxation gsk continue believe adequate provision liability likely arise open estimate assessment open issue exist ultimate liability contingent consideration include consideration matter vary amount provide payable business combination record fair value dependent outcome negotiation relevant date acquisition fair value generally base tax authority necessary litigation proceeding riskadjuste future cash flow discount appropriate posttax discount rate fair value review regular basis annually change comparative result restate consistent basis reflect income statement note contingent previously publish reflect demerger consumer consideration liability healthcare business gsk annual report note financial statement continue critical accounting judgement key source estimation uncertainty continue pension postemployment benefit discount rate derive rate corporate bond yield country deep market corporate judgement bond government bond yield sensitivity surplus define benefit scheme arise analysis provide note pension post potential surplus arise commit future employment benefit reduction discount rate contribution right trustee prevent group lead increase net pension deficit obtain refund surplus future consider approximately million increase annual pension determine necessary restrict cost approximately million similarly increase surplus recognise scheme surplus discount rate lead decrease net pension deficit scheme combine surplus million approximately million decrease annual december million recognise pension cost approximately million reduction pension surplus total million spread country discount rate lead increase net pension deficit million country gsk approximately million increase annual judgement amount meet requirement pension cost approximately million similarly recoverability increase discount rate lead decrease net pension deficit approximately million decrease estimate annual pension cost approximately million cost provide pension postemployment selection different assumption affect future result benefit assess basis assumption select group management assumption include future earning pension increase discount rate expect longterm rate return asset mortality rate disclose note pension postemployment benefit new accounting requirement amendment accounting standard issue iasb certain new accounting standard amendment adopt year end december accounting standard interpretation material impact result financial position group publish mandatory december reporting period adopt early group standard amendment interpretations expect material impact result financial position group future reporting period exchange rate group use average exchange rate prevail period translate result cash flow overseas subsidiary joint venture associate sterling period end rate translate net asset entity currency influence translation relevant exchange rate average rate period end rate euro euro yen yen gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information turnover segment information operating segment report base financial information provide chief executive officer responsibility gsk leadership team glt gsk revise operating segment previously gsk report result segment pharmaceutical pharmaceutical vaccine consumer healthcare quarter gsk report result segment commercial operation total consumer healthcare gsk report segment continue operation demerger consumer healthcare segment complete july member glt responsible segment comparative information retrospectively revise consistent basis investment essential sustainability business segment report commercial operating profit exclude allocation globally fund total segment responsibility chief scientific officer report separate segment operating cost segment include activity specialty medicine include hiv vaccine include sga cost relate regulatory function group management reporting process allocate intragroup profit product sale segment sale record profit analysis present basis revise revise turnover segment commercial operation consumer healthcare april gsk complete divestment horlick consumer healthcare nutrition product india number country exclude bangladesh unilever merger gsk indian list consumer healthcare entity hindustan unilever indian list company gsk complete divestment bangladesh june business exclude consumer healthcare joint venture include consumer healthcare segment performance product sale report product group specialty medicine vaccine general medicine revise revise commercial operation hiv oncology immunoinflammation respiratory pandemic specialty medicine meningitis influenza shingle establish vaccine pandemic vaccine vaccine respiratory general medicine general medicine total commercial operation total consumer healthcare comparative revise reflect commercial operation segmentgsk annual report note financial statement continue turnover segment information continue sale wholesaler million million million million million million million million million respectively allocate finalcustomer discount wholesaler revenue recognise year performance obligation satisfy previous period total million million include million million impact turnover arise change prior year estimate rar return rebate accrual million million milestone income million million royalty income recognise current year revise revise segment profit commercial operation research development consumer healthcare segment profit corporate unallocated cost reconcile item segment profit operating profit total operating profit finance income finance cost loss disposal interest associate share aftertax profitslosse associate joint venture profit taxation continue operation taxation profit taxation year continue operation april gsk complete divestment horlick consumer healthcare nutrition product india number country exclude bangladesh unilever merger gsk indian list consumer healthcare entity hindustan unilever indian list company gsk complete divestment bangladesh june reconcile item segment profit operating profit comprise item specifically allocate segment profit include impairment amortisation intangible asset major restructuring cost include impairment tangible asset computer software transactionrelate adjustment relate significant acquisition proceed cost disposal product business significant legal charge expense settlement litigation government investigation operate income royalty income item refer detail reconcile item segment profit operating profit analysis adjust item group financial review revise revise depreciation amortisation segment commercial operation research development segment depreciation amortisation corporate unallocated depreciation amortisation reconcile item segment depreciation amortisation total depreciation amortisation total depreciation amortisation comparative restate consistent basis previously publish reflect demerger consumer healthcare business note gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information turnover segment information continue revise revise ppe intangible asset goodwill impairment segment commercial operation research development segment impairment corporate unallocated impairment reconcile item segment impairment total impairment total impairment ppe intangible asset impairment reversal segment commercial operation research development segment impairment reversal corporate unallocated impairment reversal reconcile item segment impairment reversal total impairment reversal total impairment reversal revise net operating asset segment commercial operation research development segment net operating asset corporate unallocated net operating asset discontinue operation net operating asset net debt investment associate joint venture current equity investment derivative financial instrument current defer taxation asset hold sale exclude cash cash equivalent net asset commercial operation segment include shionogiviiv healthcare contingent consideration liability million million pfizer option million million geographical information regard group country domicile revise revised turnover location customer rest world external turnover noncurrent asset location subsidiary belgium switzerland rest world noncurrent asset noncurrent asset location exclude amount relate investment defer tax asset derivative financial instrument pension asset amount receivable insurance contract certain noncurrent receivables country individually material external revenue noncurrent asset comparative restate consistent basis previously publish reflect demerger consumer healthcare business note comparative revise reflect new segmentsgsk annual report note financial statement continue operating incomeexpense upfront settlement income fair value remeasurement equity investment disposal business asset fair value remeasurement contingent consideration recognise business combination remeasurement viiv healthcare option liability preferential dividend fair value adjustment derivative financial instrument income comparative restate consistent basis previously publish reflect demerger consumer healthcare business note february viiv healthcare reach agreement gilead sciences inc gilead settle global patent infringement litigation relate commercialisation gilead biktarvy concern viiv healthcare patent relate dolutegravir antiretroviral medication medicine treat human immunodeficiency virus hiv term global settlement licensing agreement gilead upfront payment billion million viiv healthcare february addition gilead pay royalty future sale biktarvy respect bictegravir component future bictegravircontaine product sell royalty payable gilead viiv healthcare february expiry viiv healthcare patent october record royalty income income statement fair value remeasurement equity investment include gainloss million remeasurement group retain investment haleon plc fair value december initial recognition fair value fiveday average share price demerger detail note disposal business asset include milestone income reversal provision long require disposal business asset include net gain disposal right royalty stream cabozantinib net gain disposal cephalosporin antibiotic brand sandoz disposal business asset include net profit disposal horlick consumer healthcare nutritional brand subsidiary india bangladesh million reflect reversal million embed derivative gain value share take prior year partly offset related million loss share hindustan unilever limit include fair value remeasurement loss acquisition consideration divestment gsk consumer healthcare limited india subsequent disposal operating income include increase profit milestone income number asset disposal fair value remeasurement contingent consideration recognise business combination include million related acquisition shionogiviiv healthcare joint venture million payable novartis relate vaccine acquisition fair value movement relate hedging contract gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information operating profit follow item include operate profit employee cost note advertising distribution cost depreciation property plant equipment impairment property plant equipment net reversal depreciation right use asset impairment right use asset amortisation intangible asset impairment intangible asset net reversal impairment intangible asset hold sale net reversal impairment goodwill allocate disposal group net reversal net foreign exchange gainslosse inventory cost inventory include cost sale writedown inventory reversal prior year writedown inventory shortterm lease charge lowvalue lease charge variable lease payment fees payable company auditor associate relation group reversal prior year writedown inventory principally arise reassessment usage demand expectation prior inventory expiration net foreign exchange gainslosse include net loss million million gain million loss arise recycling exchange liquidation disposal overseas subsidiary recycle exchange disposal overseas associate loss nil million report loss disposal interest associate recycle exchange disposal overseas subsidiary include recycle exchange disposal consumer healthcare subsidiary report profit taxation demerger discontinue operation include operate profit major restructuring charge million million million note major restructuring cost fee payable company auditor associate audit parent company consolidate financial statement include attestation sarbanesoxley act audit company subsidiary total audit service auditrelated assurance service total audit service auditrelate assurance service assurance service provide auditor relate agree procedure assurance service outside statutory audit requirement addition fee pay auditor respect gsk pension scheme audit immaterial fee million pay versus nil million auditor respect audits certain company subsidiary audit related assurance service include million million report accountant work perform preparation consumer healthcare demerger comparative restate consistent basis previously publish reflect demerger consumer healthcare business note gsk annual report note financial statement continue employee cost wage salary social security cost pension postemployment cost include augmentation note cost sharebase incentive plan severance cost integration restructuring activity group provide benefit employee commensurate local practice individual country include market healthcare insurance subsidise car scheme personal life assurance cost sharebase incentive plan analyse follow share value plan performance share plan share option plan cash settle plan average number person employ group include director year number number number manufacturing sell general administration research development total continue operation discontinue operation total note consumer healthcare divest july show discontinued operation table average monthly number group employee exclude temporary contract staff number group employee end financial year give financial record compensation director senior management member glt aggregate follow wage salary social security cost pension postemployment cost cost sharebase incentive plan information remuneration director give section annual report remuneration label audit page comparative restate consistent basis previously publish reflect demerger consumer healthcare business note gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information major restructuring cost pharmaceutical sector highly regulate manufacture operation supply chain long lifecycle business mean restructure programme particularly involve rationalisation closure manufacturing site likely year complete major restructuring cost relate specific boardapprove major restructuring programme include integration cost follow material acquisition structural significant scale cost individual relate project exceed million january board approve separation preparation programme prepare separation gsk company materially separation preparation restructuring programme include continue operation legacy consumer healthcare joint venture integration programme include discontinue operation acquisition sierra oncology july affinivax august board approve major restructure programme integration significant acquisition design integrate achieve synergy total restructuring cost million incur follow area restructure cost prepare separation gsk company continue transformation central function include gsk technology platform interface deliver great digital synergy simplification application staff reduction integration acquisition analysis cost charge operating profit continue operation programme follow increase provision major restructuring programme note provision reverse unused note impairment loss recognise noncash chargescredit cash cost provision reversal million million million reflect provision release mainly relate separation preparation programme asset impairment million noncash credit million principally comprise fix asset writedown manufacturing facility accelerate depreciation asset life shorten supply chain manufacturing network result major restructuring programme offset profit disposal charge settle cash include site closure cost consultancy project management cost analysis major restructuring charge continue operation programme follow cash noncash total separation preparation programme significant acquisition legacy program cash noncash total separation preparation programme legacy programme comparative restate consistent basis previously publish reflect demerger consumer healthcare business note gsk annual report note financial statement continue major restructuring cost continue analysis major restructuring charge continue operation income statement line follow cost sale sell general administration research development finance income finance income arise financial asset measure amortise cost financial asset measure fair value profit loss net gain arise forward element forward contract net investment hedge relationship finance income finance expense finance expense arise financial liability amortise cost net loss arise financial instrument mandatorily measure fair value profit loss retranslation loan reclassification hedge comprehensive income unwind discount provision finance expense arise lease liability finance expense comparative restate consistent basis previously publish reflect demerger consumer healthcare business note gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information associate joint venture group share aftertax profit loss associate joint venture set share aftertax profit associate share aftertax loss joint venture comparative restate demerged consumer healthcare business contain associate joint venture follow disposal innoviva inc detail note december december group hold significant individual associate december group hold significant associate innoviva inc summarise income statement information respect innoviva set group share aftertax profit associate comprehensive income include profit million comprehensive income nil respect innoviva result innoviva include summarise income statement information represent estimate earning innoviva relevant period base publicly available information balance sheet date figure include share innovivas turnover profit total comprehensive income date disposal turnover profit taxation total comprehensive income aggregate financial information respect gsk share associate undertaking joint venture set share aftertax loss share comprehensive incomeexpense share total comprehensive incomeexpense group sale associate joint venture nil nil nil refer balance sheet information associate joint venture note gsk annual report note financial statement continue taxation group tax charge sum total current defer tax expense taxation charge base profit year current year charge rest world current year charge chargecredit respect prior period current taxation defer taxation gsk corporate income tax payment globally billion continue discontinue operation million corporation tax pay hmrc amount corporate income tax include business taxis bear gsk year defer tax credit period reflect current year loss offset taxable profit future period probable release defer tax liability relate primarily unwind defer tax liability intangible asset defer tax credit reflect impact remeasurement defer tax asset liability follow enactment increase headline rate corporation tax follow table reconcile tax charge calculate statutory rate group profit tax actual tax charge year reconciliation taxation group profit profit tax statutory rate taxation difference overseas taxation rate benefit intellectual property incentive credit permanent difference disposal acquisition transfer permanent difference reassessment prior year current tax estimate reassessment prior year defer tax estimate change tax rate tax chargetax rate global biopharmaceutical company substantial business employment presence country world impact difference overseas taxation rate arise profit earn country tax rate high statutory rate significant belgium germany japan adverse impact offset benefit intellectual property incentive patent box belgian innovation income deduction regime provide reduce rate corporation tax profit earn qualifying patent claim incentive manner intend relevant statutory regulatory framework change tax rate include credit relation enactment increase headline rate corporate income tax effective change tax rate include credit relation reduction corporate income tax rate cancel india tax treatment dividend change effect april permanent difference disposals acquisition transfer include tax internal restructuring simplify group structure tax credit reflect tax impact disposal horlick consumer healthcare brand subsequent disposal share receive hindustan unilever group tax rate influence update estimate prior period tax liability follow closure open issue tax authority jurisdiction comparative restate consistent basis previously publish reflect demerger consumer healthcare business note gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information taxation continue future tax charge effective tax rate affect factor acquisition disposal restructuring location research development activity tax regime reform resolution open matter continue bring tax affair date world government confirm spring finance bill include legislation introduce global minimum corporate income tax rate effect line oecds pillar model framework detail measure account finalise possible accurately quantify impact gsk stage tax item charge equity statement comprehensive income current taxation sharebase payment define benefit plan fair value movement cash flow hedge fair value movement equity investment defer taxation sharebase payment define benefit plan fair value movement cash flow hedge fair value movement equity investment total credit equity statement comprehensive income comparative restate consistent basis previously publish reflect demerger consumer healthcare business note item charge statement comprehensive income tax sharebase payment issue relate taxation integrate nature group worldwide operation involve significant investment research strategic manufacture limited number location consequential crossborder supply route numerous endmarket line current oecd guideline base transfer pricing policy arm length principle support transfer price economic analysis report different tax authority seek attribute profit activity undertake jurisdiction potentially result double taxation group open item jurisdiction concern matter deductibility particular expense tax treatment certain business transaction gsk apply risk base approach determine transaction likely subject challenge probability group able obtain compensatory adjustment international tax treaty calculation group total tax charge necessarily involve degree estimation judgement respect certain item tax treatment finally determine resolution reach relevant tax authority appropriate formal legal process december group recognise provision million respect uncertain tax position million net decrease recognise provision drive reassessment estimate agreement number open issue tax authority jurisdiction amount related discontinued operation whilst ultimate liability matter vary amount provide dependent outcome agreement relevant tax authority litigation appropriate group continue consider appropriate provision period open agree tax authority provision defer tax liability million december million respect taxation payable remittance profit certain overseas subsidiary whilst aggregate unremitte profit balance sheet date approximately billion billion majority unremitted profit subject tax include withhold tax repatriation legislation relate company distribution provide exemption tax overseas profit subject certain exception defer tax provide temporary difference million million arise unremitted profit management ability control future reversal consider reversal probablegsk annual report note financial statement continue taxation continue movement defer tax asset liability pension share accelerate post option net capital intangible contingent intragroup employment tax award temporary allowance asset consideration profit benefit loss scheme difference total january exchange adjustment creditcharge income statement creditcharge statement comprehensive income acquisitionsdisposal credit utilisation december exchange adjustment creditcharge income statement creditcharge statement comprehensive income acquisitionsdisposal credit utilisation transfer asset hold sale distribution december defer tax liability relation intangible asset predominately relate temporary difference arising result historic business combination group continue recognise defer tax asset future obligation respect contingent consideration amount payable minority shareholder payment tax deductible point time payment deferred tax asset recognise intragroup profit arise intercompany inventory eliminate consolidated account intragroup profit eliminate individual entity tax return temporary difference arise reverse point time inventory sell externally defer tax asset recognise tax loss million million relate trading loss defer tax asset recognise probable future taxable profit available utilise loss support longrange product level forecast current forecast indicate asset utilise net temporary difference include accrue expense tax deduction available pay basis defer tax asset liability recognise balance sheet follow defer tax asset defer tax liability unrecognised unrecognised defer tax defer tax tax loss asset tax loss asset unrecognised tax loss trading loss expire year year available indefinitely december capital loss expire available indefinitely december defer tax asset recognise probable future taxable profit available utilise loss gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information earning share pence pence pence basic earning share continue operation basic earning share discontinue operation total basic earning share dilute earning share continue operation dilute earning share discontinue operation total diluted earning share comparative restate consistent basis previously publish reflect demerger consumer healthcare business note andor impact share consolidation note basic earning share calculate divide profit attributable shareholder weight average number share issue period deduct share hold esop trust treasury share trustee waive right cash dividend gsk share hold esop trust diluted earning share calculate adjust weight average number share basic calculation assume conversion potentially dilutive share potentially dilutive share form employee share scheme exercise price average market price gsk share period performance condition attach scheme meet balance sheet date number share calculate basic diluted earning share reconcile weight average number share issue million million million basic dilution share option award dilute restate reflect impact share consolidation note dividend dividend total dividend total dividend total share dividend share dividend share dividend paidpayable penny pay penny pay pence interim july july july second interim october october october interim january january january fourth interim april april april total estimate fourth interim dividend disclose annual report million million dividend ultimately pay dividend share retrospectively adjust reflect share consolidation period present detail note ifrs interim dividend recognise financial statement pay declare gsk normally pay dividend quarter quarter relate quarter declare financial statement recognise dividend pay fourth interim dividend second interim dividend demerger consumer healthcare business effect gsk declare interim dividend specie haleon plc share fair value distribution million amount recognise year follow cash dividend shareholder dividend specie shareholders haleon plc share note gsk annual report note financial statement continue property plant equipment plant land equipment asset building vehicle construction total cost january exchange adjustment addition capitalise borrowing cost disposal writeoff reclassification transfer asset hold saledistribution cost december exchange adjustment addition business combination addition capitalise borrowing cost disposal writeoff reclassification transfer asset hold saledistribution cost december depreciation january exchange adjustment charge year disposal writeoff transfer asset hold saledistribution depreciation december exchange adjustment charge year disposal writeoff transfer asset hold saledistribution depreciation december impairment january exchange adjustment disposal writeoff impairment loss reversal impairment impairment december exchange adjustment disposal writeoff impairment loss reversal impairment transfer asset hold saledistribution impairment december total depreciation impairment december total depreciation impairment december net book value january net book value december net book value december gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information property plant equipment continue weight average interest rate capitalise borrowing cost year disposal writeoff year include number asset nil net book value long use business impairment loss principally arise decision rationalise facility calculate base fair value cost disposal fair value cost disposal valuation methodology use significant input base observable market datum valuation technique classify level fair value hierarchy calculation determine net present value project riskadjuste posttax cash flow relevant asset cash generating unit apply discount rate group posttax weight average cost capital wacc adjust appropriate specific segment country currency risk asset continue group generally assess associate cash generating unit value use basis value use calculation posttax cash flow include impact future uncommitted restructuring plan improvement impairment indicate pretax cash flow calculation expect materially different result test reperforme pretax cash flow pretax discount rate group wacc equivalent pretax discount rate approximately net impairment loss charge cost sale million million million million sga million million include million million arise major restructuring programme reversal impairment arise subsequent review impaired asset condition gave rise original impairment deem long apply reversal credit cost sale million million computer software reclassify asset construction intangible asset ready use gsk assess qualitative quantitative impact climate relate risk asset recoverable amount conclude material impairment right use asset land plant building equipment vehicle total net book value january exchange adjustment addition depreciation disposal impairment net book value december exchange adjustment addition business combination addition depreciation transfer asset hold saledistribution disposal impairment net book value december group enter commitment lease contract commence note analysis lease liability set note net debtgsk annual report note financial statement continue goodwill cost january exchange adjustment addition business combination note movement transfer asset hold saledistribution cost december net book value january net book value december goodwill allocate group segment follow commercial operation total net book value december prior change group segment reporting note goodwill allocate follow pharmaceutical vaccine consumer healthcare net book value december goodwill million allocate consumer healthcare transfer asset hold saledistribution prior consumer healthcare demerger note recoverable amount cash generating unit assess fair value cost disposal model fair value cost disposal calculate discount cash flow approach posttax discount rate apply project riskadjuste posttax cash flow terminal value discount rate base group wacc cash generating unit integrate operation large part group discount rate adjust appropriate specific segment country currency risk valuation methodology use significant input base observable market datum valuation technique classify level fair value hierarchy segment evaluate arm length pricing model assumption detail relate discount cash flow model impairment test follow valuation basis fair value cost disposal key assumption sale growth rate profit margin terminal growth rate discount rate taxation rate determination assumption growth rate internal forecast base internal external market information margin reflect past experience adjust expect change terminal growth rate base management estimate future longterm average growth rate discount rate base group wacc adjust appropriate taxation rate base appropriate rate jurisdiction period specific project cash flow year terminal growth rate discount rate terminal growth rate discount rate commercial operation pharmaceuticals vaccines consumer healthcare terminal growth rate exceed longterm project growth rate relevant market reflect impact future generic competition account new product launch goodwill monitor impairment segmental level valuation indicate sufficient headroom reasonably possible change key assumption unlikely result impairment relate goodwill gsk assess qualitative quantitative impact climate relate risk asset recoverable amount conclude material impairment gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information intangible asset licence patent computer amortise indefinite life software brand etc brand total cost january exchange adjustment capitalise development cost addition disposal asset writeoff transfer asset hold saledistribution reclassification cost december exchange adjustment capitalise development cost addition business combination addition disposal asset writeoff transfer asset hold saledistribution reclassification cost december amortisation january exchange adjustment charge year disposal asset writeoff transfer asset hold sale amortisation december exchange adjustment charge year disposal asset writeoff transfer asset hold saledistribution amortisation december impairment january exchange adjustment impairment loss reversal impairment disposal asset writeoff impairment december exchange adjustment impairment loss transfer asset hold saledistribution reversal impairment disposal asset writeoff impairment december total amortisation impairment december total amortisation impairment december net book value january net book value december net book value december weight average interest rate capitalise borrowing cost year net book value computer software include million million internally generate cost carry value december intangible asset impairment charge year follow impairment million million carrying value december intangible asset impairment reversal charge year follow impairment reversal million million individual intangible asset account material impairment patent expiry date group significant asset relevant set page refer note group accounting policy estimate useful life intangible asset exclusivity nonexclusivity periodsgsk annual report note financial statement continue intangible asset continue amortisation impairment loss net reversal charge income statement follow amortisation net impairment loss cost sale sell general administration research development comparative restate consistent basis previously publish reflect demerger consumer healthcare business note licence patent amortise brand etc include large number acquire licence patent knowhow agreement marketing right market use development note acquisition disposal give detail addition business combination year book value large individual item follow tesaro asset meningitis portfolio momelotinib affinivax assets dolutegravir benlysta alector asset iteo asset shingrix okairos bms asset spero vir asset fluarixflulaval stiefel trade curevac asset lamisila dispose consumer healthcare demerger note july gsk complete acquisition sierra oncology inc main asset momelotinib august gsk complete acquisition affinivax inc indefinite life brand relate healthcare brand consumer healthcare business indefinite life brand dispose consumer healthcare demerger note group consider reasonably possible change key assumption cause recoverable intangible asset disclose fall carry value gsk assess qualitative quantitative impact climate relate risk asset recoverable amount conclude material impairment gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information investment associate joint venture joint joint ventures associates total ventures associates total january exchange adjustment addition disposal distribution receive net fair value movement comprehensive income impairment interest associate profitloss tax recognise consolidated income statement december group agreed innoviva inc sell share innoviva innoviva million follow settlement transaction gsk long hold innoviva stock loss million include million recycling exchange difference innoviva present loss disposal interest associate consolidate income statement transaction include change innovivas commercial interest royalty pay gsk loss disposal interest associate include million gain disposal immaterial associate refer income statement information associate joint venture note current equity investment investment measure fvtpl current january exchange adjustment addition net fair value movement profit loss december current equity investment represent haleon plc share hold demerger consumer healthcare share hold trading measure fair value profit loss fvtpl base haleon plc share price change fair value demerger present operating incomeexpense continue operation group investment haleon plc end december hold glaxo group limit scottish limited partnership slp set collateralise agree additional funding gsk define benefit pension scheme note esop trust net fair value movement profit loss million include fair value gain million million adjustmentsgsk annual report note financial statement continue investment investment investment designate investment designate investment measure measured measured measured fvtoci fvtpl fvtoci fvtpl noncurrent january exchange adjustment addition net fair value movement comprehensive income net fair value movement profit loss disposal december noncurrent investment comprise noncurrent equity investment record fair value balance sheet date investment trade active market fair value determine reference relevant stock exchange quote bid price investment fair value estimate management reference relevant available information include current market value similar instrument recent financing round discount cash flow underlie net asset movement arise translation overseas net asset consolidation group account record exchange adjustment net fair value movement include impact exchange gain million comprehensive income nil profit loss gain million comprehensive income million profit loss investment include list investment million million gsk elect designate majority equity investment measure fair value comprehensive income fvtoci significant investment hold december vir biotechnology inc fair value december million million nimbus therapeutic llc fair value december million million fair value investment curevac disclose significant investment december million december million investment include equity stake company gsk research collaboration company provide access biotechnology development potential interest disposal equity investment measure fvtoci accumulate fair value movement reclassify fair value reserve retain earning investment measure fvtoci fair value million million dispose year cumulative gain investment tax million million certain investment investment fund limited live investment acquire intention sell measure fair value profit loss fvtpl gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information noncurrent asset amount receivable insurance contract pension scheme surplus receivables amount receivable insurance contract hold cash surrender value movement profit loss receivables million million million million classified financial asset million million classify fair value profit loss remain balance million million expect credit loss allowance immaterial december inventory raw material consumable work progress finish good trade receivable trade receivables net loss allowance accrue income prepayment interest receivable employee loan advance receivables trade receivable balance nil associate joint venture significant component receivables comprise receivables taxis corporate income tax significant balance receivables royalty receivable amounts receivable collaboration partner loss allowance trade receivables january exchange adjustment charge year transfer asset hold sale subsequent recovery amount provide utilise december total trade receivables balance million million consider credit impair million million expect credit loss allowance apply purchase originated credit impair receivables million million million million classified financial asset nil nil classify hold fair value profit loss december expect credit loss allowance million million recognise respect financial asset charge report profit loss year discussion credit risk practice refer note gsk annual report note financial statement continue cash cash equivalent cash bank hand shortterm deposit million transfer asset hold sale relate consumer healthcare business demerge year note cash cash equivalent include billion billion available general use restriction apply subsidiary hold restriction include exchange control taxis repatriation asset hold sale property plant equipment noncurrent asset disposal group transfer asset hold sale expect carry amount recover principally disposal sale consider highly probable hold low carrying fair value cost sell consumer healthcare business classify hold sale follow completion demerger consumer healthcare business total billion net asset liability distributedderecognise gain demerger gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information trade payable trade payable wage salary social security viiv healthcare option payable defer income customer return rebate accrual accrual trade payable include nil nil associate joint ventures group provide limited supplier financing arrangement certain customer amount involve december material revenue recognise year include deferred income january million million customer return rebate accrual provide group point sale respect estimate rebate discount allowance payable customer fully describe group financial review december customer return rebate accrual include million million respect commercial operation accrual time sale actual amount pay base claim time initial recognition sale amount estimate fully reflect final outcome subject change dependent thing type buy group product sale mix level accrual review adjust quarterly light historical experience actual amount pay change arrangement future event cause assumption accrual base change affect future result group pfizer option shareholding viiv healthcare currently exercisable pfizer request ipo viiv healthcare time gsk consent ipo offering complete month pfizer require gsk acquire shareholding liability option hold gross redemption basis derive internal valuation viiv healthcare business utilise discount forecast future cash flow multiplesbase methodology table show indicative basis income statement balance sheet sensitivity pfizer option reasonably possible change key assumption increasedecrease financial liability lossgain income statement increase sale forecast increase sale forecast decrease sale forecast decrease sale forecast basis point increase discount rate basis point increase discount rate basis point decrease discount rate basis point decrease discount rate cent appreciation dollar cent appreciation dollar cent depreciation dollar cent depreciation dollar cent appreciation euro cent appreciation euro cent depreciation euro cent depreciation euro sale forecast viiv healthcare sale respect viiv healthcare option accrual include interest accrue financial liability amortise cost million million explanation accounting viiv healthcare set gsk annual report note financial statement continue net debt list exchange current asset liquid investment cash cash equivalent shortterm borrowing commercial paper bank loan overdraft medium term note new york stock exchange medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange medium term note new york stock exchange lease liability longterm borrowing medium term note new york stock exchange euro medium term note london stock exchange medium term note new york stock exchange medium term note new york stock exchange euro medium term note london stock exchange medium term note new york stock exchange medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange euro medium term note london stock exchange euro medium term note london stock exchange medium term note new york stock exchange euro medium term note london stock exchange medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange euro medium term note london stock exchange euro medium term note london stock exchange medium term note london stock exchange euro medium term note london stock exchange medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange medium term note new york stock exchange euro medium term note london stock exchange longterm borrowing lease liability net debt partially purchase cancel february gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information net debt continue current asset liquid investment classify financial asset amortise cost december include treasury note government bond effective interest rate liquid investment december approximately approximately liquid investment balance december earn interest float rate million million liquid investment balance december earn interest fix rate nil million balance report cash cash equivalent original maturity month effective interest rate cash cash equivalent december approximately approximately cash cash equivalent december earn interest float fix rate amount million million respectively million million noninterest bearing holding amount million million gsk policy credit quality cash cash equivalent set note financial instrument relate disclosure shortterm borrowing gsk billion billion commercial paper programme million million issue december nil gsk billion euro commercial paper programme million million issue december million million february gsk cancel billion year billion billion day commit facility replace new revolve credit facility equivalent size maturity september september respectively post separation consumer healthcare business facility reduce billion billion billion respectively weight average interest rate commercial paper borrowing december weight average interest rate current bank loan overdraft december average effective preswap interest rate note classify shortterm december longterm borrowing yearend gsk longterm borrowing billion billion billion billion fall year bond repay early original maturity medium term note medium term note medium term note gsk undertake tender outstanding sterling note repay face value million euro medium term note million euro medium term note million euro medium term note million euro medium term note average effective preswap interest rate note issue december approximately approximately longterm borrowing repayable year carry interest effective rate repayment date range effective rate exclude impact oneoff premium associate early repayment sterling note pledge asset group hold pledge investment treasury note par value million million million million security irrevocable letter credit issue group behalf respect group selfinsurance activity provision respect selfinsurance include provision legal dispute discuss note provision lease liability maturity analysis discount lease liability recognise group balance sheet follow rental payment year rental payment year rental payment year rental payment year rental payment year rental payment year total lease liability gsk annual report note financial statement continue pension postemployment benefit pension postemployment cost pension scheme pension scheme overseas pension scheme unfunded postretirement healthcare scheme analyse fund define benefithybrid pension scheme unfunded define benefit pension scheme unfunded postretirement healthcare scheme define benefit scheme define contribution pension scheme cost define benefit pension postretirement healthcare scheme charge income statement follow cost sale sell general administration research development comparative restate consistent basis previously publish reflect demerger consumer healthcare business note gsk entity operate pension arrangement cover group material obligation provide pension retire employee arrangement develop accordance local practice country concern pension benefit provide state scheme define contribution scheme retirement benefit determine value fund arise contribution pay respect employee define benefit scheme retirement benefit base employee pensionable remuneration length service pension cost define benefit scheme accounting purpose calculate project unit credit method certain country pension benefit provide unfunded basis administer trustee company formal independent actuarial valuation group main plan undertake regularly normally year remeasurement movement year recognise statement comprehensive income discount rate derive rate corporate bond yield country deep market corporate bond government bond yield discount rate select reflect term expect benefit payment project inflation rate pension increase longterm prediction base yield gap longterm indexlinke fix interest gilt mortality rate determine adjust sap standard mortality table reflect recent scheme experience rate project reflect improvement life expectancy line cmi projection longterm rate improvement year male female mortality rate calculate pri white collar table adjust reflect recent experience rate project allow future improvement life expectancy gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information pension postemployment benefit continue average life expectancy assume individual age project apply individual age follow male female male female year year year year current project asset fund scheme generally hold separately administer trust specific asset proportion general fund insurance contract asset invest different class order maintain balance risk return investment diversify limit financial effect failure individual investment physical asset allocation strategy plan returnseeke asset liabilitymatche assets buyin insurance contract purchase cover substantially obligation plan december value insurance contract million million asset allocation plan currently set returnseeke asset liabilitymatche asset pension plan expose risk arise estimate market value plan asset decline investment return reduce estimate value plan liability increase line agree mix returnseeke asset generate future return liabilitymatche asset well match future pension obligation group define overall longterm investment strategy plan investment broad range asset main market risk asset hedge portfolio credit risk interest rate long term inflation equitie property currency bank counterparty risk plan liability series future cash flow relatively long duration ias basis cash flow sensitive change expect longterm inflation rate discount rate corporate bond yield curve increase longterm inflation correspond increase liability increase discount rate correspond decrease liabilitie interest rate risk credit rate risk partially hedge target base accounting measure plan liability plan interest rate inflation hedge strategy place target base economic measure plan liability define benefit pension scheme operate benefit glaxo wellcome employee smithkline beecham employee remain separate scheme close new entrant subsequent employee entitle join define contribution scheme addition group operate number postretirement healthcare scheme principal follow period consultation impact employee announce december define benefit plan closed future accrual effective march result post closure accrue benefit active participant revalue line inflation rpi legacy glaxo wellcome plan cpi legacy smithkline beecham plan subject relevant cap arrangement cap pay increase addition define benefit plan participant active april receive define pension contribution effect closure define contribution enhancement result oneoff cost million announce plan close new entrant march april define benefit plan employee transfer define contribution plan announce september cash balance pension plan closed future accrual january change result credit million june september amendment retiree healthcare plan result credit million group apply follow financial assumption assess define benefit liability rest world rate increase future earning discount rate expect pension increase cash balance creditconversion rate inflation rate sensitivity analysis detail effect change assumption provide analysis provide reflect assumption change material impact result groupgsk annual report note financial statement continue pension postemployment benefit continue amount record income statement statement comprehensive income year end december relation define benefit pension postretirement healthcare scheme follow postretirement pension benefit rest world group group amount charge operating profit current service cost past service cost net interest cost gain settlement expense remeasurement gainslosse record statement comprehensive income postretirement pension benefit rest world group group amount charge operating profit current service cost past service costcredit net interest incomecost gain settlement expense remeasurement gainslosse record statement comprehensive income postretirement pension benefit rest world group group amount charge operating profit current service cost past service costcredit net interest incomecost gain settlement expense remeasurement loss record statement comprehensive income amount include past service cost include million million million augmentation cost arise major restructuring programme charge nil nil million relation impact closure define benefit scheme future accrual past service credit million reflect closure cash balance pension plan january amendments retiree healthcare plan result credit million past service cost post retirement benefit hese number include remeasurement gainslosse relate demerged consumer healthcare business comparative restate consistent basis previously publish reflect demerger consumer healthcare business note gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information pension postemployment benefit continue summarise balance sheet presentation group define benefit pension scheme postretirement benefit set table recognise noncurrent asset pension scheme surplus recognise pension postemployment benefit pension scheme deficit postretirement benefit event plan windup gsk believe pension scheme rule provide company right refund surplus asset follow settlement plan liability result net surplus define benefit pension scheme recognise fair value asset liability define benefit pension scheme aggregate datum define benefit pension scheme group follow rest world group december equity list unlisted multiasset fund property list unlisted corporate bond list unlisted government bond list insurance contract liabilitiesasset fair value asset present value scheme obligation net surplusobligation include noncurrent asset include pension postemployment benefit actual return plan asset multiasset fund comprise investment pool investment vehicle invest range asset class increase diversification growth portfolio value fund asset class quote market price million million liabilitiesasset category comprise cash mark market value derivative position indexlinke gilt hold repo programme include government bond relate loan million december million million deduct assetsgsk annual report note financial statement continue pension postemployment benefit continue rest world group december equity list unlisted multiasset fund property list unlisted corporate bond list unlisted government bond list insurance contract liabilitiesasset fair value asset asset ceiling restriction present value scheme obligation net surplusobligation include noncurrent asset include pension postemployment benefit actual return plan asset rest world group december equity list unlisted multiasset fund property list unlisted corporate bond list unlisted government bond list insurance contract liabilitiesasset fair value asset present value scheme obligation net surplusobligation include noncurrent asset include pension postemployment benefit actual return plan asset gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information pension postemployment benefit continue postretirement pension benefit rest world group group movement fair value asset asset january exchange adjustment interest income expense settlement curtailment remeasurement employer contribution scheme participant contribution benefit pay asset december exchange adjustment interest income expense settlement curtailment remeasurement employer contribution scheme participant contribution benefit pay asset december exchange adjustment interest income expense settlement curtailment remeasurement employer contribution scheme participant contribution transfer asset hold saledistribution benefit pay asset december connection demerger consumer healthcare december pension scheme valuation identify cash funding technical provision deficit gsk pension scheme march gsk transfer gsk consumer healthcare holdings limited gskchh ordinary share represent aggregate gsk interest gskchh scottish limited partnership slp provide funding mechanism separate gsk define benefit pension scheme step relate demerger separation slp transfer applicable portion gskchh ordinary share haleon plc haleon consideration share haleon slp hold share represent total issue share capital haleon pension scheme slp interest entitle receive distribution slp equal net proceed sale haleon share receive dividend income haleon share receive aggregate equal agree threshold proceed threshold proceed threshold total million increase notional interest remain balance time time payment fully fund cash funding technical provision deficit pension scheme show december valuation applicable proceed threshold reach gskcontrolle general partner slp entitle sell remain haleon share hold slp distribute proceed gsk pension scheme receive aggregate cash equal applicable proceed threshold month separation trustee pension scheme ability require slp instruct broker liquidate remain haleon share behalf slp accordance agree mandate group additional funding contribution pension scheme million million million additional funding nil nil scheme december total cash contribution totalling million proceed threshold leave principal million outstanding pension scheme cash contribution million include voluntary cash contribution gsk define benefit pension scheme totalling million response market volatility gilt marketsgsk annual report note financial statement continue pension postemployment benefit continue outstanding accelerated contribution collateralise creation scottish limited partnership slps gsk insert total haleon ordinary share slp principal define benefit pension scheme benefit current glaxo welcome employee benefit current smithkline beecham employee interest slp show scottish limited partnership general partner limited partner gsk scottish limited partnership gsk ltd gsk ltd berkeley square pension trustee company ltd acting behalf gsk pension scheme gsk scottish limited partnership gsk ltd gsk ltd berkeley square pension trustee company ltd acting behalf gsk pension fund gsk scottish limited partnership gsk ltd gsk ltd smithkline beecham pension plan trustee ltd acting behalf smithkline beecham pension plan slp partnership agreement limit partner involvement management business shall control slp general partner case control gsk plc responsible management control slp slp consolidated result group slp take advantage exemption regulation partnership account regulation act prepare deliver audit account registrar slp partnership agreement distribution partnership income define benefit pension scheme equivalent payment define benefit pension scheme gsk entity date million pay define benefit pension scheme gsk structure contribution structure reach million define benefit pension scheme interest slp end remain economic interest slp hold gsk ltd own subsidiary gsk plc december million additional contribution remains pay employer contribution exclude special funding contribution state estimate approximately million respect define benefit pension scheme million respect postretirement benefit postretirement pension benefit rest world group group movement define benefit obligation obligation january exchange adjustment disposal service cost past service cost interest cost settlement curtailment remeasurement scheme participant contribution benefit pay obligation december exchange adjustment service cost past service cost interest cost settlement curtailment remeasurement scheme participant contribution benefit pay obligation december exchange adjustment service cost past service cost interest cost settlement curtailment remeasurement scheme participant contribution transfer asset hold saledistribution benefit pay obligation december gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information pension postemployment benefit continue define benefit pension obligation analyse follow fund unfunded liability postretirement healthcare scheme assess assumption pension scheme assumption future medical inflation grade december postretirement healthcare scheme obligation million million million postretirement benefit unfunded movement net define benefit liability follow january exchange adjustment service cost past service cost interest cost settlement curtailment remeasurement return plan asset exclude amount include interest lossgain change demographic assumption gainloss change financial assumption experience lossgain employer contribution transfer asset hold saledistribution expense december remeasurement include postretirement benefit detailed gain change demographic assumption gainloss change financial assumption experience gain define benefit pension obligation analyse membership category follow active retire defer postretirement benefit obligation analyse membership category follow active retired defer weight average duration define benefit obligation follow year year year pension benefit postretirement benefit membership number restate disclosure relate postretirement benefit obligationsgsk annual report note financial statement continue pension postemployment benefit continue sensitivity analysis effect change assumption benefit obligation annual define benefit pension postretirement cost detailed information determine take account duration liability overall profile plan membership increase decrease discount rate decreaseincrease annual pension cost increasedecrease annual postretirement benefit cost decreaseincrease pension obligation decreaseincrease postretirement benefit obligation increase decrease decreaseincrease annual pension cost increasedecrease annual postretirement benefit cost decreaseincrease pension obligation decreaseincrease postretirement benefit obligation increase decrease inflation rate increasedecrease annual pension cost increasedecrease pension obligation increase decrease increasedecrease annual pension cost increasedecrease pension obligation year increase life expectancy increase annual pension cost increase annual postretirement benefit cost increase pension obligation increase postretirement benefit obligation increase rate future healthcare inflation increase annual postretirement benefit cost increase postretirement benefit obligation gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information provision legal major employee restructure relate dispute programme provision provision total january exchange adjustment charge year reverse unused unwind discount utilise transfer asset hold saledistribution addition business combination reclassification movement transfer pension obligation december settle year settle year december legal dispute nature group business number matter subject negotiation litigation group involve substantial number legal year litigation proceeding include dispute include notification possible claim set appeal procedure year reach resolution note legal proceeding provision legal outofcourt settlement discussion dispute include amount relate product liability protract indemnify dispute result provision antitrust government investigation contract termination charge correspond receivable self insurance group potential settlement discussion number group involved significant legal dispute amount provide proceeding respect possible base current assessment progress meaningfully assess outcome result dispute estimate million provide probable outflow quantify reliably estimate liability december settle year result ultimate resolution december expect nil million proceeding case group provide provision legal dispute appropriate disclosure case provision reimburse party discussion legal issue note legal proceeding net charge year million include reversal major restructuring programme estimate insurance recovery primarily relate provision product liability case commercial dispute group major restructure government investigation programme progress separation preparation programme focus prepare separation discount provision million nil gsk new company significant acquisition discount calculate riskadjuste project programme focus integration recent cash flow riskfree rate return acquisition respect product liability claim relate certain restructure provision primarily include severance cost product provision sufficient history management formal decision eliminate claim settlement enable management certain position communicate reliable estimate provision require cover group employee affect appropriate consultation unasserte claim ultimate liability matter procedure complete appropriate provision vary amount provide dependent staff severance payment pay immediately outcome litigation proceeding investigation possible settlement negotiation discount provision increase million increase million group position change time assurance loss result pension augmentation include million relate outcome legal proceeding exceed define benefit plan arise staff redundancy show material provision report note pension postemployment benefit group financial accountsgsk annual report note financial statement continue employee relate provision give nature provision amount likely settle year employee relate provision include obligation certain medical benefit disabled employee spouse provision include provision provision onerous december provision benefit contract insurance provision number amount million million employee provision include vehicle insurance regulatory matter benefit reflect variety provision severance cost jubilee awards longservice benefit gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information contingent consideration liability consideration certain acquisition include amount contingent future event development milestone sale performance group provide fair value contingent consideration follow shionogi viiv novartis healthcare affinivax vaccine total january remeasurement income statement cash payment operate cash flow cash payment invest activity december remeasurement income statement cash payment operate cash flow cash payment invest activity december remeasurement income statement exchange movement reserve initial recognition business combination cash payment operate cash flow cash payment invest activity december contingent consideration payable december million million expect pay year consideration payable acquisition shionogiviiv healthcare joint venture affinivax novartis vaccine business expect pay number year result total estimate liability discount present value show shionogiviiv healthcare contingent consideration liability discount affinivax contingent consideration liability discount novartis vaccine contingent consideration liability discount commercialise product pipeline asset shionogiviiv healthcare novartis vaccine contingent consideration liability calculate principally base forecast sale performance specify product live product affinivax contingent consideration base potential milestone payment billion billion pay certain pediatric clinical development milestone achieve table show indicative basis income statement balance sheet sensitivity reasonably possible change key input valuation contingent consideration liability shionogi shionogi viiv novartis viiv novartis increasedecrease financial liability healthcare affinivax vaccines healthcare vaccines lossgain income statement increase sale forecast increase sale forecast decrease sale forecast decrease sale forecast increase discount rate increase discount rate decrease discount rate decrease discount rate cent appreciation dollar cent appreciation dollar cent depreciation dollar cent depreciation dollar cent appreciation euro cent appreciation euro cent depreciation euro cent depreciation euro increase probability milestone success decrease probability milestone success sale forecast viiv healthcare sale respect shionogiviiv healthcare contingent consideration explanation accounting viiv healthcare set gsk annual report note financial statement continue noncurrent liability accrual defer income payable payable include number employeerelate liability include employee saving plan contingent liability december contingent liability gsk present obligation result past event comprise guarantee item arise normal course business amount million million december million million financial asset pledge collateral contingent liability provision outcome tax legal dispute probable group suffer outflow fund possible reliable estimate outflow possible meaningfully assess outcome result probable outflow quantify reliably estimate liability provision record description significant legal dispute group party set note legal proceeding commitment contractual obligation commitment contract provide financial statement intangible asset property plant equipment investment purchase commitment pension postretirement benefit interest loan future finance charge lease lease contract commence commitment relate intangible asset include milestone payment dependent successful clinical development meeting specify sale target represent maximum pay milestone unlikely achieve amount riskadjuste discount net decrease intangible asset commitment mainly attributable termination certain agreement offset number new collaboration include collaboration spero therapeutics inc wuxi biologics ireland limited springworks therapeutics inc arrowhead pharmaceuticals inc gsk reach agreement trustee pension scheme additional contribution million eliminate pension deficit identify december actuarial funding valuation prior consumer healthcare demerger gsk agree collateralise commitment accelerate fund additional contribution note december million additional contribution remain unpaid group commitment principally relate revenue payment licence alliance commitment respect future interest payable loan disclose take account effect interest rate swap gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information share capital share premium account share consolidation follow completion consumer healthcare business demerger july gsk plc ordinary share consolidate maintain share price comparability demerger consolidation approve gsk shareholder general meeting hold july shareholder receive new ordinary share nominal value pence exist ordinary share nominal value pence earning share dilute earning share adjust earning share dividend share retrospectively adjust reflect share consolidation period present ordinary share preshare consolidation share ordinary share postshare consolidation premium number share capital issue fully pay january issue employee share scheme ordinary share acquire esop trust december issue employee share scheme ordinary share acquire esop trust december impact share consolidation issue employee share scheme ordinary share acquire esop trust december december issue share capital share hold esop trust share hold treasury share share free issue issue share fully pay share authorise issue nominal carry market value share hold esop trust disclose note employee share scheme movement equity retain earning reserve amount million december million million million million million relate associate joint venture cumulative translation exchange equity follow net translation exchange include non total retain fair value control translation earning reserve interests exchange january exchange movement overseas net asset net investment hedge reclassification exchange movement liquidation disposal overseas subsidiary associate december exchange movement overseas net asset net investment hedge reclassification exchange movement liquidation disposal overseas subsidiary associate december exchange movement overseas net asset net investment hedge reclassification exchange movement liquidation disposal overseas subsidiary associate movement attributable continue operation movement attributable discontinue operationsa december include million reclassification consolidated income statement exchange movement relate demerger consumer healthcare businessgsk annual report note financial statement continue movement equity continue analysis comprehensive income equity category follow non retain control earning reserve interest total item subsequently reclassify income statement exchange movement overseas net asset net investment hedge reclassification exchange movement liquidation disposal subsidiary associate fair value movement cash flow hedge tax fair value movement cash flow hedge reclassification cash flow hedge income item reclassify income statement exchange movement overseas net asset noncontrolle interest fair value movement equity investment tax fair value movement equity investment remeasurement define benefit plan tax remeasurement define benefit plan fair value movement cash flow hedge comprehensive expenseincome year continue operation comprehensive expenseincome year discontinue operation total comprehensive expenseincome year non retain control earning reserve interest total item subsequently reclassify income statement exchange movement overseas net asset net investment hedge reclassification exchange movement liquidation disposal subsidiary associate fair value movement cash flow hedge tax fair value movement cash flow hedge reclassification cash flow hedge income statement item reclassify income statement exchange movement overseas net asset noncontrolle interest fair value movement equity investment tax fair value movement equity investment remeasurement loss define benefit plan tax remeasurement define benefit plan comprehensive expenseincome year non retain control earning reserve interest total item subsequently reclassify income statement exchange movement overseas net asset net investment hedge reclassification exchange movement liquidation disposal subsidiary associate fair value movement cash flow hedge tax fair value movement cash flow hedge reclassification cash flow hedge income statement item reclassify income statement exchange movement overseas net asset noncontrolle interest fair value movement equity investment tax fair value movement equity investment remeasurement gain define benefit plan tax remeasurement define benefit plan comprehensive expenseincome year information net investment hedge provide note financial instrument relate disclosure gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information movement equity continue analysis reserve follow esop trust fair value cash flow share reserve hedge reserve reserves total january exchange adjustment transfer retain earning year disposal equity investment net fair value movement year ordinary share acquire esop trust writedown share hold esop trust december exchange adjustment transfer income expense year impairment equity investment transfer retain earning year disposal equity investment net fair value movement year december exchange adjustment transfer retain earning year disposal equity investment balance derecognise demerger net fair value movement year ordinary share acquire esop trust writedown share hold esop trust december reserve include nondistributable merger premerger reserve amount million december million million reserve include capital redemption reserve create result share buyback programme amount million december million million noncontrolling interest total noncontrolle interest includes follow individually material noncontrolle interest noncontrolle interest individually material viiv healthcare gsk hold viiv healthcare subgroup give rise material noncontrolle interest summarise financial information available late practicable date respect viiv healthcare subgroup follow turnover profit taxation comprehensive incomeexpense total comprehensive income noncurrent asset current asset total asset current liability noncurrent liability total liability net liability net cash inflow operating activity net cash outflow investing activity net cash outflow financing activity increasedecrease cash bank overdraft year gsk annual report note financial statement continue noncontrolle interest continue financial information relate viiv healthcare group standalone basis impact grouprelate adjustment primarily relate recognition preferential dividend profit taxation million million million state charge preferential dividend payable gsk pfizer charge million million million remeasurement contingent consideration payable consideration expect pay number year follow amount attributable viiv healthcare group include gsk financial statement share profit year attributable noncontrolle interest dividend pay noncontrolle interest noncontrolle interest consolidate balance sheet consumer healthcare joint venture gsk hold consumer healthcare subgroup demerger july detail note give rise material noncontrolle interest summarise financial information respect consumer healthcare subgroup december follow noncurrent asset current asset total asset current liability noncurrent liability total liability net asset financial information relate consumer healthcare joint venture standalone basis impact grouprelate adjustment classification cash pooling account group company outside consumer healthcare joint venture major restructuring charge follow amount attributable consumer healthcare joint venture include gsk financial statement prior year noncontrolle interest consolidate balance sheet relate party transaction december loan gsk relate party million medicxi venture cash distribution receive investment medicxi venture million medicxi venture million longwood founder fund million apollo therapeutic llp million joint venture agreement qura therapeutics llc group obligation fund joint venture april gsk joint venture partner commit financial support million december outstanding liability qura million million group significant relate party transaction reasonably expect influence decision user financial statement aggregate compensation director glt give note employee cost gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information acquisition disposal detail acquisition disposal significant subsidiary associate joint venture business give business acquisition july gsk complete acquisition sierra oncology inc californiabase latestage biopharmaceutical company focus target therapy treatment rare form cancer billion billion main asset momelotinib target medical need myelofibrosis patient anaemia total transaction cost million august gsk complete acquisition affinivax inc clinicalstage biopharmaceutical company base cambridge boston massachusetts focus pneumococcal vaccine candidate consideration acquisition comprise upfront payment billion billion adjust work capital acquire pay close potential milestone payment billion billion pay achievement certain paediatric clinical development milestone estimate fair value contingent consideration payable million value provisional subject change total transaction cost million acquisition sale arise sierra oncology affinivax business include group turnover revenue expect regulatory approval receive acquire asset gsk continue support ongoing development acquire asset consequently asset loss make regulatory approval asset receive development asset integrate group exist activity impracticable quantify development cost impact total profit taxation period goodwill million million sierra oncology million affinivax expect deductible tax purpose recognise goodwill represent workforce place specific synergy available gsk business combination goodwill allocate group commercial operation segment refer note goodwill allocation methodology sierra oncology affinivax total net asset acquire intangible asset property plant equipment right use asset inventory trade receivables cash cash equivalent lease liability trade payable taxation goodwill total total cash fair value contingent consideration november gsk sign agreement buy noncontrolle interest glaxo saudi arabia ltd sar million million pay gsk annual report note financial statement continue acquisition disposal continue demerger consumer healthcare business july gsk plc separate consumer healthcare business gsk group form haleon independent list company separation effect way demerger gsk hold consumer healthcare business gsk shareholder follow demerger haleon hold aggregate gsk shareholder remain hold gsk include share receive gsk consolidated esop trust remains hold certain scottish limited partnership slp set provide collateral funding mechanism pursuant gsk provide additional funding gsk define benefit pension scheme note aggregate ownership gsk include ownership esop trust slp demerger measure fair value change profit loss pfizer continue hold haleon demerger ifric distribution noncash asset owner liability equity distribution measure fair value asset distribute dividend appropriately authorise long entity discretion liability equity movement associate gain distribution recognise demerger distribution authorise occur asset distribute ownership consumer healthcare business net carrying value consumer healthcare business consolidate financial statement include retain net attributable noncontrolle interest approximately billion end june gsk billion share shareholder loan advance preseparation dividend eliminate consolidated financial statement asset distribute reduced consumer healthcare transaction july principally include preseparation dividend declare settle end july dividend include billion billion attributable gsk dividend fund consumer healthcare debt partially onlent dividend billion billion attributable gsk available cash balance fair value ownership consumer healthcare business distribute billion measure reference quote average haleon share price day trade fair value measure observable input consider representative fair value distribution date gain distribution fair value book value attributable net asset consumer healthcare business billion record income statement additional gain billion remeasure retain book value fair value billion fair value methodology distribute share gain distribution remeasurement retain stake demerger present discontinue operation future gain loss retain stake haleon recognise continue operation addition reclassification group share cumulative exchange difference arise translation foreign currency net asset divest subsidiary offset net investment hedge reserve income statement billion total gain demerger consumer healthcare billion transaction present profit discontinue operation fair value consumer healthcare business distribute fair value retain ownership haleon plc total fair value carry net asset liability distributedderecognise carrying noncontrolle interest derecognise gain demerger exchange movement transaction cost reclassification exchange movement net investment hedge movement disposal overseas subsidiary total gain demerger consumer healthcare gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information acquisition disposal continued consumer healthcare present discontinue operation june disclose interim financial statement consolidated income statement consolidate cash flow statement distinguish discontinue operation continue operation comparative figure restate consistent basis financial information relate operation consumer healthcare period set include financial information july financial information differ purpose basis preparation historical financial information interim financial information include haleon prospectus publish haleon march result whilst set financial information similar certain difference accounting disclosure ifrs total result turnover expense profit tax taxation tax rate lossprofit taxation discontinue operation consumer healthcare gainslosse demerger remeasurement discontinue operation distribute shareholder demerger profit taxation demerger discontinue operation noncontrolle interest discontinue operation earning attributable shareholder discontinue operation earning share discontinue operation business disposal material business disposal business business business disposal disposal cash flow acquisition demerger cash consideration net defer consideration pay cash cash equivalent divestedacquire transaction cost pay cash outflowinflow cash consideration business acquisition include million relate business acquisition activity business acquisition gsk complete material business acquisition business disposal gsk number business disposal net cash consideration receive year million profit disposal business year million calculate follow total consideration cash consideration include currency forwards purchase adjustment defer consideration total net asset sell property plant equipment cash cash equivalent net asset total cost deal cost reclassification exchange comprehensive income gain disposal gsk annual report note financial statement continue acquisition disposal continue associate joint venture gsk agree innoviva inc innoviva sell approximately million share common stock innoviva innoviva price share raise gross proceed approximately million follow settlement transaction gsk long hold innoviva stock detail note investment associate joint venture cash flow associate joint business venture disposal disposal cash consideration receive net defer consideration pay transaction cost cash cash equivalent divestedacquire cash outflowinflow business acquisition gsk complete small business acquisition acquire pfizer biotech corporation taiwan pfizer consumer healthcare business previously recognise consumer healthcare joint venture september non cash consideration million represent goodwill million cash million asset acquire million noncontrolling interest million net liability million total net asset acquire intangible asset property plant equipment inventory trade receivables cash cash equivalent trade payable noncontrolle interest goodwill noncash consideration settlement promissory note total consideration business disposal april gsk complete divestment horlick consumer healthcare nutrition product india number country exclude bangladesh unilever merger gsk indian list consumer healthcare entity hindustan unilever indian list public company gsk receive equity stake hindustan unilever million cash gsk dispose equity stake hindustan unilever divestment bangladesh closed june total cash consideration receive million cash divest disposal india bangladesh consumer healthcare entity million gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information acquisition disposal continue profit disposal business year million calculate follow horlick divestment total consideration cash consideration receivable include currency forward purchase adjustment equity investment hindustan unilever limited total net asset dispose goodwill intangible asset property plant equipment inventory cash cash equivalent net liabilitiesasset total cost transaction cost derivative reclassification exchange comprehensive income total gain disposal exposure share price movement embed agreement merge gsk indian list consumer healthcare entity hindustan unilever limited divestment horlick nutrition product india number country recognise derivative signing agreement completion transaction million record cost table derecognition derivative asset largely reflect fair value gain recognise income statement prior period associates joint ventures year gsk investment associate million million pay cash associate joint cash flow business business venture acquisition disposal investment cash consideration receivedpaid net defer consideration transaction cost cash cash equivalent acquireddiveste cash outflowinflow include consumer healthcare disposal income statement impact restatedgsk annual report note financial statement continue djustment reconcile total profit tax operating cash flow total profit tax continue operation tax profit share aftertax profit associate joint venture finance expense net finance income depreciation amortisation intangible asset impairment asset write profit sale business profit sale intangible asset loss sale investment associate profit sale equity investment change work capital decreaseincreasein inventory increase trade receivables increase trade payable increase receivables contingent consideration pay note noncash increase contingent consideration liability increase payables increasedecrease pension provision sharebase incentive plan fair value adjustment operate cash flow continue operation operate cash flow discontinue operation total cash generate operation comparative restate consistent basis previously publish reflect demerger consumer healthcare business note gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information reconciliation net cash flow movement net debt net debt begin year adjust increase cash bank overdraft increasedecrease liquid investment increase longterm loan repayment shortterm note repayment ofincrease shortterm loan repayment medium term note mtns repayment lease liability debt subsidiary undertaking acquire exchange adjustment noncash movement decreaseincrease net debt continue operation decreaseincrease net debt discontinue operation total net debt end year january interest change reclass december exchange expense fair value ification demerger cash flow analysis change net debt liquid investment cash cash equivalent overdraft liquid investment attribute continue operation liquid investment attribute discontinued operation debt year commercial paper europeanu mtn bank facility lease liability debt year attribute continue operation debt year attribute discontinued operation debt year europeanu mtn bank facility lease liability debt year attribute continue operation debt year attribute discontinued operation net debt interest payable derivative financial instrument total liability finance activity exclude cash cash equivalent overdraft liquid investmentsgsk annual report note financial statement continue reconciliation net cash flow movement net debt continue january interest change reclass december exchange expense fair value ification cash flow analysis change net debt liquid investment cash cash equivalent overdraft debt year commercial paper europeanu mtn bank facility lease liability debt year europeanu mtn bank facility lease liability net debt interest payable derivative financial instrument total liability finance activity exclude cash cash equivalent overdraft liquid investment information significant change net debt note net debt gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information financial instrument relate disclosure objective gsk treasury activity minimise gsk access shortterm finance billion posttax net cost financial operation reduce billion commercial paper programme million volatility benefit earning cash flow gsk use variety million issue december nil financial instrument finance operation derivative gsk access shortterm finance billion euro financial instrument manage market risk commercial paper programme million million operation derivative principally comprise foreign exchange issue december million forward contract swap swap million february gsk cancel billion borrowing liquid asset currency require group year billion billion day commit facility purpose interest rate swap replace new revolve credit facility manage exposure financial risk change interest equivalent size maturity september rate financial instrument reduce uncertainty september respectively post separation consumer foreign currency transaction interest payment healthcare business facility reduce billion billion billion respectively derivative exclusively hedge purpose relation underlie business activity trade commit facility undrawn december speculative instrument gsk consider level committed facility adequate give current liquidity requirement capital management gsk billion euro medium term note programme gsk financial strategy support group strategic priority december billion note issue regularly review board gsk manage programme group billion capital structure group appropriate mix billion note issue december debt equity shelf registration gsk currently process renew capital structure group consist net debt shelf registration statement order maintain access billion note net debt total equity include debt market gsk borrowing mature date item relate noncontrolle interest billion consolidated statement change equity option own pfizer viiv healthcare total capital include provide noncontrolle exercisable review liquidity requirement gsk consider interest billion sufficient financing option available group continue manage financial policy credit option exercise profile particularly target shortterm credit rating maintain single longterm rating consistent market risk target group longterm credit rating interest rate risk management standard poor stable outlook moodys gsk objective minimise effective net interest cost investor service moodys stable outlook balance mix debt fix float rate time group shortterm credit rating standard group main interest rate risk arise borrowing poor moodys respectively investment float rate refinance mature fix rate debt change interest rate affect liquidity risk management future cash flow fair value financial instrument gsk policy borrow centrally order meet anticipate policy interest rate risk management limit net funding requirement strategy diversify liquidity float rate debt specific cap review agree source range facility maintain broad annually board access financial market day sweep cash number global subsidiary central treasury majority debt issue fix interest rate account liquidity management purpose gsk utilise change float rate interest significantly physical notional cash pool arrangement appropriate affect group net interest charge shortterm borrowing location currency notional cash pool liquidity include bank facility expose risk future draw foreign currency balance provide local change market interest rate majority cash funding central liquidity require balance liquid investment actively manage maintain appropriate level balance notional pool arrangement settle currency gross cash overdraft balance report december gsk billion borrowing repayable year hold billion cash cash equivalent liquid investment billion hold centrallygsk annual report note financial statement continue financial instrument relate disclosure continue foreign exchange risk management treasuryrelate credit risk group objective minimise exposure overseas gsk set global counterparty limit gsk banking operating subsidiary transaction risk match local investment counterpartie base longterm credit currency income local currency cost possible rating moodys standard poor usage foreign currency transaction exposure arise external limit actively monitor internal trade flow selectively hedge gsk internal gsk actively manage exposure credit risk reduce trading transaction match centrally intercompany surplus cash balance possible gsk payment term manage reduce foreign currency risk strategy regionalise cash management concentrate possible gsk manage cash surplus borrow cash centrally possible table set requirement subsidiary company centrally forward credit exposure counterpartie rate liquid contract hedge future repayment originate investment cash cash equivalent derivative currency gross asset position derivative contract order reduce foreign currency translation exposure consider purpose table isda group seek denominate borrowing currency agreement risk net position principal asset cash flow primarily counterparty table set group denominate dollar euro sterling borrowing financial asset liability offset basis swap currency require borrowing denominate swap foreign currency match investment overseas group asset treat hedge relevant asset forward contract major currency reduce exposure group investment overseas asset net investment hedge section note detail credit risk credit risk risk counterparty default contractual obligation result financial loss group arise cash cash equivalent favourable derivative financial instrument hold bank financial institution credit exposure wholesale retail customer include outstanding receivables group consider maximum credit risk december million december million total group financial asset exception investment comprise equity investment bear equity risk credit risk detail group total financial asset december gsk great concentration credit risk billion wholesaler billion wholesaler information group credit risk exposure respect large wholesaler customer change estimation technique significant assumption current reporting period assess loss allowance financial asset amortise cost fvtoci adoption ifrs start report period gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue december million million cash categorise hold unrated subinvestment grade rate counterpartie low bbbbaa nil million cash transit remain exposure concentrate overseas bank local cash management investment purpose include million nigeria hold united bank africa zenith bank access bank stanbic ibtc bank million halk bank million produbanco ecuador million trust royal bank cambodia million banco brasil brazil million banco honduras honduras million bac san jos costa rica million bank balance deposit hold bbbbaa rate counterpartie million hold bbbbaa rate counterpartie include balance deposit million state bank india india bank local investment purpose gsk measure expect credit loss cash cash equivalent function individual counterparty credit rating associate month default rate expect credit loss cash cash equivalent thirdparty financial derivative deem immaterial loss experience credit rating assign standard poor moodys respectively opinion rating agency differ gsk assign low rating counterparty local rating agency fitch datum source available rating convert global rating equivalent standard poor moodys publish conversion table credit rating form basis assessment expect credit loss treasuryrelate balance hold amortise cost bank balance deposit government security bbba aaaaaa aaaa bbbbaa unrated total bank balance deposit treasury treasury repo money market fund liquidity fund government security party financial derivative total bbba aaaaaa aaaa bbbbaa unrated total bank balance deposit treasury treasury repo money market fund liquidity fund government security party financial derivative total gsk centrally manage cash reserve amount billion concentration trade receivables reflective standard december available month market practice pharmaceutical sector include billion cash manage group viiv significant portion sale wholesaler healthcare own subsidiary group invest disclose note gsk assessment limit centrally manage liquid asset bank deposit aaaaaa rate credit risk associate customer treasury treasury repo money market fund group credit risk monitoring activity relate aaaaaa rate liquidity fund wholesaler include review quarterly financial wholesale retail credit risk information standard poor credit rating development outside customer account gsk internal risk rating establishment periodic review group trade receivable balance credit limit line pharmaceutical company group new customer subject credit vetting process sell product small number wholesaler exist customer subject review annually addition hospital pharmacie physician group vetting process subsequent review involve obtain sale large wholesaler amount approximately information include customer status government sale commercial operation private sector entity audit financial statement credit bureau business report debt rating agency moodys standard poor report payment performance history trade reference december group trade receivable industry credit group bank reference wholesaler total million total trade receivables million group expose concentration credit risk respect wholesaler encounter financial difficulty materially adversely affect group financial resultsgsk annual report note financial statement continue financial instrument relate disclosure continue trade receivables consist amount large number fair value financial asset liability customer spread diverse industry exclude lease liability geographical area ongoing credit evaluation perform table present carry amount financial condition account receivable fair value group financial asset liability appropriate credit insurance purchase factoring exclude lease liability december arrangement place december information obtain proportional level fair value financial asset liability exposure consider information evaluate include price receive sell asset quantitatively credit score qualitatively judgement pay transfer liability orderly transaction conjunction customer credit requirement determine market participant measurement date credit limit follow method assumption measure trade receivables group customer segment fair value significant financial instrument carry fair similar loss pattern assess credit risk receivables value balance sheet financial asset assess individually historical forwardlooking information consider determine investment equity investment trade active appropriate expect credit loss allowance market determine reference relevant stock exchange quote bid price equity investment group believe credit risk provision require determine reference current market value excess allowance expect credit loss note similar instrument recent financing round trade receivables discount cash flow underlie net asset credit enhancement trade receivables carry fair value base invoice group use credit enhancement include factoring credit insurance minimise credit risk trade receivables group december million interest rate swap foreign exchange forward contract million trade receivables insure order swap option base present value protect receivables loss credit risk contractual cash flow option valuation model default insolvency bankruptcy market source datum exchange rate interest rate balance sheet date group entity assess credit risk private customer determine credit insurance require cash cash equivalent carry fair value base net asset value fund factoring arrangement manage locally entity mitigate risk arise large credit risk contingent consideration business acquisition concentration factor arrangement nonrecourse divestment base present value expect future cash flow follow method assumption estimate fair value significant financial instrument measure fair value balance sheet receivables payable include option carry amortise cost approximate carry liquid investment approximate carry cash cash equivalent carry amortise cost approximate carry longterm loan base quote market price level fair value measurement case european medium term note approximate carry case fix rate borrowing float rate bank loan shortterm loan overdraft commercial paper approximate carry short maturity instrument gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue carry fair carry fair value value value value note financial asset measure amortise cost noncurrent asset trade receivables liquid investment cash cash equivalent financial asset measure fair value comprehensive income fvtoci investment designate fvtoci trade receivables financial asset mandatorily measure fair value profit loss fvtpl current equity investment investment noncurrent assets trade receivables hold trading derivative designate effective hedge relationship ade cash cash equivalent derivative designate effective hedging instrument fair value movement comprehensive income ade total financial asset financial liability measure amortise cost borrowing exclude obligation lease liability bond designate hedge relationship bond bank loan overdraft commercial paper designate hedge relationship commercial paper borrowing total borrowing exclude lease liability trade payable provision noncurrent liability financial liability mandatorily measure fair value profit loss fvtpl contingent consideration liability hold trading derivative designate effective hedge relationship ade derivative designate effective hedging instrument fair value movement comprehensive income ade total financial liability exclude lease liability net financial asset financial liability exclude lease liability valuation methodology measure fair value table describe categorise trade receivables noncurrent asset trade payable provision contingent consideration liability noncurrent liability reconcile relevant note page gsk annual report note financial statement continue financial instrument relate disclosure continue fair value investment gsk share december employee share ownership plan esop trust hold gsk share carry value million million market value million million base quote market price share hold esop trust satisfy future exercise option award employee incentive scheme carry value low cost expect proceed share recognise deduction reserve december gsk hold treasury share cost million million deduct retain earning financial instrument hold fair value follow table categorise group financial asset liability hold fair value valuation methodology apply determine fair value possible quote price active market level price available asset liability classify level provide significant input valuation model base observable market datum significant input valuation model base observable market datum instrument classified level investment classify level table comprise equity investment unlisted entity group enter research collaboration investment provide access biotechnology development potential interest level level level total december financial asset fair value financial asset measure fair value comprehensive income fvtoci investment designate fvtoci trade receivables financial asset mandatorily measure fair value profit loss fvtpl current equity investment investment noncurrent asset trade receivable hold trading derivative designate effective hedge relationship cash cash equivalent derivative designate effective hedging instrument fair value movement oci financial liability fair value financial liability mandatorily measure fair value profit loss fvtpl contingent consideration liability hold trading derivative designate effective hedging relationship derivative designate effective hedging instrument fair value movement oci level level level total december financial asset fair value financial asset measure fair value comprehensive income fvtoci investment designate fvtoci trade receivables financial asset mandatorily measure fair value profit loss fvtpl investment noncurrent asset trade receivable hold trading derivative designate effective hedge relationship cash cash equivalent derivative designate effective hedging instrument fair value movement oci financial liability fair value financial liability mandatorily measure fair value profit loss fvtpl contingent consideration liability hold trading derivative designate effective hedging relationship derivative designate effective hedging instrument fair value movement oci gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue movement year financial instrument measure level valuation method present january exchange adjustment net loss recognise income statement net gain recognise comprehensive income contingent consideration relate business acquisition period settlement contingent consideration liability addition disposal settlement transfer level december total net loss million million attributable level financial instrument recognise income statement million million respect financial instrument hold end year report operating incomeexpense charge million million arise remeasurement contingent consideration payable acquisition shionogiviiv healthcare joint venture million million arise remeasurement contingent consideration payable acquisition novartis vaccine business acquisition affinivax result additon million contingent consideration level financial liability million remeasurement charge arise period acquisition december transfer level financial instrument year transfer relate equity instrument transfer level valuation methodology result list recognise stock exchange year movement arise translation overseas net asset consolidation group account record exchange adjustment net gain loss include impact exchange movement financial liability measure level valuation method december include million million respect contingent consideration payable acquisition shionogiviiv healthcare joint venture consideration expect pay number year vary line future performance specify product movement certain foreign currency million million respect contingent consideration acquisition novartis vaccine business consideration expect pay number year vary line future performance specify product achievement certain milestone target movement certain foreign currency result group acquisition affinivax contingent consideration payable million recognise december consideration expect pay number year vary line achievement certain development milestone movement usdgbp exchange rate sensitivity analysis balance provide note contingent consideration liability trade receivables noncurrent asset scope ifrs follow table reconcile financial instrument trade receivables noncurrent asset fall scope ifrs relevant balance sheet amount financial asset predominantly noninterest earn nonfinancial instrument include tax receivables pension surplus balance prepayment outside scope ifrs non non amortise financial financial amortise financial financial fvtpl fvtoci cost instrument instrument total fvtpl fvtoci cost instrument instrument total trade receivable note noncurrent asset note trade receivables include trade receivables million million group portfolio business model ifrs million million measure fvtpl hold sell contractual cash flow receivable sell factoring arrangement million million measure fvtoci hold collect sell contractual cash flow receivables sell factoring agreement million million measure amortise cost hold collect contractual cash flow factor agreement placegsk annual report note financial statement continue financial instrument relate disclosure continue trade payable provision contingent consideration liability non current liability scope ifrs follow table reconcile financial instrument trade payable provision contingent consideration liability noncurrent liability fall scope ifrs relevant balance sheet amount financial liability predominantly noninterest bear nonfinancial instrument include payment account tax social security payable provision arise contractual obligation deliver cash financial asset outside scope ifrs non non amortise financial financial amortise financial financial fvtpl cost instrument instrument total fvtpl cost instrument instrument total trade payable note provision note contingent consideration liability note noncurrent liability note derivative financial instrument hedge programme derivative economic hedging purpose speculative investment classify hold trading designate effective hedging instrument present current asset liability expected settle month end reporting period classified noncurrent group follow derivative financial instrument fair value fair value asset liability asset liabilitie noncurrent cash flow hedge interest rate swap contract principal nil million current cash flow hedge foreign exchange contract principal million million net investment hedge foreign exchange contract principal million million derivative designate effective hedging instrument noncurrent embed derivative current foreign exchange contract principal million million embed derivative derivative classify hold trading total derivative instrument gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue fair value hedge december december group designate fair value hedge net investment hedge december certain foreign exchange contract designate net investment hedge respect foreign currency translation risk arise consolidation group net investment european euro singaporean sgd canadian cad japanese jpy foreign operation show table carry value bond include million million designate hedging instrument net investment hedge cash flow hedge group enter forward foreign exchange contract designate cash flow hedge enter hedge foreign exchange exposure arise cash flow euro denominate coupon payment relate note issue group european medium term note programme hedge foreign currency payment collaboration licensing arrangement group manage cash flow interest rate risk floatingtofixed interest rate swap addition group carry balance reserve arise prehedge fluctuation longterm interest rate pricing bond issue prior year current year balance reclassify finance cost life bond foreign exchange risk current year group designate certain foreign exchange forward contract swap cash flow net investment hedge foreign exchange derivative financial asset liability present line derivative financial instrument asset liability consolidate balance sheet follow table detail foreign exchange forward contract swap outstanding end report period information relate hedge item hedge effectiveness determined inception hedge relationship periodic prospective effectiveness assessment ensure economic relationship exist hedge item hedging instrument group enter hedge relationship critical term hedge instrument match exactly term hedge item qualitative assessment effectiveness perform change circumstance affect term hedge item critical term long match exactly critical term hedge instrument group use hypothetical derivative method assess effectiveness main source hedge ineffectiveness hedging relationship effect counterparty group credit risk fair value foreign exchange forward contract swap reflect fair value hedge item attributable change foreign exchange rate ineffectiveness roll cash flow hedge divestment mention source ineffectiveness emerge hedging relationship ineffectiveness record cash flow hedge nil ineffectiveness record net investment hedge nil periodic change value calculate average foreign notional carry hedge exchange rate currency value value ineffectiveness hedge instrument cash flow hedge foreign exchange contract buy foreign currency month usd month eur month eur sell foreign currency month eur gsk annual report note financial statement continue financial instrument relate disclosure continue periodic change value calculate average foreign notional carry hedge exchange rate currency value value ineffectiveness hedging instrument net investment hedge foreign exchange contract sell foreign currency month eur jpy month cad sgd borrowing month eur month eur month eur balance cash flow hedge cumulative balance cash reserve arise hedge periodic change value flow hedge reserveforeign relationship hedge calculate hedge currency translation reserve accounting long ineffectiveness continue hedge apply hedge item cash flow hedge variability cash flow highly probable forecast transaction variability cash flow foreign exchange exposure arise euro denominate coupon payment relate debt issue net investment hedge net investment foreign operation periodic change value calculate average foreign notional carry hedge exchange rate currency value value ineffectiveness hedge instrument cash flow hedge foreign exchange contract buy foreign currency month usd month eur month eur periodic change value calculate average foreign notional carry hedge exchange rate currency value value ineffectiveness hedging instrument net investment hedge foreign exchange contract sell foreign currency month eur sgd jpy borrowing month eur month eur gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue cumulative balance cash periodic change value flow hedge reserveforeign calculate hedge currency translation reserve ineffectiveness continue hedge hedge item cash flow hedge variability cash flow foreign exchange exposure arise euro denominate coupon payment relate debt issue net investment hedge net investment foreign operation million million balances cash flow hedge reserve arise hedging relationships hedge accounting long apply follow table detail effectiveness hedge relationship amount reclassify hedging reserve profit loss reclassify profit loss reclassify balance sheet line item hedge profit future cash line item line item hedge hedge loss flow profit loss balance gainslosse ineffectiveness hedge long hedge item hedge sheet recognise recognise ineffectiveness expect affect reclassification item affect reclassification reserve profit loss include occur profit loss adjustment balance sheet adjustment include include cash flow hedge variability cash flow finance intangible highly probable forecast income asset transaction expense variability cash flow finance finance foreign exchange exposure income income arise euro denominate expense expense coupon payment relate debt issue net investment hedge net investment foreign finance discontinue operation income operation expense reclassify profit loss reclassify balance sheet line item hedge profit future cash line item line item hedge hedge loss flow profit loss balance gainslosse ineffectiveness hedge long hedge item hedge sheet recognise recognise ineffectiveness expect affect reclassification item affect reclassification reserve profit loss include occur profit loss adjustment balance sheet adjustment include include cash flow hedge variability cash flow highly probable forecast operate operate transaction income income expense expense variability cash flow finance finance foreign exchange exposure income income arise euro denominate expense expense coupon payment relate debt issue net investment hedge net investment foreign finance finance operation income income expense expense reclassify consolidated income statement demerger consumer healthcare businessgsk annual report note financial statement continue financial instrument relate disclosure continue interest rate risk group manage cash flow interest rate risk floatingtofixed interest rate swap quarterly interval difference fix contract rate float rate interest amount calculate reference agree notional principal amount exchange swap outstanding december december interest rate risk element future debt issuance manage enter forward start interest rate swap effectively lock interest rate debt advance close time issue debt result gain loss hold cash flow hedge reserve reclassify income statement interest payment debt impact income statement debt derecognise demerger consumer healthcare business july forward start interest rate swap forward start interest rate contract exchange float interest fix interest designate cash flow hedge hedge interest variability interest cash flow associate future fix rate debt interest rate swap follow table provide information interest rate swap forward start interest rate swap contract outstanding related hedge item december swap december interest rate swap contract asset liability present line derivative financial instrument asset liability consolidate balance sheet million million balance cash flow hedge reserve arise hedge relationships hedge accounting long apply change fair value average notional recognise fair value contract principal hedge asset fix rate value ineffectiveness liability hedge instrument year year year balance change cash flow value hedge reserve calculate continue hedge hedge ineffectiveness tax hedge item prehedge longterm interest rate gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue follow table detail effectiveness hedge relationship amount reclassify hedging reserve profit loss reclassify profit loss line item line item profit hedge future profit loss hedge hedge loss cash flow gainslosse ineffectiveness hedge long hedge item reclassification recognise recognise ineffectiveness expect affect adjustment reserve profit loss include occur profit loss include cash flow hedge prehedge longterm interest rate finance finance income income mature past expense expense reclassify profit loss line item line item profit hedge future profit loss hedge hedge loss cash flow gainslosse ineffectiveness hedge long hedge item reclassification recognise recognise ineffectiveness expect affect adjustment reserve profit loss include occur profit loss include cash flow hedge variability cash flow finance finance income income expense expense prehedge longterm interest rate mature past finance finance year income income expense expense year year offset financial asset liability financial asset liability offset net report balance sheet legally enforceable right offset recognise amount intention settle net basis realise asset settle liability simultaneously arrangement meet criterion offset allow related amount offset certain circumstance bankruptcy termination contract follow table set financial asset liability offset subject enforceable master netting arrangement similar agreement offset december december column net show impact group balance sheet offset right exercise gross gross net financial relate financial financial asset amount asset liability liability set liability asset set balance sheet balance sheet net december financial asset trade receivables derivative financial instrument financial liability trade payable derivative financial instrument gsk annual report note financial statement continue financial instrument relate disclosure continue gross financial financial liability net financial relate asset asset asset amount net liability offset liability offset balance december financial asset trade receivables derivative financial instrument financial liability trade payable derivative financial instrument amount meet criterion offset balance sheet settle net certain circumstance principally relate derivative transaction isda international swap derivative association agreement party option settle amount net basis event default party presently legally enforceable right offset amount offset balance sheet present separately table debt interest rate repricing table follow table set exposure group interest rate debt include commercial paper maturity analysis fix rate debt state contractual maturity float rate debt interest rate repricing date purpose table debt define class borrowing lease liability total debt total float fix rate debt year year year year year year great year total original issuance profile fix rate interest float rate interest gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue sensitivity analysis table illustrate estimate impact income statement equity result hypothetical market movement foreign exchange interest rate relation group financial instrument range variable choose sensitivity analysis reflect management view change reasonably possible oneyear period foreign exchange sensitivity group operate internationally primarily expose foreign exchange risk relation sterling movement dollar euro japanese yen foreign exchange risk arise translation financial asset liability functional currency entity hold base group net financial asset liability december weaken strengthen sterling currency variable hold constant illustrate table table exclude financial instrument expose group foreign exchange risk risk fully hedge financial instrument increasedecrease increasedecrease income income income statement impact nonfunctional currency foreign exchange exposure cent appreciation dollar cent appreciation dollar cent appreciation euro cent appreciation euro yen appreciation yen yen appreciation yen increasedecrease increasedecrease income income income statement impact nonfunctional currency foreign exchange exposure cent depreciation dollar cent depreciation dollar cent depreciation euro cent depreciation euro yen depreciation yen yen depreciation yen equity impact show foreign exchange sensitivity relate derivative nonderivative financial instrument hedge group net investment european euro foreign operation cash flow hedge foreign exchange exposure arise euro denominate coupon payment relate note issue group european medium term note programme increasedecrease increasedecrease equity equity equity impact nonfunctional currency foreign exchange exposure cent appreciation euro cent appreciation euro increasedecrease increasedecrease equity equity equity impact nonfunctional currency foreign exchange exposure cent depreciation euro cent depreciation euro gsk annual report note financial statement continue financial instrument relate disclosure continue table present group sensitivity weakening strengthen sterle relevant currency base composition net debt show note adjust effect foreign exchange derivative net debt affect future foreign currency cash flow increasedecrease increasedecrease net debt net debt impact foreign exchange movement net debt cent appreciation dollar cent appreciation dollar cent appreciation euro cent appreciation euro yen appreciation yen yen appreciation yen increasedecrease increasedecrease net debt net debt impact foreign exchange movement net debt cent depreciation dollar cent depreciation dollar cent depreciation euro cent depreciation euro yen depreciation yen yen depreciation yen interest rate sensitivity group expose interest rate risk outstanding borrowing investment change interest rate affect future cash flow fair value financial instrument majority debt issue fix interest rate change float rate interest significantly affect group net interest charge majority cash liquid investment earn float rate interest table hypothetically show group sensitivity change interest rate relation sterling dollar euro float rate financial asset liability basis point movement usd interest rate cause increase nil equity million basis point movement usd interest rate cause increase nil equity million basis point basis point movement eur sterling interest rate deem material effect equity increasedecrease increasedecrease income income income statement impact interest rate movement basis point increase sterling interest rate basis point increase sterling interest rate basis point increase dollar interest rate basis point increase dollar interest rate basis point increase euro interest rate basis point increase euro interest rate gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue contractual cash flow nonderivative financial liability derivative instrument follow table provide analysis anticipate contractual cash flow include interest payable group nonderivative financial liability undiscounte basis purpose table debt define class borrowing lease liability interest calculate base debt hold december take account future issuance float rate interest estimate prevail interest rate balance sheet date cash flow foreign currency translate spot rate december finance trade payable charge interest lease lease liability debt debt liability liabilitie net debt total december year year year year year year great year gross contractual cash flow finance trade payable charge interest lease lease liability debt debt liability liabilitie net debt total december year year year year year year great year gross contractual cash flow table provide analysis anticipate contractual cash flow group derivative instrument exclude equity option rise cash flow embed derivative material undiscounted cash flow cash flow foreign currency translate spot rate december gross cash flow foreign exchange contract present purpose table practice group use standard settlement arrangement reduce liquidity requirement instrument gross cash inflow gross cash outflow gross cash inflow gross cash outflow foreign foreign foreign foreign forward exchange forward exchange forward exchange forward exchange start forward start forward start forward start forward interest rate contract interest rate contract interest rate contract interest rate contract swap swap swap swap swap swap swap swap year year year year year great year gross contractual cash flow gsk annual report note financial statement continue employee share scheme gsk operate employee share scheme include share value plan award grant employee acquire share ad gsk plc cost threeyear vest period performance share plan award grant employee acquire share ad gsk plc cost subject achievement group specify performance target grant restrict share award replace grant option employee cost scheme readily equate potential gain employee group operate saving relate share option scheme option grant employee acquire share gsk plc discount price grant restrict share award normally exercisable end threeyear vest performance period award normally grant employee acquire share ad gsk plc circumstance settle cash grant savingsrelate share option scheme normally exercisable year save accordance practice majority option savingsrelate share option scheme grant price market price ruling date grant option historical share option scheme grant market price ruling date grant value plan participate employee maintain demerger consumer healthcare business effect share consolidation note total charge sharebase incentive plan million million million million million million arise share value plan note employee cost detail comparative restate reflect consistent basis previously publish reflect demerger consumer healthcare business note gsk share award scheme share value plan share value plan share award grant certain employee cost award vest half year performance criterion attach fair value award determine base closing share price day grant deduct expect future dividend yield duration award share weight ad weight number share ad issuable number fair value number fair value january award grant award exercise award cancel december award grant award exercise award cancel december award grant award exercise award cancel december comparative restate reflect demerger consumer healthcare business aid year year volume comparability award grant gsk employee performance share plan performance share plan share award grant director senior executive cost percentage award vest base performance group define measurement period dividend reinveste period award grant performance condition base equally weight measure threeyear performance period adjust free cash flow tsr new product performance award grant performance condition base measure threeyear performance period adjust free cash flow tsr new product performance pipeline progress award grant performance condition base measure threeyear performance period tsr pipeline progress profit measure sale measure esg environment fair value award determine base closing share price day grant tsr performance element adjust likelihood condition meet assess time grant award continue business million share weight fair value million ad weight fair value december outstanding award million share million ad gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information employee share scheme continue share option savingsrelate option purpose value savingsrelated option arrive sharebased payment charge blackschole option pricing model assumption model follow grant grant grant riskfree interest rate dividend yield volatility expect life year year year savingsrelate option grant price include discount savingsrelate option outstanding share save plan share option scheme weight number exercise price december range exercise price option outstanding year end weight average market price exercise year weight average remain contractual life year option million share grant year savingsrelate share option scheme weight average fair value december million savingsrelate share option exercisable change effective exercise price outstanding option year employee share ownership plan trust group sponsor employee share ownership plan esop trust acquire hold share gsk plc satisfy award employee incentive plan option grant employee share option scheme trustee esop trust purchase share finance provide group way loan contribution cost run esop trust charge income statement share hold esop trust deduct reserve amortise value proceed receivable employee exercise transfer retain earning trustee waive right dividend share hold esop trust share hold share award scheme number share nominal value carry value market value share hold share option scheme number share nominal value carry value market value gsk annual report note financial statement continue rincipal group company follow represent principal subsidiary country incorporation group december equity share capital entity show percentage column company incorporate principal country operation state england scotland glaxo group limited gsk scottish limited partnershipc glaxo operation limited gsk scottish limited partnershipc glaxo wellcome limited gsk scottish limited partnershipd glaxosmithkline capital plc glaxosmithkline export limit glaxosmithkline finance plc affinivax inc glaxosmithkline holdings limiteda corixa corporation glaxosmithkline ihc limited glaxosmithkline capital inc glaxosmithkline intellectual property limited glaxosmithkline holdings americas inc glaxosmithkline intellectual property limited glaxosmithkline llc glaxosmithkline intellectual property limited gsk equity investment limited glaxosmithkline intellectual property development limit human genome sciences inc glaxosmithkline intellectual property limited stiefel laboratories inc glaxosmithkline research development limit tesaro inc glaxosmithkline service unlimiteda viiv healthcare company glaxosmithkline limited glaxosmithkline trading limit setfirst limited smithkline beecham limited viiv healthcare finance limited viiv healthcare limited viiv healthcare limited europe glaxosmithkline switzerland glaxo saudi arabia limit saudi arabia glaxosmithkline netherlands glaxo wellcome manufacturing pte ltd singapore glaxosmithkline biological belgium glaxosmithkline thailand limited thailand glaxosmithkline gmbh germany glaxosmithkline australia pty ltd australia glaxosmithkline pharma gmbh austria glaxosmithkline brasil limitada brazil glaxosmithkline pharmaceuticals belgium glaxosmithkline far east taiwan glaxosmithkline spain glaxosmithkline ilaclari sanayi ticaret turkey glaxosmithkline spa italy glaxosmithkline inc canada glaxosmithkline single member aebe greece glaxosmithkline japan glaxosmithkline trading services limited republic irelandb glaxosmithkline korea limited republic korea gsk capital netherlandsb glaxosmithkline limited hong kong gsk service poland glaxosmithkline mexico mexico gsk vaccines gmbh germany glaxosmithkline pakistan limited pakistan gsk vaccines srl italy glaxosmithkline pharmaceuticals limited india jsc glaxosmithkline trading russia gsk enterprise management ltd china laboratoire glaxosmithkline france gsk pharma vietnam company limited vietnam laboratorios viiv healthcare spain biomedical corporation quebec canada viiv healthcare gmbh germany viiv healthcare japan viiv healthcare srl italy viiv healthcare ulc canada viiv healthcare sas france irectly hold whollyowne subsidiary gsk plc resident limited subsidiary undertaking gsk plc berkeley square pension trustee company limited general partner gsk scottish limited partnership gsk scottish limited partnership gsk limited share capital indirectly own gsk plc own berkeley square pension trustee company limit limited subsidiary undertaking gsk plc general partner gsk scottish limited partnership gsk limited share capital indirectly own gsk plc subsidiary associate list principally affect figure group financial statement glaxosmithkline capital inc glaxosmithkline capital plc glaxosmithkline finance plc gsk captial glaxosmithkline llc whollyowne finance subsidiary company company fully unconditionally guarantee security issue glaxosmithkline capital inc glaxosmithkline capital plc glaxosmithkline finance plc gsk capital glaxosmithkline llc page complete list subsidiary undertaking associate joint venture form financial statement gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information legal proceeding group involve significant legal administrative december teva file petition rehear proceeding principally product liability intellectual property banc court grant tevas petition tax antitrust consumer fraud governmental rehearing threemember panel issue original investigation significant matter decision august original panel issue tax matter describe group make rehear opinion majority reinstate provision proceeding regular basis jury damage award million gsk favour summarise note accounting principle policy teva file petition rehear banc note provision note describes reject court appeal federal circuit disclosure proceeding february july teva file petition writ provision legal expense incur provision relate certiorari supreme court united states seek legal claim charge sell general administration overturn federal court decision october cost group believe information supreme court invite united states solicitor general seek plaintiff know file brief express view united states meaningful respect legal proceeding number factor include limited stage dolutegravir proceeding proceeding entitlement party appeal decision tivicaytriumeq clarity theory liability damage govern september viiv healthcare receive paragraph law letter lupin relate tivicay dosage oral december group aggregate provision suspension challenge crystal form patent legal dispute include tax matter describe november viiv healthcare file suit lupin note taxation million district court district delaware trial date assurance loss result outcome set legal proceeding exceed material dovato provision report group financial september viiv healthcare receive paragraph statement happen material letter cipla relate dovato challenge adverse impact result operation group crystal form patent november viiv healthcare file reporting period judgement incur suit cipla district court district settlement enter delaware settlement reach case juluca intellectual property january viiv healthcare receive paragraph intellectual property claim include challenge validity letter lupin relate juluca challenging crystal enforceability group patent product form patent patent relate combination process assertion noninfringement dolutegravir rilpivirine expire january patent loss case result loss february viiv healthcare file suit lupin patent protection product issue consequence patent settlement reach lupin loss significant decrease sale additionally june cipla send viiv healthcare product materially affect future result operation paragraph letter relate juluca july viiv group healthcare file suit cipla federal court delaware coreg court set trial date gsk initiate suit teva induce infringement patent relate use carvedilol product liability coreg decrease mortality cause congestive heart group currently defendant number product failure june case proceed jury trial liability lawsuit district court district delaware jury return avandia verdict gsk favour award gsk lose profit pende class action bring thirdparty reasonable royalty total award million payer assert claim racketeer influence march trial judge rule posttrial motion file corrupt organization act rico state consumer teva find substantial evidence trial protection law december circuit court support jurys find induce infringement overturning appeal reverse summary judgement grant favour jury award gsk appeal october group remand thirdparty payer case divide panel court appeal federal circuit district court discovery underway district court reverse district court rule reinstate jury award trial date set possible class gsk favour certification hearing hold gsk annual report note financial statement continue legal proceeding continue zantac california zantac litigation case jccp jccp group contact regulatory court hold sargon hearing admissibility authority detection nnitroso expert witness testimony include testimony general dimethylamine ndma zantac ranitidine product base specific causation expert witness bellwether information available time correspondence trial hearing occur fourday period february regulator group decision suspend march bellwether trial bladder release distribution supply dose form zantac cancer case expect start february market pende outcome ongoing tests california jccp court move trial date investigation precautionary action group july california bellwether trial decision initiate voluntary pharmacyretail level schedule august october recall zantac product globally date likely extend april european medicine agency ema illinois supreme court recently consolidate illinois recommend suspension ranitidine medicine ranitidine case cook county pretrial proceeding follow publication emas recommendation trial date set later date include previously company communicate decision reenter schedule madison county trial market fda request manufacturer personal injury action class action allege withdraw ranitidine product market economic injury thirdparty payer class action group name defendant approximately file federal court plaintiff move personal injury case state court federal stay class action pende appeal daubert rule zantac multidistrict litigation mdl court proceeding defendant oppose request stay ask southern district florida approximately court dismiss class action outside plaintiff name case significant majority seven class action pende group canada plaintiffs name series multiplaintiff complaint class action israel file delaware state court plaintiff give complex ownership marketing zantac previously mdl census registry remove prescription overthecounter otc medicine allege cancer cancer year numerous claim involve defendant result pursue mdl plaintiffs mdl plaintiff originally defendant serve include identify different type cancer wish pursue group notice potential indemnification claim plaintiff subsequently drop cancer possible liability connect particularly zantac otc proceed bladder esophageal gastric liver give early stage proceeding group pancreatic cancer plaintiff state court continue meaningfully assess liability pursue claim designate cancer meaningfully assess liability party relevant unfiled claim relate group indemnification provision defendant map group concern designate cancer mdl census registry addition march department justice california state court case subject doj send group notice civil investigation agreement group plaintiff open allegation false claim act violation suspend statute limitation allow plaintiff group relate zantac june doj serve bring claim later date file unfiled count civil investigative demand group formalizing subject change request document day new mexico attorney general file lawsuit multiple defendant december court preside federal include group allege violation state consumer mdl proceeding grant defendant daubert motion protection false advertising statute claim find plaintiff expert causation opinion zantac cause cancer issue mdl zofran liver bladder pancreatic esophageal stomach group defendant product liability case unreliable inadmissible expert causation involve zofran pende multidistrict litigation mdl opinions mdl court grant summary judgment gsk proceeding district massachusetts case allege brand defendant mdl court find child suffer birth defect mother scientist outside litigation conclude ingestion zofran andor generic ondansetron ranitidine cause cancer plaintiff scientist pregnancy relate nausea vomit plaintiff assert litigation systemically utilize unreliable methodology group sell zofran know unsafe pregnant fail use consistent objective sciencebased standard woman fail warn risk illegally market evenhanded evaluation datum ruling effectively zofran offlabel use pregnant woman dismiss approximately file case mdl bind claim census registry plaintiff indicate appeal mdl decision gsk annual report note financial statement continue strategic report governance remuneration financial statement investor information legal proceeding continue june mdl court grant group motion lamictal summary judgment federal preemption ground purport class direct purchaser file suit court find fda fully inform relevant district court district new jersey allege safety information zofran repeatedly group teva pharmaceuticals unlawfully conspire reject attempt add birth defect warning delay generic competition lamictal result label time court grant judgment group overcharge purchaser enter allegedly case pende mdl approximately case anticompetitive reverse payment settlement resolve patent close mdl proceeding plaintiff appeal decision infringement litigation separate count accuse group january united states court appeal monopolise market circuit affirm district court decision december trial judge grant plaintiff class favour group certification motion certify class direct purchaser remain state court case propose class group file rule motion court appeal action canada circuit challenging class certification decision april court appeal vacate low court sale marketing regulation grant class certification remand issue group marketing promotion pharmaceutical low court analysis vaccine product subject certain governmental october district court hear argument investigation private lawsuit bring litigant plaintiff renew motion class certification remand theory law april district court deny plaintiff motion gsk korea proceeding fair trade law class certification putative direct purchaser class august gsk korea indict korea leave potential class brandonly purchaser plaintiff monopoly regulation fair trade law relation move supplement expert report seek additional government tender hpv cervarix pcv synflorix discovery support addition certain generic vaccine prosecutor allege gsk purchaser january district court deny korea action employee plaintiff motion supplement expert report seek interfere tender process national additional discovery hold issue generic immunisation programme straw bidder purchaser decided deny court rule decertification party conduct gsk korea employee charge briefing class certification remain brandonly individual capacity prosecutor relation purchaser plaintiff seek add small matter number wholesaler codefendant category purchaser proceeding february court render guilty verdict respect defendant gsk korea fine february district court deny plaintiff krw million approximately appeal renew class certification motion followon complaint proceeding ongoing file district court eastern district pennsylvania february group allege korea fair trade commission commence purchaser proceeding matter gsk korea cooperate authority matter commercial corporate group involve certain contractual andor antitrustcompetition commercial dispute certain governmental action private lawsuit bring group allege violation competition zejula royalty dispute antitrust law october tesaro inc wholly own subsidiary gsk enter worldwide patent license agreement astrazeneca limit relate niraparib later approve zejula astrazeneca file lawsuit tesaro high court england wale allege tesaro fail pay royalty license agreement tesaro counterclaim base calculated overpayment trial schedule march post balance sheet event material post balance sheet event require adjustment disclosure financial statementsgsk annual report company balance sheet gaap include frs reduce disclosure framework december note fix asset investment current asset trade receivables cash bank total current asset trade payable total current liability net current asset total asset current liability provision liability noncurrent liability net asset capital reserve share capital share premium account reserve retain earning january profitloss year treasury share transfer esop trust dividend specie dividend pay shareholder equity shareholder fund financial statement page approve board march sign behalf sir jonathan symonds chair gsk plc register number company statement change equity year end december share share premium retain total capital account reserve earning equity january profit total comprehensive income attributable shareholder dividend shareholder share issue employee share scheme december profit total comprehensive income attributable shareholder treasury share transfer esop trust dividend shareholder note dividend specie note share issue employee share scheme december gsk annual report strategic report governance remuneration financial statement investor information note company balance sheet gaap include frs reduce disclosure framework presentation financial statement balance sheet prepare accordance company accounting policy approve board description business describe note policy consistently gsk plc parent company gsk major global apply state biopharma group make innovative vaccine specialty medicine prevent treat disease gsk key accounting judgement estimate focus science immune system human genetic key accounting judgement estimate require advanced technology primarily follow current year therapeutic area infectious disease hiv oncology immunologyrespiratory accounting policy preparation financial statement foreign currency transaction financial statement prepare foreign currency transaction record exchange historical cost convention modify include rate rule date transaction foreign currency asset revaluation certain financial instrument go liability translate rate exchange rule concern basis prepare accordance financial balance sheet date report standard reduce disclosure framework dividend pay receive accounting presentation company act dividend pay receive include financial december comparative figure statement period relate dividend december actually pay receive permit section company act expenditure income statement company present expenditure recognise respect good service annual report receive supply accordance contractual term company include group financial statement provision obligation exist future liability gsk plc publicly available respect past event obligation reliably estimate follow exemption requirement ifrs apply preparation financial statement investment subsidiary company accordance frs investment subsidiary company hold cost provision impairment include capital paragraph ifrs sharebase contribution relation movement contingent payment consideration ifrs financial instrument disclosure impairment investment paragraph ifrs fair value measurement carry value investment review impairment paragraph ias presentation financial statement indication investment comparative information requirement respect impaired assessment method compare paragraph ia carry value investment share net asset value investment share paragraph valuation subsidiary base expect discount ias presentation financial cash flow total investment evaluate statement group valuation basis overall market ia statement cash flow capitalisation impairment charge recognise income statement year concern paragraph ias accounting policy change accounting estimate error asset hold saledistribution noncurrent asset hold disposaldemerg paragraph ias relate party disclosure available immediate disposaldemerger present requirement ia disclose related party condition disposaldemerg highly probable transaction enter member expect complete year date group classification asset measure low accounting convention standard carry value fair value cost disposal balance sheet prepare historical sharebase payment cost convention complie applicable accounting issuance company subsidiary grant standard company share represent additional capital accounting principle policy contribution company subsidiarie additional preparation balance sheet conformity investment subsidiary result correspond increase generally accept accounting principle require shareholder equity additional capital contribution management estimate assumption affect base fair value grant issue allocate report amount asset liability disclosure underlie grant vest period contingent asset liability date balance sheet actual amount differ estimatesgsk annual report note company balance sheet gaap include frs reduce disclosure framework continue taxation financial guarantee current tax provide amount expect pay liability relate guarantee issue company apply tax rate enact substantively behalf subsidiary initially recognise fair value enact balance sheet date amortise life guarantee defer tax provide liability method perate profit temporary difference arise tax basis asset liability carry amount financial fee relate audit statement defer tax asset recognise company charge operating profit extent consider recoverable future taxable profit defer tax measure average tax rate expect apply period temporary difference expect realise settle defer tax liability asset discount dividend director declare interim dividend result dividend year penny adjust share consolidation detail note group financial statement dividend addition demerger consumer healthcare business implement gsk declare interim dividend follow dividend specie haleon plc share distribute external shareholder dividend specie haleon plc share distribute esop trust fix asset investment share glaxosmithkline service unlimited share glaxosmithkline holding limited share glaxosmithkline holdings limited share glaxosmithkline consumer healthcare holdings limited shares glaxosmithkline mercury limited share gsk limited capital contribution relate sharebased payment contribution relate contingent consideration investment glaxosmithkline consumer healthcare holding limit derecognised demerger consumer healthcare business execute specie share note group financial statement trade receivables amount year corporation tax recoverable debtor amount owe group undertaking amount year amount owe group undertaking movement amount owe group undertaking period reflect note primarily reflect receipt dividend income subsidiary include predemerger dividend glaxosmithkline consumer healthcare holding limited utilisation company current account fund payment interim dividend gsk annual report strategic report governance remuneration financial statement investor information note company balance sheet gaap include frs reduce disclosure framework continue trade payable amount year creditor contingent consideration payable corporation tax amount owe group undertaking company guarantee debt issue subsidiary company receive fee aggregate company outstanding guarantee billion debt instrument billion amount subsidiary company relation guarantee fee recover life bond disclose trade receivable note provision liability january charge year utilise december provision relate number legal dispute company currently involve noncurrent liability contingent consideration payable contingent consideration relate payable acquisition novartis vaccine portfolio current year liability include trade payable detail note group financial statement contingent consideration liability share capital share premium account share premium ordinary share account number share capital issue fully pay january issue employee share scheme december impact share consolidation issue employee share scheme ordinary share acquire esop trust december december issue share capital share hold esop trust share hold treasury share share free issue issue share fully pay share authorise issue nominal carry market value share hold esop trust disclose note employee share schemesgsk annual report note company balance sheet gaap include frs reduce disclosure framework continue retain earning reserve profit gsk plc year million million profit dividend pay distribute specie million include consumer healthcare business demerger dividend million million effect million treasury share transfer subsidiary company nil retain earning december stand million million million unrealise million dividend shareholder pay realise profit company december amount million million reserve include capital redemption reserve reserve reflect historical contribution share company issue satisfy share option award grant employee subsidiary company divestment july gsk plc separate consumer healthcare business gsk group form haleon plc independent list company separation effect way demerger gsk hold consumer healthcare business gsk shareholder follow demerger haleon plc hold aggregate gsk shareholder hold gsk include share receive gsk consolidated esot trust hold scottish limited partnership slp set provide collateral funding mechanism pursuant gsk provide additional funding gsk pension scheme aggregate ownership gsk include ownership esot trust slp demerger follow completion consumer healthcare business demerger july gsk plc ordinary share consolidate order maintain share price comparability demerger consolidation approve gsk plc shareholder general meeting hold july shareholders gsk plc receive new ordinary share nominal value penny exist ordinary share nominal value penny group company page complete list subsidiary associate joint venture significant shareholding form financial statement gsk annual report investor information section commercial operation turnover year record product development pipeline product competition intellectual property principal risk uncertainty share capital control dividend financial calendar annual general meeting tax information shareholder shareholder service contact law regulation group company glossary term gsk annual report financial record commercial operation turnover therapeutic area total europe international growth growth growth growth cer cer cer cer hiv dolutegravir product tivicay triumeq juluca dovato rukobia cabenuva apretude oncology zejula blenrep jemperli immunoinflamm respiratory benlysta nucala specialty medicine excl pandemic pandemic xevudy specialty medicine meningitis bexsero menveo influenza fluarixflulaval shingle shringrix establish vaccine infanrix pediarix boostrix hepatitis rotarix synflorix priorix priorix tetra varilrix cervarix vaccine exclude pandemic pandemic vaccine pandemic adjuvant vaccine respiratory arnuity ellipta anoro ellipta avamysveramyst flixotideflovent incruse ellipta relvarbreo ellipta seretideadvair trelegy ellipta ventolin respiratory general medicine dermatology augmentin avodart lamictal general medicine total commercial operation gsk annual report financial record continue strategic report governance remuneration financial statement investor information commercial operation turnover therapeutic area total europe international growth growth growth growth cer cer cer cer hiv dolutegravir product tivicay triumeq juluca dovato rukobia cabenuva apretude oncology zejula blenrep jemperli immunoinflamm respiratory benlysta nucala specialty medicine excl pandemic pandemic xevudy specialty medicine meningitis bexsero menveo influenza fluarixflulaval shingle shringrix establish vaccine infanrix pediarix boostrix hepatitis rotarix synflorix priorix priorix tetra varilrix cervarix vaccine exclude pandemic pandemic vaccine pandemic adjuvant vaccine respiratory arnuity ellipta anoro ellipta avamysveramyst flixotideflovent incruse ellipta relvarbreo ellipta seretideadvair trelegy ellipta ventolin respiratory general medicine dermatology augmentin avodart lamictal general medicine total commercial operation gsk annual report financial record continue threeyear select financial datum record financial performance provide analysed accordance current reporting practice information include select financial datum number employee adjust result prepare accordance international accounting standard conformity requirement company act ifrs issue international accounting standard board year financial datum present reflect restate result follow demerger consumer healthcare business financial result restate present revise revise group turnover geographic region europe international revise revise group turnover product group specialty medicine vaccine general medicine consumer healthcare revise revise specialty medicine turnover hiv oncology immunoinflammation pandemic vaccine turnover meningitis influenza shingle establish vaccine pandemic vaccine general medicine respiratory general medicine financial result total turnover profit taxation continue operation profit taxation discontinue operation gainslosse demerger remeasurement discontinue operation distribute shareholder demerger profit taxation discontinue operation profit taxation year pence pence pence basic earning share continue operation basic earning share discontinue operation total basic earning share dilute earning share continue operation dilute earning share discontinue operation total diluted earning share revised operating segment year note consolidated financial statement detail april gsk complete divestment horlick consumer healthcare nutrition product india number country exclude bangladesh unilever merger gsk indian list consumer healthcare entity hindustan unilever indian list public company gsk complete divestment bangladesh june comparatives restate consistent basis previously publish reflect demerger consumer healthcare business note impact share consolidation note consolidated financial statement gsk annual report financial record continue strategic report governance remuneration financial statement investor information year select financial datum continue financial result adjust turnover continue operating profit continue profit taxation continue profit taxation reconciliation total adjusted operating profit year summarise follow total continue operate profit intangible asset amortisation intangible asset impairment major restructuring transactionrelate item divestment significant legal item adjust continue operate profit reconciliation total adjust earning share year summarise follow pence pence pence total continue earning share intangible asset amortisation intangible asset impairment major restructuring transactionrelate item divestment significant legal item adjust continue earning share return capital employ return capital employ calculated total profit taxation percentage average net asset year restate return capital employ calculate meaningful average net asset year include consumer healthcare balance sheet noncurrent asset current asset total asset current liability noncurrent liability total liability net asset shareholder equity noncontrolle interest total equity number employee europe international manufacturing sell administration research development geographic distribution employee table base location gsk subsidiary company number employee number permanent employ staff end financial period exclude employee employ manage gsk contract basis employee number restate purpose consumer healthcare demergergsk annual report pipeline product competition pharmaceutical vaccine product development pipeline key nlicense alliance relationship party eua emergency use authorisation iiv healthcare global specialist hiv company phase valuation clinical pharmacology usually conduct gsk pfizer inc shionogi limited shareholder volunteer responsible developing deliver hiv medicine phase etermination dose initial evaluation efficacy bla biological licence application conduct small number patient maa marketing authorisation application europe phase iii arge comparative study compound versus placebo nda new drug application andor establish treatment patient establish approve clinical benefit safety submit maa ndabla regulatory review milestone show table achieve future filing date include list achieve regulatory review milestone compound mechanism actionvaccine type indication phase maa ndabla oncology momelotinib jak jak acvr inhibitor myelofibrosis registration snov sjun jemperli antiprogramme cell death protein receptor endometrial cancer iii dostarlimab antibody endometrial cancer combination iii zejula niraparib nonsmall cell lung cancer zejula poly adpribose polymerase parp inhibitor maintenance ovarian cancer combination iii niraparib jemperli dostarlimab maintenance non small cell lung cancer iii nsclc combination pembrolizumab premetastatic select biomarker population iii breast cancer blenrep adc target bcell maturation antigen multiple myeloma combination iii belantamab pomalyst dexamethasone mafodotin multiple myeloma combination iii velcade dexamethasone multiple myeloma combination anticancer treatment platform study multiple myeloma combination velcade revlimid dexamethasone cobolimab antitcell immunoglobulin mucin domain nonsmall cell lung cancer combination iii tim antibody jemperli dostarlimab docetaxel antitigit nonsmall cell lung cancer combination eos jemperli platform study antilymphocyte activation gene lag cancer antibody antipvrig cancer sting cytosolic dna pathway agonist advance solid tumor myeloid malignancy anticd cancer xmt sting agonist adc cancer wholly own mersana therapeutic hiv apretude hiv integrase strand transfer inhibitor longacte hiv preexposure prophylaxis approve sjun dec cabotegravir hiv infection mgml formulation hiv maturation inhibitor hiv infection hiv broadly neutralise antibody hiv infection hiv maturation inhibitor hiv infection hiv capsid protein inhibitor hiv infection hiv capsid protein inhibitor hiv infection hiv integrase inhibitor hiv infection brand name appear italic trade mark own license gsk group company footnote nonregistrational gsk exclusive global license option codevelop commercialize candidate progress phase gsk annual report strategic report governance remuneration financial statement investor information pipeline product competition continue pharmaceutical vaccine product development pipeline continue achieve regulatory review milestone compound mechanism actionvaccine type indication phase maa ndabla infectious disease xevudy sotrovimab antispike protein antibody covid approve adec eua priorix mmr vaccine live attenuate measle mump rubella prophylaxis approve jun menveo vaccine conjugatedliquid formulation meningococcal disease prophylaxis approve oct adolescent rotarix vaccine live attenuate pcv porcine circovirus rotavirus prophylaxis approve nov free vidprevtyn beta recombinant proteinadjuvante covid approve nov covid vaccine vaccine sanofi recombinant protein adjuvante respiratory syncytial virus prophylaxis old adult registration soct soct rsv vaccine vaccine population year age old respiratory syncytial virus prophylaxis old adult iii population year age skycovione recombinant protein nanoparticle covid registrationsjul bioscience adjuvante vaccine gepotidacin triazaacenaphthylene bacterial type uncomplicated urinary tract infection uuti iii topoisomerase inhibitor urogenital gonorrhea iii bepirovirsen hbv antisense hepatitis iii hepatitis sequential therapy pegylate interferon bexsero vaccine recombinant protein vaccine meningococcal disease prophylaxis month iii age old recombinant protein conjugate meningococcal disease prophylaxis iii man abcwy vaccine vaccine adolescent tebipenem pivoxil antibacterial carbapenem complicated urinary tract infection uti iii leucyl trna synthetase inhibitor tuberculosis bvlgsk ethionamide booster tuberculosis vir neutralize monoclonal antibody influenza recombinant protein adjuvante malaria prophylaxis plasmodium falciparum malaria fractional vaccine dose generalize modules membrane shigella diarrhea prophylaxis antigen gmma vaccine primeboost viral vector treatment chronic hepatitis infection aim therapeutic hbv sequentially administrate functional cure controlling resolving adjuvante recombinant protein clinical sequelae infection reduce need treatment recombinant protein conjugate meningococcal disease prophylaxis man abcwy genvaccine adolescent child week old live attenuate vaccine active immunization prevention varicella varicella new strain individual month age old sanfetrinem cilexetil serine beta lactamase inhibitor tuberculosis recombinant proteinadjuvante active immunization girl woman boys vaccine man year prevention cancer genital wart precancerous dysplastic lesion girl boy cause human papillomavirus hpv brand name appear italic trade mark own license gsk group company footnote apr sotrovimab long authorize treat covid increase proportion covid case cause omicron subvariant gsk contribute pandemic adjuvant covid vaccine collaboration approve south korea jun phase study start expect gsk exclusive option codevelop post phase gsk annual report pipeline product competition continue pharmaceutical vaccine product development pipeline continue achieve regulatory review milestone compound mechanism actionvaccine type indication phase maa ndabla infectious disease continue targeted immunotherapy viral vector treatment chronic hepatitis virus infection chbv aso combo adjuvante recombinant protein individual year decompensate direct act antiviral gsk cirrhosis bepirovirsen vaccine multiple antigen prevention pneumonia invasive presenting system map platform pneumococcal disease cause streptococcus pneumoniae serotype include vaccine child aged week year vaccine multiple antigen prevention pneumonia invasive presenting system map platform pneumococcal disease cause streptococcus pneumoniae serotype include vaccine adult aged year old live attenuate vaccine active immunization prevention measles mmrv new strain mump rubella varicella child month year age fimh antagonist uncomplicate urinary tract infection uuti crk inhibitor visceral leishmaniasis proteasome inhibitor visceral leishmaniasis mtb cholesterol dependent inhibitor tuberculosis vir antispike protein antibody covid pik beta inhibitor viral copd exacerbation recombinant protein adjuvante active immunization prevention primary vaccine difficile disease prevention recurrence recombinant protein bioconjugate klebsiella pneumoniae prophylaxis adjuvante vaccine recombinant subunit adjuvante cytomegalovirus cmv infection prophylaxis vaccine female year age mrna vaccine active immunization prevention disease cause influenza virus adult year old mrna vaccine active immunization prevent covid disease cause sarscov virus individual year old recombinant proteinadjuvante active immunization suppress recurrence therapeutic hsv genital herpe adult aged year old bivalent generalize module invasive nontyphoidal salmonella membrane antigen gmma vaccine bivalent generalize module invasive nontyphoidal salmonella typhoid membrane antigen gmma vaccine fever typhoid conjugate vaccine tcv bivalent typhoid paratyphoid salmonella typhoid paratyphoid enteric feveri conjugate papdpapd inhibitor hepatitis tlr agonist hepatitis falciparum cell inhibitor malaria pyrrolidine amide generalize module membrane active immunization prevent gonorrhea antigen gmma vaccine individual age year old regardless previous gonorrhea infection history brand name appear italic trade mark own license gsk group company footnote transition activity underway enable progression partner gsk annual report strategic report governance remuneration financial statement investor information pipeline product competition continue pharmaceutical vaccine product development pipeline continue achieve regulatory review milestone compound mechanism actionvaccine type indication phase maa ndabla immunology respiratory nucala mepolizumab antiil copd iii depemokimab antiil longacting asthma iii chronic rhinosinusitis nasal polyps crswnp iii eosinophilic granulomatosis polyangiitis egpa iii hypereosinophilic syndrome iii latozinemab antisortilin monoclonal antibody frontotemporal dementia ftd iii heterozygous mutation progranulin gene amyotrophic lateral sclerosis al frontotemporal dementia ftd mutations corf gene benlysta lymphocyte stimulator monoclonal systemic sclerosis associate interstitial lung belimumab antibody disease anticcl osteoarthritis pain antisortilin monoclonal antibody neurodegenerative disease antiil atopic dermatitis antiil multiple sclerosis opportunity drive jesduvroq prolyl hydroxylase inhibitor anaemia chronic kidney disease approve sfeb afeb daprodustat linerixibat ileal bile acid transporter ibat cholestatic pruritus pbc primary biliary iii inhibitor cholangitis hsdb silencer nonalcoholic steatohepatitis nash dnmt inhibitor sickle cell disease brand name appear italic trade mark own license gsk group company footnote phase study start expect imminent study startgsk annual report pipeline product competition continue pharmaceutical product competition intellectual property major patent expiry date product compound indication competitor brand respiratory anoro ellipta umeclidinium bromide copd spioltostiolto respimat vilanterol trifenatate utibronultibro nce nce breezhaler duaklir genuair device device bevespi aerosphere brimica genuair avamysveramyst fluticasone furoate allergic rhinitis dymista xhance expire expire nasonex fluticasone relvarbreo ellipta fluticasone furoate asthma copd symbicort foster vilanterol trifenatate budesonideformoterol nce nce sirdupla dulera device device seretideadvair salmeterol xinafoate asthma copd symbicort foster expire expire fluticasone propionate budesonide diskus device diskus device formoterol expire sirdupla dulera hfadevice hfadevice trelegy ellipta fluticasone furoate copd asthma trimbow pmdi vilanterol trifenatate nexthaler breztri nce nce umeclidinium bromide aerosphere trixeo aerosphere enerzair device device breezhaler ventolin hfa salbutamol sulphate asthma copd generic company expire hfadevice hfadevice xevudy sotrovimab early treatment regencov covid bamlanivimab nbe etesevimab evusheld central nervous system lamictal lamotrigine epilepsy bipolar disorder vimpat trokendi expire expire inovelon keppra keppra levetiracetam epilepsy briviact vimpat lamictal depakene depacon cardiovascular urogenital avodart duodart dutasteride benign prostatic generic product expire expire dutasteride tamsulosin hyperplasia bph finasteride alpha blocker antibacterial augmentin amoxicillin trihydratepotassium common bacterial generic product expire clavulanate infection clavam moxikindcv enhancin curam calamox oral cephalosporin cefuroxime axetil cefixime cefpodoxime cefdinir cephalexin oral macrolide azithromycin clarithromycin include supplementary protection certificate grant multiple country include patent term extension grant gsk annual report strategic report governance remuneration financial statement investor information pipeline product competition continue pharmaceutical product competition intellectual property continue major patent expiry date product compound indication competitor brand dermatology dermovate clobetasol propionate inflammatory skin generic product market expired betnovate betamethasone valerate condition topical cutivate fluticasone propionate corticosteroid like eumovate clobetasone butyrate mometasone furoate methylprednisolone aceponate hydrocortisone oncology zejula niraparib ovarian cancer lynparza rubraca nce nce blenrep belantamab mafodotin relapsedrefractory sarclisa xpovio multiple myeloma jemperli dostarlimab dmmr recurrent keytruda advanced endometrial nbe nbe cancer solid tumour immunoinflammation benlysta benlysta belimumab systemic lupus erythematosus lupkynis saphnelo lupus nephritis jesduvroq duvroq daprodustat anaemia chronic kidney evrenzo roxadustat disease vadadustat nce nce hiv apretude cabotegravir hiv prevention descovy truvada nce nce cabenuvavocabria cabotegravir rilpivirine hivaids descovy genvoya rekamby odefsey biktarvy nce nce rukobia fostemsavir hivaids trogarzo nce nce dovato dolutegravir lamivudine hivaids descovy genvoya odefsey biktarvy nce nce juluca dolutegravir rilpivirine hivaids descovy genvoya odefsey biktarvy nce nce triumeq dolutegravir lamivudine hivaids descovy genvoya abacavir odefsey biktarvy nce nce tivicay dolutegravir hivaid isentress prezista symtuza reyataz nce nce biktarvy note financial statement legal proceeding include supplementary protection certificate grant multiple country include patent term extension grant relate compoundsindication measle mump rubella vaccineprophylaxisb relate compound varicella vaccinegsk annual report pipeline product competition continue vaccine product competition intellectual property major patent expiry date product compound indication competitor brand bexsero meningococcal groupb vaccine meningitis group prevention trumenba boostrix diphtheria tetanus acellular diphtheria tetanus acellular adacel expire expire pertussis pertussis booster vaccination infanrix hexapediarix diphtheria tetanus pertussis prophylaxis diphtheria pentacel pediacel expire expired polio hepatitis haemophilus tetanus pertussis polio pentaxim pentavac influenzae type hepatitis haemophilus hexaxim hexyon influenzae type vaxeli cervarix hpv virus like human papilloma virus gardasil silgard expire particle vlps type adjuvant mpl aluminium hydroxide fluarix tetra split inactivated influenza seasonal influenza prophylaxis intenza flumist qiv expire expire antigen virus subtype vaxigrip qiv subtype fluzone qiv fluzone high dose flulaval split inactivated influenza seasonal influenza prophylaxis vaxigrip mutagrip expire expired antigen virus subtype fluzone influvac subtype aggripal fluad intenza flumist menveo meningococcal group meningitis group nimenrix menactra conjugate vaccine prophylaxis priorix priorix tetraab live attenuate measle mump measle mump rubella mmr mmrvaxpro expire expire varilrixb rubella varicella vaccine chickenpox prophylaxis proquad varivax rotarix human rotavirus rix strain rotavirus prophylaxis rotateq synflorix conjugate pneumococcal prophylaxis invasive prevenar prevnar polysaccharide disease pneumonia acute otitis medium shingrix zoster vaccine herpe zoster zostavax recombinant adjuvante shingle note financial statement legal proceeding include supplementary protection certificate grant multiple country include patent term extension grant relate compoundsindication measle mump rubella vaccineprophylaxisb relate compound varicella vaccine gsk annual report strategic report governance remuneration financial statement investor information principal risk uncertainty outline principal risk uncertaintie relevant detail status uncertainty gsk business financial condition operation significant unresolved dispute potential litigation set affect performance ability achieve objective note legal proceeding risk believe cause actual detail risk management framework result differ materially expect historical result identify principal risk find page operate biopharmaceutical sector carry incorporate risk level inherent risk uncertainty affect business principal risk opportunity relate environmental social governance esg include environmental comply broad range law regulation sustainability climate change manage apply research development manufacture focus area describe esg performance report test approval distribution sale market additional information climate relate risk management pharmaceutical vaccine product affect cost climate relate financial disclosure page product development time require reach market likelihood successfully uninterrupted basis regulation require description principal risk uncertaintie explanation rule regulation change government interpretation manage mitigated description evolve business activity develop nature principal risk summary manage particular risk alter change regulatory regime risk business list order substantial alteration failure comply significance consistent principal risk detail applicable law regulation materially page july board agree adversely affect financial result separation long principal risk follow similarly global business expose litigation successful demerger analysis residual risk government investigation include product liability litigation patent antitrust litigation sale marketing litigation litigation government investigation relate provision unfavourable outcome increase related cost insurance premium materially adversely affect financial result patient safety risk definition context risk gsk include party potentially fail fully accountable safeguarding patient failure appropriately collect review follow report human safety effectively result importantly harm information include adverse event potential patient reputational damage andor product source gsk potentially fail act relevant liability litigation conduct internal safety surveillance finding timely manner rely access safety information external source information safety efficacy product risk impact human collect clinical development gsk tolerate unfavourable benefittorisk profile comprehensive information incorporate realworld use patient use product important product market example consequence ineffective pharmacovigilance potential regulatory agency realworld evidence source harm patient maintain robust process accessible industry supplement manage human safety information conduct timely safety validate evidence use support safety efficacy signal detection ensure appropriate measure product potential emerge risk place manage risk patient gsk intend fully technology company datum custodian similarly comply pharmacovigilance relevant regulation draw communicate conclusion safety worldwide noncompliance result inspection finding product base digital health datum collect regulatory scrutiny civil criminal sanction platform inaccessible industry temporary permanent loss product marketing regulatory agency authorisation regularly review respond patient safety risk limit potential reputational damage loss trust patient healthcare provider productrelate litigation loss shareholder confidence gsk annual report principal risk uncertainty continue patient safety continue licence operate depend compliance party oversight framework ensure party regulatory requirement worldwide directly encounter human safety information identify relate patient safety extend privacy train appropriately manage safety information information security regulation regulatory product source compliance global compliance depend appropriate identification regulation information allow detect safety signal management human safety information employee product timely action information party act behalf pursue change product riskbenefit profile innovative solution enhance ability perform action discuss regulatory pharmacovigilance include artificial intelligence authority include update prescribing machine learn technology augment capacity information communicate healthcare provider manage increase volume adverse event report restrict product prescribingavailability help assure safe varied source advance technical solution use carry clinical trial certain case deliver safety information risk minimisation measure appropriate stop clinical trial withdraw patient health care provider product specific batch market covid pandemic impact complete simplification optimisation pharmacovigilance activity increase public focus core patient safety process expect improve safety efficacy medicine vaccine highlight crossfunctional stakeholder engagement safety activity importance robust business continuity planning gsk begin automate endtoend process uninterrupted safety oversight regulatory compliance individual case safety report deliver well case quality include ability accommodate remote regulatory consistency enhance efficiency inspection accelerate automation manage pharmacovigilance operation model expand ensure increase volume adverse event connectivity central local safety team create resource leader enable mitigate activity advocate need industry access safety datum chief medical officer accountable patient safety source good way safeguard patient enterprise risk human safety matter collaboration transition twovendor singlevendor model key head global safety crossenterprise safety governance operational activity improve efficiency reduce board oversee implementation control framework risk regulatory noncompliance expand include risk management global safety board ensure global safety team include additional expertise optimise address human safety proactively strategy approach productrelate risk mitigation product lifecycle global policy management human minimisation safety information require employee immediately report issue relate safety product product quality risk definition context risk gsk party potentially fail ensure external environment product quality remain appropriate control governance quality challenge increase cyberattack datum breach development commercial product compliance industry cyberattack remain key risk industry practice regulation manufacturing integrity product quality datum audit trail meet distribution activity term gsk product license commitment european medicine agency ema support regulatory activity requirement license medical device continue plan deployment new annex guidance risk impact manufacture sterile medicinal product publish failure ensure product quality farreache september set expectation compliance implication patient safety cause product launch delay august actively manage implementation drug shortage product recall regulatory legal context global equipment component supply chain financial consequence materially constraint effecting industry increasingly apply adversely affect gsk reputation financial result advance digital technology insight drive scientific excellence enhance development manufacture testing product example use new electronic documentation system advance laboratory information management tool quality organisation align sure quality procedure governance facilitate new company strategy prepandemic level onsite inspection resume continue step ensure inspection readiness gsk annual report principal risk uncertainty continue strategic report governance remuneration financial statement investor information product quality continue mitigating activity implement riskbase approach assess manage party supplier provide material align extensive global network quality finished product expect contract compliance professional sitelevel senior manufacturer product comply gsk management business unit provide oversight standard regularly conduct audits provide assist delivery quality performance assurance product incident committee operational compliance deliver management process place investigate product issue oversight hierarchy quality council recommendation remediation activity include independent chief product quality officer global product necessary recall medicine vaccine protect quality office oversee product quality risk patient public company develop implement single quality management system define quality standard establish complaint process ensure respond system business associate appropriately product quality issue raise patient development commercialisation vaccine specialty independent function review triage allegation general medicine consolidation regulatory noncompliance misconduct receive formal requirement market world augment informal speak channel global disciplinary system mean meet external expectation enforcement procedure apply breach product quality market supply system base standard initiate appropriate follow internationally recognise principle ich investigation use key risk indicator support risk pharmaceutical quality system framework management activity provide gsk leadership team risk oversight compliance council integrate routinely update quality management system qms assessment product quality performance keep pace evolve external regulatory complete product assessment presence environment new scientific understanding product nitrosamine report necessary health process policy authority develop mitigation plan procedure simple understand implement execute regulatory adopt innovative tool userfriendly requirement actively work industry body regularly train staff regulatory expectation learning european regulatory authority complete inspection exist procedure maintain safety evaluation titanium dioxide medicine current good manufacturing practice standard identify potential substitute financial control report risk definition context risk gsk fail comply current tax law fail require law jurisdiction publicly report accurate financial information compliance disclose financial result event materially accounting standard applicable legislation incur affect group financial result regulator routinely review significant loss treasury activity financial statement list company compliance new revise exist account regulatory risk impact requirement believe comply appropriate noncompliance exist new financial new esg regulatory requirement concern financial statement report disclosure requirement change disclosure material information include recognition income expense expose gsk transaction relate business restructure litigation regulatory action materially acquisition divestiture subject adversely affect financial result failure comply investigation potential noncompliance change substance application law govern accounting disclosure requirement lead transfer pricing dividend tax credit intellectual property restatement previously report result significant materially adversely affect financial result penalty failure comply applicable sanction law treasury group deal daily high value transaction regulation result gsk investigate relevant foreign exchange cash management transaction government agency authority andor legal transaction involve market volatility counterparty proceeding government investigation risk group effective tax rate reflect location litigation unpredictable regardless activity value generate determine outcome costly require significant management jurisdiction profit arise applicable tax rate attention damage reputation inconsistent application treasury policy transactional settlement error counterparty default lead significant loss gsk annual report principal risk uncertainty continue financial control report continue higher low statutory rate disclosure committee reporting board review reflect regime encourage innovation investment gsk quarterly result annual report year provide tax incentive change consultation legal advisor disclosure affect gsk tax rate addition worldwide nature committee determine necessary disclose operation mean crossborder supply route publicly information group stock exchange necessary ensure supply medicine vaccine announcement treasury management group meet result conflict claim tax authority profit regularly ensure liquidity interest rate counterparty tax individual country lead double foreign currency transaction foreign currency translation taxation profit tax country risk manage line prudent approach complexity tax regulation mean detail risk strategy policy adopt occasionally disagree tax authority technical board interpretation particular area tax law tax charge counterparty exposure subject define limit approve include financial statement good estimate tax board credit rating individual counterpartie liability pende audits tax authority expect middle office treasury monitor management continue focus tax reform drive initiative counterparty risk line agree policy oversight oecd address tax challenge arise corporate compliance officer operate independently digitalisation economy domestic treasury detail mitigation treasury risk initiative world result significant find page manage tax risk change establish tax principle increase tax robust internal policy process train compliance authority dispute regardless merit outcome programme costly divert management attention adversely impact reputation relationship key stakeholder maintain open constructive relationship tax law regulation order measure restrict dealing authority worldwide monitor government debate tax certain country government government official policy key jurisdiction understand entity individual use financial institution movement potential future change tax law share inform fund circumvention sanction export control point view relevant provide pragmatic criminal offence gsk seek comply constructive business input tax policy maker directly sanction obligation believe group complie industry trade body include advocate applicable sanction material respect law reform support economic growth job creation complex continue evolve rapidly need patient key stakeholder tax affairs manage global basis team tax mitigating activity professional lead global head tax work closely date late development financial business daytoday basis global tax team report requirement review update regulator suitably qualified role perform support work external auditor legal advisor training need provide date technical performing respond emerge risk financial result advice line responsibility submit tax return review approve regional management accord statutory time limit engage proactively review gsk group financial controller chief tax authority ensure tax affair current enter financial officer cfo allow financial controller continuous audit programme advance pricing cfo assess evolution business time agreement appropriate arrangement provide evaluate performance plan significant judgement longterm certainty tax authority gsk review confirm senior management tax treatment business base disclosure integrate technical organisational transformation newly relevant fact seek resolve difference acquire activity external risk risk assessment interpretation tax legislation tax authority apply appropriate control review maintain cooperative manner exceptional case control environment design identify material error resolve dispute formal proceeding gsk financial reporting disclosure standardise committed comply applicable sanction law global financial reporting operating model regulation deploy programme enable management sanction risk programme jointly lead design operating effectiveness key financial gsk finance legal compliance reporting control regularly review management system control include limited policy test external party location procedure train awareness screen monitor standard model apply minimum standard set risk reporting control review management monitor independently give assurance control key financial reporting disclosure process operate effectively global finance risk management control frmc group provide extra support significant transformation system deployment management structural reorganisation add operational resource adapt programme timeline ensure process control maintain significant change gsk annual report principal risk uncertainty continue strategic report governance remuneration financial statement investor information antibribery corruption abac risk definition continue assess understand money launder risk exposure mitigate exist risk risk gsk party potentially fail comply applicable law regulation internal requirement code conduct culture commitment zero ensure appropriate control governance bribery tolerance bribery corruption integral corruption business activity mitigate risk light complexity geographic breadth risk constantly evolve oversight risk impact activity datum reinforce workforce gsk clear failure mitigate risk expose gsk associate expectation acceptable behaviour maintain person governmental investigation regulatory action regular communication local market civil criminal liability compromise gsk ability build abac programme base bestinclass supply product certain government contract principle help manage risk addition failure prevent bribery corruption example programme include seniorlevel substantial implication gsk reputation credibility commitment board leadership datum senior leader erode investor confidence analytic programme create embe local key risk governance risk management future performance indicator enable target intervention risk consequential negative impact share performance management activity continue actively consider lead imposition significant financial improvement programme penalty imposition additional reporting obligation abac programme underpin global abac policy write standard control address context business activity rise bribery corruption continue strong enforcement appetite risk establish diligence requirement foreign bribery investigation prosecution engagement party programme mandate particular focus conduct multinational company enhance control interaction government official operate financial penalty hand business development transaction prove corruption case significant dedicated team responsible programme implementation evolution abac team work disruption global supply chain commercial group organisation address improve pressure cause high usual inflation rate likely control monitoring requirement audit assurance increase risk bribery corruption certain independent business monitoring team complement context abac team work provide add assurance great transparency collaboration use issue find oversight assurance exercise enforcement authority advance technology use investigation identify area specific intervention datum analytic provide well platform streamline market drive continuous improvement process detect potential issue programme mitigating activity provide mandatory abac training annually enterprisewide abac programme design employee relevant party differentiate accord ensure compliance applicable law regulation seniority role responsibilitie geographic location prohibit bribery corruption relate offence formal informal speak channel available build business standard culture form report misconduct noncompliance central comprehensive practical approach compliance investigation team review triage allegation non respond evolve nature business gsk abac compliance trigger investigation appropriate governance board oversee provide programme governance enterprise risk management include representation key functional area continue enhance control thirdparty engagement ensure sufficient meet evolve emerge risk plan continue pre posttransaction abac diligence increase capability organisation onboarde continual monitoring management party gsk annual report principal risk uncertainty continue commercial practice risk definition mitigate activity risk gsk party potentially engage achieve strategic objective meet price commercial activity fail comply law regulation expectation payer hcp consumer community industry code internal control requirement culture provide guide lead decision constantly strive right thing deliver risk impact quality medicine vaccine sustain reliable supply failure engage activity consistent letter meet customer need seek ensure action spirit law industry regulation group reflect gsk value behaviour purpose understand requirement relate sale promotion medicine impact datum industry strive vaccine appropriate interaction healthcare organisation make datadriven decision approach professional hcp organisation patient align effort agile work pace legitimate transparent transfer value pricing gsk act enhance improve policy competition antitrust regulation commercial standard application datum analytic channel practice include trade channel activity business activity evolve policy standard incrementally tender materially adversely affect ability ensure commercial activity undertake deliver strategy longterm priority additionally conduct behalf execute establish result incomplete awareness riskbenefit profile governance train employee relevant information product possibly suboptimal treatment patient focus interactive learning element behavioural consumer governmental investigation regulatory action science commercial activity worldwide conform legal proceeding bring group high ethical regulatory industry standard local governmental private plaintiff result standard differ global one apply government sanction criminal andor financial penalty stringent standard acquire company joint practice find misaligned value venture partner differ global standard remediate expectation result reputational harm legacy policy implement revision align dilute trust establish external stakeholder business continue use internal control framework support assessment management risk business context unit risk management compliance board manage operate highly regulated extremely competitive risk global incountry business activity oversee biopharma industry peer significant commercial activity monitor programme product innovation technical advance intensify promotional material activity review price competition additional external factor impact approve accord policy standard business operation include ongoing effect conduct accordance local law regulation covid global pandemic access limitation requirement seek ensure material customer macroeconomic inflationary dynamic pricing activity fairly represent group product service pressure market achieve strategic objective necessary event misconduct continue develop commercially viable new discipline employee include termination product deliver additional use exist product contract claw remuneration senior address need patient consumer hcp payer management continue evolve incentive financially new productsindication carry programme sale representative well recognise uncertainty regard future success product reward individual effort nearly market cap development costly lengthy uncertain carry variable pay element representative compensation potential failure stage successful evaluate basis individual sale target product development face challenge launch competitor product pricing strategy allow fairmarket value payment gsk render asset competitive support product expert practitioner speak innovative medicine innovation continue focus inperson vaccine restrict period product lifecycle virtual engagement constant focus patient new competitive datum publish support roll global endtoend process gsk approve medicine vaccine drive consistent way work efficiency obligation provide important information healthcare strengthen control automation use datum community way responsible legal permit report payment individual hcp ethical manner appropriate product promotion ensure hcp commitment transparency responsible disclosure access information need patient consumer fact medicine vaccine require product prescribe recommend manner provide healthcare benefit commit ethical responsible commercialisation product support purpose improve quality human life ahead disease gsk annual report principal risk uncertainty continue strategic report governance remuneration financial statement investor information scientific patient engagement risk definition expect activity scientifically sound accurate conduct ethically transparently risk gsk party potentially fail engage compliant applicable code law regulation externally gain insight educate communicate industry local code law science medicine associate disease area regulation apply privacy datum integrity provide grant donation legitimate transparent mean measure risktake root sound ethical manner compliant law regulation industry code consideration principlesbase decisionmake internal control requirement train communication monitoring activity risk impact key manage risk enable appropriate engagement control place risk result real perceive disguised promotion include offlabel prior mitigate activity authorisation promotion real perceive provision chief medical officer cmo oversee nonpromotional medical advice turn lead criminal scientific patient engagement enterprise risk owner investigation penalty civil litigation competitor gsk code practice key internal policy non complaint time engage fully promotional engagement activity activity include appropriately result patient harm failure scientific interaction support medical education advice advance science innovation reputational damage seek gathering insight unmet need patient financial loss consequence reduce trust scientific communication research disease public patient healthcare professional payer regulator awareness government covid pandemic see continue context increase virtual engagement external expert scientific patient engagement diverse non advisory board patient advocacy patient engagement promotional activity direct healthcare professional scientific congress develop modernised patient payer external stakeholder digital approach hcp patient engagement engagement aim improve patient care framework insightgathere apply internal exchange provision knowledge use product principle policy rapidly change grow relate disease scientific patient engagement environment external stakeholder group vital gsk research continuously improve internal control network base biopharma company ambitious patient identify emerge risk early support staff conduct necessary advance science medicine activity compliance gsk culture policy local law regulation build effective risk management management monitor system datum ethic privacy risk definition context risk gsk party potentially fail ethically datum protection privacy legislation diverse limited collect use reuse artificial intelligence datum analytic global harmonisation simplification challenge automation secure share destroy personal information multinational standardise approach compliance accordance law regulation internal control datum privacy law government enforce compliance requirement datum protection privacy law rigorously approach focus datum protection privacy regulator risk impact differ region country noncompliance datum privacy law globally lead create challenge global organisation seek harm individual gsk damage trust implement single harmonise global privacy programme gsk individual community business partner increase volume datum process advance government authority country increase technology result great focus datum enforcement power datum protection authority governance ethical use personal information allow impose significant fine impact crossborder compliance datum privacy law company datum flow temporarily ban datum process new seek foster innovation artificial intelligence national law enable individual bring collective legal new technology face evolve decision action company gsk failure follow global policymaker well promote trust datum privacy law system avoid unintended outcome harmful impact gsk annual report principal risk uncertaintie continue data ethic privacy continue additionally number emerge law concern head dpc lead global crossfunctional core team localisation datum restriction international transfer digital privacyqualifie attorney privacy datum security change exist framework compliance professional support network privacy gsk previously rely increase trend leader business unitsfunction privacy contract datum sovereignty affect ability drive medical innovation locally wide legal compliance team gsk effectively operate internationally global privacy framework base general data protection regulation deploy market mitigating activity base factor include robustness local privacy general counsel gsk enterprise risk owner ero legislation establish datum protection authority gsk chair privacy governance board oversee gsk footprint country deploy overall datum privacy operating model gsk business area proportionate control framework set minimum privacy appoint risk owner accountable overseeing standard irrespective applicable legislation privacy risk support privacy leader core team responsible business country local datum privacy law require appointment datum protection officer dpo gsk operate improve centralised global privacy appointment include dpo control framework result gsk focus technology datadriven science continuously assess provide relevant use artificial intelligencemachine learn evolve proportionate control aid nondeploye market global datum strategy seek address key risk monitor new change law adapt privacy create new team group legal compliance framework accordingly responsible advise global digital privacy deploy comprehensive training programme drive cybersecurity strategy ero appoint head great awareness accountability manage digital privacy cybersecurity head dpc personal information entire organisation daytoday accountability designing implement control framework certify key gsk privacy network role sufficient training experience carry role effectively continuously improve process issue identification report handle monitor core team work business ensure build privacy control exist new business initiative ensure meet accountability obligation accordance global datum protection privacy law research practice risk definition context risk gsk party potentially fail research involve animal raise ethical concern adequately conduct ethical credible preclinical case research involve animal way clinical research collaborate research activity compliant investigate effect potential new medicine living law regulation internal control requirement body human animal research provide critical information cause mechanism disease risk impact remain vital research potential impact risk include harm human continually seek way minimise use subject reputational damage failure obtain necessary animal research development test regulatory approval product governmental comply regulatory requirement reduce investigation legal proceeding bring gsk impact animal human subject research critical governmental private plaintiff product liability suit assess demonstrate safety efficacy claim damage loss revenue inadequate patent investigational product evaluate product protection inability supply product regulatory approve research include clinical action fine penalty loss product authorisation trial healthy volunteer patient adhere poor datum integrity governance compromise gsk regulation high ethical medical scientific standard effort negatively impact reputation disclose result research externally regardless materially adversely affect financial result reflect positively negatively product damage trust patient customer scientific community learn outcome research work human biological sample fundamental discovery development safety monitoring product gsk annual report principal risk uncertainty continue strategic report governance remuneration financial statement investor information research practice continued committed manage human biological sample establish office animal welfare ethic accordance relevant law regulation ethical strategy risk oawesr lead chief veterinary officer principle manner respect interest support humane responsible care animal sample donor data pivotal strategy carry ethical review independent scientific review maximise use datum serve patient govern animal study share knowledge advocate datum accordance relevant law regulation contractual application nonanimal alternative oawesr provide obligation expectation culture privacy framework animal welfare governance define provide information security datum integrity essential oversight training animal care promote replacement refinement reduction animal research conduct quality use wide variety biological material discovery assessment manage programme external animal research development asset diligence develop deploy strategy reproduce convention biological diversity cbd nagoya experiment translate human clinical end point protocol international community establish global ensuring implement maintain proper data governance framework regulate access use genetic resource control remain important priority especially scientific nonhuman origin research development support strategy evolve advantage breadth principle access benefitshare genetic datum example genomic artificial intelligence resource outline cbd nagoya protocol machine learn focus build datum integrity privacy recognise importance appropriate effective usage control internal control framework quality proportionate implementation measure national assurance team conduct audits provide independent regional level business monitor internal control mitigating activity organisation maintain control prepublication procedure guard public disclosure patent application research practice risk overseen enterprise file addition lack datum integrity framework seeks strengthen governance prepare patent application datum information lead leadership research practice enterprise risk loss patent protection legal expert collaborate owner management risk take pragmatic approach support review process new patent application information sharing streamline risk identification organisation collaborate legal expert escalation ensure ownership risk mitigation stay development asset account business relevant thirdparty patent right environment health safety eh risk definition mitigate activity risk gsk party potentially fail ensure gsk leadership team responsible ehs governance appropriate control governance organization risk oversight ensure effective control asset facility infrastructure business activity framework inplace inuse manage ehs risk include execution hazardous activity handle impact legal compliance issue business hazardous material release substance harmful include assign responsibility senior manager environment disrupt supply harm employee provide maintain control ensure party environment tiere monitoring governance process place business unit function leader ensure ehs control risk impact framework implement effectively respective business failure manage ehs risk lead significant harm area compliant applicable law regulation people environment community adequately resource maintain communicate operate fine inability meet stakeholder expectation monitor employee qualified contractor act regulatory requirement litigation regulatory action behalf gsk personally responsible ensure damage company reputation materially follow applicable local standard operating procedure adversely affect financial result riskbase proactive approach articulate global ehs policy detailed global ehs standard context audit operation ensure compliance ensure gsk subject health safety environmental law hazard appropriately control design jurisdiction law impose duty protect facility equipment system rigorous procedure people environment community apply correctly effective barrier place protect operate employee health safety create safety improvement plan focus life save rule safety leadership warehouse safety significant milestone programme deliver accord plan safety leadership experience warehouse improvement continue implementation gsk annual report principal risk uncertainty continue information security risk definition mitigate activity risk gsk party potentially fail ensure cyber security office cyber maturity programme appropriate control governance unauthorised gsk cyber security office chief information access disclosure theft unavailability corruption gsk security officer responsible identify put information key system technology infrastructure place measure help gsk mitigate manage cyber risk impact security risk include active monitoring initiate remediation action response cyber security failure adequately protect information system intelligence threat enhance capability cause harm patient workforce customer ongoing programme investment people disruption business andor loss commercial process technology improve ability prevent strategic advantage regulatory sanction damage detect respond recover cyber security incident reputation risk base thirdparty security risk management program context place aid assess cyber security risk selection party provide ongoing monitor external environment continue extremely external partner supplier ecosystem challenge make hard pace increasingly sophisticated cyber threat factor information security governance include increase geopolitical conflict digital cyber security office periodically provide update key nationalism rise frequency severity datum breach information security risk issue progress report grow capability sophistication bad actor cyber maturity programme risk oversight cyber criminal gsk business relie operate highly compliance council audit risk committee connect information network internal external information security enterprise risk plan cyber maturity system hold confidential research development programme oversee chief digital technology manufacture commercial workforce financial data officer chief financial officer mean system information cyber security awareness training readiness continue target cyberattack acceleration use digital datum analytic cloud compute cyber security awareness training program include capability drive gsk pipeline performance require phishe simulation program place increase continuously adapt strengthen control awareness cyber relate risk reinforce message defensive capability gsk rely thirdparty security everyone responsibility gsk periodic crisis contractor partner supplier face similar cyber simulation tabletop exercise plan level threat continue vector risk manage organisation test ability respond cyber incident compliance governmental cyber security regulation cyber security office general counsel guidance work stay abreast emergent governmental regulation emergent trend compliance expectation cyber security information security new regulatory guidance available remedial compliance relate action place appropriate gsk annual report principal risk uncertainty continue strategic report governance remuneration financial statement investor information supply continuity risk definition new technology modality platform supply chain change requirement skillset people risk gsk party potentially fail deliver work field implement new chemistry continuous supply compliant finished product respond manufacturing control operating model effectively crisis incident timely manner recover bring crossfertilisation talent focus skill need sustain critical supply operation future innovative manufacturing risk impact industrial relation current risk supply continuity recognise important continuity supply threat industrial action avert product patient rely supply disruption manufacturing site successful dialogue union lead continued business monitoring place assess risk product shortage product recall spread industrial relation challenge result global cost living pressure regulatory intervention mitigate activity reputational harm lose sale revenue risk management medicine vaccine supply chain set ensure consequently need sophisticated endtoend supply chain sustainable global supply gsk internal control framework management robust crisis management business drive approach risk management continuity plan place respond design identify emerge new risk support clear decision make risk oversight manage context hierarchy risk management compliance board run supply chain continually evolve highly assure risk mitigation include identify new emerge regulated environment single set global threat regulation govern manufacture distribution medicine adhere requirement inventory management market licence sell manufacture product supply chain governance committee medicine rely internal quality management system vaccine closely monitor inventory status delivery internal control framework ensure continue product core commercial cycle link supply chain preserve licence operate forecast commercial ambition design reduce risk demand fluctuation manage temporary complex endtoend supply chain involve shortage supply periodically review node party supplier active pharmaceutical ingredient api supply chain ensure hold adequate safety stock whilst manufacturer raw material supplier balance work capital particular emphasis party logistic provider contract engineering firm mitigate supply risk associate medicallycritical embed integrate risk management source day highrevenue product new product launch example day business process alongside thirdparty oversight dual source key product apis use programme monthly performance management process supply external factor continue challenge supply continuity chain monitor business activity highlight adverse early year covid continue trend supply operation budget workforce capability disrupt source biosciences material medicine vaccine supply chain vial syringe business continuity singleuse system component ukraine conflict crisis management business continuity plan place result supply disruption region manage supply chain include authorise response disruption deploy bespoke deriske plan crisis recovery strategy key area responsibility clear continuity plan manage detail mitigate risk communication route regularly use business continuity supply continuity problem dual source plan manage potential supply disruption material reroute shipment avoid conflict zone manufacturing site crisis management plan keep patient supply medicine place plan tested annually ensure priority maintenance core skill crisis management gsk annual report shareholder information demerger share consolidation monday july company complete circular relation demerger share demerger consumer healthcare business consolidation circular prospectus group form haleon group demerger term admission haleon ordinary share premium list demerger shareholder receive haleon plc share segment official list financial conduct authority gsk plc share hold record time fca trade main market london stock friday july exchange lse publish company haleon plc respectively wednesday june follow demerger company consolidated share capital share consolidation share consolidation take effect tuesday july result shareholder receive new gsk plc share nominal value pence gsk plc share nominal value penny hold record time monday july share capital control detail issue share capital number share similarly certain economic sanction hold treasury december find force time time limitation relate note financial statement share capital share nonresident english law company premium account article association right holder vote respect company share ordinary share list lse quote new york stock exchange nyse form interest vote right american depositary share ad ad represent state far aware ordinary share detail list debt list person significant direct indirect holding company refer note financial statement net debt information provide company pursuant fca holder ordinary share ad entitle receive disclosure guidance transparency rule dtr dividend declare company annual report publish regulatory information service entitle attend speak appoint proxy company website gskcom exercise voting right general meeting company company receive notification accordance restriction transfer limitation dtr follow notifiable interest voting right hold ordinary share ad requirement company issue share capital obtain approval prior transfer ordinary share december march ad carry special right regard control percentage percentage company restriction vote right major total total shareholder voting right share voting voting voting voting right right right right shareholder know arrangement blackrock inc financial right hold person holder share know agreement restriction share dodge cox transfer vote right ercentage total voting right date notification share acquire group employee share plan company rank equally share issue special omprise indirect interest ordinary share hold qualify financial instrument contract right trustee employee share ownership plan difference trust waive right dividend share hold omprise indirect interest ordinary share trust ad exchange control limitation company acquire disposed interest affect holder share period review certain economic sanction force time time currently applicable law decree regulation force restrict import export capital restrict remittance dividend payment holder company share nonresident strategic report governance remuneration financial statement investor information gsk annual report shareholder information continue share capital control continue share buyback programme share price board authorise issue allot ordinary january share article company article association december power article authority company increasedecrease purchase share subject shareholder high year authority seek annual basis annual low year general meeting agm share purchase company cancel hold treasury share table set middle market closing price satisfy share option grant group company share price decrease employee share plan compares increase ftse index year middle market closing share price march programme cover purchase share cancellation hold treasury share accordance authority renew shareholder agm share price trend year end company authorise purchase maximum december million share detail share purchase cancel hold treasury share subsequently transfer treasury satisfy awards group employee share plan disclose note financial statement share capital share premium account determine specific share repurchase level company consider development free cash flow year treasury share purchase company confirm currently intend market purchase company review potential future share buyback line usual annual cycle subject return rating criterion market capitalisation market capitalisation base share issue exclude treasury share gsk december billion date gsk large company market capitalisation ftse index share price ad price nature trading market follow table set period indicate high low middle market closing price company ordinary share lse ad nyse ordinary share ad share share high low high low march february january december november october september quarter end december quarter end september quarter end june quarter end march quarter end december quarter end september quarter end june quarter end march year end december year end december year end december year end december march gsk annual report shareholder information continue analysis shareholding december number total total number account account share share hold share hold institutional corporate holder individual corporate body guaranty nominee limit adr programme hold treasury share gsk morgan chase bank depositary company american depository receipt adr programme company ad list nyse ordinary share represent company adr programme manage depositary register guaranty nominee limit march guaranty nominee limit hold ordinary share represent issue share capital exclude treasury share march number holder ordinary share holding ordinary share number register holder ad holding ad certain ordinary share ad hold broker nominee result number holder record register holder representative number beneficial holder residence beneficial holder dividend company pay dividend quarterly continue return gsk previously state expect declare cash shareholder dividend policy dividend share dividend half share remain essential component total shareholder return dividend second half share gsk recognise importance dividend shareholder dividend share consolidation target dividend share increase step june new gsk investor update gsk share consolidation maintain aggregate set progressive dividend policy dividend payout absolute pound sterling term accordingly implement guide percent payout ratio consolidation ratio gsk expect dividend investment cycle dividend policy total fourth quarter convert new ordinary expect cash distribution respective dividend share result expect total dividend second payout ratio gsk remain unchanged half new ordinary share expect dividend new ordinary share line dividend share original expectation convert share table set dividend share ad consolidation round year dividend ad translate detail dividend declare amount dollar applicable exchange rate payment date give note financial statement year penny dividend dividend calendar quarter exdividend date record date payment date february february april july annual fee ad ad quarter charge august august october depository amount show dividend pay ad november november january annual fee charge february february april adjusted share consolidation prior year adjust dividend declare pay respect share share share dividend share declare ordinary dividend receivable ad holder calculate base exchange rate april cumulative dividend receivable ad holder strategic report governance remuneration financial statement investor information gsk annual report shareholder information continue financial calendar event date result announcement quarter result announcement april result announcement issue lse available annual general meeting news service send security quarter result announcement july exchange commission sec nyse issue quarter result announcement november media available website preliminaryquarter result announcement january financial report annual report publication februarymarch annual report distribution march company publish annual report available website date publication information company include share ad shareholder elect receive notification email price available website gskcom information publication annual report register available website constitute annual wwwshareviewcouk elect receive report print copy annual report contact registrar equiniti limited copy previous annual report available website print copy obtain registrar contact detail annual general meeting annual general meeting agm hold ad holder wish attend meet electronically time wednesday sofitel london refer agm notice detail request heathrow terminal london heathrow airport proxy appointment depositary morgan chase broadcast live join electronically bank enable attend ask question vote electronically business transact agm company principal forum communication meeting ad holder remind instruct private shareholder addition formal agm depositary way share represent business presentation ceo ad vote complete return performance group future development voting card provide depositary share opportunity question ask board vote chair board committee available question relate role document display detail access agm electronically article association company director attend person ask question vote find service contract applicable letter appointment notice annual general meeting agm notice director company subsidiary available website gskcom letter relate severance term pension investor hold share nominee service arrangement available inspection company arrange service appoint proxy register office available inspection respect shareholding attend vote agm meeting electronically tax information shareholder summary certain tax federal income tax holder ad generally treat owner consequence holder share ad citizen underlie share purpose current ukus set complete double taxation convention relate income gain analysis possible tax consequence purchase income tax convention estate gift taxis estate gift ownership sale security intend tax convention purpose internal revenue general guide holder advise consult advisers code amend respect tax consequence purchase ownership sale share ad consequence state local tax law implication current ukus tax conventionsgsk annual report shareholder information continue tax information shareholder continue shareholder overall exposure dependent specific circumstance situation important note summary apply resident shareholder tax charge arise jurisdiction bespoke advice hold share capital asset tailor individual personal circumstance taxation dividend obtain tax professional tax year resident individual stamp duty stamp duty reserve tax entitle dividend tax allowance stamp duty andor stamp duty reserve tax sdrt dividend receive tax year free subject certain exemption payable transfer tax dividend excess allowance tax share rate round near case basic rate taxpayer high rate stamp duty consideration transfer taxpayer additional rate taxpayer note notwithstanding provide instrument execute april dividend allowance reduce pursuance agreement give rise charge sdrt april dividend allowance instrument stamp year agreement reduce include stamp exempt sdrt charge resident shareholder corporation taxpayer cancel sdrt pay note dividend payable ordinary share repay list share transfer company generally entitle exemption corporation tax connect transferor chargeable consideration deem market value share taxation capital gain transfer market value override apply resident shareholder liable tax gain nonliste share transfer company connect disposal share ad transferor consideration include issue share disposal individual tax year shareholder taxable capital gain accrue disposal share ad tax basic rate taxpayer summary apply shareholder citizen allowable deduction individual taxable income resident domestic corporation person year exceed basic rate income tax banding note subject federal income tax net income follow use exemption available basis respect share ad hold share ad individual taxpayer annual exempt capital asset resident tax purpose hold share purpose trade profession corporation taxpayer entitle indexation vocation carry branch agency allowance apply reduce capital gain extent gain arise inflation indexation allowance summary address tax treatment holder reduce chargeable gain create allowable subject special tax rule bank taxexempt loss asset acquire january entity insurance company dealer security currency legislation finance act freeze level person hold share ad integrate indexation allowance give calculate company investment include straddle comprise share ad chargeable gain value apply disposal position person directly asset december asset acquire indirectly constructively company stock january onwards legislation finance act vote value address tax treatment remove indexation allowance disposal applicable result international income tax treaty inheritance tax taxation dividend individual ukdomicile shareholder gross dividend receive treat foreign liable inheritance tax transfer share ad source dividend income tax purpose eligible exposure inheritance tax charge typically occur dividend receive deduction allow corporation death asset owner transfer share dividend ad payable dollar dividend commercial sale year death remain relevant ordinary share payable sterling dividend pay inheritance tax exposure death transfer sterling include income dollar trust arrangement lifetime rise immediate calculate reference exchange rate day inheritance tax charge dividend receive holder subject certain exception shortterm hedge position individual tax charge value eligible holder subject taxation maximum shareholder estate reduce result transfer way federal rate plus applicable state local tax lifetime gift disposal market value respect qualified dividend qualified dividend define case bequest death tax charge internal revenue service irs dividend value share date shareholder death meet follow criterion exposure inheritance tax estate gift tax exist careful planning undertake understand ust issue corporation corporation opportunity utilise usuk estate gift double tax incorporate possession corporation convention manage tax credit avoid double taxation eligible benefit comprehensive income tax treaty deem satisfactory publish irs strategic report governance remuneration financial statement investor information gsk annual report shareholder information continue tax information shareholder continue dividend type list irs estate gift taxis dividend qualify estate gift tax convention shareholder require dividend hold period meet generally subject inheritance tax share own holder subject federal estate gift tax day hold period define stamp duty day period begin day exdividend date day stock trade stamp duty andor sdrt subject certain dividend price example stock exdividend exemption payable transfer share ad date october share hold custodian depository rate day period august november consideration provide transfer sale value year order count qualified dividend transfer consideration dividend qualified subject taxation stamp duty sdrt payable federal graduate tax rate maximum rate transfer agreement transfer ad transfer type dividend automatically exclude clearance service notwithstanding qualified dividend meet clearance service operator election requirement include limited finance act broadly stamp duty sdrt charge arise transfer capital gain distribution clearance service transfer system dividend bank deposit change beneficial ownership ividend hold corporation employee stock attract charge ownership plan esop demerger share consolidation dividend pay taxexempt corporation summary certain tax consequence respect state local tax rate qualify nonqualified demerger share consolidation relevant dividend vary assess addition company shareholder resident case federal tax rate communicate individual resident domicile tax purpose citizen resident tax taxation capital gain purpose set circular page generally holder subject capital gain circular information tax subject tax capital gain realise demerger share consolidation find gskcom sale disposal share ad gain demerger section longterm capital gain subject reduce rate taxation information tax base cost allocation assist individual holder share ad hold shareholder apportion base cost gsk plc year date share vestedrelease shares haleon plc share capital gain tax shortterm capital gain subject taxation rate purpose follow demerger include work example longterm capital gain subject find tax section gskcom demerger rate state local tax rate capital section gain apply information report backup withholding dividend payment proceed sale share ad pay certain usrelated financial intermediary subject information reporting subject backup withholding holder corporation exempt recipient provide taxpayer identification number certifie loss exemption occur nonus holder generally subject information report backup withholding require provide certification nonus status connection payment receive amount withhold allow refund credit holder federal income tax liability provide require information furnish irsgsk annual report statutory disclosure shareholder service contact registrar company registrar equiniti limited aspect house spencer road lance wwwshareviewcouk tel equiniti provide range service shareholder service offer participate dividend reinvestment plan alternative receive cash dividend choose drip election form term condition drip reinvest dividend buy gsk share information fee download wwwshareviewcouk request contact equiniti dividend payment direct dividend pay directly bank building society dividend bank mandate form bank account bank mandate account receive cash dividend provide equiniti download wwwshareviewcouk bank building society account detail quick request contact equiniti secure method payment dividend payment direct bank equiniti convert dividend local currency send information overseas payment account overseas shareholder direct local bank account overseas payment service service include information fee overseas payment service available approximately country worldwide find wwwshareviewcouk contact equiniti electronic communication shareholder elect receive electronic notification register wwwshareviewcouk company communication include annual report dividend payment dividend confirmation availability online vote general meeting time gsk publish shareholder document receive email contain link document relevant website shareview portfolio service enable create free online portfolio view register wwwshareviewcouk share balance movement update address dividend payment instruction register vote general meeting deduplication publication receive duplicate copy mailing contact equiniti mailing account contact equiniti arrange account merge convenience avoid waste unnecessary cost share deal service shareholder trade share hold certificate information share deal note market trading form corporate sponsor nominee online telephone service include information fee hour postal dealing service provide equiniti financial service find wwwshareviewcoukdeale time monday friday limit online transaction log exclude public holiday wwwshareviewcoukdeale england wale telephone transaction outside line open time monday friday exclude public holiday postal transaction request deal form corporate sponsor nominee convenient way manage share require application form request account share certificate service provide facility hold wwwshareviewcouk share nominee account sponsor company contact equiniti continue receive dividend payment attend vote company general meeting shareholder name appear publicly available share register service free join individual saving account isas equiniti financial service limit provide eqi flexible isa detail include information fee hold gsk share available wwweqicouk request call equiniti customer experience team line open time monday friday exclude public holiday line open time monday friday exclude public holiday england wale use country code dialling outside provision share deal detail intend invitation inducement engage investment activity advice share dealing obtain stockbroker independent financial adviser strategic report governance remuneration financial statement investor information gsk annual report shareholder information continue shareholder service contact continue ad depositary contact adr programme administer morgan investor relation chase bank investor relation contact follow regular correspondence shareowner services great west road box brentford middlesex paul tel delivery stock certificate overnight mail shareowner services walnut street centre pointe curve suite philadelphia mendota heights tel toll free shareowneronlinecominformationalcontactus tel outside gsk response center outside tel toll free depository provide global invest direct direct tel outside ad purchasesale dividend reinvestment plan ad holder detail enrol visit wwwadrcom share scam alert receive unsolicited telephone offering sell helpline number obtain enrolment buy share extra care caller pack highly organise financial scam donate share save child shareholder contact financial gsk embark ambitious global partnership conduct authority wwwfcaorgukconsumer save child share expertise resource consumer helpline aim find innovative way reduce number child die preventable disease tel shareholder small number share value tel outside make uneconomical sell wish consider donate line open time monday friday save child donate share aggregate public holiday saturday sell behalf save child use fund raise help reach goal obtain share donation form contact registrar equiniti manage donation sale share save child free charge provision share deal detail intend invitation inducement engage investment activity advice share dealing obtain stockbroker independent financial adviser stock exchange announcement notification provide shareholder service receive automatic email notification publish stock exchange announcement receive email notification sign announcement gskcom investor sectiongsk annual report statutory disclosure continue law regulation number provision law regulation apply section corporate responsibility company share quote nyse financial report form ad sarbanesoxley require ceo cfo complete nyse rule formal certification confirm general nyse rule permit company follow review annual report form corporate governance practice instead apply base knowledge annual report form provide explain significant variation contain material misstatement omission explanation contain form access sec edgar database website base knowledge financial statement nyse rule require file annual interim write financial information fairly present material affirmation concern audit risk committee arc respect financial condition result operation statement significant difference corporate cash flow date period present governance annual report form responsible establish maintain sarbanesoxley act disclosure control procedure ensure material follow number corporate accounting scandal information know evaluate congress pass sarbanesoxley act effectiveness control procedure year sarbanesoxley wideranging piece legislation end result evaluation contain concerned largely financial report corporate annual report form governance responsible establish maintaining recommend sec company establish internal control financial reporting provide disclosure committee committee report ceo reasonable assurance reliability financial cfo arc chair company secretary reporting preparation financial statement member consist senior manager finance external purpose accordance generally accept legal corporate communication investor relation accounting principle appropriate external legal counsel external disclose annual report form auditor sponsor bank internal expert invite change internal control financial reporting attend disclosure committee meeting periodically period cover annual report form committee responsibility consider materiality materially affect reasonably likely affect information timely basis determine disclosure materially company internal control financial information responsibility timely filing reporting disclose base report sec formal review annual recent evaluation internal control financial reporting report form committee meet time external auditor arc significant include purpose receive relevant appropriate deficiency material weakness design training operation internal control financial reporting sarbanesoxley require annual report form reasonably likely affect adversely company contain statement member arc ability record process summarise report financial audit committee financial expert define rule information fraud regardless materiality sarbanesoxley statement relevant member involve person significant role arc charles bancroft include board company internal control financial reporting committee information area corporate governance group carry evaluation supervision report biography participation management include additional disclosure requirement arise section ceo cfo effectiveness design operation section sarbanesoxley respect disclosure control group disclosure control procedure procedure internal control financial reporting december inherent limitation effectiveness system disclosure control procedure include possibility human error circumvention override control procedure accordingly effective disclosure control procedure provide reasonable assurance achieve control objective strategic report governance remuneration financial statement investor information gsk annual report statutory disclosure continue law regulation continue ceo cfo expect complete certification group export certain pharmaceutical vaccine report conclusion effectiveness disclosure consumer product iran sale nonus entity control procedure march follow subsidiary entity privately hold iranian certification file sec group distributor form group regularly receive information identity distributor downstream customer section management annual report intermediary iran possible party internal control financial reporting include entity governmentowne hospital accordance requirement section pharmacy own directly indirectly iranian sarbanesoxley follow report provide government person entity sanction connection management respect company internal control terrorism proliferation activity financial report define rule group regularly receive information securities exchange act amend identity distributor downstream customer exchange act establish proportion gross revenue sale management responsible establish maintain potentially attributable entity affiliate iranian adequate internal control financial reporting government party sanction disclosable activity group internal control financial reporting design result group report entire gross revenue provide reasonable assurance reliability million net profit million group financial reporting preparation financial sale iran statement external purpose accordance ifrs group aware hospital medical management conduct evaluation effectiveness facility lebanon affiliated control internal control financial reporting base hezbollah group designate united framework internal control integrate framework state pursuant executive order group issue committee sponsor organisation deal directly hospital facility treadway commission coso instead sell distributor group unable change group internal control establish proportion gross revenue sale potentially financial reporting materially attributable reportable activity result group affect reasonably likely materially affect report entire gross revenue million net loss group internal control financial reporting million group sale lebanon management assess effectiveness internal note group intend continue activity control financial reporting december describe conclusion file group form addition section exchange act law generally restrict dealing person dealing deloitte llp audit consolidated financial subject jurisdiction certain country statement group year end december territory subject comprehensive sanction assess effectiveness group currently crimea cuba socalle donetsk people internal control financial reporting auditing republic iran socalle luhansk people republic north standard public company accounting oversight korea syria government venezuela board united states audit report file country venezuela group form group business nonus entity own control entity certain jurisdiction section exchange act believe group complie applicable sanction section exchange act require issuer material respect law complex continue specific disclosure annual report certain type evolve rapidly dealing iran include transaction dealing governmentowne orcontrolle entity dealing entity sanction activity relate terrorism proliferation weapon mass destruction activity prohibit law involve personsgsk annual report statutory disclosure continue donation political organisation political expenditure ensure consistent approach political contribution result definition cover legitimate business group global policy introduce activity ordinary sense consider political voluntarily stop corporate political contribution donation political expenditure design support political party independent election candidate period january december group political donation notwithstanding policy noneu organisation intend donation political party organisation incur political expenditure notwithstanding introduction policy accordance annually seek shareholder authorisation inadvertent federal election campaign act continue expenditure support employeeoperate political action committee pac facilitate voluntary political donation eligible authority precautionary measure ensure gsk employee company subsidiary inadvertently breach legislation pac control gsk decision amount recipient contribution govern pac board authorisation process expenditure director contribution pac year date agm hold follow participate eligible employee exercise legal right introduction political party election pool resource political contribution referendum act authority subject strict limitation law total renew annually donate political organisation gsk employee pac english law require prior shareholder approval political contribution political party independent election candidate political expenditure definition political donation political expenditure political organisation legislation broad particular definition political organisation extend body concern policy review law reform representation business community special interest group concern environment company subsidiary wish support strategic report governance remuneration financial statement investor information gsk annual report statutory disclosure continue group company accordance section company act list subsidiary associate joint venture joint arrangement address register office effective percentage equity own december disclose state share capital disclose comprise ordinary share indirectly hold gsk plc percentage hold class share state state subsidiary company register office tax resident country incorporation security register address wholly own subsidiary alberta ulc common street calgary canada action potential venture capital limit ordinary great west road brentford middlesex england adechsa gmbh ordinary prv provide treuhandgesellschaft dorfstrasse baar switzerland affinivax securities corporation common affinivax inc binney street cambridge united states affinivax inc common corporation service company little fall drive wilmington united states allen hanburys limited ordinary great west road brentford middlesex england allen hanburys pharmaceutical nigeria limited ordinary town planning way ilupeju lagos nigeria allen pharmazeutika gesellschaft mbh ordinary wienerbergstrae wien austria austria beecham group plc ordinary great west road brentford middlesex england ordinary beecham pharmaceutical pte limited ordinary quality road jurong industrial estate jurong singapore beecham portuguesaproduto farmaceuticos quimicos lda quota rua antonio loureiro borge arquiparque miraflore alge portugal beecham ordinary avenue fleming wavre belgium biovesta ilalari ltd sti nominative bykdere caddesi levent plaza blok levent istanbul turkey cascan gmbh partnership capital prinzregentenplatz munich germany cellzome gmbh ordinary meyerhofstrasse heidelberg germany cellzome limited liquidation ordinary bdo llp temple square temple street liverpool united kingdom charles midgley limited liquidation ordinary bdo llp temple square temple street liverpool united kingdom clarges pharmaceutical limited liquidation ordinary bdo llp temple square temple street liverpool united preference kingdom clarge pharmaceutical trustee limited ordinary great west road brentford middlesex england colleen corporation common corporation service company little fall drive wilmington united states corixa corporation common corporation service company little fall drive wilmington united states dealcyber limited ordinary great west road brentford middlesex england desarrollo energia solar alternativa ordinary severo ochoa parque tecnologico madrid tres cantos madrid spain duncan pharmaceuticals philippines inc common floor finance centre street corner avenue bonifacio global city taguig city philippines etex farmaceutica ltda social capital andrs bello costanera center torre piso providencia santiago chile genelabs technologies inc common corporation service company gateway oak drive suite sacramento united states glaxo group limit ordinary great west road brentford middlesex england glaxo kabushiki kaisha ordinary akasaka minatoku tokyo japan glaxo laboratories nigeria limited ordinary marine road apapa lagos nigeria glaxo laboratory limit liquidation ordinary baker street london united kingdom glaxo new zealand pension plan trustee limited ordinary level generator gridakl madden street wynyard quarter auckland new zealand glaxo operation limit ordinary great west road brentford middlesex england glaxo property ordinary van asch van wijckstraat amersfoort netherlands glaxo trustee limited liquidation ordinary baker street london united kingdom glaxo verwaltung gmbh ordinary prinzregentenplatz munich germany glaxo wellcome farmaceutica limitada ordinary quota rua antonio loureiro borge arquiparque miraflore alge portugal glaxo wellcome manufacturing pte ltd ordinary pioneer sector jurong industrial estate jurong singapore glaxo wellcome production ordinary rue franois jacob rueilmalmaison france glaxo wellcome vidhyasom limited ordinary floor wave place wireless road lumpini pathumwan bangkok thailandgsk annual report statutory disclosure continue group company continue security register address wholly own subsidiary continue glaxo wellcome ordinary poligono industrial allendeduero avenida extremadura aranda duero burgo spain glaxo ordinary severo ochoa parque tecnologico madrid tres cantos madrid spain glaxoallenburys nigeria limited ordinary creek road apapa lago pmb nigeria glaxochem pte ltd iii ordinary rochester park singapore glaxosmithkline produtos farmaceuticos limitada ordinary quota rua antonio loureiro borge arquiparque miraflore alge portugal glaxosmithkline cambodia ltd ordinary floor dksh building preah monivong boulevard sangkat phsar deum thakov khan chamkarmon phnom penh cambodia glaxosmithkline china investment ltd ordinary room unit floor mid east ring road chaoyang district beijing china glaxosmithkline china company limited equity building huanke road pilot free trade zone shanghai china glaxosmithkline gsk srl ordinary costache negri street opera center floor zone district bucharest romania glaxosmithkline ireland limit ordinary riverwalk citywest business campus dublin ireland glaxosmithkline israel ltd ordinary basel street box petachtikva israel glaxosmithkline malta limit ordinary floor cruz avenue qormi qrm malta glaxosmithkline private limited ordinary unit anthony road msasa harare zimbabwe glaxosmithkline thailand limited ordinary floor wave place wireless road lumpini pathumwan bangkok thailand glaxosmithkline ordinary hemvarnsg solna sweden glaxosmithkline ordinary talstrasse muenchenbuchsee switzerland glaxosmithkline angola unipessoal limitada quota luanda bairro petrangol estrada cacuaco angola glaxosmithkline argentina ordinary tucumn piso buenos aire caaa argentina glaxosmithkline ordinary drammensveien oslo norway glaxosmithkline australia pty ltd ordinary mountain highway boronia victoria vic australia glaxosmithkline ordinary van asch van wijckstraat amersfoort netherlands netherlands glaxosmithkline beteiligung gmbh ordinary prinzregentenplatz munchen germany glaxosmithkline biological kft ordinary gdll homoki nagy istvn utca hungary glaxosmithkline biological sas ordinary rue des aulnois saintamand les eaux france glaxosmithkline biological ordinary rue rixensart belgium preference glaxosmithkline brasil limitada quotas estrada do banderiantes rio janeiro brazil glaxosmithkline capital inc common wilmington trust services inc market street floor wilmington united states glaxosmithkline capital plc ordinary great west road brentford middlesex england glaxosmithkline caribbean limited ordinary great west road brentford middlesex england glaxosmithkline chile farmaceutica limitada social capital andrs bello torre piso providencia santiago regin metropolitana chile glaxosmithkline colombia ordinary avenida dorado bpiso bogota colombia glaxosmithkline consumer hold ordinary van asch van wijckstraat amersfoort netherlands glaxosmithkline doo sarajevo likvidaciji liquidation quota zmja bosne broj sarajevo bosnia herzegovina glaxosmithkline doo equity capital ulica damira tomljanovica gavrana zagreb croatia glaxosmithkline doo beogradnovi beograd likvidaciji ordinary milutin milankovic novi beograd belgrade serbia liquidation glaxosmithkline ecuador ordinary agosto naciones unidas edificio electroectuatoriana piso quito ecuador glaxosmithkline salvador ordinary municipio san salvador departamento san salvador salvador glaxosmithkline eood ordinary nedelcho bonchev str sofia bulgaria glaxosmithkline export limit ordinary great west road brentford middlesex england glaxosmithkline export panama ordinary panama city republic panama panama glaxosmithkline far east ordinary van asch van wijckstraat amersfoort netherlands glaxosmithkline finance plc ordinary great west road brentford middlesex england glaxosmithkline gmbh partnership capital prinzregentenplatz munchen germany glaxosmithkline guatemala ordinary zona torre citibank nivel guatemala city guatemala glaxosmithkline hold ordinary drammensveien oslo norway glaxosmithkline holdings americas inc common wilmington trust services inc north market street floor wilmington delaware glaxosmithkline holding limited ordinary great west road brentford middlesex england glaxosmithkline holding limit ordinary great west road brentford middlesex england strategic report governance remuneration financial statement investor information gsk annual report statutory disclosure continue group company continue security register address wholly own subsidiary continue glaxosmithkline holdings pty ltd ordinary mountain highway boronia victoria vic australia glaxosmithkline honduras ordinary tegucigalpa mdc honduras glaxosmithkline ihc limit ordinary great west road brentford middlesex england glaxosmithkline ilaclari sanayi ticaret nominative bykdere caddesi levent plaza blok levent istanbul turkey glaxosmithkline inc class common milverton drive suite mississauga canada class preference glaxosmithkline insurance ltd ordinary trinity corporate services ltd trinity hall cedar avenue hamilton hamilton bermuda glaxosmithkline intellectual property limit ordinary great west road brentford middlesex england glaxosmithkline intellectual property development limit ordinary great west road brentford middlesex england glaxosmithkline intellectual property holding limit ordinary great west road brentford middlesex england ordinary glaxosmithkline intellectual property limit defer great west road brentford middlesex england ordinary glaxosmithkline intellectual property management limit ordinary great west road brentford middlesex england glaxosmithkline investigacin desarrollo ordinary severo ochoa parque tecnolgico madrid tres cantos madrid spain glaxosmithkline investments pty ltd ordinary mountain highway boronia victoria vic australia glaxosmithkline ordinary akasaka minatoku tokyo japan glaxosmithkline korea limited ordinary yongsan tower hangangdaero yongsangu seoul korea republic glaxosmithkline latin america ordinary panama city republic panama panama glaxosmithkline lietuva uab ordinary ukmerge vilnius lithuania glaxosmithkline limit ordinary tower gateway canton road tsimshatsui kowloon hong kong glaxosmithkline limited ordinary great west road brentford middlesex england glaxosmithkline llc llc interest corporation service company little fall drive wilmington united states glaxosmithkline manufacture spa ordinary viale dellagricoltura verona italy glaxosmithkline maroc ordinary angle rachidi abou ham glaza casablanca morocco glaxosmithkline medical healthcare product limit ordinary csorsz utca budapest hungary glaxosmithkline mercury limit ordinary great west road brentford middlesex england glaxosmithkline mexico ordinary real mayorazgo piso colonia xoco alcaldia benito jurez ordinary ciudad mexico mexico glaxosmithkline limit ordinary level generator gridakl madden street wynyard quarter auckland new zealand glaxosmithkline ordinary piispansilta box espoo fin finland glaxosmithkline peru ordinary vctor andrs belande principal piso distrito san isidro lima lima glaxosmithkline pharma ordinary vallensbk company house iii delta park valle denmark glaxosmithkline pharma gmbh ordinary wienerbergstrae wien austria austria glaxosmithkline pharmaceutical kenya limit ordinary likoni road nairobi kenya glaxosmithkline pharmaceutical nigeria limited ordinary industrial avenue ilupeju ikeja lagos nigeria glaxosmithkline pharmaceutical sdn bhd ordinary horizon penthouse powerhouse persiaran bandar utama bandar utama petale jaya selangor malaysia glaxosmithkline pharmaceuticals pvt ltd ordinary galle road kaldemulla moratuwa sri lanka glaxosmithkline pharmaceuticals costa rica ordinary autopista florencia del castillo kilmetro siete oficentro terracampus edificio uno cuarto piso san diego cartago costa rica glaxosmithkline pharmaceuticals ordinary site apollo avenue pascal wavre belgium glaxosmithkline pharmaceutical ukraine llc charter capital pavla tychyny avenue kiev ukraine glaxosmithkline philippines inc ordinary floor finance centre street corner avenue bonifacio global city taguig city philippines glaxosmithkline pte ltd ordinary rochester park singapore glaxosmithkline puerto rico inc common corporation service company puerto rico inc rvm professional service llc reparto mendoza humacao puerto rico glaxosmithkline republica dominicana ordinary blue mall tower floor ave winston churchill santo domingo dominican republic glaxosmithkline research development limit ordinary great west road brentford middlesex england glaxosmithkline ordinary severo ochoa parque tecnologico madrid tres cantos madrid spain glaxosmithkline spa ordinary viale dellagricoltura verona italy glaxosmithkline sro ordinary hvezdova prague czech republic glaxosmithkline services gmbh partnership capital prinzregentenplatz munchen germanygsk annual report statutory disclosure continue group company continue security register address wholly own subsidiary continue glaxosmithkline service unlimite ordinary great west road brentford middlesex england glaxosmithkline single member aebe ordinary kifissias avenue halandri athens greece glaxosmithkline llc llc interest corporation service company little fall drive wilmington united states glaxosmithkline viii partnership great west road brentford middlesex england glaxosmithkline slovakia sro likvidcii liquidation ordinary kpmg slovensko advisory dvokovo nbreie bratislava slovakia glaxosmithkline south africa pty limited ordinary flush meadow build campus sloane street bryanston south africa glaxosmithkline trading services limit iii ordinary riverwalk citywest business campus dublin ireland glaxosmithkline tunisia sarl ordinary immeuble regus lot centre urbain nord tunis tunisia glaxosmithkline limit ordinary great west road brentford middlesex england glaxosmithkline uruguay register provisory stock salto montevideo uruguay glaxosmithkline trading limit ordinary great west road brentford middlesex england glaxosmithkline venezuela ordinary calle altagracia edificio piso mezzanina torre torre sur urbanizacion sorokaima trinidad caracas venezuela bolivarian republic glaxosmithkline vietnam limited liability company equity capital metropolitan dong khoi street district floor unit chi minh city vietnam glycovaxyn common grabenstrasse schlieren switzerland prefer preferred prefer groupe glaxosmithkline ordinary rue franois jacob rueilmalmaison france gsk scottish limited partnership partnership lothian road festival square edinburgh scotland united kingdom gsk biopharma argentina nominative non endorseable ordinary tucumn piso buenos aire caaa argentina gsk business service centre sdn bhd ordinary level quill jalan prof khoo kay kim petale jaya selangor malaysia gsk capital ordinary akasaka minatoku tokyo japan gsk commercial ordinary rzymowskiego warsaw poland gsk doo ljubljana ordinary amerika ulica ljubljana slovenia gsk enterprise management ltd ordinary floor lane huanke road zhongke road shanghai china gsk equity investment limited unit corporation service company interstate drive suite harrisburg united states gsk finance limit ordinary great west road brentford middlesex england gsk finance plc ordinary great west road brentford middlesex england gsk india global services private limited equity level luxor north tower bagmane capital business park outer ring road bangalore karnataka india gsk international hold finance ordinary van asch van wijckstraat amersfoort netherlands gsk kazakhstan llp participation interest furmanov street almaty medeu district kazakhstan gsk pharma india private limited equity battery house bhulabhai desai raod mumbai maharashtra india gsk pharma vietnam company limited charter capital unit floor metropolitan tower dong khoi street ben nghe ward district chi minh vietnam gsk pharmaceutical trading ordinary buchar costache negri street opera center floor discussion room district romania gsk psc poland equal indivisible share grunwaldzka pozna pol gsk service ordinary grunwaldzka poznan poland gsk vaccine ordinary hullenbergweg amsterdam netherlands gsk vaccine gmbh ordinary emilvonbehringstr marburg germany gsk vaccines institute global health srl quota fiorentina siena italy gsk vaccines srl quota fiorentina siena italy gsk vaccines vertriebs gmbh ordinary rudolfdieselring holzkirchen germany human genome sciences inc common corporation service company little fall drive wilmington united states biomedical corporation quebec common boul parc technologique qubec qubec canada instituto luso farmaco limitada quotas rua antonio loureiro borge arquiparque miraflore alge portugal interpharma dienstleistungen gmbh quotas wienerbergstrae wien austria austria technologies llc interest corporation service company shockoe slip floor richmond united states jsc glaxosmithkline trading ordinary leningradskiy prospect build floor premise room moscow russian federation strategic report governance remuneration financial statement investor information gsk annual report statutory disclosure continue group company continue security register address wholly own subsidiary continue laboratoire glaxosmithkline ordinary rue franois jacob rueilmalmaison france laboratoire pharmaceutique algrien lpa production spa ordinary zone industrielle est boudouaou boumerde algeria laboratoire pharmaceutique algrien spa ordinary zone industrielle est boudouaou boumerde algeria laboratoires paucourt ordinary rue franois jacob rueilmalmaison france laboratoire saintgermain ordinary rue franois jacob rueilmalmaison france laboratorios dermatologico darier ordinary real mayorazgo piso colonia xoco alcaldia benito jurez ordinary ciudad mexico mexico laboratorios farmaceuticos stiefel portugal ltda ordinary rua antonio loureiro borge arquiparque miraflore alge portugal laboratorios stiefel venezuela ordinary calle altagracia edificio nivel mezzanina piso mezzanina local torre sur urbanizacion sorokaima trinidad caracas venezuela bolivarian republic laboratorios stiefel ltda ordinary rua professor joao cavalheiro salem bairro bonsucesso municipality guarulhos sao paulo cep brazil laboratorios wellcome portugal limitada quotas rua antonio loureiro borge arquiparque miraflore alge portugal montrose pharma company limited ordinary quota csorsz utca budap hungary glaxo wellcome indonesia class pulobuaran raya kaviiidd kws industri pulogadung class jatinegara cakung jakarta timur indonesia setfirst limit ordinary great west road brentford middlesex england sierra oncology australia pty ltd ordinary maddock lawyer angel place level pitt street sydney australia sierra oncology canada ulc common burrard street suite vancouver british columbia canada sierra oncology canada llc llc interest corporation service company little fall drive wilmington united states sierra oncology llc common stock corporation service company little fall drive wilmington united states sitari pharma inc common stock corporation service company little fall drive wilmington united states smith kline french portuguesaprodutos farmaceutico ordinary rua antonio loureiro borges arquiparque miraflore lda alge portugal smithkline beecham bangladesh private limited ordinary housea roadgulshan dhaka bangladesh smithkline beecham cork limit ordinary riverwalk citywest business campus dublin ireland smithkline beecham manufacturing limit liquidation ordinary riverwalk citywest business campus dublin ireland smithkline beecham egypt llc quotas amoun street salam city cairo egypt smithkline beecham farma ordinary severo ochoa parque tecnologico madrid tres cantos madrid spain smithkline beecham limit ordinary great west road brentford middlesex england smithkline beecham legacy limited ordinary great west road brentford middlesex england smithkline beecham pension plan trustee limited ordinary great west road brentford middlesex england smithkline beecham pension trustee limit liquidation ordinary baker street london united kingdom smithkline beecham pharma gmbh partnership capital prinzregentenplatz munchen germany smithkline beecham pharma verwaltung gmbh ordinary prinzregentenplatz munchen germany smithkline beecham pharmaceuticals pty limited ordinary flush meadow build campus sloane street bryanston south africa smithkline beecham pharmaceutical common corporation service company little fall drive wilmington united states smithkline beecham senior executive pension plan trustee ordinary great west road brentford middlesex england limited stiefel gmbh partnership capital prinzregentenplatz munchen germany stiefel laboratory legacy ireland limited ordinary unit build avenue cork airport business park cork ireland stiefel laboratory limit liquidation ordinary bdo llp temple square temple street liverpool united kingdom stiefel laboratory pte limited ordinary pioneer sector singapore stiefel laboratories inc common corporation service company little fall drive wilmington united states stiefel maroc sarl ordinary boulevard zerktouni casablanca morocco stiefel research australia holdings pty ltd ordinary mountain highway boronia victoria vic australia stiefel research australia pty ltd ordinary mountain highway boronia victoria vic australia stiefel west coast llc llc interest corporation service company little fall drive wilmington united states strebor inc common corporation service company little fall drive wilmington united statesgsk annual report statutory disclosure continue group company continue security register address wholly own subsidiary continue tesaro bio gmbh liquidation ordinary poststrasse zug switzerland tesaro bio netherlands ordinary joop geesinkweg amsterdamduivendrecht netherland tesaro development ltd ordinary clarendon house church street hamilton bermuda tesaro inc common corporation service company little fall drive wilmington united states sydney ross ordinary corporation service company princeton south corporate center suite charle ewing blvd ewe united states ucb pharma asia pacific sdn bhd ordinary floor menara symphony jalan prof khoo kay kim seksyen petale jaya malaysia wellcome consumer healthcare limited ordinary great west road brentford middlesex england wellcome consumer product limit liquidation ordinary bdo llp temple square temple street liverpool united kingdom wellcome limited ordinary great west road brentford middlesex england effective security ownership register address subsidiary effective interest amoun pharmaceutical industry sae new monetary share salam city box cairo egypt biddle sawyer limited equity annie besant road mumbai india british pharma group limited capital great west road brentford middlesex england galvani bioelectronics inc common corporation service company little fall drive wilmington united states galvani bioelectronic limit ordinary great west road brentford middlesex england ordinary glaxo saudi arabia limit ordinary box area warehouse city stage khomrah jeddah saudi arabia glaxosmithkline tianjin ltd ordinary fifth avenue tai feng industrial park tianjin economic technolog tianjin china glaxosmithkline algrie spa ordinary zone industrielle est boudouaou wilaya boumerdes algeria glaxosmithkline consumer nigeria plc ordinary industrial avenue ilupeju ikeja lagos nigeria glaxosmithkline pakistan limit ordinary syke building dockyard road west wharf karachi pakistan glaxosmithkline pharmaceuticals limited equity annie besant road mumbai india glaxosmithkline sae ordinary boomerang office building land zone district town center tagammoe new cairo city egypt gsk scottish limited partnership partnership lothian road festival square edinburgh scotland united kingdom gsk scottish limited partnership partnership lothian road festival square edinburgh scotland united kingdom laboratorios viiv healthcare ordinary severo ochoa parque tecnologico madrid tres cantos madrid spain modern pharma trading company llc quotas amoun street box salam city cairo egypt phivco llc llc interest corporation service company little fall drive wilmington united states phivco llc llc interest corporation service company little fall drive wilmington united states shionogiviiv healthcare llc common interest corporation service company little fall drive wilmington united states smithkline beechambiome ooo participation interest leningradskiy prospect build floor premise xiv room moscow russian federation stiefel egypt llc quotas amoun street box salam city cairo egypt viiv healthcare south africa proprietary limited ordinary flush meadow build campus sloane street bryanston south africa viiv healthcare ordinary van asch van wijckstraat amersfoort netherlands netherlands viiv healthcare company common corporation service company little fall drive wilmington united states viiv healthcare finance limit liquidation ordinary bdo llp temple square temple street liverpool united kingdom viiv healthcare finance limit ordinary great west road brentford middlesex england viiv healthcare finance limit ordinary great west road brentford middlesex england redeemable preference viiv healthcare gmbh ordinary prinzregentenplatz munchen germany viiv healthcare gmbh ordinary talstrasse muenchenbuchsee switzerland strategic report governance remuneration financial statement investor information gsk annual report statutory disclosure continue group company continue effective security ownership register address subsidiary effective interest continued viiv healthcare hong kong limit ordinary tower gateway canton road harbour city tsimshatsui kowloon hong kong viiv healthcare ordinary akasaka minatoku tokyo japan viiv healthcare limit ordinary great west road brentford middlesex england ordinary ordinary preference ordinary defer cumulative preference viiv healthcare pty ltd ordinary mountain highway boronia victoria vic australia viiv healthcare puerto rico llc llc interest corporation service company puerto rico inc rvm professional service llc reparto mendoza humacao puerto rico viiv healthcare srl quotas viale dellagricoltura verona italy viiv healthcare sas ordinary rue franois jacob rueilmalmaison france viiv healthcare sprl ordinary site apollo avenue pascal wavre belgium viiv healthcare trading llc participation interest leningradskiy prospect build floor premise xiv room moscow russian federation viiv healthcare trading service limit ordinary great west road brentford middlesex england viiv healthcare limit ordinary great west road brentford middlesex england viiv healthcare limit ordinary great west road brentford middlesex england viiv healthcare limit ordinary great west road brentford middlesex england viiv healthcare limit ordinary great west road brentford middlesex england viiv healthcare limit ordinary great west road brentford middlesex england viiv healthcare limit ordinary great west road brentford middlesex england viiv healthcare ulc common street calgary canada viiv healthcare venture llc llc interest corporation service company little fall drive wilmington united states viivhiv healthcare unipessoal lda quota rua antonio loureiro borge arquiparque miraflore alge portugal winster pharmaceutical limit ordinary association avenue ilupeju industrial estate lago box nigeria effective security ownership register address associate glaxosmithkline landholde company inc common floor finance centre street corner avenue bonifacio global city taguig city philippines index ventures life jersey partnership interest esplanade helier jersey channel islands kurma biofund fcpr partnership interest rue royale floor paris france longwood fund partnership interest prudential tower suite boylston street boston medicxi ventures partnership interest esplanade helier jersey channel island joint ventures chiron panacea vaccines private limit equity share floor wing sagar tech plaza saki naka andheri east mumbai maharashtra india qualivax pte limit ordinary robinson road singapore qura therapeutics llc unit corporation service company little fall drive wilmington united states significant holding axon therapy inc common west street new york usa series preference alpheus medical inc series preference hopkin place north oakdale minnesota usa series preference global farm share mendoza ciudad autnoma buenos aires argentina shares shares longwood fund partnership interest prudential tower suite boylston street boston sanderle ventures vii partnership interest camino real suite san mateo capital fund partnership interest corporation service company little fall drive city wilmington county new castle delaware gsk annual report statutory disclosure continue group company continue follow subsidiary advantage audit exemption set section company act period end december state undertaking list own directly indirectly gsk plc effective company security ownership register address number register subsidiary exempt audit burrough wellcome international limited ordinary great west road brentford middlesex england domantis limit ordinary great west road brentford middlesex england edinburgh pharmaceutical industry limited ordinary shewalton road irvine ayrshire united kingdom preference eskaylab limit ordinary great west road brentford middlesex england glaxo wellcome limit ordinary great west road brentford middlesex england glaxo wellcome international iii ordinary huis ter heideweg zeist netherlands glaxochem unlimited ordinary great west road brentford middlesex england ordinary ordinary glaxosmithkline intellectual property ordinary great west road brentford middlesex england limited glaxosmithkline intellectual property ordinary great west road brentford middlesex england limited glaxosmithkline intellectual property ordinary great west road brentford middlesex england limited glaxosmithkline international limited ordinary great west road brentford middlesex england gsk capital iii ordinary great west road brentford middlesex england gsk limit share lothian road festival square edinburgh scotland shares united kingdom gsk limit ordinary lothian road festival square edinburgh scotland united kingdom gsk limited ordinary great west road brentford middlesex england montrose fine chemical company ltd ordinary shewalton road irvine ayrshire united kingdom phivco limited ordinary great west road brentford middlesex england phivco limit ordinary great west road brentford middlesex england smith kline french laboratory limit ordinary great west road brentford middlesex england smithkline beecham export limit ordinary great west road brentford middlesex england smithkline beecham limited noncumulative great west road brentford middlesex england nonredeemable ordinary smithkline beecham investment limit ordinary great west road brentford middlesex england smithkline beecham marketing technical ordinary great west road brentford middlesex england services limited smithkline beecham nominee limit ordinary great west road brentford middlesex england smithkline beecham overseas limit ordinary great west road brentford middlesex england stiefel laboratory ltd ordinary great west road brentford middlesex england tesaro limit ordinary great west road brentford middlesex england wellcome foundation limit ordinary great west road brentford middlesex england viiv healthcare overseas limited ordinary great west road brentford middlesex england accordance section company act company guarantee debt liability subsidiary undertaking december total sum debt liabilitie million million key directly own gsk plc ormant entity iii resident xempt regulation partnership account regulation requirement deliver registrar financial statement qualify partnership entity member accordance company act incorporate netherlands consolidated subsidiary accordance section company act ground dominant influence vii principal business address puerto rico viii exempt provision regulation partnership account regulation accordance exemption note regulation regulation gsk limited subsidiary undertaking gsk plc berkeley square pension trustee company limited general partner gsk scottish limited partnership gsk scottish limited partnership gsk limited share capital indirectly own gsk plc own berkeley square pension trustee company limited gsk limited subsidiary undertaking gsk plc general partner gsk scottish limited partnership gsk limited share capital indirectly own gsk plc strategic report governance remuneration financial statement investor information gsk annual report glossary term term annual report equivalent brief description accelerate capital allowance tax allowance excess depreciation arise purchase fix asset delay charge payment tax equivalent tax depreciation american depositary receipt adr receipt evidence title ad gsk adr represent ordinary share american depositary share ad list new york stock exchange represent ordinary share basic earning share basic income share call share capital ordinary share issue fully pay cer growth growth constant exchange rate company gsk plc currency swap exchange currency couple subsequent reexchange currency agree exchange rate date define benefit plan pension plan specific employee benefit call final salary scheme define contribution plan pension plan specific contribution level pension dependent growth pension fund derivative financial instrument financial instrument derives value price rate underlie item dilute earning share diluted income share employee share ownership plan trust trust establish group satisfy sharebase employee incentive plan equity shareholder fund shareholder equity finance lease capital lease freehold ownership absolute right perpetuity group gsk plc subsidiary undertakings gsk gsk plc subsidiary undertaking hedging reduction risk normally relation foreign currency interest rate movement make offset commitment intangible fix asset asset physical substance computer software brand licence patent knowhow marketing right purchase outside party ordinary share fully pay ordinary share capital company profit income profit attributable shareholder net income share capital ordinary share capital stock common stock issue fully pay share option stock option share premium account additional paidup capital paidin surplus distributable share issue number share outstanding subsidiary entity gsk exercise control treasury share treasury stock turnover revenue corporate governance code require list authority company disclose annual report apply good practice corporate governance provision financial reporting council corporate governance codegsk annual report shareholder information continue index remuneration policy summary key performance indicator access legal proceeding accounting principle policy major restructuring cost acquisition disposal movement equity adjustment reconcile total profit tax operate net debt cash flow new accounting requirement annual general meeting nominations committee report approach tax noncontrolle interest asset hold sale noncontrolle interest viiv healthcare associate joint venture nonexecutive director fee audit risk committee report nonfinancial information statement business model note financial statement cash cash equivalent operate profit cash generation conversion intangible asset ceo statement investment chair statement noncurrent asset chair governance statement noncurrent liabilitie chair remuneration annual statement operating incomeexpense climaterelate financial disclosure provision commitment culture consolidate balance sheet external environment consolidate cash flow statement longterm priority consolidated income statement pension postemployment benefit consolidate statement change equity performance consolidated statement comprehensive income pharmaceutical product competition contingent consideration liability intellectual property contingent liability pipeline corporate governance post balance sheet event corporate responsibility committee report presentation financial statement critical accounting judgement key source principal group company estimation uncertainty principal risk uncertaintie critical accounting policy property plant equipment datum engagement reconciliation net cash flow movement net debt demerger consumer healthcare business registrar director senior management relate party transaction director interest share reliable supply director report remuneration governance director statement responsibility remuneration report dividend report framework donation political organisation responsible business political expenditure right use asset earning share risk management employee cost science technology employee share scheme science committee report environment section statement ethical standard share capital control exchange rate share capital share premium account finance expense share consolidation finance income shareholder information financial calendar shareholder service contact financial instrument relate disclosure specialty medicine financial performance stakeholder engagement financial position resource task force climaterelate financial disclosure financial statement gsk plc prepare taxation gaap tax information shareholder general medicine threeyear select financial datum glossary term board goodwill trade payable group company trade receivable group financial review treasury policy gsk leadership team trust independent auditor report turnover segment information innovation law regulation inventory vaccine investment associate joint venture vaccine product competition intellectual property investor relation viability statement gsk glaxosmithkline plc incorporate english brand name appear italic report trade mark own public limited company december andor license gsk associate company trade mark property form merger glaxo wellcome plc respective owners smithkline beecham plc gsk acquire print sustainably pureprint english company december carbonneutral company fsc chain custody iso certify merger arrangement effective environmental management system recycle dry waste glaxosmithkline plc change gsk plc print arena eco smooth wood july gsk plc separate consumer free uncoated paper ecf fsc certification recycle fibre healthcare business gsk group form haleon independent list company share list london stock exchange new york stock exchange download pdfs wwwgskcom annual report form esg performance report cautionary statement impact covid pandemic forward change healthcare environment unexpected forwardlooke statement look statement behalf group significant change pricing result government group report file furnish speak date base competitor action guidance factor securities exchange commission sec include knowledge information available divestment product exit announce date document write information director date annual report group guidance assume successful delivery release oral statement public number nonifrs measure report group integration restructuring plan future behalf group contain performance business measure material cost investment new product launch forwardlooke statement forwardlooke define page reconciliation factored expectation statement group current expectation adjust result total result set page give give potential development option forecast future event investor identify group pipeline outlook affect statement fact relate information document constitute additional datadriven investment decision strictly historical current fact use word offer sell invitation buy share gsk plc guidance give constant currency basis anticipate estimate expect intend invitation inducement engage outlook ambition expectation project plan believe target word investment activity past performance read page stock exchange term similar meaning connection rely guide future performance announcement relate update investor discussion future operate financial performance annual report construe profit date june paragraph particular include statement relate forecast circular shareholder relate demerger future action prospective product product haleon date june guidance approval future performance result current assumption relate guidance assumption cautionary statement group anticipate product sale effort expense outline guidance group earning release outcome contingency legal proceeding certain assumption healthcare sector dividend payment financial result different market group operate notice limitation director liability accordance legal regulatory obligation delivery revenue financial benefit english law include market abuse regulation current portfolio pipeline restructure company act safe harbour list rule disclosure transparency programme phase quarterly result limit liability director respect statement rule financial conduct authority group result comparator gsk expect omission director report undertake obligation update forward turnover adjust operate profit growth strategic report remuneration look statement result new slightly low half include report english law director liable information future event reader challenge comparator somewhat company party consult additional disclosure high second half relative fullyear report contain error result group document expectation despite recovery healthcare recklessness know misstatement dishonest publishe andor file sec readers system uncertain economic condition prevail concealment material fact locate note disclosure market gsk operate continue liable page accordingly assurance give expect variability performance inclusive comprise director report page particular expectation meet investor quarter inclusive comprise strategic report page caution place undue reliance expect sale specialty medicine increase mid inclusive comprise remuneration report forwardlooke statement high singledigit cent sale vaccine draw present forwardlooke statement subject increase midteen cent sale general accordance reliance english company assumption inherent risk uncertaintie medicine decrease slightly law liability director connection report shall subject limitation relate factor group plan assumption operate profit restriction provide law control precise estimate group caution guidance dividend expectation assume investor number important factor include material interruption supply group website document cause actual result product material merger acquisition gsk website wwwgskcom give additional differ materially express imply disposal material litigation investigation cost information group notwithstanding forwardlooke statement company save reference annual report gsk factor include limit recognise provision website information available discuss principal risk uncertainty change group shareholding viiv website constitute annual report shall page annual report healthcare assumption assume material deem incorporate reference unite science technology talent ahead disease head office register office gsk plc great west road brentford middlesex united kingdom tel register number